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Abstract 
Colorectal cancer is the 4th most common and 2nd deadliest cancer. Problems exist with 
predicting which patients will respond best to certain therapy regimens. Diffuse reflectance 
spectroscopy has been suggested as a candidate to optically monitor a patient’s early response to 
therapy and has been received favorably in experimentally managing other cancers such as breast 
and skin. In this dissertation, two diffuse reflectance spectroscopy probes were designed: one 
with a combined high-resolution microendoscopy modality, and one that was optimized for 
acquiring data from subcutaneous murine tumors. For both probes, percent errors for estimating 
tissue optical properties (reduced scattering coefficient and absorption coefficient) were less than 
5% and 10%, respectively. Then, studies on tissue-simulating phantoms were performed to test 
probe sensitivity and to serve as testing platforms for investigators in biomedical optics. Next, 
the diffuse reflectance spectroscopy probe was applied to subcutaneous murine colon tumors 
(n=61) undergoing either antibody immunotherapy or standard 5-fluorouracil chemotherapy. 
Mice treated with a combination of these therapies showed reduced tumor growth compared to 
saline control, isotype control, immunotherapy, and chemotherapy groups (p<0.001, <0.001, 
<0.001, and 0.046, respectively) 7 days post-treatment. Additionally, at 7 days post-treatment, 
oxyhemoglobin, a marker currently being explored as a functional prognostic cancer marker, 
trended to increase in immunotherapy, chemotherapy, and combination therapy groups compared 
to controls (p=0.315, 0.149, and 0.190). Also of interest, an oxyhemoglobin flare (average 
increase of 1.44x from baseline, p=0.03 compared to controls) was shown in tumors treated with 
chemotherapy, indicating that diffuse reflectance spectroscopy may be useful as a complimentary 
tool to monitor early tumor therapeutic response in colon cancer. However, subject-to-subject 
variability was high and studies correlating survival to early oxyhemoglobin flares are suggested.   
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Chapter 1: Introduction 
1. Background 
The overall health focus of this dissertation is colorectal cancer (CRC). Murine 
subcutaneous allografts were used as a model for CRC. No clinical human work was performed 
in CRC. Mice with subcutaneous CRC were treated with chemotherapy and immunotherapy, and 
the tumor therapeutic response was measured using a non-invasive optical technique, diffuse 
reflectance spectroscopy (DRS).  
Figure 1 shows the general dissertation workflow. Before DRS was implemented in the 
scientific investigation of therapy response in murine subcutaneous CRC allografts, an 
engineering approach was taken to design a DRS probe, design tissue-simulating phantoms with 
tunable optical properties, and perform calibration and validation of DRS hardware to ensure 
robust results. 
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Figure 1. DRS was used as a non-invasive optical tool to monitor tumor 
therapeutic response to chemotherapy and immunotherapy in a subcutaneous 
mouse model of CRC. Aims 1 and 2 primarily focus on engineering design and 
testing of a DRS probe and the calibration and validation of DRS hardware using 
tissue-simulating phantoms. Aim 3 primarily focuses scientific results from 
treating murine subcutaneous CRC allografts with chemotherapy and 
immunotherapy. Photo of DRS probe and mouse taken by author. Image of colon 
and colon cancer sourced from the Smart Servier Medical Art, which are free to 
share, copy, and redistribute under Create Commons License CC BY 3.0. Image 
of antibodies sourced from the Library of Science Medical Figures by 
somersault1824, which are free to share, copy, and redistribute under Create 
Commons License CC BY-NC-SA 4.0. 
 
 Therefore, this introduction opens with a discussion on the overall clinical health 
problem: CRC. This discussion introduces basic CRC epidemiological statistics, the 
biology of tumorigenesis, hypoxia, and angiogenesis, the current diagnostic and treatment 
standards for CRC, the emerging role of immunotherapy in CRC, and the current 
methods to assess CRC tumor response to therapy, and how DRS can offer additional 
clinically relevant information to better assess CRC tumor response to therapy. The 
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introduction next turns to describing DRS in detail, including the exact DRS platforms 
used for various studies in this dissertation. We discuss the optical physics of DRS, and 
how information gathered from light that has scattered and absorbed in body tissues 
relates to both structural and functional biological characteristics. Finally, the 
introduction closes with a brief summary of all three specific aims. Chapters 2 and 3 
represent specific aims 1 and 2, respectively. Aim 3, on the other hand, is longer, and 
consists of chapters 4, 5, and 6.     
1.1 Clinical health focus: colorectal cancer 
In the United States, CRC is the 4th most common cancer with 140,000 new cases and 
50,000 deaths in the United States annually. CRC has the 7th worst 5-year survival rate (~65%) 
of all cancers (Siegel et al., 2018). CRC makes up 8.1% of all cancers cases and 8.3% of all 
cancer-related death (Siegel et al., 2018). It has been estimated that individuals have a 2% and 
0.9% cumulative lifetime risk of developing and dying from CRC, respectively (Stigliano et al., 
2014), and the disease is more prevalent in 
males (54% of cases) compared to females 
(46% of cases) (Siegel et al., 2018). Although 
the incidence of CRC in the U.S. has been 
decreasing over the past several decades, there 
are still nearly 1.25 million U.S. residents 
(~0.4% of the population) living with CRC 
(Marley et al., 2016), costing the U.S. $14 
billion annually (Yabroff et al., 2007; Yabroff 
et al., 2011). Furthermore, per person costs 
Summary of acronyms 
5-FU 5-fluorouracil 
CCL2 Monocyte chemoattractant protein-1 
CSF2 Colony-stimulating factor 2 
DRS Diffuse reflectance spectroscopy 
Hb Hemoglobin 
LACC Locally advanced colorectal cancer 
LCC Left-sided colorectal cancer 
pCR Pathological complete response 
RCC Right-sided colorectal cancer 
RTE Radiative transport equation 
StO2 Tissue oxygen saturation 
SDS Source-detector separation 
TAM Tumor-associated macrophage 
THC Total hemoglobin concentration 
TME Tumor microenvironment 
TNM Tumor, node, and metastasis 
μa Absorption coefficient 
μs’ Reduced scattering coefficient 
 
4 
 
associated with CRC treatment are $30 thousand within a year of diagnosis (Luo et al., 2009). In 
developing countries, on the other hand, CRC incidence is expected to increase over the next 
decade as population and life expectancy increase (Stigliano et al., 2014). Although there has 
been a steady reduction in CRC incidence and mortality since the 1970’s, primarily attributed to 
reduction in preventable risk factors, advances in early detection, and nationwide screening 
initiatives (Siegel et al., 2018; Levin, 2016), research into monitoring tumor therapeutic response 
to better personalize patient treatment is still needed and an active area of research in the field of 
CRC (Park et al., 2014).  
CRC (Figure 2) is classified in multiple ways. CRCs can either be sporadic (70-85% of 
cases) (Yamagishi et al., 2016; Mundade et al., 2014) or familial (15-30% of cases) (Stigliano et 
al., 2014; Jasperson et al., 2010). Sporadic cases arise as a result of multiple rare variants, which 
are genetic variants occurring in < 1% of the population. Familial cases arise when individuals 
have a genetic disposition or family history of CRC, although family history is often unreported 
which contributes to the large percent range of cases (Stigliano et al., 2014). Treatment of 
sporadic vs. familial CRC currently does not differ significantly as chemotherapy and surgical 
resection remain the curative standard, although patients with certain subtypes of familial CRC 
may be screened and treated earlier (Esplin et al., 2014). Alternatively, CRC can be classified on 
where the disease occurs. CRC can arise in the rectum (31% of cases), left colon (30% of cases), 
or right colon (39% of cases) (Mik et al., 2017; Siegel et al., 2018). The left and right colon have 
different embryological origins (hindgut vs. midgut, respectively) (Baek, 2017) and many 
believe that left-sided (LCC) and right-sided CRC (RCC) should be considered separate diseases 
because they have different characteristics and oncological outcomes (Lim et al., 2017; Qin et 
al., 2017; Hussain et al., 2016). Although LCC and RCC are currently treated identically, these 
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diseases may be screened and treated differently in the future (Mik et al., 2017). Next, CRC can 
be histologically classified into adenocarcinomas (>90% of cases) or other types (<10% of 
cases), such as neuroendocrine, squamous cell, adenosquamous, spindle cell, and 
undifferentiated carcinoma (Fleming et al., 2012). Finally, a recent 2015 collaborative gene 
expression-based subtyping initiative has classified CRC into four distinct subtypes: CMS1 
(14%), CMS2 (37%), CMS3 (13%), CMS4 (23%), as well as 13% of cases with mixed features. 
It is anticipated that the CMS subtype classification will have the biggest impact on future 
targeted therapies (Guinney et al., 2015).  
 
Figure 2. The primary health focus of this dissertation is CRC. Images sourced 
from the Smart Servier Medical Art, which are free to share, copy, and 
redistribute under Create Commons License CC BY 3.0. 
 
1.1.1 Hypoxia in colorectal cancer 
Hypoxia is a condition of insufficient tissue oxygen saturation and arises due to 
uncontrolled and rapid proliferation of cancer cells in the absence of efficient vasculature (Eales 
et al., 2016). Initial tumor growth occurs without angiogenesis (Tafani et al., 2016). When 
intercapillary distances exceed the diffusion limit of oxygen (200 μm), average oxygen partial 
pressure (pO2) drops from ~35 mmHg to ~10 mmHg (Tafani et al., 2016). Intratumoral hypoxia 
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is spatially heterogenous, with between 50-60% of a solid tumor’s mass being hypoxic on 
average (Vadde et al., 2017). While much is known about how hypoxia affects the tumor 
microenvironment, the exact biological mechanism by which cells first detect low oxygen levels 
is under active investigation (Hamanaka et al., 2009). Despite this knowledge gap, hypoxia has 
several broad effects on tumors which will be briefly described here, including maintaining 
cancer cell stemness (Vadde et al., 2017), inducing release of damage-associated molecular 
patterns (DAMPs) (Tafani et al., 2016), increasing production of reactive oxygen species (ROS) 
(Tafani et al., 2016), and triggering angiogenesis and vascularization of the tumor mass (Eales et 
al., 2016). 
In the colon and rectum, superficial glandular epithelial cells (of which > 95% of CRC 
cases arise)(Marley et al., 2016; Hinck et al., 2014; Xue et al., 2012) ubiquitously express a 
family of transcription factors, known as hypoxia inducible factors (HIF) (Ulivi et al., 2016), of 
which HIF-1 is the best studied (Vadde et al., 2017). HIF-1 consists of two subunits: HIF-1α and 
HIF-1β (Ulivi et al., 2016). HIF-1β is constitutively active whereas the activity of HIF-1α is 
oxygen-regulated (Ulivi et al., 2016). HIF-1α gene expression has been shown to significantly 
increase with increased CRC stage (Mansour et al., 2016). In normoxic conditions, HIF-1α 
undergoes hydroxylation of two proline residues (P402 and P564) via prolyl hydroxylase 2 
(PHD-2) (Ulivi et al., 2016; Vadde et al., 2017; Cejudo-Martin et al., 2005). Hydroxylated HIF-
1α then binds to the Hippel-Lindau tumor suppression protein (pVHL) located on the E3 
ubiquitin ligase complex, which mediates ubiquitination and proteasomal degradation of HIF-1α 
(Maxwell et al., 2001; Vadde et al., 2017). Alternatively, in hypoxic conditions, HIF-1α 
circumvents ubiquitination. From here, HIF-1α, or the structurally related HIF-2α, can act alone 
to regulate the tumor microenvironment or move inside the cell to the nucleus  where it 
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dimerizes with HIF-1β to form a complex which serves as a transcription factor for a variety of 
genes that support CRC progression (Ulivi et al., 2016). An extensive list of HIF-1 or HIF-1α 
target genes that support cancer progression has been previously published (Semenza, 2010). 
In the stem cell theory of cancer, stemness is defined as the property of self-renewal and 
proliferative and differentiation potential of a subpopulation of cancer cells (Lathia et al., 2017). 
With regards to maintaining stemness of CRC in hypoxic conditions, activated HIF-1α interacts 
with the intracellular domain of the transmembrane protein, Notch1. In the presence of HIF-1α, 
the half-life of Notch1 increases which stimulates the Notch signaling cascade (Vadde et al., 
2017; Cejudo-Martin et al., 2005). The Notch signaling cascade, described in detail elsewhere 
(Wang et al., 2012), maintains cancer cell stemness by increasing proliferation and 
differentiation potential (Vadde et al., 2017). Additionally, HIF-2α (also known as EPAS 1, 
HLF, or HRF), which is also expressed in CRC, acts as a transcription factor for the Octamer-
binding transcription factor 4 gene (Oct-4) and thus upregulates Oct-4 expression (Covello et al., 
2006; Santoyo-Ramos et al., 2014). Oct-4 expression has been shown to increase going from 
normal tissue to benign polyps to CRC tissue with expression ratios of 4.4%, 12.7%, and 42,4%, 
respectively (Zhou et al., 2015). Specifically, Oct-4 maintains cell stemness within the CRC 
tumor microenvironment and is also a useful biomarker and potential therapeutic target (Vadde 
et al., 2017; Lathia et al., 2017), Therefore, hypoxic conditions contribute to stemness, 
progression, and malignancy of CRC. 
Next, hypoxia induces necrosis and the subsequent release of DAMPs (Hernandez et al., 
2016). DAMPs are a broad array of intracellularly sequestered molecules, which, upon necrosis 
or other cellular injury or stress, are actively secreted or passively released extracellularly (Land, 
2015; Eppensteiner et al., 2018). In CRC, DAMPs include adenosine, ATP, calreticulin, 
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HMGB1, S100A4, S100A8, S100A9, and IL-33 (Hernandez et al., 2016). These DAMPs act as 
ligands for receptors on nearby tumor cells, dendritic cells, myofibroblasts, or mast cells. Broad 
downstream pro-tumor effects include tumor growth and progression, tumor regrowth in wound-
healing sites such as tumor margins, and metastasis (Hernandez et al., 2016). Additionally, 
DAMPs such as HMGB1 has been shown to be highly expressed in solid CRC tumors (Sims et 
al., 2010). However, ATP has been shown to induce an anti-tumor immune response 
(Ghiringhelli et al., 2009) and calreticulin has been shown to improve chemotherapy-induced 
tumor regression (Obeid et al., 2007), and thus DAMPs are considered “double-edged” in that 
they can have both pro-tumor and anti-tumor effects (Hernandez et al., 2016). However, data 
regarding hypoxia-necrosis-DAMP pathways in CRC is relatively sparse, yielding an intriguing 
research gap (Hernandez et al., 2016). 
Cancer cells require high ROS levels to proliferate (Sosa et al., 2013). In both normal and 
cancerous cells, mitochondria are the main producers of ROS, which include hydroxyl radicals, 
superoxides, and hydroperoxides (Tafani et al., 2016). Under normoxic conditions, complexes I, 
II, and III of the mitochondrial electron transport chain (ETC) produce low concentrations of 
ROS during oxidative phosphorylation (Kondoh et al., 2013; Görlach et al., 2015; Hamanaka et 
al., 2009). Alternatively, under hypoxic conditions in solid tumors, ROS levels increase, 
although the exact biological mechanism is currently under investigation (Tafani et al., 2016). 
ROS levels also increase early in the tumorigenesis, such as during carcinogen exposure or 
chronic inflammation (Tafani et al., 2016). Increases in ROS can cause mitochondrial DNA 
damage and mutation (Lievre et al., 2005), as well as inactivation of PHD-2, which would 
otherwise inactivate HIF-1α. Thus, ROS increase activation of HIF-1α, which, as described 
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previously, drives gene expression that contribute to CRC progression and malignancy 
(Semenza, 2010).  
In summary, hypoxic conditions promote non-angiogenic CRC tumor progression by 
maintaining cancer cell stemness (Vadde et al., 2017), inducing release of damage-associated 
molecular patterns (DAMPs)(Tafani et al., 2016), and increasing production of reactive oxygen 
species (ROS) (Tafani et al., 2016). However, the most prominent effect of CRC tumor hypoxia 
is angiogenesis, which will be described in the following section.  
1.1.2 Angiogenesis in colorectal cancer 
The most well-known and studied effect of hypoxia is angiogenesis. As previously stated, 
HIF-1α is activated during hypoxia and translocates to the nucleus where it dimerizes with HIF-
1β. This dimerized complex, also known as HIF-α/Arnt, undergoes posttranslational 
modification and binds to hypoxia response elements (HREs) of target gene promoters and 
enhancers with the sequence G/ACGTG (Krock et al., 2011). HIF upregulates a variety of pro-
angiogenic proteins including fibroblast growth factor (FGF)(Korc et al., 2009), vascular 
endothelial growth factor (VEGF) (Duff et al., 2006), angiopoietin-1 and 2(Ellis et al., 2002), 
platelet-derived growth factor (PDGF) (Manzat Saplacan et al., 2017), as well as the angiogenic 
chemokine, monocyte chemoattractant protein-1 (CCL2 aka MCP-1)(Yoshidome et al., 2009), 
and a variety of interleukins (Krock et al., 2011). The angiogenic effects of FGF, VEGF, PDGF, 
angiopoietins, and interleukins are well-understood.  
The less well-known effects of CCL2, and its receptor, CCR2, are briefly described here. 
After CCL2 is transcribed and translated by CRC cells and monocytes/macrophages, in part due 
to HIF-1, it binds to CCR2 on target cells which include monocytes, macrophages, memory T 
lymphocytes, natural killer (NK) cells, and arterial endothelial cells (Deshmane et al., 2009). The 
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CCL2-CCR2 binding on endothelial cells causes upregulation of MCP-1-induced protein 
(MCPIP), which is a transcription factor for cadherins 12 (cdh12) and cadherin 19 (cdh19). It has 
been shown that in vitro knockdown of cdh12 and cdh19 reduced capillary formation (Niu et al., 
2008), although the exact biological mechanism is not fully elucidated (Roy et al., 2012). 
Finally, CCL2 induces gene expression of HIF-1α, creating a pro-angiogenic feedback loop 
(Hong et al., 2005). Thus, HIF-1 mediates CRC tumor angiogenesis by up-regulation of myriad 
pro-angiogenic growth factors, cytokines, and chemokines.  
1.1.3 Clinical background: diagnostic standard for colorectal cancer 
Colonoscopy is the gold standard for CRC diagnosis because of its ability to quickly 
examine the entire colon while simultaneously performing biopsies and polypectomies (Geiger et 
al., 2009) (Figure 3). Colonoscopies are recommended every 10 years beginning at age 50 for 
average-risk individuals, although screening prevalence is only 63% for this group (Burt et al., 
2010; Society, 2017).  
 
Figure 3. Colonoscopy is the gold standard for CRC diagnosis because of its 
ability to quickly examine the entire colon while simultaneously performing 
biopsies and polypectomies. Images sourced from the Smart Servier Medical Art, 
which are free to share, copy, and redistribute under Create Commons License 
CC BY 3.0. 
 
Other diagnostic tests do exist, such as the fecal occult blood test (FOBT), fecal 
immunochemical based stool test (FIT), double-contrast barium enema (DCBE), and computed 
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tomography colonography (CTC), but colonoscopy is still used to confirm abnormal results in 
most cases (Geiger et al., 2009; Society, 2017; Navarro et al., 2017). Treatment for CRC is based 
on the Tumor, Node and Metastasis (TNM) staging system. The TNM system stages tumors I-IV 
(Figure 4) based on how deep the tumor has spread, how many lymph nodes contain tumor cells, 
and number of distant metastases (Dienstmann et al., 2017). Stages I, II, III, and IV account for 
28%, 27%, 26%, and 19% of cases at diagnosis, respectively, according to a 2013 meta-analysis 
of 132,696 patients based on data from the Surveillance, Epidemiology, and End Results 
Program (SEER) database (Lee et al., 2013). 
 
Figure 4. The TNM system stages tumors I-IV based on how deep the tumor has 
spread, how many lymph nodes contain tumor cells, and the number of distant 
metastases. Image sourced from the Smart Servier Medical Art, which are free to 
share, copy, and redistribute under Create Commons License CC BY 3.0. 
 
However, in locally advanced CRC (stages II and III), which account for over half of 
patients at diagnosis, TNM staging less clearly predicts patient prognosis, so standard treatment 
for both stages includes colectomy with postoperative adjuvant chemotherapy (Dienstmann et 
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al., 2017; Lee et al., 2013). Currently, the most clinically valuable method to classify tumors is 
the tumor, node, and metastasis (TNM) staging system, which is used to guide treatment. 
1.1.4 Clinical background: treatment standard for colorectal cancer 
In recent years, growing evidence has supported using preoperative neoadjuvant 
chemotherapy prior to surgical resection to achieve a complete eradication of cancer cells before 
surgery, or, at least, a reduction in intraoperative tumor cell shedding (Zhou et al., 2013; Boland 
et al., 2014). Such preoperative therapy typically uses a fluorouracil-based regimen, such as 
FOLFOX (Jeon et al., 2011). A patient’s response to neoadjuvant chemotherapy is a critical 
prognostic indicator; patients who exhibit a significant reduction in tumor burden during 
neoadjuvant chemotherapy are more likely to experience complete resection of the tumor during 
colectomy, have fewer local and distal recurrences (Zhou et al., 2013), and have greater 5-year 
disease-free survival (Martin et al., 2012). However, in patients treated with neoadjuvant 
chemotherapy, pathologic complete response (pCR), a complete eradication of tumor cells, and 
surgical downstaging still remain low (both ~20-25%) (Zhou et al., 2013). Predicting which 
patients will respond to neoadjuvant chemotherapy, and which drugs are most appropriate, 
remains challenging (Wang et al., 2017). Ideally, CRC preoperative treatment would be tailored 
to each patient based on initial therapeutic response, with the end goal of avoiding surgery if 
possible (Walker et al., 2014). At present, in locally advanced CRC, fluorouracil-based 
FOLFOX chemotherapy is generally given to patients in 3-4 cycles over 6-8 weeks in the 
neoadjuvant setting, following by surgery and by 9-12 cycles of adjuvant chemotherapy over 18-
24 weeks (Zhou et al., 2013; Cheeseman et al., 2008; Habr-Gama et al., 2010). The current 
FOLFOX treatment regimen consists of 2,400 mg/m2 of 5-FU, 400 mg/m2 of leucovorin, and 85 
mg/m2 of oxaliplatin per cycle. Occasionally, irinotecan is given instead of oxaliplatin at a dose 
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of 180 mg/m2 in the FOLFIRI treatment regimen (de Gramont et al., 2000; Cheeseman et al., 
2008; Maindrault-Goebel et al., 2000; Fuchs et al., 2007; Goldberg et al., 2004). Tumor 
therapeutic response to neoadjuvant chemotherapy is assessed using radiological techniques (CT, 
PET-CT, or MRI) following conclusion of neoadjuvant chemotherapy (after 1.5-2 months) and 
before surgery (Habr-Gama et al., 2010) (Figure 5).  
 
Figure 5. Tumor therapeutic response is not assessed until nearly 2 months 
following chemotherapy initiation 
 
However, several studies have shown that therapeutic response can, in fact, be assessed 
on a scale of days, rather than months, using a variety of methods. However, most methods lack 
practicality as routine clinical applications (Park et al., 2014). Therefore, one branch of CRC 
research is devoted to developing clinically-translatable methods to rapidly assess (within 72 
hours following therapy initiation) whether a therapy regimen is effective on a per patient basis 
(Berger et al., 2017; Roblyer et al., 2011). A second branch is devoted to exploring 
immunotherapy, a broad term for any treatment that modulates the host immune system to fight 
cancer, to compliment neoadjuvant chemotherapy and increase rates of pCR and decrease rates 
of distal recurrence (Boland et al., 2017; Walker et al., 2014; Bouvier et al., 2015; Xiang et al., 
2014). The research in this proposal exists at the interface between these two branches. 
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1.1.5 Effects of chemotherapy on colorectal cancer tumors 
Fluorouracil-based chemotherapy, especially 5-fluorouracil (5-FU) used in the FOLFOX 
regimen (combined 5-FU, leucovorin, and oxaliplatin), has been a staple in CRC treatment for 
nearly 60 years (Noordhuis et al., 2004; Monteil et al., 2009), with leucovorin and oxaliplatin 
becoming standard in first-line chemotherapy in the early-to-mid 2000’s after successful Phase 
III clinical trials (Jeon et al., 2011; Wolmark et al., 1999; de Gramont et al., 2000; Andre et al., 
2003; Goldberg et al., 2004). In the body, 5-FU is converted to fluorodeoxyuridine 
monophosphate (FdUMP). FdUMP forms a complex with thymidylate synthase (TS), an enzyme 
that catalyzes deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP), which is a DNA monomer and key for DNA replication. Thus, 5-FU-
mediated depletion of dTMP results in cytotoxicity and apoptosis in the rapidly growing cells in 
CRC (Zhang et al., 2008).  
1.1.6 Immunotherapy in colorectal cancer 
Immunotherapy is an emerging approach to treat a variety of cancers by modulating the 
immune system. Although the pathogenesis of CRC is well understood, the effects of 
immunotherapy on the TME is less understood (Boland et al., 2017). Immunotherapy, in general, 
can fall into one of several categories: 1) adoptive cell transfer therapy (ACT) (Rosenberg et al., 
2008), 2) monoclonal antibody (mAb) therapy (Weiner et al., 2009), 3) immune checkpoint 
inhibitors (Dine et al., 2017; Jacobs et al., 2015), 4) cancer vaccines (Guo et al., 2014), and 5) 
cytokine-targeted immunotherapy (Lee et al., 2011; Waldmann, 2017). The immunotherapy 
focus of this proposal is on cytokine-targeted immunotherapy; for brevity and focus, other 
categories of immunotherapy are not discussed. Several mAb immunotherapy drugs are FDA 
approved for CRC, including nivolumab (Mehrvarz Sarshekeh et al., 2018) and pembrolizumab 
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(Birendra et al., 2017), as well as ipilimumab, which is currently under FDA priority review. 
Other drugs such as durvalumab and tremelimumab, also mAbs, are undergoing clinical trials 
(Grierson et al., 2017). The mAb immunotherapy drugs have been a breakthrough for treating 
MSI-high metastatic CRC (Grierson et al., 2017), one of several subtypes of CRC (Guinney et 
al., 2015). However, this subtype is estimated to represent less than 20% of all CRC cases 
(Guinney et al., 2015; Boland et al., 2011). Thus, there has been renewed research interest in 
cytokine-targeted immunotherapy to compliment neoadjuvant chemotherapy regimens to capture 
a wider variety of patients (Lynch et al., 2016). Whereas most cancers have, in general, 
benefitted from immunotherapeutics, CRC, aside from MSI-high metastatic CRC, has not 
(Boland et al., 2017). One overarching hypothesis as to why CRC has benefitted less from 
immunotherapy compared to other cancers is the controversial role of tumor-associated 
macrophages (TAMs) in the TME (Erreni et al., 2011).  
1.1.7 Tumor-associated macrophage controversy in colorectal cancer 
TAMs, the most abundant immune cell in the TME, also have the most substantial and 
pervasive effect of any immune cell in the TME (Allavena et al., 2008; Chen et al., 2005; Erreni 
et al., 2011; Marech et al., 2016). In CRC, TAMs have been shown to have both anti-tumor and 
pro-tumor functions, depending on whether they are polarized more towards an M1 (classical) or 
M2 (alternative) phenotype and their physical location within the tumor (Marech et al., 2016). 
CRC cells, independent of sub-type (Lim et al., 2016; Becht et al., 2016), recruit circulating 
monocytes via chemotaxis to the TME through monocyte chemoattractant protein-1 (CCL2), a 
highly elevated chemokine in CRC (Marech et al., 2016; Chun et al., 2015; Becht et al., 2016; 
Lim et al., 2016). Monocytes differentiate into M2-polarized TAMs through a variety of 
cytokines and chemokines including IL-4, IL-10, IL-13, CSF-1, CSF2 (primary cytokine 
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responsible for monocyte-TAM differentiation), CCL2, CXCL12, TGFα, MFG-E8, and MIF 
produced by CRC cells, helper T-cells, regulatory T-cells, mesenchymal stem cells, and 
previously differentiated TAMs (Liu et al., 2015). CCL2 is primarily responsible for monocyte 
recruitment, which leads to TAM infiltration into the TME. Broad anti-tumor functions of 
classically activated M1-polarized TAMs include inflammation and immune response (Funada et 
al., 2003; Sugita et al., 2002; Zhou et al., 2010). On the other hand, pro-tumor functions of 
alternatively activated M2-polarized TAMs include tumor growth, angiogenesis, 
immunosuppression, and matrix remodeling (Liu et al., 2015) (Figure 6).  
 
Figure 6. TAMs in CRC generally have pro-tumor functions. Image of 
macrophage sourced from the Library of Science Medical Figures by 
somersault1824, which are free to share, copy, and redistribute under Create 
Commons License CC BY-NC-SA 4.0. 
 
For tumor growth and angiogenesis, TAMs release a variety of pro-angiogenic growth 
factors (GFs) including VEGF, PDGF, EGF, FGF, TGF-β, MMP9, CXCL8, IL-1, IL-6, and IL-8 
(Liu et al., 2015). Additionally, TAMs suppress the activity of cytotoxic (CD8+) T-cells, whose 
otherwise elevated expression is associated with increased 5-year survival in CRC patients (Ziai 
et al., 2018), by releasing immunosuppressive factors including IL-10, TGF-β, CCL17, CCL18, 
CCL22, and PGE2 (Liu et al., 2015). For matrix remodeling, TAMs release a variety of 
proteolytic enzymes called matrix metalloproteases (MMPs) which allow for tumor expansion 
and release of ECM-sequestered pro-angiogenic GFs. Finally, TAMs release a variety of 
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cytokines such as IL-10, CXCL12, and MIF that help differentiate monocytes into TAMs 
(Marech et al., 2016; Erreni et al., 2011; Barbera-Guillem et al., 2002; Burmeister et al., 2017; 
Ucuzian et al., 2011). It has recently been shown that macrophages induce resistance to 5-FU 
chemotherapy, and that this TAM-induced resistance may contribute to the heterogenous patient 
response to chemotherapy (Zhang et al., 2016; Zhang et al., 2008). Currently, a gap in CRC 
research is how cytokine-targeted immunotherapy affects tumor-associated macrophages in the 
colon TME. Furthermore, does altering TAM population impact tumor response to 
chemotherapy? If so, can this impact be quantified by clinically translatable tools on a scale of 
days rather than months after treatment initiation? 
1.1.8 Current methods to assess tumor response to therapy 
This study proposes using DRS as a tool to monitor early tumor therapeutic response to 
chemotherapy and CCL2-targeted immunotherapy. However, other methods to quantify 
therapeutic response do exist. Clinically, after initiation of neoadjuvant chemotherapy, tumor 
response is not assessed for nearly 2 months using radiological imaging methods (Kim et al., 
2015; Habr-Gama et al., 2010). There are several solutions to this problem, all with advantages 
and disadvantages. One clinical assessment tool is quantifying carcinoembryonic antigen (CEA), 
a cell adhesion glycoprotein elevated in the blood of CRC patients that correlates with tumor 
stage. However, this test, although widely used and inexpensive, is non-specific does not 
sufficiently predict positive responders to therapy (Dreyer et al., 2017). Many biomarkers, such 
as p53, Ki67, and VEGF, are under investigation to correlate with initial tumor response, but the 
literature shows conflicting results (Kim et al., 2015). Both cancer stem cell markers (CD133, 
CD44, and CD24) and gene expression profiling show promising results for predicting tumor 
response, although it is generally agreed that these methods have several practical limitations in 
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clinical practice despite high potential for elucidating the complex genetic response of CRC 
(Kim et al., 2015). On the other hand, several optical and spectroscopic methods have shown 
promise in assessing tumor response after neoadjuvant chemotherapy. Several diffuse 
spectroscopy-based studies have shown a significant increase in oxyhemoglobin, or 
concentration of oxygen-bound heme in blood (Stadler et al., 2008), within one day after starting 
neoadjuvant chemotherapy (Figure 7).  
 
Figure 7. DRS is a clinically translatable & complimentary tool that can quantify 
oxy-hemoglobin flare (tumor response) to guide clinicians in modifying or ceasing 
treatment. 
 
This increase, referred to as the “oxyhemoglobin flare,” was shown in patients with 
partially or pathologically complete responding tumors but not in nonresponding patients 
(Roblyer et al., 2011). The oxyhemoglobin flare has been extensively shown by the Tromberg 
group in clinical trials of locally advanced breast cancer patients receiving neoadjuvant 
chemotherapy (Falou et al., 2012; Ueda et al., 2013; Tromberg et al., 2017). However, a gap in 
research is that the oxyhemoglobin flare has not been quantified after combinatorial 
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chemotherapy and immunotherapy, and furthermore, has not been quantified in CRC tumors. 
DRS is a probe-based spectroscopy tool, operating under the same principals as described in the 
above studies, with the ability to accurately assess oxyhemoglobin in vivo (Chin et al., 2017; 
Rajaram, Gopal, et al., 2010; Rajaram et al., 2016; Jayanthi et al., 2011; Greening, Rajaram, et 
al., "Multimodal Imaging and Spectroscopy Fiber-Bundle Microendoscopy Platform for Non-
Invasive, in Vivo Tissue Analysis," 2016; Greening, James, et al., 2016; Greening, Rajaram, et 
al., "In Vivo Measurement of Non-Keratinized Squamous Epithelium Using a Spectroscopic 
Microendoscope with Multiple Source-Detector Separations," 2016; Hennessy et al., 2015; 
Glennie et al., 2015; Yu et al., 2014; Glennie et al., 2014; Karsten et al., 2013; Spliethoff et al., 
2014). In the past decade, there have been 6 clinical trials using DRS in CRC (Jermyn et al., 
2017; Tanis, Evers, et al., 2016; Spliethoff et al., 2016; Tanis, Spliethoff, et al., 2016; Wang et 
al., 2009; Douplik et al., 2010). However, all trials focus on early cancer diagnostics and 
intraoperative surgical guidance, rather than tracking tissue response to therapy. Thus, our group 
believes that non-invasively quantifying the oxyhemoglobin flare following initiation of 
chemotherapy and cytokine-targeted immunotherapy via DRS is worth exploring.  
1.1.9 Significance of clinical health problem 
At present, there have been no studies correlating tumor perfusion response (via clinically 
translatable DRS) with biological correlates, such as TAMs and associated cytokines, in the 
TME following combinatorial cytokine-targeted immunotherapy and chemotherapy in a mouse 
model of CRC. We expect that DRS can potentially be used in the clinic to monitor the 
oxyhemoglobin flare in colon tumors of patients in response to neoadjuvant therapy initiation 
(Fig. X). We have built and validated a DRS platform that can monitor the oxyhemoglobin flare 
in response to therapy initiation in a mouse model of CRC. We note that, although we have 
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claimed DRS is potentially clinically translatable (i.e. fits through the biopsy port of a standard 
colonoscope with minimal interference with established clinical workflow), the specific DRS 
platform used in this study is not translatable since we hope to quantify daily perfusion metrics in 
mouse subcutaneous tumor allografts, which necessarily require a larger probe size.  
1.1.10 Research perspectives of diffuse reflectance spectroscopy 
DRS has been received favorably in the clinical management of certain cancers such as 
breast and skin cancer, pioneered in part by the Tromberg and Tunnell groups, respectively 
(Tromberg et al., 2017; Ueda et al., 2013; Roblyer et al., 2011; Shah et al., 2004; Hennessy et 
al., 2015; Bish et al., 2014; Sharma et al., 2014; Bish et al., 2011; Rajaram, Reichenberg, et al., 
2010; Rajaram, Aramil, et al., 2010). Adoptability in CRC has been milder, although the 
Richards-Kortum group has done a lot of work with microendoscopy imaging systems 
compatible with the biopsy port of standard colonoscopes (Parikh et al., 2014; Chang et al., 
2013) or upper GI endoscopes (Muldoon et al., 2011; Muldoon et al., 2010; Muldoon et al., 
2008; Muldoon et al., 2007; Pierce, Schwarz, et al., 2012; Pavlova et al., 2009; Schwarz et al., 
2008). DRS systems, which can be of comparable physical size to microendoscopes, have also 
been integrated with colonoscopes in clinical research studies (Schols et al., 2015). In fact, future 
studies in the Translational Biophotonics and Imaging Laboratory at the University of Arkansas 
will explore DRS in a colonoscope in an orthotopic mouse model of CRC. Although physically 
feasible, clinical adoptability of DRS (i.e. integration of DRS within standard colonoscopy 
workflow) is not yet scientifically justified. Therefore, one goal of my PhD work was to lay the 
foundation for our laboratory to be a pioneer in compiling evidence to justify using DRS in the 
clinical management of CRC. In addition to DRS, long-term clinical prospects of cytokine-
targeted immunotherapy are promising. Neutralizing antibodies for specific cytokines involved 
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in pro-tumor pathways have shown therapeutic activity in both murine models and in several 
human cancers. Several research groups are engineering innovative targeted cytokine delivery 
approaches to reduce systemic toxicity. Overall, cytokine-targeted immunotherapy will continue 
to be an active cancer research field (Lee et al., 2011; Waldmann, 2017). This research 
capitalizes on this prospect and will help clarify how blocking of several key intercellular 
communication pathways affects certain aspects of the colon TME and tumor therapeutic 
response. 
1.1.11 Murine subcutaneous allograft model of colorectal cancer 
In the studies reported in this dissertation, Balb/c mice were subcutaneously injected with 
CT26 cells in sterile saline (Figure 8). CT26 cells are colon carcinoma cells derived from the 
Balb/c mouse strain. CT26 cells were originally induced in 1975 via N-nitroso-N-
methylurethane-(NNMU) and are an undifferentiated cell line (Ojo-Amaize et al., 2007). The 
CT26 cell line is currently one of the most common models of murine CRC. As such, Balb/c 
mice were chosen as the host organism since CT26 cells were originally derived from this mouse 
strain (Castle et al., 2014). A 2014 genomic report verified that subcutaneous CT26 tumor 
allografts in Balb/c mice have gene expression profiles similar to sporadic, undifferentiated, and 
metastatic human CRC (Castle et al., 2014) and are a valid model for an in vivo CRC test 
system.     
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Figure 8. Balb/c mice were the model organization for the studies presented here. 
CT26 cells were injected subcutaneously into the left flank to form colon tumor 
allografts. Image of mouse and syringe sourced from the Library of Science 
Medical Figures by somersault1824, which are free to share, copy, and 
redistribute under Create Commons License BY-NC-SA 4.0. 
 
1.2 Engineering focus: diffuse reflectance spectroscopy 
1.2.1 Introduction to diffuse reflectance spectroscopy platforms 
In this dissertation, we have engineered three DRS systems (Figure 9); however, only two 
systems were used for data collection in this dissertation. The first system, described in detail in 
Chapter 2 and briefly in Chapter 3, combines DRS with fiber-based high-resolution 
microendoscopy (HRME) (Figure 9, acf). This system was used for initial feasibility testing to 
investigate a combined DRS-HRME system and was tested on various in vitro and human in vivo 
platforms. Additionally, a novel third modality was included, diffuse reflectance intensity 
mapping (DRIM), although this modality was only briefly explored in Chapter 2. The second 
system, described in detail in Chapters 4-6, is a uni-modal DRS system that was optimized to 
quantify tissue optical parameters in subcutaneous colon tumors in mice (Figure 9, abe). This 
system was designed to test the feasibility of using DRS as a method to quantify tumor 
therapeutic response to chemotherapy and immunotherapy. A third DRS system, described 
briefly in the overall discussion (Chapter 7), is a combined DRS-HRME system optimized to fit 
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within the biopsy port of a small animal colonoscope to test the feasibility of using combined 
DRS-HRME as a method to monitor tumor therapeutic response in orthotopic murine colorectal 
tumors (Figure 9, adg). The engineering of this third system was pioneered by Ariel Mundo of 
the Translational Biophotonics and Imaging Laboratory (Muldoon Lab), while I served as a 
technical advisor based on my previous DRS experience.  
 
Figure 9. In this dissertation, we have engineered three DRS systems (a). The 
first system (c, f) was used for initial feasibility testing to investigate a combined 
DRS-HRME system and was tested on various in vitro and human in vivo 
platforms. The second system (b, e) was designed to test the feasibility of using 
DRS as a method to quantify tumor therapeutic response to chemotherapy and 
immunotherapy in the Balb/c-CT26 subcutaneous model of CRC. The third 
system (d, g) is a combined DRS-HRME system optimized to fit within the 
biopsy port of a small animal colonoscope to test the feasibility of using 
combined DRS-HRME as a method to monitor tumor therapeutic response in 
orthotopic murine colorectal tumors. Photo and 3D renderings of probe taken and 
created by the author. 
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1.2.2 High-resolution microendoscopy 
HRME will be briefly described here since it is used as an imaging modality for two of 
the three DRS systems. HRME is a non-invasive diagnostic imaging technique that provides sub-
cellular resolution images of tissue in vivo. Tissue samples are topically stained with a 
fluorescent contrast agent like proflavine, an acridine-derive fluorescent dye that intercalates 
DNA. Proflavine highlights cell nuclei with appropriate excitation light to allow visualization of 
morphological features (Muldoon et al., 2007; Pierce, Guan, et al., 2012; Pierce et al., 2011; 
Quinn et al., 2012; Chang et al., 2013; Keahey et al., 2015; Parikh et al., 2014; Prieto et al., 
2015). Other contrast agents, such as benzoporphyrin-derivative monoacid ring A (BPD-MA) 
and fluorescein, have also been investigated for similar purposes (Pierce et al., 2011). Generally, 
excitation light is delivered to the specimen though a coherent image fiber consisting of tens of 
thousands of individual fibers. The image fiber is placed in direct contact with tissue to excite 
fluorescent contrast agent and resultant fluorescence is collected by the same image fiber. Lateral 
and axial resolution are approximately 4 and 20 µm, respectively, with variable fields-of-view 
depending on the diameter of the image fiber and any distal optics. The primary advantages of 
HRME are low cost and portability, making this technique clinically translatable (Muldoon et al., 
2007; Muldoon et al., 2011; Parikh et al., 2014; Chang et al., 2013; Quinn et al., 2012; Pierce, 
Guan, et al., 2012; Keahey et al., 2015; Pierce et al., 2011). Development of these systems has 
led to clinical studies in the upper and lower gastrointestinal tracts (Muldoon et al., 2007; 
Muldoon et al., 2011; Parikh et al., 2014; Chang et al., 2013) and cervix (Quinn et al., 2012; 
Pierce, Guan, et al., 2012; Keahey et al., 2015). However, a limitation of HRME is insufficient 
depth resolution, minimizing effectiveness in detecting dysplastic changes in the sub-epithelial 
microenvironment. Only cells on the topmost 20 µm can be visualized and thus some 
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information is lost that would normally be apparent with histopathological analysis (Keahey et 
al., 2015; Muldoon et al., 2007; Muldoon et al., 2011). While other microendoscopy methods, 
such as laser scanning confocal systems, are able to perform axial optical sectioning to resolve 
cellular structures below the surface, these systems require the use of complex galvanometer or 
microelectromechanical (MEMS)-based approaches to raster scan the excitation source across 
the surface of the tissue (Rivera et al., 2011; Piyawattanametha et al., 2010; Chen et al., 2015). 
Fiber bundle microendoscopy, as described in this manuscript, does not include these features in 
favor of increased robustness and decreased cost. An additional limitation of HRME is its 
inability to quantify changes in tissue scattering and absorption (Muldoon et al., 2007; Pierce, 
Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Chang et al., 2013; Keahey et al., 
2015; Parikh et al., 2014). Thus, HRME techniques could benefit from additional quantitative 
and depth sensitive modalities.  
1.2.3 Diffuse reflectance spectroscopy 
Recent work has described DRS, which uses short source-detector separations (SDS) 
(less than 1 mm) to non-invasively interrogate deeper within epithelia and quantify optical 
properties (Kanick et al., 2014; Kanick et al., 2009; Hennessy et al., 2014; Jayanthi et al., 2011; 
Zonios et al., 1999; Marin et al., 2005; Rajaram, Reichenberg, et al., 2010). Optical properties 
depend on tissue morphology and can provide a means to quantify dysplastic changes (Jayanthi 
et al., 2011). More specifically, broadband DRS has been used in multiple clinical studies 
including quantifying hemoglobin absorption to distinguish between different grades of oral 
cancer (Jayanthi et al., 2011), distinguishing between adenomatous colon polyps and normal 
tissue (Zonios et al., 1999), diagnosing cervical dysplasia in vivo (Marin et al., 2005), and 
quantifying changes associated with non-melanoma skin cancer (Rajaram, Reichenberg, et al., 
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2010). These studies have shown that DRS can be a useful, non-invasive method to quantify the 
health of small volumes of tissue although the ability to resolve fine cellular detail with 
spectroscopy is non-existent (Rajaram, Reichenberg, et al., 2010; Marin et al., 2005; Zonios et 
al., 1999; Jayanthi et al., 2011). DRS is used in this study because it can indicate tumor 
perfusion, which is affected by treatment with chemotherapy and immunotherapy. Alteration of 
the monocyte and TAM population in the colon TME via cytokine-targeted immunotherapy is 
hypothesized to alter downstream pro-angiogenic signals (Liu et al., 2015). As tumors grow, 
they require an adequate oxygen supply, nutrients, and the ability to remove waste such as CO2, 
catabolites, and other toxins (Cuenod et al., 2013). Angiogenesis is a normal process of new 
blood vessel formation from already existing nearby blood vessels, and is utilized by tumors to 
meet their growing metabolic demands (Nishida et al., 2006; Dighe et al., 2012). Angiogenesis is 
known to increase tumor perfusion, defined as blood flow through the tumor’s circulatory 
network (Cuenod et al., 2013). Functional changes in angiogenesis-induced perfusion occur prior 
to structural/morphological changes, such as tumor growth (Cuenod et al., 2013; Hu et al., 
2007). It is well known that tumor perfusion is a strong predictor of therapeutic response to 
chemotherapy. Delivery of cytotoxic drugs, such as 5-FU, and availability of oxygen are critical 
factors in inducing apoptosis of colon tumor cells (Turley et al., 2012). DRS is a probe-based 
technique that can measure bulk tumor perfusion. DRS has several advantages including ability 
to quantify the functional oxyhemoglobin flare (as a quantifier of early perfusion) and tissue 
optical properties, non-invasiveness, depth-sensitivity, potential for clinical translation, ease-of-
implementation in the laboratory, and scalability (physical size) for different tissue types in 
question. Because of the inherent scalability and adaptability of DRS, each DRS system and 
probe must be extensively calibrated to extract accurate perfusion metrics. This aim focuses on 
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validating a DRS platform for in vivo assessment of tissue perfusion and quantification of tissue 
optical properties, all of which may be affected by chemo- and/or immunotherapy-induced 
changes to the TME. Fundamental tissue optical properties are the reduced scattering coefficient 
(μs’), which depends on light scattering from cell nuclei, lipid membranes of cells and organelles, 
keratin (in skin), and collagenous, elastic, and reticular fibers (Lister et al., 2012; Arifler et al., 
2007; Kumka et al., 2012; Sandell et al., 2011), and absorption coefficient (μa), which depends 
on hemoglobin concentration ([Hb]) and oxygen saturation (SaO2) (Prahl, 2015; Greening, 
James, et al., 2016; Rajaram, Reichenberg, et al., 2010; Rajaram, Aramil, et al., 2010; Rajaram, 
Gopal, et al., 2010; Rajaram et al., 2008). The μa also relies on melanin, fat, and water, although 
these physiological parameters are not quantified in this study (Spliethoff et al., 2014; Prahl, 
2015). A mobile, all-inclusive spectroscopy suite, which integrates with all three custom DRS 
probes, was created to monitor in vivo tissue properties (Figure 10).  
 
Figure 10. DRS setup for in vivo measurements on tissue or tissue-simulating 
phantoms. Photo taken by the author. 
 
Bulk, volume-averaged tumor perfusion was optically quantified by DRS-derived 
oxyhemoglobin (product of total hemoglobin concentration and tissue oxygen saturation). The 
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post-processing DRS software to quantify µs’ and µa is based on the damped least-squares fitting 
method, in which a curve is iterated to “best-fit” the raw spectra. Based on the best-fit curve, µs’ 
and µa experimental values are extracted. Once µa is accurately quantified, THC and StO2 of in 
vivo tissue can be derived (process described in detail in Chapters 2 and 4). 
1.3 Diffuse reflectance physics 
1.3.1 Turbid media 
DRS is one a simple and widely used technique for non-invasively studying biological 
tissues. All biological tissues, including colorectal and CRC tissue, are considered turbid media 
(Zonios et al., 2011). But what is exactly meant by the term, turbid media? Turbid media is any 
medium which has significant scattering due to randomly distributed optical nonuniformities. A 
light wave/photon contacting or passing through the turbid media will change direction based on 
the index of refraction throughout the medium (Figure 11). A photon will continue scattering 
throughout the turbid media until it is absorbed by an absorber or is transmitted or diffusely 
reflected from the media. Light propagation through biological tissues can indicate the structural 
and functional makeup of the tissue due to scattering, absorption, and fluorescence events; 
however, light propagation through turbid media is a challenging problem (Romanov et al., 
2012).  
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Figure 11. An oversimplification of the movement of photons through turbid 
media. Photons can be scattered by scattering agents (white circles) or absorbed 
by absorbing agents (red circles). Image created by the author. 
 
Light propagation in tissue can be fully described by the radiative transport equation 
(RTE). The RTE states that the total radiance for photons traveling in a specific direction through 
time and space is equal to the sum of all sources that affect (increase or decrease) radiance. 
Radiance is defined as the quantity of photons per unit volume. A more detailed description of 
the RTE can be found in numerous sources (Liemert et al., 2012; Liemert et al., 2014; Wilson et 
al., 2011). The RTE has been successfully used to model photon transport in turbid media. 
However, the RTE is mathematically and computationally intensive, and because of this, 
research has sought to create simpler models that approximate the RTE (Liemert et al., 2014; 
Liemert et al., 2012; Wilson et al., 2011; Kim et al., 2006; Kim, 2004; Kim et al., 2003). 
One such simplification used in biological tissues is the diffuse approximation. The 
diffusion approximation is a method that has been used to determine μs’ and μa in tissue (Wilson 
et al., 2011; Reif et al., 2007; Gibson et al., 2005; Kim, 2004; Kim et al., 2003). However, the 
diffusion approximation is only valid in turbid media if the following requirements are met: 1) 
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the μs’ must be much greater than the μa, and 2) large source-detector separations must exist 
(Reif et al., 2007). Some sources have also claimed that the diffusion approximation is not valid 
in media that exhibit anisotropic scattering (Gibson et al., 2005). These requirements ensure that 
any collected photons have traveled through large volumes of tissue. In turn, this ensures that 
extracted optical properties represent an accurate average of the real optical properties. However, 
in many cases, investigators used small endoscopy devices, to sample thin tissues with a small 
sampling depth. This is the case for dysplasia or cancers that are confined to the epithelium, 
which is only between 100-500 µm thick (Rajaram et al., 2008).  
Therefore, a distinction must be made between what is meant by the diffuse 
regime, in which the diffusion approximation is valid, and the sub-diffuse regime, in 
which the diffusion approximation is not valid (Reif et al., 2007; Subramanian et al., 
2007; Turzhitsky, Rogers, et al., 2010; Turzhitsky, Radosevich, et al., 2010; Bosschaart 
et al., 2011; Kanick et al., 2014). For many of the cases listed here, the validity of the 
diffusion approximation begins to fail for one of two reasons. The first reason is that μs’ 
is not much greater than μa (Reif et al., 2007; Turzhitsky, Radosevich, et al., 2010; 
Turzhitsky, Rogers, et al., 2010; Subramanian et al., 2007; Bosschaart et al., 2011). The 
μs’ is considered “not much greater” than the μa when albedo is less than 0.9 (Rajaram et 
al., 2008). The second reason the diffusion approximation begins to fail is the use of 
small source-detector separations common to small endoscopic probes. A source-detector 
separation is considered “small” if it is less than approximately one reduced mean free 
path (Rajaram et al., 2008; Subramanian et al., 2007; Bosschaart et al., 2011; Kanick et 
al., 2014). Therefore, although most “diffuse reflectance spectroscopy” is really “sub-
diffuse reflectance spectroscopy”, the term “sub-diffuse” will not be used for clarity. 
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1.3.2 Light scattering in turbid media 
There are two primary types of scattering: Rayleigh scattering and Mie scattering (Figure 
12). Simply, Rayleigh scattering refers to scattering by particles much smaller than the 
wavelength of light. Mie scattering refers to scattering by particles larger or of comparable size 
to the wavelength of light. However, it is more correct to say that all scattering is Mie scattering, 
and Rayleigh scattering is the Rayleigh limit of Mie scattering (Jacques, 2013). Biological tissue 
typically exhibits Mie scattering. In biological tissue, organelles such as mitochondria and cell 
nuclei are the primary scattering agents (Mourant et al., 1998). Striations in collagen fibrils are 
also responsible for scattering (Arifler et al., 2007). The magnitude of scattering is typically 
quantified with μs’, which can be measured with DRS. 
 
Figure 12. Rayleigh and Mie scattering in biological tissue (a turbid media). Mie 
scattering is the name for scattering by a sphere of any size, whereas Rayleigh 
scattering is a type of Mie scattering in which the scattering agents are much 
smaller than the wavelength of light (Jacques, 2013). Image created by the author. 
 
1.3.3 Light absorption in turbid media 
In addition to μs’, DRS can also measure μa. The μa depends on the concentration of 
absorbing agents in the biological tissue. In living systems, there are 5 primary absorbers 
spanning the ultraviolet to near-infrared spectrum (approximately between 300-2000 nm): 
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melanin, oxygenated hemoglobin, deoxygenated hemoglobin, fat, and water. The normalized μa 
of these 5 absorbers are shown in Figure 13 (Prahl, 2015).  
 
Figure 13. Normalized absorption coefficients of melanin, oxygenated 
hemoglobin, deoxygenated hemoglobin, fat, and water in biological tissues. 
Graph created by the author using data by Scott Prahl (Prahl, 2015). 
 
Our studies report absorption in the visible and very near-infrared spectrum (~450 
to 800 nm). Therefore, in the following studies for this dissertation, water is not looked at 
because absorption is negligible below 1400 nm. Melanin is not analyzed since albino 
mice (Balb/c) were used as the test subjects. Additionally, some studies were done in the 
oral mucosa of health human volunteers – oral mucosa does not contain melanin. Finally, 
fat was not analyzed because, although fat does contribute slightly to absorption in the 
visible to near-infrared spectrum, it is negligible compared to the two primary absorbers, 
oxygenated and deoxygenated hemoglobin. Figure 14 shows the absolute μa of 
oxygenated and deoxygenated hemoglobin in whole blood compared to the μa of fat 
(Prahl, 2015; Greening, James, et al., 2016; Greening, James, et al., 2015; Greening et 
al., 2018; Greening, Powless, et al., 2015).  
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Figure 14. Absorption coefficients of melanin, oxygenated hemoglobin, and 
deoxygenated hemoglobin below 1000 nm. Graph created by the author using 
data by Scott Prahl (Prahl, 2015). 
 
1.4 Concluding remarks to introduction 
Chapters 2 and 3 represent specific aims 1 and 2, respectively. Aim 3, on the other hand, 
is longer, and consists of chapters 4, 5, and 6. The following aims were designed to address the 
investigation and optimization of using DRS as a technique to monitor in vivo tissue health and 
tumor therapeutic response, specifically in murine colon cancer.      
1.5 Specific Aims 
The overall health focus of this dissertation is CRC. Murine subcutaneous allografts were 
used as a model for CRC. Specifically, for my dissertation work, I looked at murine 
subcutaneous CRC allografts as a model for CRC from two angles. First, can DRS be used as a 
platform to monitor tumor therapeutic response in this CRC tumor model? Second, does 
treatment with standard chemotherapy and macrophage-targeted immunotherapy alter the TME? 
Combining these two angles (Figure 1), do these TME alterations correlate with DRS data? 
Before DRS was implemented in the scientific investigation of therapy response in 
murine subcutaneous CRC allografts, the first step (Aim 1) was to engineer and characterize a 
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DRS probe for in vivo tissue analysis. The second step (Aim 2) was to design tissue-simulating 
phantoms with tunable optical properties to test the sensitivity of our probe to phantom-based, 
sub-surface optical heterogeneities. Additionally, this phantom design sparked a non-DRS-based 
collaboration with Boston University who used these phantoms to improve longitudinal 
preclinical tumor imaging in the spatial frequency domain (Tabassum et al., 2018). The third 
step (Aim 3) was to develop the murine subcutaneous CRC allografts, optimize probe design for 
subcutaneous tumor allografts, test isoflurane anesthesia as a potential confounding variable, and 
implement DRS in a longitudinal study on treating mice with chemotherapy and macrophage-
targeted immunotherapy to see how this therapy would affect DRS results.  
Specific Aim 1: Design and characterization of broadband diffuse reflectance spectroscopy 
probes for in vivo tissue analysis 
Publications: 
▪ Greening GJ, Powless AJ, Hutcheson JA, James HM, Dierks MK, Rajaram N, Muldoon 
TJ, “Fiber-bundle microendoscopy with sub-diffuse reflectance spectroscopy and 
intensity mapping for multimodal optical biopsy of stratified epithelium,” Biomedical 
Optics Express, 6(12), (2015). 
▪ Greening GJ, James HM, Dierks MK, Vongkittiargorn N, Osterholm SM, Rajaram N, 
Muldoon TJ. “Towards monitoring dysplastic progression in the oral cavity using a 
hybrid fiber-bundle imaging and spectroscopy probe,” Scientific Reports, 6(26734), 
(2016). 
▪ Greening GJ, Rajaram N, Muldoon TJ. “Multimodal imaging and spectroscopy fiber-
bundle microendoscopy platform for non-invasive in vivo tissue analysis,” Journal of 
Visualized Experiments, 116, (2016). 
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Background: Early detection of structural or functional changes in dysplastic epithelia is crucial 
for improving long-term patient care. Recent work has explored non-invasive or minimally 
invasive optical biopsy techniques for diagnosing early dysplasia, such as HRME, a method to 
resolve sub-cellular features of apical epithelia, as well as DRS, a method that evaluates bulk 
health of a small volume of tissue. It is possible that the high-resolution imaging modality may 
be beneficial in providing image data of later stage moderate and severe dysplasia while the DRS 
modality may be sensitive to tissue optical changes associated with early dysplasia. 
Objective: Develop and validate a quantitative hybrid imaging and spectroscopy microendoscope 
to monitor dysplastic progression within epithelial tissues. Co-registration of both techniques is 
important because this technique can be potentially used to not only detect dysplasia using two 
different modalities, but also to monitor personalized response of sub-surface dysplastic lesions to 
anti-tumor therapy at multiple source-detector separations.  
Central Hypothesis: High-resolution microendoscopy and DRS can be combined within a single 
optical probe to co-register image and spectral data of in vivo epithelia. 
Significance: With this multimodal system, epithelial morphological data can be correlated with 
quantitative spectroscopy data of the subsurface microenvironment, including associated optical 
properties. This multimodal microendoscopy approach encompasses both structural and 
spectroscopic reporters of perfusion within the tissue microenvironment and can potentially be 
used to monitor tumor response to therapy. This hybrid imaging and spectroscopy platform may 
be capable of collecting a wealth of information about the structural and functional properties of 
tissue at various imaging sites in ex vivo and in vivo models.  The potential of this technique to be 
coupled to the biopsy port of a conventional endoscope makes further clinical translation and 
complimentary optical biopsy in the oral cavity and other epithelial tissues feasible.  
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Specific Aim 2: Characterization of poly(dimethylsiloxane)-based tissue-simulating 
phantoms with tunable reduced scattering and absorption coefficients with applications for 
diffuse reflectance spectroscopy 
Publications: 
▪ Greening GJ, Istfan R, Higgins LM, Balachandran K, Roblyer D, Pierce MC, Muldoon 
TJ, “Characterization of thin poly (dimethylsiloxane)-based tissue simulating phantoms 
with tunablereduced scattering and absorption coefficients at visible and near infrared 
wavelength,” Journal of Biomedical Optics, 19(11), (2014). 
▪ Greening GJ, James HM, Muldoon TJ. “Optical Phantoms: Diffuse and sub-diffuse 
imaging and spectroscopy validation,” SPIE Spotlights, (2015). 
▪ Tabassum S, Pera V, Greening GJ, Muldoon TJ, Roblyer D. “Two-layer inverse model 
for improved longitudinal preclinical tumor imaging in the spatial frequency domain,” 
Journal of Biomedical Optics, 23(7), (2018). 
Background: Optical phantoms are used in the development of various imaging systems. For 
certain applications, the development of thin phantoms that simulate physical size and optical 
properties of tissue is important. 
Objective: Here, we demonstrate a method for producing thin phantom layers with tunable 
optical properties using poly(dimethylsiloxane) (PDMS) as a substrate material at six discrete 
wavelengths (591, 631, 659, 691, 731, and 851 nm) at varying concentrations of titanium dioxide 
and nigrosin. 
Central Hypothesis: Thin, PDMS-based optical phantoms can accurately simulate the geometry 
and optical properties of target epithelia, and can be used to tst the sensitivity of various imaging 
and spectroscopy equipment to heterogeneities.  
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Significance: From the presented data, we provide lookup tables to determine appropriate 
concentrations of scattering and absorbing agents to be used in the design of PDMS-based 
phantoms with specific optical coefficients. In addition, heterogeneous phantoms, mimicking the 
layered features of certain tissue types, may be fabricated from multiple stacked layers, each with 
custom optical properties. These thin, tunable PDMS optical phantoms can simulate many tissue 
types and have broad imaging calibration applications in endoscopy, diffuse optical spectroscopic 
imaging (DOSI), or optical coherence tomography (OCT), among others.  
Specific Aim 3: Optical property quantification of subcutaneous murine colon carcinoma 
tumors in response to chemotherapy and macrophage-targeted immunotherapy measured 
using diffuse reflectance spectroscopy 
Publications: 
▪ Greening GJ, Mundo AI, Rajaram N, Muldoon TJ. “Sampling depth of a diffuse 
reflectance spectroscopy probe for in vivo physiologic quantification of murine 
subcutaneous tumor allografts,” Journal of Biomedical Optics, 23(8), (2018). 
▪ Greening GJ, Miller KP, Spainhour CR, Cato MD, Muldoon TJ. “Effects of isoflurane 
anesthesia on physiological parameters in murine subcutaneous tumor allografts 
measured via diffuse reflectance spectroscopy,” Biomedical Optics Express, 9(6), (2018).  
▪ Greening GJ, Bess SN, Muldoon TJ. “Immunohistochemistry staining for tumor-
associated macrophage polarization in murine subcutaneous colon tumor allografts,” Bio-
101, 3106, (2018). 
Background: (1) DRS is a probe-based spectral biopsy technique used in cancer studies to 
quantify tissue reduced scattering (μs’) and absorption (μa) coefficients and vary in source-
detector separation (SDS) to fine tune sampling depth. In subcutaneous murine tumor allografts 
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or xenografts, a key design requirement is ensuring the source light interrogates past the skin 
layer into the tumor without significantly sacrificing signal-to-noise ratio (target of ≥ 15 dB). 
Once this has been verified, DRS can be used in cancer allograft or xenograft studies, such as 
those subject to chemotherapy and/or immunotherapy regimens. (2) Immunotherapy in colorectal 
cancer (CRC) describes therapy that regulates specific immune checkpoints, and when used in 
combination with chemotherapy, can improve prognosis. One specific immune checkpoint is 
recruitment of circulating monocytes, which differentiate into tumor-associated macrophages 
(TAMs) and promote angiogenesis and tumor progression. Thus, immunotherapeutic strategies 
blocking monocyte recruitment may play an anti-tumor role. Vascularization can be non-
invasively assessed via DRS, which quantifies metrics such as hemoglobin concentration and 
oxygenation in a localized tumor volume. However, there have been no studies investigating the 
efficacy of DRS in evaluating therapeutic response of combined immunotherapy and 
chemotherapy. 
Objecive: (1) Design a DRS probe with four SDSs (0.75, 2.00, 3.00, and 4.00 mm) to interrogate 
increasing tissue volumes between 450-900 nm. The goal was to quantify percent errors in 
extracting μa and μs’, and to quantify sampling depth into subcutaneous Balb/c-CT26 colon 
tumor allografts. Using an optical phantom-based experimental method, lookup-tables were 
constructed relating μa, μs’, diffuse reflectance, and sampling depth. (2) Examine whether 
blockade of monocyte recruitment via anti-CCL2 (macrophage chemoattractant protein-1) leads 
to enhanced sensitivity of 5-FU (5-fluorouracil) therapy in a CT26-Balb/c mouse model of CRC, 
and whether this effect can be quantified via DRS. 
Central Hypothesis: The oxyhemoglobin flare has not been quantified after combinatorial 
chemotherapy and immunotherapy, and furthermore, has not been quantified in colon cancer 
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tumors. Can DRS be used to quantify the therapy-induced oxyhemoglobin flare in a mouse 
model of colon cancer? The central hypothesis is that tumors treated with immunotherapy will 
have increased tumor therapeutic response to chemotherapy, as measured via tumor size and 
DRS-derived metrics. 
Significance: This work shows that the DRS probe can accurately extract optical properties, and 
the resultant physiological parameters such as total hemoglobin concentration and tissue oxygen 
saturation, from sufficient depth within subcutaneous Balb/c-CT26 colon tumor allografts. 
Methods described here can be generalized for other murine tumor models. 
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Chapter 2 (Specific Aim 1): Design and characterization of broadband diffuse reflectance 
spectroscopy probes for in vivo tissue analysis  
 
2.1 Introduction 
Several recent non-invasive translational endoscopy-based techniques have aimed at 
improving cancer detection and monitoring tumor therapeutic response in both oral 
intraepithelial dysplasia and colon carcinoma.  
Intraepithelial dysplastic progression within the oral mucosa is a dynamic process that 
typically arises at the basement membrane and is classified into stages based on how far it has 
spread towards the upper epithelial layers (Zhu and Liu, 2011; Speight, 2007; Warnakulasuriya 
et al., 2008; Bouquot et al., 2006). For example, mild dysplasia occurs in the basal epithelial 
layers, directly above the basement membrane. As dysplasia progresses upwards towards the 
apical epithelial surface, the stages are characterized as moderate and severe (or carcinoma in-
situ), respectively (Speight, 2007; Warnakulasuriya et al., 2008; Bouquot et al., 2006). These 
stages are not considered invasive cancer since they have not yet penetrated the basement 
membrane and metastasized, although the severity of dysplasia increases this risk (Speight, 2007; 
Bouquot et al., 2006). It has been found that <5%, 3-15%, and >15% of patients with mild, 
moderate, and severe dysplasia, respectively, progressed to carcinoma (Speight, 2007; Bouquot 
et al., 2006). Oral squamous cell carcinoma (OSCC) is the most common form of this carcinoma 
in the oral cavity and patients diagnosed with OSCC have a 5-year survival rate of less than 60-
70% and this number decreases in developing countries (Speight, 2007; Davies et al., 2015; 
Cheng et al., 2015; Muldoon et al., 2011). This is because primary detection of dysplastic 
malignancies typically occurs upon visual inspection by non-specialized dentists, who then refer 
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patients to specialists (Davies et al., 2015; Brailo, 2015; Brocklehurst et al., 2015). Diagnoses at 
this point are often late-stage (Brailo, 2015). Therefore, detection of oral dysplasia at its various 
stages via affordable, available, and non-invasive techniques is crucial in limiting the number of 
cases that progress to OSCC. 
Gastrointestinal dysplasia is an abnormal but non-invasive proliferation of cells in the 
gastrointestinal epithelium that, when diagnosed, is assumed to progress to carcinoma (Sharma, 
2013; Speight, 2007). In the oral cavity and esophagus, dysplasia can potentially become 
squamous cell carcinoma (SCC) or adenocarcinoma, cancer of the stratified squamous 
epithelium or  columnar glandular cells, respectively (Speight, 2007). Most adenocarcinomas 
arise from dysplastic changes associated with Barrett’s esophagus, although SCC is more 
prevalent in the upper digestive tract worldwide (Zhang, 2013). In the colorectal region, 
dysplasia can form adenomatous polyps which become invasive upon penetration into the 
submucosa (Harpaz and Polydorides, 2010; Ponz de Leon and Di Gregorio, 2001). Dysplasia can 
also arise in the epithelia of other organs. For example, cervical dysplasia, which can be either 
squamous or columnar in origin, leads to increased risk of cervical cancer (Arends et al., 1998). 
Conventional practice for diagnosing dysplasia in the lumen of the gastrointestinal tract is 
endoscopy-guided biopsy with wide-field, broadband illumination followed by histological 
examination by a pathologist using hematoxylin and eosin (H&E) staining (Hwang and Shroyer, 
2012; Dacosta et al., 2002; Muldoon et al., 2011). However, diagnosis in this way may be 
subject to sampling errors and is subjective to the experience of the pathologist, potentially 
limiting reproducibility (Appelman, 2005; Dacosta et al., 2002; Muldoon et al., 2011).  
One such technique aimed at improving cancer detection and monitoring tumor 
therapeutic response is high-resolution microendoscopy, which can provide clinicians rapid, 
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high-resolution visualization of tissue architecture and histology when compared to that of the 
naked eye alone. These techniques provide a step towards point-of-care “optical biopsy,” 
potentially reducing the number of biopsies performed each year (Muldoon et al., 2011; Shukla 
et al., 2011). Preclinical and clinical studies using high-resolution microendoscopy techniques 
have been demonstrated in various body organs including the oral cavity (Muldoon et al., 2011; 
Pierce, Schwarz, et al., 2012), esophagus (Hur et al., 2015; Muldoon et al., 2008; Muldoon et al., 
2010; Shin et al., 2015), lower gastrointestinal tract (Carns et al., 2013; Chang et al., 2013; Elahi 
et al., 2011; Louie et al., 2014; Parikh et al., 2014; Prieto, Powless, Lai, et al., 2015), cervix 
(Pierce, Guan, et al., 2012; Quinn et al., 2012), ear (Campbell et al., 2010; Levy et al., 2013; 
Monfared et al., 2006), and liver and pancreas (Regunathan et al., 2012). Furthermore, several 
studies have developed high-resolution imaging techniques compatible with the biopsy port of 
conventional white-light endoscopes, making it more attractive for clinicians to adopt these new 
techniques (Muldoon et al., 2008; Shukla et al., 2011; Louie et al., 2014). Work has also been 
performed in quantifying high-resolution microendoscopy image data, but for the most part this 
remains a qualitative screening technique (Muldoon et al., 2010; Shin et al., 2015; Prieto, 
Powless, Lai, et al., 2015; Ishijimi et al., 2015). The advantages of high-resolution 
microendoscopy are low cost, portability, and instantaneous imaging of tissue architecture. 
However, a drawback of high-resolution microendoscopy is lack of depth sectioning, meaning it 
can only resolve tissue architecture at the apical epithelial surface. More complex 
instrumentation does exist to overcome this drawback, including laser scanning confocal 
systems, but this instrumentation requires galvanometers or microelectromechanical (MEMS)-
based technology to do so. Additionally, information gathered by these more complex depth-
sensitive technologies are primarily qualitative (Greening, James, Powless, et al., 2015; Rivera et 
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al., 2011; Chen et al., 2015; Piyawattanametha and Wang, 2010). High-resolution 
microendoscopy can thus benefit from additional depth sensitive modalities since mild and 
moderate dysplasia are often sub-epithelial surface phenomena, but relatively simple and 
quantitative techniques are desirable. 
One depth sensitive technique that has demonstrated diagnostic efficacy is diffuse 
reflectance spectroscopy (DRS), a well-established method capable of non-invasively 
quantifying volume-averaged tissue optical parameters using simple probe designs (Glennie et 
al., 2014; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram, Reichenberg, et 
al., 2010; Bish et al., 2014; Karsten et al., "Diffuse Reflectance Spectroscopy as a Tool to 
Measure the Absorption Coefficient in Skin: South African Skin Phototypes," 2013; Hennessy et 
al., 2013), Raw DRS data is given in terms of reflectance, that is, the percentage of light 
recovered from a detection fiber to light delivered by a source fiber. Studies have shown that 
volume-averaged optical properties, such as reduced scattering coefficient (µs’) and absorption 
coefficient (µa) can be determined from in vivo samples (Rajaram, Aramil, et al., 2010; Karsten 
et al., "Diffuse Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in 
Skin: South African Skin Phototypes," 2013; Rajaram et al., 2008; Karsten et al., "Diffuse 
Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: System 
Calibration," 2013; Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011; 
Pimenta et al., 2012; Nichols et al., 2015). It should be noted that these extracted values are 
based on the delivery and collection of light throughout an often inhomogeneous layered media, 
such as tissue, and extracted optical properties thus represent volume averaged, rather than 
axially resolved, values. Several in vivo DRS studies have extracted other clinically relevant 
optical parameters including blood volume fraction, hemoglobin concentration, oxygen 
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saturation, mean blood vessel diameter, nicotinamide adenine dinucleotide (NADH) 
concentration, and tissue thickness (Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; 
Rajaram, Reichenberg, et al., 2010; Bish et al., 2014; Lim et al., 2011; Nichols et al., 2012; 
Sharma et al., 2014; Sharma et al., 2013; Hennessy et al., 2015). Furthermore, DRS is an 
appealing non-invasive screening technique because it is sensitive to optical changes beneath the 
apical tissue layer (Glennie et al., 2014; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 
2010; Rajaram, Reichenberg, et al., 2010; Bish et al., 2014; Karsten et al., "Diffuse Reflectance 
Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: South African Skin 
Phototypes," 2013; Hennessy et al., 2013; Rajaram et al., 2008; Karsten et al., "Diffuse 
Reflectance Spectroscopy as a Tool to Measure the Absorption Coefficient in Skin: System 
Calibration," 2013; Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011; 
Pimenta et al., 2012; Nichols et al., 2015; Lim et al., 2011; Nichols et al., 2012; Sharma et al., 
2013; Sharma et al., 2014; Hennessy et al., 2015). However, a drawback of DRS is inability to 
spatially resolve tissue architecture.  
We have recently reported on a probe-based technique that combines high-resolution 
microendoscopy imaging, and DRS (Rajaram et al., 2008; Durduran et al., 2010; Dehghani et 
al., 2009; Subramanian et al., 2007; Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et 
al., 2010). This hybrid fiber-bundle spectroscopy and imaging probe is capable of co-registering 
qualitative high-resolution images of tissue surface microarchitecture with complimentary 
quantitative and depth-sensitive spectral data (Greening, James, Powless, et al., 2015; Greening, 
Powless, et al., 2015). Furthermore, our design uses two SDSs (shallow and deep channels) to 
collect data at two different sampling depths with the goal of sampling different tissue volumes. 
Therefore, the high-resolution imaging modality may be beneficial in providing image data of 
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later stage moderate and severe dysplasia while the DRS modality may be sensitive to tissue 
optical changes associated with early dysplasia arising at the basement membrane (Greening, 
James, Powless, et al., 2015). 
In this manuscript, we validate the DRS portion of the quantitative hybrid imaging and 
spectroscopy microendoscope and present a pilot phantom and pre-clinical study to extract in 
vivo optical parameters of the human oral mucosa. First, a set of calibration phantoms was used 
to generate reflectance lookup tables (LUT) describing the relationship between reflectance and 
optical properties (µs’ and µa) for the DRS modality (Rajaram et al., 2008). Then, to validate the 
LUT, the probe and LUT-based inverse model was used to extract µs’ and µa from a set of 
hemoglobin-based validation phantoms with known µs’ and µa (Rajaram et al., 2008). Extracted 
optical properties were compared to theoretical values and reported as percent errors. Next, we 
quantify sampling depth for the shallow and deep SDSs of the DRS modality and validate results 
using the same calibration and validation phantoms (Hennessy et al., 2014). Following this, we 
present a simple phantom study simulating the physical layered progression from healthy tissue 
to severe dysplasia to show how reflectance changes with an optically scattering heterogeneity 
buried at various depths (Zhu and Liu, 2011; Bouquot et al., 2006; Speight, 2007). Finally, the 
LUT-based inverse model was demonstrated on in vivo human oral mucosa from thirteen healthy 
volunteers in a laboratory setting to determine volume-averaged scattering exponent, hemoglobin 
concentration, oxygen saturation, and sampling depth. The extracted in vivo quantitative optical 
parameters were compared to an in vivo high-resolution image of healthy, non-keratinized oral 
tissue. These studies validate our hybrid fiber-bundle imaging and spectroscopy technique and 
demonstrate the translational potential to a clinical setting. This technique can potentially be used 
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to for diagnostic purposes as well as dynamically monitoring personalized tumor response to 
therapy. 
2.2 Rationale 
This multimodal instrumentation and associated technique is the first combination of 
these modalities within a single probe, although other combined structural/functional techniques 
do exist that combine different modalities. For example, hyperspectral imaging combines wide-
field imaging with quantitative hemoglobin and melanin properties (Ghassemi et al., 2014; 
Vasefi et al., 2014), and other techniques have been developed that combine optical coherence 
tomography (OCT) with analysis of tissue protein expression (Winkler et al., 2010), to name a 
few. This article reports on a compact and easy-to-implement instrumentation setup that uses a 
general fiber-optic probe which can be optimized for various purposes including endoscopic use 
in the lower gastrointestinal tract and esophagus or as a handheld probe for use in the oral cavity 
and external skin placement (Greening, James, Powless, et al., 2015; Bish et al., 2014).  
The hardware for this instrumentation requires both custom data acquisition and post-
processing code to acquire diffuse reflectance spectra and then extract the resulting volume-
averaged tissue physiological parameters including THC, [Mel], and StO2. The custom data 
acquisition code was built to allow the simultaneous acquisition from a camera (for high-
resolution fluorescence microscopy) and a spectrometer (for diffuse reflectance spectroscopy). 
Drivers are often available from the manufacturers’ websites to allow integration with a variety 
of programming languages. The custom post-processing code imports a priori absorption values 
of in vivo THC and [Mel](Prahl, 1999) and then utilizes a previously developed nonlinear 
optimization fitting process that creates a fitted curve of the spectra (Rajaram, Aramil, et al., 
2010). The fitted curve is built by minimizing the χ2 value between itself and the raw spectra and 
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determining the tissue physiological parameters (THC, [Mel], and StO2) from the fitted curve 
and with the lowest χ2 value (Rajaram, Aramil, et al., 2010). The code can be modified to include 
absorption from other chromophores as well, such as the exogenous pyranine ink used here, so 
that target physiological parameters are unaffected. 
Physiological indicators of tissue health, such as THC, [Mel], and StO2, can be used as 
reports of tumor response to therapy or as indicators of local vascularization and angiogenesis 
(Hennessy et al., 2015; Chang et al., 2009). Including a high-resolution fluorescence 
microendoscopy modality helps guide probe placement and provides investigators with a more 
complete picture of the relationship between epithelial tissue structure and function. In this 
article, construction and application of the multimodal microendoscope is described (Greening, 
James, Powless, et al., 2015). 
2.3 Materials and Methods 
2.3.1 Fiber-Optic Probe Design 
The custom fiber-optic probe (Myriad Fiber Imaging, USA) used for this trimodal 
microendoscopy technique uses five 200/220 µm core/cladding, 0.22 NA multimode fibers 
(Molex Inc., USA) surrounding a 1 mm Fujikura image fiber (Myriad Fiber Imaging, USA) for a 
total of six fibers. The central 1 mm image fiber contains approximately 50,000 individual fiber 
elements 4.5 µm in diameter with center-to-center spacing of approximately 4.5 µm. The center-
to-center separation between any one of the 200 µm fibers and the image fiber is 864 µm. 
Therefore, the closest edge of the image fiber to the center of any 200 µm fiber is approximately 
350 µm. Similarly, the farthest edge of the image fiber to the center of any 200 µm fiber is 
approximately 1,350 µm. The centers of each of the 200 µm fibers are separated by 25°. Based 
on this geometry, center-to-center SDS between adjacent 200 µm fibers with respect to the 
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leftmost fiber are 374, 730, 1,051, and 1,323 µm. For the purposes of this paper, only the first 
two SDSs (374 and 730 µm) were used for DRS measurements. The total length of the fiber-
optic probe is 4 ft. in which the distal 2 ft. of the fiber-optic probe consists of a single probe tip 3 
mm in diameter and the proximal 2 ft. of the fiber-optic probe, nearest the optical 
instrumentation, splits into six individual fibers corresponding to each fiber within the bundle. 
Each of the six fibers ends in an SMA905 connector and can be readily coupled to the 
microendoscopy instrumentation. Figure 1 shows the details of the fiber-optic probe (Greening, 
Powless, et al., 2015). Figure 2 shows the details of the hybrid fiber-bundle imaging and 
spectroscopy system including the proximal instrumentation such as the imaging hardware, 
spectroscopy hardware, and the optical fiber switch.  
 
Figure 1. Fiber-optic probe showing (a) the full length (4 ft.) of the probe with 
the single bundle at the distal end and splitting into six individual bundles at the 
proximal end, (b) a schematic of the probe tip with the central 1 mm image fiber 
(#6) surrounded by five 200 µm multimode fibers (#1-5) separated by 25º. SDS 
between fiber #1 and the four adjacent fibers (#2-5) are 374, 730, 1051, and 1323 
µm, respectively, and (c) close-up of the distal end of the fiber-optic probe (scale 
bar = 2 mm). 
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Figure 2. Representation of the hybrid fiber-bundle imaging and spectroscopy 
system showing (a) the major instrumentation components including (from left to 
right) fiber switch, imaging portion, and spectroscopy portion, (b) a SolidWorks 
representation of the distal probe (scale bar = 1 cm) showing the (c) en face view 
of the central 1 mm-diameter image fiber and 5 surrounding 200 μm multimode 
fibers (scale bar = 2.5 mm), (d) distal probe (scale bar = 1 cm), and (e) en face 
view of the distal probe tip (scale bar = 2.5 mm). 
 
2.3.2 Instrumentation Design 
Three light sources, corresponding to the three optical modes of the instrumentation, are 
delivered to the sample via the custom fiber-optic probe: an LED light source (Philips, USA) 
centered at 455 nm (20 nm FWHM), a broadband tungsten-halogen white light source (Ocean 
Optics, USA), and a 635 nm laser (Thorlabs, USA).  
For the first mode (high-resolution, image fiber-based fluorescence imaging), light from 
the 455 nm LED passes through a 460 nm short pass excitation filter (Chroma Technology 
Corp., USA) and is directed into the back aperture of a 10X/0.30 NA infinity-corrected objective 
lens (Olympus Corp., Japan) using a 475 nm cut-off dichroic mirror (Chroma Technology Corp., 
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USA). 455 nm excitation light passes through the 1 mm image fiber to the distal end of the 
probe, illuminating the sample with 1 mW of power. Samples fluorescently stained with 
proflavine excite in this wavelength range and emit light centered at approximately 515 nm 
which is collected by the image fiber (Prieto, Powless, Boice, et al., 2015). Emission light passes 
through the 475 nm dichroic mirror and is reflected by a second dichroic mirror with a cut-off 
wavelength of 590 nm (Chroma Technology Corp., USA). This reflected emission light 
(centered at 515 nm) then passes through a 525/40 nm emission bandpass filter (Chroma 
Technology Corp., USA), a 50 mm tube lens (Thorlabs), and into an 8-bit, Flea3 USB 3.0 
monochrome CMOS camera (Point Grey, Canada) (Greening, Powless, et al., 2015; Muldoon et 
al., 2007; Muldoon et al., 2011; Pierce, Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; 
Chang et al., 2013; Keahey et al., 2015; Parikh et al., 2014). The CMOS camera thus provides 
magnified apical cell morphological data from the 1 mm-diameter field-of-view (FOV).  
For the second mode (broadband DRS), broadband light (450-750 nm) from the tungsten-
halogen lamp is coupled into one 200 µm fiber (fiber #1 from Figure 1) of the fiber-optic probe 
to deliver white light to the sample. The wavelength range is limited by the output of the 
tungsten-halogen source lamp. Sub-diffusely reflected light is collected by two adjacent 200 µm 
fibers (fiber #2 and #3 from Figure 1) with corresponding center-to-center SDS of 374 and 730 
µm and delivered to a single visible-to-near infrared spectrometer (Ocean Optics, USA) with a 
spectral resolution of 0.36 nm. A custom designed motorized optical fiber switch allows the 
spectrometer to sequentially acquire from each collection fiber (Greening, Powless, et al., 2015).  
For the third mode (DRIM), the 635 nm laser is coupled into one 200 µm fiber (fiber #5 
from Figure 1) of the fiber-optic probe to deliver light to the sample. Within the sample, laser 
light undergoes multiple scattering events and emitted light is collected by the central 1 mm 
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image fiber (Kanick et al., 2014; Turzhitsky, Radosevich, et al., 2010). This emitted 635 nm 
light passes through both the 475 and 590 nm cut-off dichroic mirrors before being reflected by a 
1-inch aluminum mirror (Thorlabs, USA). The collected 635 nm light then passes through a 610 
nm long pass emission filter (Chroma Technology Corp., USA), a 50 mm tube lens (Thorlabs, 
USA), and into a second 8-bit, Flea3 USB 3.0 monochrome CMOS camera (Point Grey, 
Canada). A second camera is necessary so the resultant 2D sub-diffuse reflectance image maps 
have the same FOV and image area as the apical cell morphological data and thus can be directly 
compared. Both CMOS cameras presented here have a sensor array of 2080 x 1552 pixels 2.5 
µm wide, a corresponding sensor size of 5.2 x 3.9 mm, and a dynamic range of 62.9 dB 
(Greening, Powless, et al., 2015). 
All modalities of the instrumentation are controlled with custom LabVIEW software 
(National Instruments, USA). Figure 3 shows a schematic of the fiber-bundle microendoscopy 
system along with images of the physical bench-top instrumentation. 
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Figure 3. The trimodal microendoscope showing (a) a schematic illustrating 
major components. 455 nm light passes through a 460 nm short pass excitation 
filter (Ex). Emitted signal passes through a 10X objective, 475 nm dichroic mirror 
(DCM1), 525/40 nm emission filter (Em1), and into a camera (Cam 1). 635 nm 
DRIM signal passes through the objective lens, 475 (DCM1) and 590 nm dichroic 
mirrors (DCM2), 610 long pass filter (Em2), and into a camera (Cam 2). An 
optical fiber switch delivers reflected broadband light from the tungsten halogen 
lamp to a spectrometer.  Finally, (b) shows a close-up of the optical components 
and (c) shows the optical components and custom LabVIEW software acquiring 
data from a hybrid cell phantom. 
 
2.3.3 Assembly of the High-Resolution Fluorescence Microendoscopy Modality 
Note: The outlined steps for assembly of the high-resolution fluorescence 
microendoscopy modality can be visualized in Figure 4. 
1.1) Place a 470 nm dichroic mirror inside a 30 mm cage cube.  
1.1.1) Obtain a 30 mm cage cube and remove the dichroic filter mount. 
1.1.2) Place a 470 nm dichroic mirror in the dichroic filter mount. 
1.1.3) Re-insert and secure the dichroic filter mount back inside the cage cube. 
1.2) Attach cage assembly rods to the 30 mm cage cube. 
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1.2.1) Secure four 1.5 in. cage assembly rods to the front of the cage cube.  
1.2.2) Secure four 3.0 in. cage assembly rods to the right side of the cage cube. 
1.2.3) Secure two 2.0 in. cage assembly rods diagonally on the left side of the cage cube. 
1.3) Build a cage plate/lens tube assembly. 
1.3.1) Obtain a 1.0 in. threaded 30 mm cage plate and attach a stress free retaining ring to the 
inside of the cage plate using the provided threading. 
1.3.2) Screw in a 1.0 in. lens tube to the stress-free retaining ring. 
1.3.3) Attach a second 1.0 in. threaded 30 mm cage plate to the 1.0 in. lens tube and adjust the 
standard retaining rings so that the two cage plates are flush. 
1.4) Slide the 1.0 in. cage plate/lens tube assembly onto the left side of the 30 mm cage cube. 
1.5) Build the right-angle mirror mount assembly. 
1.5.1) Obtain a right-angle mirror mount and a 1.0 in. UV-enhanced aluminum mirror. 
1.5.2) Place the 1.0 in. UV-enhanced aluminum mirror into the mirror mount and tighten.  
1.5.3) Secure four 2.0 in. cage assembly rods to the front of mirror mount  
1.5.4) Secure two 2.0 in. cage assembly rods diagonally on the right side of the cage cube. 
1.6) Connect the right-angle mirror mount assembly onto the left side of the 1.0 in. cage 
plate/lens tube assembly by placing the opposing cage assembly rods through the respective 
openings of the 30 mm cage plate. 
1.7) Thread a z-axis translation mount through the 3.0 in. cage assembly rods on the right side 
of the assembly.  
1.8) Attach a 10X achromatic objective lens to the z-axis translation mount.  
1.9) Build a 1.0 in. fiber adaptor plate/xy-axis translation lens mount assembly. 
1.9.1) Obtain an xy-axis translation mount and an 1.0 in. fiber adaptor plate. 
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1.9.2) Secure the 1.0 in. fiber adaptor plate into the xy-axis translation lens mount. 
1.10) Slide the 1.0 in. fiber adaptor/xy-axis translation lens mount assembly in front of the 
objective lens. 
1.11) Obtain two 0.5 in. long, 1.0 in. diameter lens tubes, one 440/40 nm bandpass filter 
(excitation filter) and one 525/36 nm bandpass filter (emission filter). 
1.12) Place each filter inside a 0.5 in. long, 1.0 in. diameter lens tube, such that the arrow on 
the outside of the filter is facing the side of the lens tube with the external threads. 
1.13) Attach the filters to the assembly.  
1.13.1) Obtain two standard retaining rings. 
1.13.2) Secure the filters inside the 0.5 in. long, 1.0 in. diameter lens tubes with the standard 
retaining rings. 
1.13.3) Screw in the lens tube with the excitation filter to the front of the 30 mm cage cube and 
screw in the lens tube with the emission filter to the right-angle mirror mount.  
1.13.4) Screw in the 0.5 in. lens tube with the emission filter to the front of the right-angle mirror 
mount. 
1.14) Obtain two 1.0 in. threaded 30 mm cage plates and place them in front of the 0.5 in. long, 
1.0 in. diameter lens tubes containing the filters. 
1.15) Using epoxy or strong adhesive, attach a 455 nm LED to the cage plate connected to the 
excitation filter.  
1.16) Obtain one 0.5 in. long, 1.0 in. diameter lens tube and a 1.0 in. achromatic doublet tube 
lens with focal length of 50 mm.  
1.17) Place the tube lens inside the lens tube such that the arrow on the outside of lens is facing 
the side of the lens tube with the external threads. 
70 
1.18) Screw in the tube lens to the assembly.  
1.18.1) Obtain one standard retaining ring. 
1.18.2) Secure the lens inside the 0.5 in. long, 1.0 in. diameter lens tube with the standard 
retaining ring. 
1.18.3) Attach the lens tube with the tube lens to the left-most cage plate.  
1.19) Place a 30 mm cage plate in front of the 0.5 in. long, 1.0 in. diameter lens tube containing 
the tube lens.  
1.20) Attach a stress-free retaining ring to the inside of the 30 mm cage plate. 
1.21) Attach a USB monochrome camera to the cage plate with the stress-free retaining ring.  
1.22) Construct the optical post mounting devices.  
1.22.1) Obtain four 0.5 in. post holders, four 0.5 in. optical posts, and four mounting 
bases. 
1.22.2) Secure the 0.5 in. optical posts inside the 0.5 in. post holders. 
1.23.3) Secure the 0.5 in. post holders onto the mounting bases. 
1.23) Screw in the four optical post mounting devices to the screw holes located under the 30 
mm cage cube, the right-angle mirror mount, the cage plate connected to the LED, and the cage 
plate connected to the camera. 
1.24) Screw in the four the optical post mounting devices to either an optical breadboard or 
optical table to finish construction of the high-resolution fluorescence microendoscopy modality. 
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Figure 4. Assembly of the high-resolution fluorescence microendoscopy 
modality. The high-resolution fluorescence microendoscopy modality can be 
constructed by building a shell of 1.0 in. diameter-sized components, with special 
care taken in handling the dichroic mirror, objective lens, excitation/emission 
filters, and tube lens. Glass surfaces of these components must be carefully 
handled using lens paper.  
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2.3.4 Assembly of the Diffuse Reflectance Spectroscopy Modality 
Note: The outlined steps for assembly of the sub-diffuse reflectance spectroscopy 
modality can be visualized in Figure 5. 
2.1) Obtain a tungsten-halogen light source and, using epoxy or a strong adhesive, secure a 
1.0 in. threaded 30 mm cage plate onto the front.  
2.2) Secure four 3.0 in. cage assembly rods to the cage plate. 
2.3) Attach a z-axis translation mount to the cage assembly rods. 
2.4) Screw in a 20X achromatic objective lens to the z-axis translation mount.  
2.5) Build a fiber adaptor plate/xy-axis translation lens mount assembly. 
2.5.1) Obtain an xy-axis translation mount and an 1.0 in. fiber adaptor plate.  
2.5.2) Secure the fiber adaptor plate into the xy-axis translation lens mount. 
2.6) Slide the 1.0 in. fiber adaptor/xy-translation mount assembly in front of the objective 
lens. 
2.7) Build the motor arm assembly.  
2.7.1) Obtain the custom-built aluminum motor arm and one SMA fiber adaptor plate. 
2.7.2) Screw in the fiber adaptor plate (with external threading) into the aluminum motor 
arm (with internal threading). 
2.7.3) Attach the custom-built aluminum motor arm adaptor to the motor arm with four 
#4-40 0.5 in. screws. 
2.8) Build the motor/motor arm/motor housing assembly. 
2.8.1) Obtain the custom-built aluminum motor housing and the 400-step stepper motor.  
2.8.2) Line up the screw holes on the stepper motor and motor housing and then secure 
with four #4-40 0.5 in. screws. 
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2.8.3) Feed the rotating motor rod of the stepper motor through the opening of the motor 
arm assembly and tighten the locking screw on the aluminum motor arm adaptor.  
2.9) Build the optical switch assembly. 
2.9.1) Obtain the custom-built aluminum optical switch and three 1.0 in.  fiber adaptor 
plates.  
2.9.2) Thread the adaptor plates into the threaded holes in the optical switch. 
2.9.3) Attach the custom-built aluminum optical switch face-plate onto the optical switch 
with four #4-40 0.5 in. screws. 
2.10) Attach the motor/motor arm/motor housing assembly to the optical switch by feeding the 
rotating motor rod of the stepper motor through the central hole of the optical switch. 
2.11) Obtain an electric circuit board and stepper motor driver, and then place the stepper 
motor driver across the central groove of the breadboard. 
2.12) Observe the electrical connection schematic (Figure 5, 2.12) for the stepper motor driver, 
12V power supply, and stepper motor. 
2.13) Connect the stepper motor driver, 12V power supply, and stepper motor as specified in 
the circuit diagram (Figure 3, 2.12) to complete construction of the motorized optical switch. 
2.14) Screw in the optical switch components and tungsten-halogen light source to an optical 
breadboard or optical table near the previously constructed (Figure 4, 1.24) high-resolution 
fluorescence microendoscopy assembly. 
2.15) Attach one end of a 550 µm, 0.22 NA patch cable to the 1.0 in. fiber adaptor plate of the 
motor arm assembly. 
2.16) Attach the other end of the 550 µm, 0.22 NA patch cable to the fiber connector of the 
USB spectrometer.  
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2.17) Screw in the five distal probe cables to the respective 1.0 in. fiber adaptor plates on the 
instrumentation to finish completion of the multimodal high-resolution imaging and sub-diffuse 
reflectance spectroscopy fiber-bundle microendoscope. 
2.17.1) Screw in the central 1 mm-diameter image fiber cable to the 1.0 in. fiber adaptor 
plate mentioned in step 1.9.2. 
2.17.2) Screw in the leftmost 200 µm multimode fiber cable to the 1.0 in. fiber adaptor 
plate mentioned in step 2.6. 
2.17.3) Screw in the 2nd 200 µm multimode fiber cable to the leftmost 1.0 in. fiber 
adaptor attached to the tungsten-halogen lamp mentioned in step 2.9.2. 
2.17.4) Screw in the 3rd 200 µm multimode fiber cable to the middle 1.0 in. fiber adaptor 
plate mentioned in step 2.9.2. 
2.17.5) Screw in the 4th 200 µm multimode fiber cable to the rightmost 1.0 in. fiber 
adaptor plate mentioned in step 2.9.2. 
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Figure 5. Assembly of the sub-diffuse reflectance spectroscopy modality. The 
sub-diffuse reflectance spectroscopy modality can be constructed using a basic 
tungsten-halogen lamp coupled to an objective lens to focus light through the 200 
μm multimode delivery fiber, and a spectrometer. Additionally, a custom-built 
motorized optical switch can be constructed within the lamp-fiber-spectrometer 
path to switch between each SDS. Investigators using multiple spectrometers to 
acquire from multiple SDSs can bypass the optical switch component.  
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2.3.5 Characterization of the High-Resolution Microendoscopy Modality 
The instrumentation was characterized to determine the following specifications: 1) 
spatial resolution, 2) magnification, 3) percent of maximum field-of-view, and 4) sampling 
frequency. These values were determined with three objective/tube lenses with focal lengths of 
50, 100, and 150 mm. For each lens, a 10X/0.30 NA infinity-corrected objective lens was used. 
Next, the ability of the DRS modality to extract optical properties (absorption and reduced 
scattering coefficients) was quantified using a lookup table (LUT) approach (Rajaram et al., 
2008; Rajaram, Aramil, et al., 2010) Finally, sampling depth was determined for the broadband 
DRS modality (Hennessy et al., 2014).  
First, spatial resolution and maximum field-of-view (FOV) was determined by the 
geometry of the fiber-optic probe. The image fiber consists of approximately 50,000 individual 
4.5 µm-diameter fiber elements with center-to-center spacing of 4.5 µm. The probe is placed in 
direct contact with a sample; therefore, the optimal spatial resolution that can be achieved is 4.5 
µm. In addition, the maximum FOV was approximately 0.8 mm2, which was determined by the 
diameter (≈ 1 mm) of the image fiber. Depending on the objective/tube lens configuration, values 
for magnification, percent-of-maximum FOV, and sampling frequency vary.    
A positive 1951 USAF resolution test target was back-illuminated with a white LED and 
imaged at group 3/element 3 (linewidth = 49.50 µm) with three tube lenses (focal lengths = 50, 
100, and 150 mm). The number of image sensor pixels per micron within the images was then 
computed. This number was multiplied by the width of the individual pixels (2.5 µm/pixel) to 
obtain magnification. Percent of maximum FOV was determined by dividing the sampled area 
projected onto the image sensor by the maximum FOV (0.8 mm2). Finally, sampling frequency 
was determined by multiplying the individual fiber element diameter (4.5 µm) by the number of 
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pixels per micron within the images. Equations for obtaining spatial resolution, magnification, 
percent of maximum FOV, and sampling frequency are shown below as Eq. (1), Eq. (2), Eq. (3), 
and Eq. (4), respectively. In the following equations, R is spatial resolution, D is diameter of 
individual fiber elements (4.5 μm), M is magnification, N is the number of pixels per micron, W 
is pixel width (2.5 μm), FOV is percent of maximum field-of-view, A is area, and F is sampling 
frequency.   
𝑅(𝜇𝑚) = 𝐷𝑓𝑖𝑏𝑒𝑟𝑠 (
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2.3.6 Generation of and validation of lookup tables for volume-averaged optical property 
extraction 
The second objective of this study was to use the DRS modality to extract volume-
averaged optical parameters. To accomplish this, reflectance lookup tables (LUTs) were 
generated describing the relationship between absolute reflectance and optical properties (µs’ and 
µa) for the two SDSs (374 and 730 µm). The target ranges of the LUTs were µs’ and µa between 
5-26 cm-1 and 0-10 cm-1, respectively. These LUTs required calibration phantoms of similar 
order of magnitude as biological tissue (Rajaram et al., 2008; Sandell and Zhu, 2011).  
Calibration phantoms were constructed to exceed the target range using deionized water 
as the solvent (Rajaram et al., 2008). The scattering agent was 1.0 µm-diameter polystyrene 
78 
microspheres (07310-15, Polysciences, USA) and the associated µs’ range (3-31 cm-1) was 
calculated using Mie theory (Nichols et al., 2012; Sharma et al., 2014; Fu et al., 2010). The 
absorbing agent was a combination of yellow, red, and blue food dye (McCormick & Company, 
USA), in ratio of 20:6:2, which contained propylene glycol, Yellow 5, Red 40, Red 3, Blue 1, 
and 0.1% propylparaben. The µa range (0-47 cm
-1) was calculated by measuring the dye solution 
in deionized water using a spectrophotometer (5102-00, PerkinElmer, USA) and Beer’s Law. All 
calibration phantoms were homogenous so µs’ and µa were identical throughout the phantom 
volume.  
A total of 12 liquid calibration phantoms was created which was sufficient to build the 
LUTs. Six of the 12 phantoms were considered “scattering-only” and contained only deionized 
water and polystyrene microspheres without dye. Deionized water and polystyrene microspheres 
were gently mixed inside 7 mL scintillation vials (66022-300, VWR, USA) to yield six µs’ 
ranges of 3.0-4.9, 4.4-7.1, 6.4-10.2, 9.2-14.7, 13.2-21.2, and 19.5-31.0 cm-1. These values were 
chosen so there was sufficient overlap between the maximum µs’ value of one phantom at 450 
nm and the minimum µs’ value of another phantom at 750 nm. Sufficient overlap was determined 
such that the minimum µs’ value of one phantom was no greater than 90% of the maximum µs’ 
value of the proceeding phantom. This ensured the six scattering-only phantoms spanned a 
continuous µs’ range. Eq. 5 expresses this relationship in which n is the phantom number. 
𝜇𝑠,𝑚𝑖𝑛,𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝑛)
′ ≤ 0.9 ∙ 𝜇𝑠,𝑚𝑎𝑥,𝑝ℎ𝑎𝑛𝑡𝑜𝑚(𝑛−1)
′ , (5) 
 
The remaining six phantoms contained both polystyrene microspheres and the dye 
combination. Deionized water, polystyrene microspheres, and dye were gently mixed inside 7 
mL scintillation vials to yield a continuous µs’ range of 3-31 cm-1 and continuous µa range of 0-
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47 cm-1. The wavelength-dependent variations in μs’ and μa provide the wide range of scattering 
and absorbing values.  
To generate the reflectance LUTs, the probe was placed in each phantom so it was 
completely submerged at a distance of 2 cm from the bottom of the 7 mL scintillation vial. 
Broadband DRS data (450-750 nm) were recorded at each SDS (374 and 730 µm) with an 
integration time of 400 ms. Five spectra were averaged for all measurements. Spectra were 
converted to absolute reflectance values by calibrating with a Spectralon® 20% diffuse 
reflectance standard (SRS-20-010, Labsphere, USA) which was spectrally flat between 200-2600 
nm. A custom, 3D printed probe holder was used to fix the distance between the probe tip and 
the Spectralon® 20% diffuse reflectance standard to acquire maximum reflectance at each SDS 
(Figure 6 and 7). 
 
 
 
 
 
80 
 
Figure 6. Calibration of the sub-diffuse reflectance spectroscopy modality. For 
experimental calibration, the fiber-optic probe tip must be placed at different 
perpendicular distances from the 20% diffuse reflectance standard depending on 
the SDS. To consistently achieve these perpendicular distances across all 
experiments, a calibration standard device was designed (device cross section 
shown in (a)) to hold the probe at exact distances from the 20% diffuse 
reflectance standard. In this specific fiber-optic probe setup, light from the 
tungsten-halogen lamp is shown through the optical switch at source-detector 
separations of (b) 374 μm and (c) 730 μm (with motor and motor arm removed 
from the optical path for clarity). Distances of (d) 2.1 mm for the 374 μm SDS, 
and (e) 3.9 mm for the 730 μm SDS are required for calibration.  
 
 
 
Figure 7. The final design, including during 3D printing 
 
All spectra were corrected for background noise (Glennie et al., 2014; Rajaram, Aramil, 
et al., 2010; Rajaram et al., 2008; Nichols et al., 2015; Nichols et al., 2012). After acquiring 
absolute reflectance spectra at a resolution of 0.35 nm, the LUTs relating reflectance (R) to µs’ 
and µa were generated using MATLAB. Raw data from the 12 calibration phantoms (C.P. #1-12) 
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was interpolated to generate a color-mapped mesh with an optical property resolution of 0.02 cm-
1. The reflectance LUTs were interpolated in the target μs’ and μa ranges of 5-26 cm-1 and 0-10 
cm-1, respectively.  
To validate the reflectance LUTs, a set of liquid validation phantoms with known optical 
properties was built of similar order of magnitude as biological tissue (Sandell and Zhu, 2011; 
Rajaram et al., 2008). Validation phantoms were constructed in a similar manner to calibration 
phantoms, but contained bovine hemoglobin (H2625, Sigma-Aldrich, USA), rather than food 
dye, as the absorbing agent. The µs’ was calculated using Mie theory and µa was calculated by 
measuring a solution of bovine hemoglobin in deionized water using a spectrophotometer (5102-
00, PerkinElmer, USA) and Beer’s Law. It was necessary to validate the LUTs using a different 
absorber and different scattering ranges than those used to generate the LUTs so that the 
interpolated range of the LUTs were tested. All validation phantoms were homogenous so µs’ 
and µa were identical throughout the phantom volume. 
A 3 x 3 (9 total) set of validation phantoms was created, corresponding to three µs’ ranges 
and three µa ranges. Deionized water, polystyrene microspheres and diluted bovine hemoglobin 
were gently mixed inside 7 mL scintillation vials. This yielded µs’ values from 5-26 cm-1 and µa 
values from 0-10 cm-1 to validate 100% of the reflectance LUTs. Figure 8 shows the µs’ and µa 
for the calibration phantoms (C.P. 1-12) and validation phantoms (V.P. 1-9).  
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Figure 8. Comparison of the optical properties of the (a, b) 6x2 (12 total) 
calibration phantoms (C.P.) and the (c, d) 3x3 (9 total) validation phantoms 
(V.P.). Calibration phantoms were made with polystyrene microspheres and a 
combination of yellow, red, and blue dye and the validation phantoms were made 
with polystyrene microspheres and bovine hemoglobin as the scattering and 
absorbing agents, respectively. Calibration phantoms had μs’ spanning 3-31 cm-1 
and μa spanning 0-47 cm-1 and the validation phantoms had a μs’ spanning 5-26 
cm-1 and μa spanning 0-10 cm-1 to validate the target LUT range. 
 
Broadband DRS data on validation phantoms were collected in the same method as the 
calibration phantoms. The LUT-based inverse model was used to extract µs’ and µa from the 
validation phantoms. Theoretical optical properties of the validation phantoms were compared to 
extracted optical properties and reported as percent errors. To quantify percent errors, the LUT-
based inverse model extracted μs’ and μa for the 3x3 validation phantoms at a spectral resolution 
of 0.35 nm and percent errors were calculated using Eq. 6 and Eq. 7, 
𝐸𝑟𝑟𝑜𝑟%,𝜇𝑠′ = |
𝜇𝑠,𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑
′ − 𝜇𝑠,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
′
𝜇𝑠,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
′ | ∙ 100% (6) 
𝐸𝑟𝑟𝑜𝑟%,𝜇𝑎 = |
𝜇𝑎,𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 − 𝜇𝑎,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
𝜇𝑎,𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
| ∙ 100%, (7) 
 
2.3.7 Generation of and validation of lookup tables for sampling depth quantification 
The third objective of this study was to determine the sampling depth of the DRS 
modality. To accomplish this, sampling depth lookup tables (LUTs) were generated describing 
the relationship between sampling depth and volume-averaged optical properties (µs’ and µa) for 
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the two SDSs (374 and 730 µm). The target ranges of the sampling depth LUTs were µs’ and µa 
between 5-26 cm-1 and 0-10 cm-1, respectively. The same calibration phantoms as described 
previously were used to generate the sampling depth LUTs. 
A highly absorbing phantom layer (μa ≥ 100 cm-1 for all wavelengths between 450-750 
nm) was created in a 5 mL beaker using 6.5% w/w India Ink in PDMS (Hennessy et al., 2014; Di 
Ninni et al., 2010). Contributions from specular reflection were proven negligible by placing the 
probe in contact with the absorbing layer and acquiring DRS data between distances of 0-2 mm 
in 50 µm increments (Hennessy et al., 2014).  
Next, the six dye-containing calibration phantoms (Figure 8, C.P. 7-12) were placed on 
top of the highly absorbing layer within the beaker. Spectra (450-750 nm) at each SDS were 
taken by varying the distance of the probe-tip and absorbing layer between 0-2 mm in 50 µm 
increments (Hennessy et al., 2014). Sampling depth is been defined as the depth reached by 50% 
of photons (Hennessy et al., 2014). At a certain probe-absorbing layer distance (around 2 mm), 
there were no significant changes in signal intensity, meaning that nearly 100% of incident 
photons were not reaching the highly absorbing layer. Figure 9 shows how sampling depth was 
quantified for the DRS modality in representative data (Hennessy et al., 2014). As the probe is 
translated away from the absorbing layer, as shown in Figure 9(a), reflectance increases until 
plateauing as shown in Figure 9(b). A depth (x-axis) can then be identified that correlates with 
the 50% cutoff point (y-axis) which is defined as the sampling depth as shown in Figure 9(c)  
(Hennessy et al., 2014). 
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Figure 9. The probe is placed (a) in contact with the highly absorbing (µa ≥ 100 
cm-1 for 450-750 nm) inside a 5 mL beaker and translated upwards in 50 µm 
increments to (b) acquire DRS data from a calibration phantom (C.P. 11) at a 374 
µm SDS. (c) Representative data from the 374 µm SDS shows the percentage of 
photons not reaching the highly absorbing layer as a function of depth for C.P. 11 
at 585 nm. Sampling depth is defined as the depth reached by 50% of photons. 
 
The process from Figure 3 was repeated for all wavelengths at a spectral resolution of 
0.35 nm for the 6 calibration phantoms (C.P. 7-12).  Raw data was interpolated in MATLAB to 
generate a color-mapped mesh with a maximum optical property resolution of 0.02 cm-1. The 
sampling depth LUTs were interpolated in a target μs’ range of 5-26 cm-1 and μa range of 0-10 
cm-1.  
To validate sampling depth, spectra (450-750 nm) at each SDS of the previously 
described validation phantoms were acquired by varying the distance of the probe-tip and 
absorbing layer between 0-2 mm in 50 µm increments. To quantify percent errors, sampling 
depths of the validation phantoms were compared to the sampling depths (D) from the 
calibration phantoms. Percent errors were calculated using Eq. 8, 
𝐸𝑟𝑟𝑜𝑟%,𝐷 = |
𝐷𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 − 𝐷𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑖𝑜𝑛
𝐷𝑣𝑎𝑙𝑖𝑑𝑎𝑡𝑖𝑜𝑛
| ∙ 100% (8) 
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2.3.8 Hybrid Cell Phantoms 
To demonstrate the three modalities, two hybrid cell phantoms were constructed using 
PDMS as a substrate material and titanium dioxide (Sigma Aldrich, USA) and nigrosin (Sigma 
Aldrich, USA) as the scattering and absorbing agents, respectively (Greening et al., 2014). Both 
phantoms consisted of a 2.5 cm thick layer containing a scattering concentration of 8.0 mg/g 
TiO2/PDMS and absorbing concentration of 5.0 µL/g 1% w/v distilled nigrosin/PDMS. The 
second phantom consisted of an additional 500 µm thin absorbing layer which had had a 
scattering concentration of 8.0 mg/g TiO2/PDMS and absorbing concentration of 10.0 µL/g 1% 
w/v distilled nigrosin/PDMS (Greening et al., 2014).  
After curing, hybrid cell phantoms were autoclaved, and MDA-MB-468 breast 
adenocarcinoma cells were cultured on top. MDA-MB-468 breast adenocarcinoma cells (ATCC, 
USA) were cultured up to the fourth passage in Dulbecco’s Modified Eagle Medium (DMEM) 
(ATCC, USA) containing 10% fetal bovine serum (ATCC, USA) and 5% antibiotics (Sigma 
Aldrich, USA) at 37°C in 5% CO2. 24 hours after passaging, 200,000 cells in 4 mL DMEM were 
seeded onto the phantoms. Each phantom was then transferred to the fiber-optic probe tip. A 
0.01% w/v solution (1 mL) of proflavine in saline was added to the cell culture media to provide 
fluorescent contrast of the nuclei (Prieto, Powless, Boice, et al., 2015). The 455 nm LED and 635 
nm laser provided optical powers at the sample plane of 1.00 mW and 0.25 mW, respectively. 
Both high-resolution fluorescence and DRIM data were collected simultaneously. DRIM data 
were quantified by using a MATLAB script to compute a line plot through the center of the 
image circle and plotting intensity over continuous SDS between 400 and 1,300 µm. Ten raw 
DRIM images were averaged. Immediately following this, the tungsten-halogen lamp delivered 
0.35 mW of power at the sample plane. Broadband DRS measurements were then acquired at 
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both tested SDSs of 374 and 730 µm. For this experiment, both cameras were set to an exposure 
time of 150 ms and gain of 10 dB. The spectrometer had an integration time of 0.5 s and boxcar 
width (Kiisk, 2014) of 3. Three spectra were averaged at each SDS for both hybrid phantoms.  
The hypothesis for this experiment was that there would be no discernable difference 
between high-resolution image data of cultured MDA-MB-468 breast adenocarcinoma cells 
between the two phantoms, but differences would be seen in the reflectance intensities for DRIM 
and DRS data due to the underlying absorbing layer. Table 1 shows specifications for all 
phantom layers. 
Table 1. Specifications for non-biological components of hybrid tissue-simulating phantoms 
Phantom Number 1 (single-layer) 2 (double-layer) 
Layer Bottom Top Bottom Top 
Thickness (mm) 25 0 25 0.5 
[Scattering] (mg/g TiO2/PDMS) 8.0 0 8.0 8.0 
Estimated µs’ (cm-1) 10.0 0 10.0 10.0 
[Absorption] (µL/g dist. Nigrosin/PDMS) 5.0 0 5.0 10.0 
Estimated µa (cm
-1) 1.0 0 1.0 2.0 
 
2.3.9 In vivo human melanocytic nevus 
The trimodal technique was tested on a selected benign melanocytic nevus and adjacent 
normal skin from a healthy Caucasian volunteer. All procedures were approved by the University 
of Arkansas Institutional Review Board (IRB #15-09-149). A benign melanocytic nevi was 
chosen as a demonstration because of its similar cellular arrangement to surrounding normal 
tissue. Contributions from melanin cannot be discerned using high-resolution fluorescence 
imaging, but these highly absorbing contributions become apparent when using the integrated 
sub-diffuse reflectance modalities, DRIM and DRS (Zonios et al., 2008; Tseng et al., 2009). 
Highlighter ink, which contains the fluorescence compound, pyranine, was applied to the 
skin instead of proflavine. Excitation of pyranine was accomplished using the 455 nm LED as 
the excitation source, similar to proflavine. However, unlike proflavine, pyranine does not 
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intercalate DNA and thus preferentially stains cell membranes rather than nuclei. The probe tip 
was placed in direct contact with the skin surface while the 455 nm LED, 635 nm laser, and 
tungsten-halogen lamp provided optical powers of 1.00 mW, 0.25 mW, and 0.35 mW, 
respectively. Both high-resolution fluorescence imaging and DRIM data were collected with an 
exposure time of 150 ms and gain of 10 dB whereas broadband DRS data used an integration 
time of 500 ms and boxcar width of 3 (Kiisk, 2014). Ten high-resolution fluorescence images, 
ten DRIM data, and three DRS data were acquired from each site. The best qualitative high-
resolution fluorescence image was selected while ten DRIM and three DRS data were averaged 
together. After acquisition, the LUT-based inverse model was used to extract µs’ and μa (@ 630 
nm) from the in vivo DRS data of the melanocytic nevus and adjacent normal skin tissue 
(Rajaram, Gopal, et al., 2010; Rajaram et al., 2008; Rajaram, Reichenberg, et al., 2010; Rajaram, 
Aramil, et al., 2010).  
The hypothesis for this experiment was that there would be no discernable difference 
between high-resolution image data between the keratinocytes of the benign melanocytic nevus 
and surrounding tissue, but differences would be seen in the reflectance intensities for DRIM and 
DRS data due to increases in melanin concentration.  
2.3.10 Ex vivo murine colon tissue 
As a demonstration of the technique in a murine model, a 16-week old wild-type 
(C57BL/6J) mouse (Jackson Laboratories, USA) was housed in a room with a 16:8-hour light-
dark cycle and had access to standard rodent food (8640 Teklad 22/5 Rodent Diet, Harlan 
Sprague Dawley Inc., USA) and water ad libitum. Seven days prior to data collection, the mouse 
was switched to a 50/50 mix of standard rodent food and purified food (AIN-93G Purified Diet, 
Harlan Sprague Dawley Inc., USA). The mouse was switched to 100% purified food four days 
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prior to data collection and no food 24 hours prior. All procedures were approved by the 
University of Arkansas Institutional Animal Care and Use Committee (IACUC, #15009) (Moser 
et al., 1990; Su et al., 1992; Karim and Huso, 2013).  
A 1 cm2 square section of colonic tissue (4-5 cm from anus) was isolated. A segment of 
this tissue site was immediately placed in 10% formalin for 24 hours for fixation prior to H&E 
staining. The 4-5 cm section was placed lumen-side up on a solid PDMS-based phantom. An 
underlying PDMS-based phantom was used to eliminate transmitted light because of the thinness 
of tissue (≈ 200 μm thick) (Lim et al., 2011; Shangguan et al., 1998; Simpson et al., 1998). The 
phantom had a refractive index of 1.4 to match that of tissue to avoid artifacts due to Fresnel 
reflection and contained 1% w/v nigrosin/EtOH (5.0 µL/g PDMS, µa ≈ 1.0 cm-1 at 635nm) and 
TiO2 (8.0 mg/g PDMS, µs’ ≈ 10 cm-1 at 635nm) to approximate the optical coefficients of 
colonic tissue at 635 nm (Pogue and Patterson, 2006; Siegman, 2010; Sandell and Zhu, 2011; 
Bashkatov et al., 2014; Wei et al., 2005; Wall and Barton, 2014). 
Cold PBS at 4°C was used to keep tissue moist throughout data collection which took 
place within an hour after time of death. A 4°C, 0.01% w/v solution (1 mL) of proflavine in 
saline was topically applied to the tissue sample immediately prior to data collection. The 455 
nm LED, 635 nm laser, and tungsten-halogen lamp provided optical powers at the sample plane 
of 1.00 mW, 0.25 mW, and 0.35 mW, respectively. High-resolution fluorescence imaging and 
DRIM data were collected with an exposure time of 150 ms and gain of 10 dB whereas 
broadband DRS data used an integration time of 500 ms and boxcar width of 3 (Kiisk, 2014).  
Ten high-resolution fluorescence images, ten DRIM data, and three DRS data were acquired 
from the colon section. The best qualitative high-resolution fluorescence image was selected for 
comparison to H&E while the ten DRIM and three DRS data were averaged. 
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2.3.11 In vivo assessment of oral structural and optical properties 
The final objective of this study was to extract optical parameters from in vivo oral 
mucosa and elucidate the differences of the optical parameters for each SDS (374 and 730 μm). 
The multimodal technique was demonstrated in the inner lip of thirteen healthy volunteers, with 
no history of tobacco use, between the ages of 18-35. Institutional Review Board approval (IRB 
#15-09-149) was obtained from the Human Subjects Research program at the University of 
Arkansas for all aspects of this study. The methods described were carried out in accordance 
with the approved guidelines, and informed consent was obtained from all participants.  
Extracting optical parameters required two steps. First, in vivo data acquisition was 
carried out with custom LabVIEW software (Greening, James, Powless, et al., 2015). The probe 
was directly placed in contact with the inner lip and broadband DRS were acquired at both SDSs 
(374 and 730 µm). The tungsten-halogen lamp delivered 0.35 mW of power at the probe tip for 
500 ms. Additionally, in one volunteer, a single high-resolution fluorescence image was taken 
using topical proflavine (0.01% w/v in saline) as a contrast agent with an exposure of 100 ms and 
gain of 5 dB, thus demonstrating the capability of the probe to sequentially and non-invasively 
extract image and optical property data. Second, for post-processing, raw broadband DRS data 
was imported into custom MATLAB software which was integrated with the LUT-based inverse 
model and sampling depth LUT to extract optical parameters. The use of this post-processing 
algorithm to extract optical parameters has been previously described (Rajaram, Reichenberg, et 
al., 2010; Rajaram, Gopal, et al., 2010; Rajaram, Aramil, et al., 2010). 
The optical parameters extracted in this study were volume-averaged scattering exponent 
(B), hemoglobin concentration (THC), and oxygen saturation (StO2). Sampling depth was also 
quantified which is a function of the underlying optical parameters (Rajaram, Gopal, et al., 2010; 
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Rajaram et al., 2008; Sharma et al., 2013; Hennessy et al., 2014). The scattering exponent relates 
to the size of a tissue’s scattering particles, and thus can provide reasoning for changes in 
scattering when comparing groups within the same SDS (Mourant et al., 1998). Hemoglobin 
concentration and oxygen saturation are commonly derived measurements in optical 
spectroscopy to assess angiogenesis, and since blood vessel density has been shown to increase 
as oral tissue progresses from normal to dysplastic, extracting these parameters was important 
(Mourant et al., 2014). These optical parameters and their relation to µs’ and µa are given in Eq. 
9 and Eq. 10. The μs’ was calculated based on Eq. 9, 
𝜇𝑠
′(𝜆) = 𝜇𝑠
′(𝜆0) ∙ (
𝜆
𝜆0
)
−𝐵
 (9) 
where μs’(λ) is the reduced scattering coefficient (cm-1) at any wavelength, λ is a 
wavelength (nm), λ0 is 630 nm, and B is the scattering exponent (Sharma et al., 2013). The μa 
was calculated based on Eq. 10, 
𝜇𝑎(𝜆) = 2.303 ∙ [𝐻𝑏] ∙ (
1
𝑀𝑊
) ∙ [𝛼 (𝜀𝐻𝑏𝑜𝑥𝑦) + (1 − 𝛼) (𝜀𝐻𝑏𝑑𝑒𝑜𝑥𝑦)] (10) 
where μa is the absorption coefficient (cm-1) , THC is the bulk tissue hemoglobin 
concentration mg/mL), MW is the gram molecular weight of hemoglobin which is assumed to be 
64,500 g/mole (Prahl, 1999), α is the bulk tissue oxygen saturation, and ε is the molar extinction 
coefficient (cm-1M-1) of oxygenated hemoglobin (Hboxy) and deoxygenated hemoglobin (Hbde-
oxy). Some groups have also included a packaging correction factor when calculating µa for 
sampling wavelengths below 450 nm, but this was shown to have no impact on the LUT-based 
inverse model fits presented here since spectra were taken between 500-750 nm (Rajaram, 
Gopal, et al., 2010). 
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Figure 10 shows the experimental setup with the instrumentation, hybrid fiber-bundle 
probe, and post-processing software. For this experiment, it was hypothesized that the 730 μm 
SDS would yield reduced B values due longer SDSs having greater reflectance from longer 
wavelengths. Alternatively, the 730 μm SDS should yield greater THC values because of 
increased sampling into the sub-epithelia, where the blood vessels exist (Sharma et al., 2013; 
Chang et al., 2009). StO2 was expected to be comparable when sampling at different depths since 
changes in StO2 have been shown to not be depth dependent (Bezemer et al., 2009). Finally, we 
expected increased sampling depth for the longer SDS (Hennessy et al., 2014; Sharma et al., 
2013). Results from this study were expected to show the value of including two different sub-
diffuse reflectance spectroscopy SDSs along with a high-resolution fluorescence imaging 
capability.  
 
Figure 10. An image of the experimental setup showing the optical 
instrumentation, post-processing software based in MATLAB showing a high-
resolution fluorescence image of the inner lip, LUT-based inverse model fit of 
raw reflectance data, sampling depth, µs’, and µa from one volunteer (image 
center), and the proximal and distal hybrid fiber-bundle probe.  
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2.4 Results 
2.4.1 Characterization of the High-Resolution Microendoscopy Modality 
Figure 11 shows images taken of a positive 1951 USAF resolution test target at group 
3/element 3 (linewidth = 49.50 µm). These images were used to quantify spatial resolution, 
magnification, percent maximum FOV, and sampling frequency, listed in Table 2. The 50 mm 
tube lens (Figure 11(a)) was chosen for use with the 10X/0.30 NA infinity-corrected objective 
lens for data collection because of the desirable percent maximum FOV (%) and sampling 
frequency (pixels/fiber element) which were 100% and 5.4, respectively. This configuration 
maximizes the field-of-view while satisfying the Nyquist sampling requirement.  
 
Figure 11. Images of group 3/element 3 (linewidth = 49.50 µm) of a positive 
1951 USAF resolution test target taken with a 10X/0.30 NA infinity-corrected 
objective lens and tube lenses with focal lengths of (a) 50 mm, (b) 100 mm, and 
(c) 150 mm. The yellow arrow points to the same target on each image. 
 
Table 2. System specifications for the high-resolution modality with different tube lenses 
Focal Length of Tube Lens 50 mm 100 mm 150 mm 
Spatial Resolution [µm] 4.5 4.5 4.5 
Image sensor pixels/µm [pixels/µm] 1.21 2.65 3.61 
Magnification on CCD sensor 3.0 6.6 9.0 
Percent of Maximum FOV 100% 56% 30% 
Sampling Frequency [pixels/fiber] 5.4 11.9 16.2 
 
2.4.2 Generation of and validation of lookup tables for volume-averaged optical property 
extraction 
 
Figure 12 (a, b) shows the reflectance LUTs (μs’ = 5-26 cm-1 and μa = 0-10 cm-1) overlaid 
with the respective reflectance data from the dye-based calibration phantoms. Similarly, Figure 
12 (d, e) shows the reflectance LUTs overlaid with the respective data from the bovine 
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hemoglobin-based validation phantoms. Validation phantom data that perfectly overlays the 
LUT would indicate a 0% error; however, minor errors do exist. Additionally, Figure 12 (c, f) 
shows a ratio of the 730 to 374 μm SDS LUTs. The mean ratio is 1.14, with a standard deviation 
of 0.27, indicating a variable reflectance ratio as μs’ and μa vary. Notice that at high reduced 
mean free paths (low μs’ and μa) in Figure 12 (c, f), the reflectance ratio is at a maximum of 1.69, 
and at low reduced mean free paths (high μs’ and μa), the reflectance ratio is at a minimum of 
0.58. This trend supports the observation that longer SDSs are more sensitive to lower scattering 
values, especially at longer wavelengths. Similarly, shorter SDSs are more sensitive to higher 
scattering values. Thus, this reflectance ratio trend supports the validity of our LUTs.  
 
Figure 12. 100% (μs’ = 5-26 cm-1, μa = 0-10 cm-1) of both reflectance LUTs were 
validated with acceptable percent errors less than 10%. Following validation, 
optical properties can be reliably extracted from samples with unknown optical 
properties using the LUT-based inverse model. (a, b) Reflectance LUTs were 
interpolated with raw data from calibration phantoms and (c) shows a ratio of the 
730 µm SDS to 374 µm SDS LUTs. (d, e) Reflectance LUTs were validated with 
raw data from the bovine hemoglobin-based validation phantoms and (f) shows 
the validated ratio of the 730 µm SDS to 374 µm SDS LUTs. 
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The LUT-based inverse model correctly estimated µs’ of the validation phantoms with 
average percent errors of 1.6% and 2.5% for the 374 and 730 µm SDS, respectively. Minimum 
and maximum percent errors for µs’ extraction were 0.1% and 5.3% for the 374 µm SDS and 
1.2% and 11.4% for the 730 µm SDS, respectively. Additionally, the LUT-based inverse model 
correctly estimated µa of the validation phantoms with average percent errors of 4.2% and 7.2% 
for the 374 and 730 µm SDS, respectively. Minimum and maximum percent errors for µa 
extraction were 2.1% and 18.4% for the 374 µm SDS and 0.1% and 22.1% for the 730 µm SDS, 
respectively.  
Average percent errors were comparable to similar studies (< 10%) and considered 
acceptable (Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram et al., 2008; 
Rajaram, Reichenberg, et al., 2010; Vishwanath et al., 2011; Yu et al., 2010; Yu et al., 2008; 
Nichols et al., 2012; Sharma et al., 2013; Sharma et al., 2014). Thus, 100% of the optical 
property range of the LUTs were validated, and could be used to reliably extract volume-
averaged optical properties from unknown samples. Figure 13 shows the ability of the 
reflectance LUTs to extract accurate µs’ and µa.  
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Figure 13. The LUT-based inverse model correctly estimated µs’ with average 
percent errors of 1.6% and 2.5% for the 374 and 730 µm SDS, respectively, and 
correctly estimated µa with average percent errors of 4.2% and 7.2% for the 374 
and 730 µm SDS, respectively. The ability to extract optical properties is shown 
with a perfect fit line. 
 
2.4.3 Generation of and validation of lookup tables for sampling depth quantification 
 
Sampling depth ranged between 240 to 530 µm and 300 to 680 µm for the 374 and 730 
µm SDSs, respectively (Figure 14). In both cases, maximum sampling depth occurred when µs’ 
and µa were 0 cm
-1 and minimum sampling depth occurred at the maximum µs’ (26 cm-1) and 
maximum µa (10 cm
-1) in the target range of the LUTs. After validation with hemoglobin-based 
validation phantoms, sampling depth was estimated with average percent errors of 1.9% and 
1.6% for the 374 and 730 µm SDS, respectively. Minimum and maximum percent errors for µs’ 
extraction were 1.8% and 5.3% for the 374 µm SDS and 1.1% and 2.1% for the 730 µm SDS, 
respectively. Average percent errors, all under 2%, were considered acceptable in this study. 
Additionally, the ratio of sampling depths for the 730 to 374 µm SDS were calculated for the 
entire LUT range (Figure 14 (c, f)). On average, the sampling depth ratio was 1.20 with a 
standard deviation of 0.08, and relatively flat as expected. This indicates the sampling depth of 
the longer SDS is approximately 1.2x that of the shorter SDS across all wavelengths. 
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Figure 14. 100% (μs’ = 5-26 cm-1, μa = 0-10 cm-1) of both sampling depth LUTs 
were validated with acceptable percent errors much less than 10%. (a, b) 
Sampling depth LUTs were interpolated with raw data from calibration phantoms 
and (c) shows a ratio (1.2x) of the 730 µm SDS to 374 µm SDS sampling depths. 
(d, e) Sampling depths LUTs were validated with raw data from the bovine 
hemoglobin-based validation phantoms and (f) shows the validated ratio of the 
730 µm SDS to 374 µm SDS sampling depths. 
 
2.4.4 Hybrid Cell Phantoms 
A representation of the hybrid cell phantoms are shown in Figure 15(a, d). Sample data 
from the high-resolution, fiber-based fluorescence imaging modality are shown for both hybrid 
cell phantoms in Figure 15(b, e). DRIM data are shown in Figure 15(c, f) and the quantification 
of these maps is shown in Figure 15(g). DRIM data were quantified by using a MATLAB script 
to take a line plot through the center of the image circle and plotting intensity (in pixel values) 
over continuous SDS between 400 and 1,300 µm. Finally, broadband DRS data for both SDSs 
(374 and 730 µm) from both hybrid cell phantoms are shown in Figure 15(h, i).  
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Our hypothesis was supported. There was no discernable difference between high-
resolution image data of cultured breast adenocarcinoma cells between the two phantoms, but 
clear differences were seen in reflectance for the DRIM and DRS data. DRIM data shows greater 
signal closer to the 635 nm source delivery fiber, and intensity is markedly reduced for the 
double-layer phantom containing the more highly absorbing underlying layer. The overall shape 
of the DRIM profiles remains similar between samples, as expected. The shape of DRIM profiles 
are similar to those predicted by established Monte Carlo models of reflectance (Martinelli et al., 
2011). For the DRS data, intensity changes are due to increases in nigrosin concentration, which 
have a flat absorption spectra across the tested wavelengths (Greening et al., 2014). Also note 
that for the 730 µm SDS, there are increased reflectance contributions from longer wavelengths 
when compared to the 374 μm SDS, consistent with the 730 µm SDS sampling a greater depth 
range (Hennessy et al., 2014).  
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Figure 15. Demonstration of the three modalities showing data from the hybrid 
cell phantoms containing (a-c) one or (d-f) two layers. The figure shows (a, d) a 
SolidWorks representation of the single and double layer hybrid cell phantoms 
(with white arrows pointing at layers), (b, e) enhanced high-resolution 
fluorescence images after topical staining of MDA-MB-468 breast 
adenocarcinoma cells with proflavine (scale bar = 225 µm), (c, f) DRIM data 
(scale bar = 225 µm, color bar = 0-130), (g) quantification of the DRIM data 
taken across the face of the image fiber (400-1,300 µm SDS from laser source), 
(h) broadband DRS data (374 µm SDS), and (i) broadband DRS data (730 µm 
SDS).  
 
2.4.5 In vivo human melanocytic nevus 
For the healthy skin tissue and adjacent melanocytic nevus, data were collected for all 
three modalities, shown in Figure 16. A DSLR image of both tissue sites is shown in Figure 16(a, 
d) alongside the high-resolution fluorescence image (Figure 16(b, e)), DRIM data (Figure 16(c, f, 
g)), and broadband DRS at both SDSs of 374 and 730 µm (Figure 16(h, i)).  
Our hypothesis was supported. There were no discernable differences between high-
resolution image data between the keratinocytes of the benign melanocytic nevus and 
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surrounding tissue. In addition, differences were seen in DRIM and DRS modalities due to 
increased melanin concentration, contributing to increased μa (Jacques, 2015). 
Keratinocyte morphology can be distinguished in both sites in the high-resolution 
fluorescence images. Nuclei are not visualized in Fig 16(b, e) because pyranine-derived ink does 
not intercalate DNA, and thus only the cell membranes boundaries are visualized.  
Next, a comparison of DRIM data shows markedly different reflectance intensities across 
the face of the image fiber. The overall shape of the DRIM profiles remains similar between 
samples, as expected. The shape of DRIM profiles are similar to those predicted by established 
Monte Carlo models of reflectance (Martinelli et al., 2011). Finally, in vivo broadband DRS data 
was fit using the validated LUT-based model approach as previously described. Raw data (dots) 
and model fits (lines) are plotted together in Figure 16(h, i). DRS data shows Q-bands of 
hemoglobin at 542 and 577 nm for surrounding healthy tissue, although these Q-bands are 
masked by melanin contributions in the benign melanocytic nevus. The appearance of the Q-
bands in the reflectance spectra indicated that our instrument was sampling into the vascularized 
dermis (Prahl, 1999). 
Next, the LUT-based model extracted μs’ and μa from the normal skin and melanocytic 
nevus for both SDSs (374 and 730 μm). All listed optical properties were referenced at 630 nm. 
For normal skin, μs’ was estimated at 16.0 and 11.6 cm-1 while μa was estimated at 0.9 cm-1 for 
both the 374 and 730 μm SDS, respectively. For the melanocytic nevus, μs’ was estimated at 23.9 
and 28.0 cm-1 while μa was estimated at 13.8 and 12.3 cm-1 for the 374 and 730 μm SDS, 
respectively. These values for normal skin, as well as the relative increase in both μs’ and μa for 
the melanocytic nevus, are consistent with previously published results (Tseng et al., 2009; van 
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Leeuwen-van Zaane et al., 2013; Rajaram, Reichenberg, et al., 2010; Meglinski and Matcher, 
2002; Garcia-Uribe et al., 2011).  
 
Figure 16. Demonstration of technique showing data from (a-c) human healthy 
skin tissue and (d-f) adjacent melanocytic nevus. The figure shows (a, d) a digital 
image of the healthy skin and adjacent melanocytic nevus (scale bar = 1 mm), (b, 
e) cropped and enhanced high-resolution fluorescence images after topical 
staining with pyranine-derived highlighter ink (scale bar = 50 µm), (c, f) DRIM 
data (scale bar = 225 µm, color bar = 0-225), (g) quantification of the DRIM data 
taken across the face of the image fiber (400-1,300 µm SDS from 635 nm laser 
source), (h) broadband DRS data (374 µm SDS), and (i) broadband DRS data 
(730 µm SDS). Raw data are shown as dots and the LUT-based inverse model fits 
are shown as a curve.  
 
2.4.6 Ex vivo murine colon tissue 
For the healthy (C57BL/6J) mouse, data was collected for all three modalities, shown in 
Figure 17. A DSLR image of the resected piece of colon is shown in Figure 17(a) alongside the 
associated histology (Figure 17(b)) and high-resolution fluorescence image (Figure 17(c)), 
DRIM (Figure 17(d)), and broadband DRS at both SDSs of 374 and 730 µm (Figure 17(f, g)). 
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For the DRIM data, a line plot was taken through the center of each intensity map (Figure 17(d)) 
to create a plot of intensity as a function of SDS between 400 and 1,300 µm, shown in Figure 
17(e).  
Note the ability to clearly resolve glandular structure in the murine colon alongside 
spatially resolved sub-diffuse reflectance intensity. For the DRIM data, the overall shape is 
similar to previous results presented here with a shape similar to that predicted by Monte Carlo 
models of reflectance (Martinelli et al., 2011). The Soret bands due to hemoglobin can be clearly 
distinguished from the DRS data. The Q-bands (542 and 577 nm) are less apparent, most likely 
due to contributions from the underlying phantom layer. Also note that for the 730 µm SDS, 
there was increased reflectance contributions from longer wavelengths when compared to the 
374 μm SDS. This data demonstrates that data can be acquired from murine colon tissue. Future 
studies will forego the use of an underlying phantom in in vivo studies to elucidate the 
effectiveness of the DRIM and DRS modalities within a larger sample size.  
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Figure 17. Demonstration of the three modalities showing data from a 16-week 
old wild-type (C57BL/6J) male mouse. The figure shows (a) digital image of the 
4-5 cm colon tissue (lumen side facing up, scale bar = 5 mm), (b) histology of an 
adjacent section (scale bar = 50 µm), (c) cropped and enhanced high-resolution 
fluorescence image after topical staining with 0.01% w/v proflavine (scale bar = 
50 µm), (d) DRIM data (scale bar = 225 µm, color bar = 0-200), (e) quantification 
of the DRIM data taken across the face of the image fiber (400-1,300 µm SDS 
from 635 nm laser source), (f) broadband DRS data (374 µm SDS), and (g) 
broadband DRS data (730 µm SDS).  
 
2.4.7 In vivo assessment of oral structural and optical properties  
Thirteen volunteers underwent data collection in the oral mucosa via the hybrid imaging 
and spectroscopy microendoscope (Figure 18). One high-resolution fluorescence image is 
presented in Figure 18 (a) which shows the 1 mm-diameter image circle of the image fiber in 
direct contact with proflavine-stained oral mucosa. Individual cell nuclei appear as distinct white 
spots in the image. Figure 18 (b) shows representative absolute reflectance data from both the 
374 and 730 μm SDS from a single volunteer. Reflectance is presented as black dots and the 
LUT-based inverse model (Figure 12) and an established hemoglobin absorption spectrum 
(Prahl, 1999) was used to fit the data via custom post-processing software based in MATLAB. 
The fitted reflectance is a function of the volume-averaged optical parameters, B, THC, and StO2 
(Eq. 9 and Eq. 10). These values are presented as averages with standard deviations from the 13 
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volunteers in Figure 18 (d-f) and Table 1. Sampling depth was quantified and presented in Figure 
10 (c) after μs’ and μa were determined using the LUT-based inverse model (Figure 13). 
The 730 μm SDS typically demonstrates increased reflectance values, especially at 
wavelengths greater than 600 nm, indicating a greater contribution from the red and near-infrared 
region at larger source-detector separations. This phenomenon was responsible for the decreased 
B values at the longer SDS of 0.48 compared to 0.80 of the shorter SDS as shown in Figure 18 
(d). Average THC was significantly different at 2.39 and 2.91 mg/mL for the 374 and 730 μm 
SDS, respectively (Fig 18 (e)). These values support our hypothesis and demonstrate increased 
THC for the longer SDS compared to the shorter SDS. Average StO2 was not significantly 
different at 94.1% and 91.7% for the 374 and 730 μm SDS, respectively (Figure 18 (f)), 
supporting our hypothesis that oxygen saturation does not significantly vary with sampling 
depth. Finally, sampling depth ranged between 355 and 447 μm for the 374 μm SDS and 
between 435 and 563 μm for the 730 μm SDS, with the sampling depth minima occurring at the 
first Q-band of hemoglobin at 542 nm and the sampling depth maxima occurring at the furthest 
tested wavelength at 750 nm. Complete paired t-test statistics for optical parameters are shown in 
Table 3. 
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Figure 18. Comparison of qualitative and quantitative data acquired by the hybrid 
imaging and spectroscopy technique from 13 healthy volunteers showing (a) a 
high-resolution fluorescence image of apical oral mucosa from the inner lip of one 
volunteer (scale bar = 200 μm), (b) representative absolute reflectance profiles 
showing reflectance data and the overlaid LUT-based inverse model fits from the 
same volunteer from (a), (c) average sampling depths for each SDS, (d) scattering 
exponent (B), (e) hemoglobin concentration (THC), and (f) oxygen saturation 
(StO2). Error bars from (c-f) represent standard deviation. 
 
Table 3. Paired t-test statistics for extracted in vivo oral optical properties from LUT-based 
inverse model 
Optical 
Property 
374 μm SDS (n=13) 730 μm SDS (n=13) 
P-Value 
Significance 
(Y/N), α=0.01 Mean Std. Dev. Mean Std. Dev. 
B 0.80 0.19 0.48 0.25 8.8x10-4 Y 
THC (mg/mL) 2.39 0.44 2.91 0.65 8.8x10-3 Y 
StO2 (%) 94.1 10.0 91.7 9.10 4.6x10
-1 N 
 
2.5 Discussion 
We have demonstrated a hybrid spectroscopy and imaging probe capable of acquiring 
qualitative and quantitative data by combining high-resolution microendoscopy and broadband 
DRS. High-resolution fiber-bundle microendoscopy provides a highly resolved and magnified 
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image of apical epithelial architecture in a small 1 mm-diameter field-of-view while DRS 
provides quantitative optical parameters of tissue in approximately the same image region 
(Figure 1 and 2). By combining these two modalities, we can co-register qualitative image data 
and quantitative spectral data within a single probe. Co-registration is important because this 
technique can be potentially used to not only detect dysplasia using two different modalities, but 
also to monitor personalized response of sub-surface dysplastic lesions to anti-tumor therapy at 
two different source-detector separations.  
We characterized our technique in terms of spatial resolution, magnification, field-of-
view, sampling frequency, optical property extraction, and sampling depth (Figure 11-13, Table 
2). The technique was demonstrated in optical phantoms containing cultured MDA-MB-468 
breast adenocarcinoma cells (Figure 15, Table 1), an in vivo human melanocytic nevus of the 
skin (Figure 16), and ex vivo murine colon epithelial tissue (Figure 17). The validated LUT-
based inverse model was used to extract tissue optical properties of the in vivo human 
melanocytic nevus and surrounding healthy skin tissue.  
High-resolution fluorescence imaging, using a coherent fiber bundle image fiber, was 
chosen as the first modality because of its established success in diagnosis of dysplasia in various 
endoscopically accessible organs. This modality can provide highly-resolved qualitative data 
regarding structure and morphology of the apical layers of epithelial tissue. However, alone, it 
lacks the capability of providing functional information and imaging deeply into tissue. To 
overcome this limitation, broadband DRS was chosen as a second modality to provide 
quantitative functional, rather than structural, information at various sampling depth ranges in 
tissue. Thus, these modalities have great complimentary potential. A third modality, DRIM, was 
developed to provide 2D, spatially-resolved image maps of sub-diffuse reflectance intensity of 
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the same image area and field-of-view as the high-resolution fluorescence imaging modality. 
These additionally modalities, DRS and DRIM, can collect information below the surface, which 
wasn’t possible with conventional end-on fiber bundle microendoscopy (Gu et al., 2014; 
Muldoon et al., 2007; Pierce, Guan, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Chang et 
al., 2013; Keahey et al., 2015; Parikh et al., 2014; Kanick et al., 2014; Kanick et al., 2009; 
Hennessy et al., 2014; Jayanthi et al., 2011; Zonios et al., 1999; Marin et al., 2005; Greening, 
Powless, et al., 2015; Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Rajaram et al., 
2008; Rajaram, Reichenberg, et al., 2010). 
Other techniques have attempted to address similar technical limitations. For example, 
high-resolution imaging techniques have been coupled with wide-field autofluorescence 
imaging, such as with the commercially available VELscope, to increase field-of-view while 
increasing diagnostic specificity in dysplastic lesions (Pierce, Schwarz, et al., 2012). However, 
no functional depth-sensitive information is acquired. Several clinically available systems 
capable of providing highly resolved morphological information at varying depths are the Pentax 
ISC-1000 confocal endomicroscopy system (Pentax/Hoya, Japan and Optiscan Pty Ltd, 
Australia), and the Cellvizio system (Mauna Kea Technology, France), which have the capability 
of being coupled to conventional video endoscopes for combined widefield and confocal 
imaging (Jabbour et al., 2012). These commercial systems have significantly increased 
sensitivity and specific in cancer diagnostics, but still lack the quantitative features that make 
spectroscopy attractive. Additionally, the scanning optics necessary for such confocal systems 
can be costly to miniaturize (Jabbour et al., 2012). Our instrumentation design eliminates the 
need for scanning optics in favor of simple optics that combine high-resolution probe-based 
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fluorescence imaging with additional spectroscopy and reflectance modalities that can be 
potentially miniaturized for clinical use.    
In this study, we designed two sets of liquid phantoms (Figure 8) to generate and validate 
a LUT-based inverse model that was used to extract material optical parameters from raw DRS 
data for each SDS (Figure 12). As of the current report, the LUTs are valid for µs’ between 5-26 
cm-1 and µa between 0-10 cm
-1. These ranges of optical properties are sufficient to acquire 
accurate DRS data for many tissue types between 500-750 nm. Furthermore, our calibration and 
validation methods were optimized until all average percent errors were below 10% (Figure 12 
and 7), a benchmark error value comparable to many similar studies (Rajaram, Aramil, et al., 
2010; Rajaram, Gopal, et al., 2010; Rajaram et al., 2008; Rajaram, Reichenberg, et al., 2010; 
Bish et al., 2011; Bish et al., 2014; Sharma et al., 2013; Sharma et al., 2014; Nichols et al., 
2012; Nichols et al., 2015; Yu et al., 2008; Yu et al., 2010; Vishwanath et al., 2011; Hennessy et 
al., 2013). 
In the same set of calibration phantoms (Figure 8), sampling depth was determined for 
each SDS (Hennessy et al., 2014). A demonstration of calculating sampling depth was presented 
(Figure 9) and an empirical relationship was determined for sampling depth as a function of µa 
and µs’ (Figure 14). Sampling depths were comparable to a similar study by Hennessy et al 
(Hennessy et al., 2014).    
Next, the bench-top technique was applied to in vivo oral mucosa by collecting DRS data 
from the inner lip of 13 healthy volunteers (Figure 10). The LUT-based inverse model was used 
to extract the wavelength-dependent B, THC, and StO2 values from all 13 volunteers (Figure 18). 
The representative reflectance data demonstrates increased reflectance for the 730 μm SDS 
compared to the 374 μm SDS at wavelengths greater than approximately 600 nm, consistent with 
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previous findings (Greening, James, Powless, et al., 2015; Mirabal et al., 2002). It is well known 
that longer SDSs penetrate deeper into tissue, and thus longer wavelengths will dominate 
reflectance for longer SDSs (Sharma et al., 2013; Hennessy et al., 2014; Mirabal et al., 2002). 
This phenomenon is apparent when analyzing the scattering exponent (B). At longer separations, 
B values decrease because of greater reflectance from longer wavelengths.  
The extracted absorption-based optical properties, THC and StO2, were comparable to 
other studies (Amelink et al., 2011; Rajaram, Gopal, et al., 2010). The longer 730 μm SDS 
extracted greater THC compared to the shorter 374 μm SDS. This supports our hypothesis that 
the longer SDS sampled deeper into the tissue vasculature, although it is clear the vasculature is 
still being sampled with the 374 μm SDS (Prahl, 1999; Sharma et al., 2013; Chang et al., 2009). 
This penetration into the vasculature was expected since sampling depth in the short SDS was 
greater than 300 µm, which exceeds the non-vascularized epithelial thickness of the oral cavity 
(Greening, James and Muldoon, 2015). We anticipate the standard deviations for THC and StO2 
values (Figure 18 and Table 3) to be most likely due to variations in the pressure applied 
between the probe tip and volunteer’s inner lip. It has been shown that probe-pressure variations 
among measurements can induce large errors in THC and StO2, so future studies will seek to 
develop a real-time probe-pressure monitoring system similar in concept to those reported in 
other studies (Yu et al., 2014).  
The study presented here was an extensive validation of the quantitative spectroscopy 
modality of this technique. Since this technique has been validated, its ability to monitor tissue 
health in response to anti-tumor therapy can be further evaluated in pre-clinical and clinical 
studies. Additionally, future studies will explore quantitative measures regarding the high-
resolution fluorescence imaging modality, such as automated nuclear-to-cytoplasmic ratio and 
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cells-per-area calculations and co-register these values with DRS extracted optical parameters. 
Since this hybrid imaging and spectroscopy technique lacks a widefield imaging modality, future 
trials will explore designing probes with identical probe-tip geometries that are compatible with 
conventional endoscopes.  
The multimodal high-resolution imaging and sub-diffuse reflectance spectroscopy fiber-
bundle microendoscope reported here can be optimized and used by investigators for a variety of 
applications including endoscopic or handheld use for human or animal studies. It thus provides 
a flexible method for visualizing in vivo apical tissue micro-architecture alongside measurements 
of hemoglobin concentration, melanin concentration, and tissue oxygen saturation from two 
different tissue depths. This article describes the specifications for the fiber-optic probe, outlined 
a protocol for assembling the high-resolution imaging system and sub-diffuse reflectance 
imaging system, and shown its application in human tissues in vivo, using pyranine ink as the 
fluorescent contrast agent for tissue visualization. Other inks, such as proflavine or fluorescein, 
can be used instead of pyranine ink with appropriate approval (Chang et al., 2013; Muldoon et 
al., 2011; Greening, James, Powless, et al., 2015; Prieto, Powless, Boice, et al., 2015; Muldoon 
et al., 2010).   
Any probe feature may be modified from this design. For the high-resolution 
fluorescence microendoscopy modality, the 1 mm-diameter image fiber consisted of 50,000 
individual core fibers with 4.5 µm spacing, resulting in a constant sub-cellular spatial resolution 
of 4.5 µm. Investigators wanting a different sized image fiber to obtain a smaller or larger field-
of-view can find these image fibers readily available with diameters between 0.14 and 1.40 mm. 
A tube lens with focal length of 50 mm was chosen such that the CMOS sensor captured the full 
1-mm field-of-view from the image fiber. When keeping the objective lens constant, increasing 
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the focal length of the tube lens will increase magnification and sampling frequency but decrease 
field-of-view (Greening, James, Powless, et al., 2015). Thus, the magnification of the objective 
lens, focal length of the tube lens, size of the image sensor, and size of the image fiber can and 
should be optimized depending on need. Finally, filters and excitation light source may be 
modified depending on the excitation/emission spectra of fluorescent dyes (Muldoon et al., 2010; 
Chang et al., 2013; Prieto, Powless, Boice, et al., 2015; Muldoon et al., 2011). In addition to 
modifying the probe and high-resolution fluorescence microendoscopy instrumentation, the sub-
diffuse reflectance spectroscopy instrumentation can be modified. 
For the sub-diffuse reflectance spectroscopy modality, different sized multimode fibers 
can be used at each SDS. Smaller diameter multimode fibers will be able to deliver and collect 
light over a smaller area, but it is recommended to use an array of identically spaced fibers to 
increase signal-to-noise if fiber diameters less than 200 µm are used. Investigators analyzing skin 
or oral tissue may benefit from an overall larger probe to increase field-of-view and signal-to-
noise, but in narrower luminous organs, such as the esophagus or gastrointestinal tract, 
investigators will face added constraints regarding probe size, especially for compatibility with 
the biopsy port of conventional endoscopes (Parikh et al., 2014). Other spectroscopy components 
that may be modified include the broadband light source and motorized optical switch. A 
tungsten-halogen lamp was chosen in this case, although other light sources can and have been 
used in other studies, including xenon arc lamps and LEDs, which may increase signal-to-noise 
and lower integration times (Rajaram, Reichenberg, et al., 2010; Yu et al., 2014; Bish et al., 
2014). The motorized optical switch presented here was custom built to handle up to three SDSs, 
but can be modified to include more or less inputs. It should be noted that the motorized optical 
switch does add an additional optical component between the broadband light source and 
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spectrometer, decreasing signal-to-noise. The switch may not be necessary for investigators with 
multiple spectrometers that acquire data simultaneously, but including an optical switch 
component ultimately reduces instrumentation cost by approximately $3,000USD per SDS. 
Construction of the instrumentation (Figure 4 and 5) is fairly straightforward. The most 
critical step in this protocol is the calibration of the sub-diffuse reflectance spectroscopy 
modality (Figure 6 and 7). Calibration must be completed immediately prior to spectral data 
collection. Once calibration has been completed, ensure no pieces of the instruments are shut 
off or re-calibration may be necessary. Proper calibration is necessary to obtain accurate 
reflectance spectra, and thus obtain accurate values for underlying melanin concentration, 
hemoglobin concentration, and tissue oxygen saturation from an unknown sample. Conveniently, 
most investigators use similar calibration techniques which have been well described (Greening, 
James, Powless, et al., 2015; Rajaram, Gopal, et al., 2010; Rajaram, Reichenberg, et al., 2010; 
Nichols et al., 2012). Information regarding software requirements for converting reflectance 
spectra into optical parameters can be found elsewhere (Rajaram et al., 2008; Greening, James 
and Muldoon, 2015; Greening, James, Powless, et al., 2015). 
In regard to troubleshooting, spectra resulting in poor fits (average percent errors greater 
than 10% between raw data and fitted data) will yield unreliable values for the three tissue 
physiological parameters (THC, [Mel], and StO2) presented here. Poor fits are most likely the 
result of either movement between the probe and skin site during data acquisition, narrow 
boundary conditions in the post-processing code, or unreliable a priori values of THC and [Mel] 
(Prahl, 1999; Greening, James, Powless, et al., 2015; Rajaram et al., 2008; Greening, James and 
Muldoon, 2015). Improvements in these three common error occurrences should fix the accurate 
fitting of sub-diffuse reflectance spectra. Thus, data collection can be improved by reducing 
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spectrometer integration time to reduce motion artifacts within the spectra. Additionally, 
boundary conditions represent the range of possible computational output values for THC, [Mel], 
and StO2 following post-processing. In these studies, boundary conditions were 0-10 mg/mL for 
THC (Prahl, 1999; Rajaram, Aramil, et al., 2010), 0-40 mg/mL for [Mel] (Karsten and Smit, 
2012; Glennie et al., 2015), and 0-100% for StO2 (Lim et al., 2011), which are based on values 
from previous studies (Prahl, 1999; Karsten and Smit, 2012; Lim et al., 2011; Rajaram, Aramil, 
et al., 2010; Glennie et al., 2015). If measuring tissue without melanin, the lower and upper 
bounds for [Mel] can both simply be set to 0 mg/mL. Finally, it is recommended to use 
established a priori absorbance values for hemoglobin and melanin published by Prahl et al 
(Prahl, 1999). These simple improvements should fix the accurate fitting of sub-diffuse 
reflectance spectra, and if questions remain, spectra can be validated with phantoms with known 
optical properties (reduced scattering and absorption coefficients).  
The primary limitation to this multimodal imaging and spectroscopy fiber-bundle 
microendoscopy platform is the lack of a widefield imaging modality. The high-resolution 
fluorescence microendoscopy modality has a circular field-of-view that is 1 mm in diameter, 
making it difficult to rapidly scan a large area of tissue. One computational method to overcome 
this limitation is image mosaicking, a technique used to provide a broader field-of-view by 
stacking adjacent micro-scale images into a single, larger image map (Prieto, Powless, Lai, et al., 
2015). Such image mosaicking has been previously demonstrated by Prieto et al. to investigate 
colonic image features (Prieto, Powless, Lai, et al., 2015). An instrumentation modification to 
overcome this limitation would be making the probe compatible with the biopsy port of a 
conventional endoscope, such as the probe presented by Parikh et al. to investigate colorectal 
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neoplasia (Parikh et al., 2014). This feature combines the advantages of a wide field-of-view 
with micro-scale imaging of high-resolution fluorescence microendoscopy (Parikh et al., 2014).  
Overall, this technique was demonstrated on in vivo human skin and shows the value of 
co-registering high-resolution tissue micro-architectural images with the underlying melanin 
concentration, hemoglobin concentration, and tissue oxygen saturation. This technique can be 
used by researchers wishing to investigate the link between structural and functional tissue 
abnormalities in vivo or analyzing tissue functional changes in the absence of observable 
structural changes. Future studies will investigate the viability of this technique in various 
epithelial disease states.  
2.6 Conclusion 
We have developed a hybrid spectroscopy and imaging technique comprising of a 
conventional fluorescence fiber-bundle microendoscopy platform coupled with a series of off-
axis broadband spectroscopy (DRS) channels. Since dysplasia can initially arise near the 
epithelial basement membrane, collecting structural and functional information from deeper 
within the tissue microenvironment is critical for many applications, including detection of early 
dysplasia, analysis of tumorigenesis, and monitoring of therapeutic response. As a result, this 
hybrid imaging and spectroscopy platform may be capable of collecting a wealth of information 
about the structural and functional properties of tissue at various imaging sites in ex vivo and in 
vivo models.  Finally, the potential of this technique to be coupled to the biopsy port of a 
conventional endoscope makes further clinical translation and complimentary optical biopsy in 
the oral cavity and other epithelial tissues feasible.  
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Chapter 3 (Specific Aim 2): Characterization of poly(dimethylsiloxane)-based tissue-
simulating phantoms with tunable reduced scattering and absorption coefficients with 
applications for diffuse reflectance spectroscopy 
 
3.1 Introduction 
The translation of novel optical imaging techniques from a basic laboratory setting to a 
clinical setting requires substantial calibration and validation, which is often performed on 
tissue-simulating materials known as phantoms. Tissue-simulating phantoms have several broad 
applications in regard to imaging systems including optimizing software and hardware, gathering 
preclinical data in advance of clinical trials, and are necessary for providing proof of 
reproducibility between trials of certain optical imaging techniques (de Bruin et al., 2010; Saager 
et al., 2010; Cerussi et al., 2012). For example, optical coherence tomography (OCT) may use 
phantoms to determine vital instrumentation characteristics including axial and lateral resolution 
and point spread function (Gu et al., 2012; Agrawal et al., 2013). Diffuse Optical Spectroscopic 
Imaging (DOSI) techniques may use phantoms for initial calibration and stability measurements 
between trials (Cerussi et al., 2012). Features of phantoms that are viewed as especially 
important include precise control of phantom geometry, the ability to easily modify and quantify 
scattering and absorption properties across commonly used wavelengths, stability over time, a 
comparable refractive index to human tissue, and the ability to introduce thin layers of different 
optical properties to simulate heterogeneities commonly seen in tissue (de Bruin et al., 2010; 
Saager et al., 2010; Cerussi et al., 2012; Moffitt et al., 2006; Pogue et al., 2006). These 
heterogeneities may represent layers of different cell types as seen in the interface between the 
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dermis and epidermis of the skin, or as malignant morphological changes in a single tissue type 
as a result of disease (de Bruin et al., 2010).         
Optical phantoms are a widely used tool to validate optical instrumentation. In essence, 
phantoms are “false-tissues” made of various materials and can be liquid, solid, or gelatinous. 
Generally, phantoms are made to either simulate a tissue’s optical, mechanical, chemical, or 
physical properties, or a combination of these. These structures are typically comprised of a base 
substrate material which can be doped with certain additives that give the material specific 
optical, mechanical, or chemical properties. Additionally, depending on the substrate material 
used and desired geometry, optical phantoms can be molded into a variety of shapes and sizes for 
different applications (Pogue et al., 2006; Greening et al., 2014; Lamouche et al., 2012). 
This chapter opens with a review of optical phantoms as validation tools for imaging and 
spectroscopy platforms, with a majority of the discussed optical instrumentation being probe-
based. This will provide insight into the use of optical phantoms within the context of current 
biomedical optics research. Following this, the “diffuse” and “sub-diffuse” scattering regimes 
governing light transport through tissue will be addressed. Distinguishing between the “diffuse” 
and “sub-diffuse” scattering regimes is important for several reasons including 1) generating 
design requirements for probe-based instrumentation, especially for determining appropriate 
source-detector separations in spectroscopy probes, 2) evaluating the accuracy of computational 
or numerical models of light transport, and 3) understanding the optical properties of target 
human tissues and designing optical phantoms to mimic such tissues. Finally, this chapter 
concludes with a tutorial on how to construct thin, solid, multilayer tissue-simulating phantoms 
using a spin-coating technique for a variety of applications, and a tutorial on how to construct 
liquid phantoms to build a lookup table (LUT) inverse model to extract optical properties using 
125 
 
diffuse or sub-diffuse reflectance spectroscopy.  
3.2 Phantoms in Probe-Based Optical Systems 
Each subtype of optical phantom discussed in this section will be described based on their 
intended application, substrate material, scattering and absorbing agents, corresponding reduced 
scattering coefficients (μs’) and absorption coefficients (μa), and experimental design. 
Additionally, the probe and/or detector used to acquire data will be briefly described. Optical 
phantoms for validating instrumentation in high-resolution microendoscopy, hyperspectral 
imaging, diffuse optical tomography, reflectance spectroscopy, fluorescence spectroscopy, and 
Raman spectroscopy will be discussed.  
3.2.1 High-resolution microendoscopy 
High-resolution microendoscopy is a non-invasive, imaging technique that couples a light 
source to a small image fiber probe. The probe is placed in contact with an exogenously stained 
sample, is excited via an illumination source, and then fluorescence emission travels back 
through the probe, distal optics, and into an image sensor to provide high-resolution, spatially 
resolved images of tissue morphology. Contrast may be provided by a variety of exogenous 
tissue stains. Various high-resolution microendoscopy techniques have been explored to reduce 
signal contributions from outside the focal plane, including two-photon and confocal 
microendoscopic systems, as well as structured illumination (SI). Optical phantoms are a useful 
tool in high-resolution microendoscopy to investigate imaging parameters or for a demonstration 
of technique prior to imaging ex vivo or in vivo tissue samples (Bedard et al., 2012; S. S. Chang 
et al., 2013; Campbell et al., 2010; Muldoon et al., 2008; Muldoon et al., 2007; Muldoon et al., 
2011; Kyrish et al., 2013; Louie et al., 2014; Parikh et al., 2014; Prieto et al., 2015; Pierce, 
Guan, et al., 2012; Pierce, Schwarz, et al., 2012; Pierce et al., 2011; Quinn et al., 2012; Shin et 
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al., 2015; Shukla et al., 2011; Koucky et al., 2013; Gu et al., 2010; Shahmoon et al., 2013; 
Keahey et al., 2015; Maitland et al., 2006; Makhlouf et al., 2011; Rogers et al., 2008). Figure 1 
shows a simple schematic of high-resolution microendoscopy instrumentation. Note that some of 
the specific research discussed in the following paragraphs employs modified instrumentation. 
 
Figure 1. Simple schematic of high-resolution microendoscopy instrumentation 
showing an LED delivering light through an excitation filter (Ex.F.), lens (Lens), 
dichroic mirror (D.M.), and objective lens (Obj.) through a probe to a phantom. 
Fluorescence emission light travels through the probe, objective (Obj.), dichroic 
mirror (D.M.), tube lens (T.L.), emission filter (Em.F.), and camera (Cam.). 
 
One common technique for optical phantom creation is constructing cell-based phantoms 
using buffered collagen type I from rat tail tendons as a substrate material. For this technique, 
collagen type I is added to a pellet of target epithelial cells cultured via conventional in vitro 
methods, such as human cervical adenocarcinoma cells, cervical squamous cell carcinoma, or 
oral squamous cell carcinoma. This mixture is transferred to a well plate and allowed to culture 
until the collagen-cell matrix forms a gel with a desired thickness. The resultant gel is densely 
packed with collagen and epithelial cells throughout (Gu et al., 2010; Maitland et al., 2006; 
Rogers et al., 2008; Sokolov et al., 2003). Studies have modified this technique with various cell 
types and exogenous contrast agents for high-resolution microendoscopic imaging. One study 
used a non-linear, probe-based microendoscope to investigate a collagen-based optical phantom 
containing human cervical adenocarcinoma (HeLa) cells for targeted photothermal therapy 
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microsurgery. The HeLa cells were labeled with transferrin-conjugated gold nanorods and mixed 
with propidium iodide. The probe was placed in gentle contact with the phantom surface and a 
near infrared (NIR) laser irradiated the phantom at the nanorod peak absorption (790 nm) from 
0-252 μm in depth at 4 μm increments to induce HeLa cell necrosis. Then, a 740 nm laser was 
used to image the propidium iodide, which was used to stain necrotic cell death. In this way, the 
HeLa cell-based phantom’s response to photothermal therapy could be quantified (Gu et al., 
2010). In another case, collage type I was infused with human cervical squamous cell carcinoma 
(SiHa) cells to demonstrate the imaging and video capture capabilities of a single fiber 
reflectance confocal microendoscope (SFCM) with a 140 μm x 100 μm field-of-view (FOV). For 
this system, the probe was placed in contact with the SiHa cell-based phantom surface and a 635 
nm laser diode and micro-electro-mechanical system (MEMS) scanning device were used to 
raster scan the full FOV (Maitland et al., 2006). As another demonstration of a separate high-
resolution imaging device, optical phantoms were created using collagen type I as the substrate 
material with suspended human oral squamous cell carcinoma cells (1483 line). The cell-based 
collagen phantom was labeled with 10 nM streptavidin-coated quantum dots,(Stanisavljevic et 
al., 2015) small semiconductor materials whose fluorescent properties are governed by their size, 
and gold nanoparticles, and then fixed in 10% formalin to preserve the phantom’s structure. For 
imaging of fluorescent contrast agents within the collagen-based phantom, the probe contained a 
multimode fiber coupled to a 450 nm LED with a circular 250 μm-diameter FOV (Rogers et al., 
2008; Sokolov et al., 2003). In addition to cells, other groups use fluorescent beads to 
characterize or demonstrate their high-resolution microendoscopy systems. 
Three-dimensional phantoms can be created using water and agar, instead of collagen, as 
the substrate material and Intralipid, a soybean oil emulsion, as the scattering agent. 
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Microendoscopy studies typically use this design to study the effects of out-of-plane scattering, 
which can decrease image contrast (Koucky et al., 2013; Keahey et al., 2015). One confocal-
based microendoscopy study built agar-based phantoms with 14.8 μm-diameter green fluorescent 
beads as the fluorescent agent. Intralipid was added at increasing concentrations from 0%, 0.5%, 
and 2.0% to create non-scattering, low-scattering, and high-scattering phantoms molded into a 
petri dish. At 520 nm, the low and high scattering phantoms had a μs’ of 10.8 and 25.4 cm-1. The 
3D phantoms were imaged by placing a 455 nm LED-coupled probe in contact with the phantom 
and exciting fluorescence from the beads. Additionally, the phantom was imaged with the 
objective lens only to acquire in-focus images of beads at various depths within the phantom 
(Koucky et al., 2013). Another similar microendoscopy study, using structured illumination, 
constructed optical phantoms using agar and deionized water as the substrate material and 
Intralipid as the scattering agent. Fluorescent polystyrene microspheres were used as the 
fluorescent agent. The phantom was constructed to simulate the optical properties of cervical 
columnar epithelium and was imaged by placing the 455 nm LED-coupled probe in gentle 
contact with the phantom surface to acquire images with and without structured illumination for 
comparison (Keahey et al., 2015).  
Thus far, the explored experimental setups have revolved around using a probe in contact 
with the phantom surface, although one technique uses microendoscopy submerged within a 
blood-mimicking liquid phantom (Shahmoon et al., 2013). The purpose of this technique is to 
quantify hemoglobin concentration using a microendoscopy imaging probe. A liquid phantom 
was created with a mixture of water as the substrate material, and Intralipid and human 
hemoglobin and Intralipid as the scattering and absorbing agents, respectively, to mimic human 
blood. The mixture was flowed through a 400 μm-diameter channel within a solid phantom block 
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made of polyurethane and titanium dioxide (TiO2). Different oxygenation levels of hemoglobin 
were used to test the instrument’s capability of monitoring hemoglobin concentration. A 532 nm 
laser-coupled probe was submerged within the flow channel to illuminate the liquid hemoglobin 
phantom to quantify the difference between absorbance intensities to indicate hemoglobin 
concentration (Shahmoon et al., 2013).  
As demonstrated, optical phantom use in microendoscopy has myriad applications, 
including but not limited to demonstration of imaging technique, photothermal therapy, and 
investigating methods to reduce out-of-focus light (Koucky et al., 2013; Gu et al., 2010; 
Shahmoon et al., 2013; Keahey et al., 2015; Maitland et al., 2006; Rogers et al., 2008; Makhlouf 
et al., 2011).  
3.2.2 Hyperspectral imaging 
Hyperspectral imaging is a non-invasive hybrid technique that combines spectroscopy 
and imaging. A two-dimensional (2D) detector array is used to collect images of a region of 
interest. The novelty of hyperspectral imaging is that each pixel on the 2D detector array also 
collects a spectrum that can potentially span the entire UV-NIR region. This generates what is 
known as a hypercube, a 3D dataset containing spectral and spatial information. Since 
hyperspectral imaging produces spectra at each pixel, optical properties at each pixel can often 
be quantified using LUT inverse models, Monte Carlo (MC) inverse models, or diffusion models 
(Lu et al., 2014; Bish et al., 2014; Lue et al., 2012; Xu et al., 2012; Tseng et al., 2011; Zonios et 
al., 1999). Figure 2 shows a simple schematic of hyperspectral imaging instrumentation. Note 
that some of the specific research discussed in the following paragraphs employs modified 
instrumentation.  
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Figure 2. Simple schematic of hyperspectral imaging instrumentation showing a 
source (Wht. Light) delivering broadband light through a polarizer (Pol.) and lens 
(Lens) to a phantom. Emitted light from the phantom passes through a lens 
(Lens), polarizer (Pol.), and another lens (Lens) into a spectrograph. 
 
 Water-based liquid phantoms are the most common medium for phantom construction in 
hyperspectral imaging. One study developed two sets of optical phantoms to test the accuracy of 
a LUT-based inverse model in estimating μs’ and total hemoglobin concentration (THC) using a 
handheld hyperspectral imaging system. The first set of water-based liquid phantoms were 
constructed inside a container and polystyrene microspheres and red food dye were added to 
simulate scattering and absorbing properties, respectively. Hyperspectral images were taken of 
the phantoms and spectra from each pixel were used to create a LUT of reflectance as a function 
of μs’ and absorber concentration. Accuracy of the LUT was validated on a second set of water-
based phantoms containing polystyrene microspheres and human lyophilized powder and was 
shown to be accurate with μs’ values between 10 to 30 cm-1 and THC between 0 to 3 mg/mL. 
Following validation, the hyperspectral imaging system was tested on in vivo skin (Bish et al., 
2014).  
A similar study acquired hyperspectral images of optical phantoms to validate the ability 
of an MC inverse model, rather than a LUT inverse model, to extract tissue optical properties. 
Three liquid phantoms were prepared inside a clear cylinder 10 mm in diameter and 200 mm in 
height using polystyrene microspheres and red ink as the scattering and absorbing agents, 
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respectively. Ranges of μs’ were from ~10 to 20 cm-1 and ranges of μa were from ~0 to 4 cm-1. A 
fiber bundle containing an image-fiber coupled to a hyperspectral imaging camera and off-axis 
broadband source fiber was dipped into the liquid phantoms to acquire spatially-resolved diffuse 
reflectance spectra. These spectra were compared to simulated reflectance spectra from MC 
models (Tseng et al., 2011). In addition to using inverse models such as LUT and MC models, 
diffusion models have also been developed to extract a sample’s optical properties with low 
errors.  
The diffusion model can be applied in a similar mechanism to LUT and MC inverse 
models, in which phantoms with known optical properties are created and actual spectral data is 
compared to spectral data predicted by the diffusion model. For example, one group developed 
hyperspectral instrumentation to delineate tumor margins during surgery by quantifying optical 
properties, specifically THC. To quantify THC in vivo, 15 liquid-based phantoms were first 
prepared with 2% Intralipid as the scattering agent, and either hemoglobin or blood as the 
absorbing agent. Liquid phantoms with known THC were pipetted into a container until the 
liquid was 2.5 mm deep and diffuse reflectance spectra were acquired from each pixel of the 
hyperspectral scanner. The diffusion model was shown to be accurate for extracting THC from 
~0 to 6 mg/mL. Following phantom validation testing, the scanner was used to delineate tumor 
margins in resected, diseased breast tissue (Lue et al., 2012; Zonios et al., 1999). Building 
phantoms is an important step for instrumentation and model validation. However, there is a 
need for readily available phantoms for investigators to use to cut down on the time and research 
costs required to build such validation tools (Xu et al., 2012).  
To address this need for standardization, digital tissue phantoms (DTPs) have recently 
been developed that could potentially be accessed by investigators and medical device 
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manufacturers around the world for their validation needs. The DNP was specifically created for 
hyperspectral imaging applications to measure oxygenation in chronic ischemic wounds. The 
DTP was built by acquiring hyperspectral data cubes from a biological system and digitally 
reproducing the cube. The liquid phantoms for DNP construction were made using phosphate 
buffered saline (PBS) as a substrate material, powdered milk solution as the scattering agent, and 
4% porcine whole blood and India ink as the absorbing agents, yielding a μs’ of 6.0 cm-1 at 690 
nm. The hyperspectral data cube was acquired with a hyperspectral linear camera at 240 
wavelengths between 380 and 885 nm at phantom oxygenation levels between 4-96% (Xu et al., 
2012).   
The primary objective for constructing phantoms for hyperspectral imaging is to validate 
a model’s ability to extract optical properties of phantoms with known values. Additionally, 
work has been done to standardize and digitize this technique for hyperspectral imaging 
applications (Lu et al., 2014; Bish et al., 2014; Lue et al., 2012; Xu et al., 2012; Tseng et al., 
2011; Zonios et al., 1999).  
3.2.3 Diffuse optical tomography 
Diffuse optical tomography (DOT) is a non-invasive imaging technique that aims to 
quantify optical properties of tissues using various image reconstruction algorithms. Far red and 
near-infrared light, encompassing the spectral region between 650-1000 nm, is delivered to tissue 
and collected. Light in this range can penetrate several centimeters into a sample because of the 
low μa of water, lipids, and hemoglobin. Collected light is used to construct tomographic maps of 
tissue optical properties using various image reconstruction algorithms (Dehghani et al., 2009; 
Mora et al., 2015; Gonzalez-Rodriguez et al., 2015; Bi et al., 2015; Wu et al., 2014; Saikia et al., 
2014; Valim et al., 2013; Ansari et al., 2014; Guggenheim et al., 2013; Puszka et al., 2013; 
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Sharikova et al., 2014; Tavakoli et al., 2011). Figure 3 shows a simple schematic of DOT 
instrumentation. Note that some of the specific research discussed in the following paragraphs 
employs modified instrumentation. 
 
Figure 3. Simple schematic of diffuse optical tomography instrumentation 
showing a laser delivering light to a mirror (Mir.) and lens (Lens) and is raster 
scanned across a phantom using a mirror galvanometer (Gal.). Emitted light is 
delivered to a lens (Lens) and image sensor (Cam.) which is controlled with a 
delay mechanism (Delay). 
 
Most optical phantom studies for DOT involve validating an image reconstruction 
algorithm within optical phantoms containing heterogeneities to investigate the instrument’s 
ability to detect or delineate these inclusions. For the DOT phantom studies presented here, 
heterogeneities are solids that are contained within a surrounding bulk solid or liquid substrate 
material. For example, one study constructed breast-tissue mimicking phantoms with known 
optical properties (μs’ = 1.14 cm-1, μa = 0.07 cm-1 at 780 nm). Optical phantoms were constructed 
using agarose as the substrate material to create a gel-based phantom with 10% Intralipid as the 
scatterer and India ink as the absorber. Cylindrical heterogeneities (0.7 cm in diameter) 
simulating the optical properties of malignant breast tissue (μs’ = 1.92 cm-1, μa = 0.15 cm-1 at 780 
nm) were placed inside the normal phantoms at varying locations and the image reconstruction 
algorithm was used to identify and delineate the inclusion (Ansari et al., 2014). Similarly, DOT 
image reconstruction algorithms have been demonstrated in cylindrical gel-based optical 
phantoms with TiO2 as the scatter and whole porcine blood as the absorber. Within this 
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cylindrical phantom, a 25 mm-diameter hole was drilled 10 mm from the phantom’s edge which 
was filled with a 0.75% Intralipid and 4% porcine blood. This created a heterogeneity that 
contained an approximately 2:1 ratio of total hemoglobin compared to the background phantom. 
Six wavelengths between 649-850 nm were used to acquire images, and the DOT image 
reconstruction algorithm was subsequently applied (Dehghani et al., 2009).  
Solid optical phantoms with heterogeneities are also beneficial for small animal imaging 
using DOT. For example, phantoms can be designed to simulate the size and optical properties of 
a whole mouse. This mouse-simulating phantom was designed to be of similar size to a mouse 
and was made in a 25 mm-diameter, 50 mm-long cylinder. The phantom was built with a 
spatially homogenous solid plastic as the substrate material with varying μs’ between 16.3 and 
17.9 cm-1 and μa between 0.07 and 0.12 cm-1 within a spectral range of 500 to 850 nm. Two 6 
mm-diameter holes were drilled in the phantom in which either inclusions or background-
matching rods could be added. Images were collected of the phantom under different 
illumination patterns and the reconstruction algorithm was applied to produce an reconstructed 
image of the inclusion rods (Guggenheim et al., 2013). 
Other groups have explored their DOT instrument’s capability to resolve solid inclusions 
within a surrounding liquid phantom. For example, time-resolved DOT at short source-detector 
separations was investigated using a liquid phantom built inside a 17 cm (length), 10 cm (width), 
and 7 cm (height) container. The liquid phantom was made using water, Intralipid and black ink, 
corresponding to a μs’ and μa were 10 cm-1 and 0.1 cm-1 of 820 nm. Inside the container was a 
solid, resin-based cylinder doped with TiO2 and black ink that served as an inclusion to measure 
depth sensitivity. At 820 nm, the cylinder’s μs’ and μa were 10 cm-1 and 0.6 cm-1. NIR spectral 
measurements were taken with an 820 nm light source at 6 source-detector separations between 5 
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and 15 mm and a reconstruction algorithm was applied (Puszka et al., 2013). Similarly, a 
prostate-simulating optical phantom with μs’ of 7 cm-1 and μa of 0.3 cm-1 was created inside 
container. Two solid PVC-based inclusions were added to the liquid phantom. The first inclusion 
had a μs’ of 15 cm-1 and μa of 0.5 cm-1 and the second had a μs’ of 15 cm-1 and μa of 0.9 cm-1. A 
robotically-controlled DOT platform and custom reconstruction algorithm, based on the steady-
state light diffuse equation, was used to reconstruct images of the inclusions within the prostate-
simulating phantoms (Sharikova et al., 2014). In another study, a bulk liquid phantom was made 
to simulate healthy breast tissue. The breast tissue-simulating phantom was constructed with 
0.8% Intralipid to yield a μs’ range from 6.9 to 7.8 cm-1 and a near-negligible μa range from 0.02 
to 0.03 cm-1 at 780 nm. A low-contrast breast lesion phantom was made using a solid plastisol, a 
suspension of polyvinyl chloride (PVC), as the substrate material to have μs’ and μa of 5.6 cm-1 
and 0.075 cm-1. Additionally, a high-contrast breast lesion phantom was made, also using solid 
plastisol, to have μs’ and μa of 6.53 cm-1 and 0.158 cm-1. These low and high-contrast 
heterogeneities were submerged at different depths with the background Intralipid-based 
phantom and measurements were taken with a handheld DOT system and post-processed using 
the depth-correction algorithm (Tavakoli et al., 2011). 
As discussed here, optical phantoms for DOT applications usually have some type of 
optical or mechanical inclusion that can be detected after an image reconstruction algorithm has 
been applied to DOT-acquired data (Dehghani et al., 2009; Ansari et al., 2014; Tavakoli et al., 
2011; Sharikova et al., 2014; Puszka et al., 2013; Guggenheim et al., 2013).  
3.2.4 Diffuse reflectance spectroscopy 
Diffuse reflectance spectroscopy is a non-invasive spectroscopic technique in which a 
light source, typically a broadband source, is coupled to a fiber-optic cable embedded within a 
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small probe. Light is delivered to tissue by placing the probe in contact or near-contact with the 
tissue surface. Light reflects back into an adjacent, embedded fiber-optic cable that delivers 
reflected light to a spectrometer to recover tissue spectra. Models, such as LUT, MC, and 
diffusion models can be used in conjunction with the tissue reflectance spectra to extract the 
tissue’s optical properties, similar to techniques discussed with hyperspectral imaging (Alerstam 
et al., 2008; Baran, Fenn, et al., 2013; Bender et al., 2009; Bosschaart et al., 2011; Bremmer et 
al., 2011; Bremmer et al., 2013; Bydlon et al., 2010; Chang et al., 2011; Dhar et al., 2012; Fu et 
al., 2010; Sharma et al., 2014; Nichols et al., 2012; Glennie et al., 2014; Rajaram et al., 2008; 
Rajaram, Aramil, et al., 2010; Rajaram, Reichenberg, et al., 2010; Rajaram, Gopal, et al., 2010). 
Figure 4 shows a simple schematic of reflectance spectroscopy instrumentation. Note that some 
of the specific research discussed in the following paragraphs employs modified instrumentation. 
 
Figure 4. Simple schematic of reflectance spectroscopy instrumentation showing 
a broadband source (Wht. Light) delivering light through a probe to a phantom. 
Emitted light from the phantom passes through the probe into a spectrometer. 
 
The most common types of phantoms used in reflectance spectroscopy are water-based 
liquid phantoms. Water-based phantom make it easy and convenient to build and validate LUTs 
for the purpose of optical property extraction. In one study, a discrete matrix of optical phantoms 
made with polystyrene beads and India ink was created to span a wide range of known μs’ (4-47 
cm-1) and μa (0-25 cm-1). A diffuse reflectance spectra was acquired from each phantom in the 
matrix and these reflectance values were interpolated to generate a topographic LUT describing 
the relationship between reflectance, µa, and µs’ in three-dimensional (3D) space. The 
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topographic LUT was validated on a second set of optical phantoms made with polystyrene 
beads and red food dye with μs’ between ~5-35 cm-1 and μa between ~0-25 cm-1. The validated 
LUT was used to extract optical properties from cancerous skin tissue.(Sharma et al., 2014) 
Another similar LUT study investigated broadband diffuse reflectance spectra between 350-750 
nm for phantoms made with water, polystyrene microspheres and India ink to span a wide range 
of known μs’ (2-71 cm-1) and μa (0-53 cm-1). The LUT was validated on a second set of tissue 
simulating phantoms made with water, polystyrene microspheres as the scatterer and powdered 
hemoglobin as the absorber (Rajaram, Reichenberg, et al., 2010). The LUT was used to extract 
in vivo optical properties from a malignant basal cell carcinoma. Another method for optical 
property extraction are computational models, such as MC-based inverse models.  
One study validated an MC-based inverse model by constructing optical phantoms in a 3 
liter container using deionized water as the substrate material, 20% Intralipid as the scattering 
agent, and either manganese meso-tetra porphine (MnTPPS) or isolated human erythrocytes as 
the absorber. The probe, consisting of one delivery fiber and six surrounding collection fibers, 
was dipped into the phantoms 3 cm below the surface to simulate an infinite homogenous 
medium. Optical property extraction was shown to be valid between a μs’ range from ~15 to 30 
cm-1 and a μa range from ~0.1 to 1.3 cm-1. Additionally, oxygen partial pressure of the 
erythrocyte-based phantoms were monitored using an oxygen-sensitive microelectrode (Baran, 
Fenn, et al., 2013). Another group limited their study to using breast tissue-simulating phantoms 
to evaluate the robustness of their inverse MC model for optical property extraction. The optical 
phantom was made using deionized water as the substrate material and polystyrene microspheres 
and powered hemoglobin and/or crocin as the scatterer and absorber, respectively. Powdered 
hemoglobin was used to simulate blood and crocin was used to simulate beta-carotene, the most 
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common absorbers in breast tissue. The μs’ and μa ranged from ~5-25 cm-1 and ~0-3 cm-1, 
respectively, while THC ranged from 0-30 μM and [crocin] ranged from 0-500 μM. Multiple 
probe geometries were explored for wavelength ranges between 350-600 nm (Bender et al., 
2009). A similar study used an MC inverse model to extract μs’ between 3-10 cm-1, THC 
between 40-80 μM, and [crocin] between 0-400 μM from a breast-tissue mimicking phantom 
(Bydlon et al., 2010). This technique for evaluating MC inverse models in breast tissue-
mimicking phantoms has also been translated to other tissue types, including cervical epithelium. 
Cervical epithelia-mimicking phantoms, made with distilled water as the substrate material and 
polystyrene microspheres and lyophilized human hemoglobin, were used to test the accuracy of 
an MC model so that it could be used in low-resource settings. The μs’ and μa ranged from 8.4 to 
10.4 cm-1 and 0.04 to 0.39 cm-1 over a range of 450-600 nm, respectively. The probe consisted of 
6 illumination fibers surrounding a single collection fiber and was submerged within the liquid 
cervical-simulating phantoms for measurements and the MC inverse model extracted the optical 
properties (Chang et al., 2011). 
In addition to LUT and MC models, diffusion models have been shown to be accurate in 
neonatal skin-simulating phantoms. These phantoms were made with water as the substrate 
material and 1.5% Intralipid and non-scattering, magenta dye as the scattering and absorbing 
agents, respectively. This corresponded to a μs’ range of 3 to 37 cm-1 and a μa range of 0 to 27 
cm-1. These neonatal skin phantoms allowed the investigators to assess their ability to extract 
optical properties using the steady state diffusion approximation to the photon transport equation 
and determine instrumentation probing depth. The probe consisted of one illumination fiber and 
four collection fibers coupled to an imaging spectrograph and was submersed at varying 
distances (0-5 mm in 100 μm steps) from the bottom a blackened container holding a neonatal 
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skin-simulating phantom. Following phantom measurements, the investigators assessed the 
optical properties of neonatal skin in vivo (Bosschaart et al., 2011). 
Reflectance spectroscopy is primarily concerned with using their probe-based 
instrumentation and model to non-invasively extract optical properties from in vivo tissue. In 
order to do this, the technique must be validated on phantoms with known optical properties 
(Chang et al., 2011; Rajaram et al., 2008; Sharma et al., 2014; Baran, Fenn, et al., 2013; Bender 
et al., 2009; Bosschaart et al., 2011; Bydlon et al., 2010).   
3.2.5 Fluorescence spectroscopy 
Fluorescence spectroscopy is a non-invasive probe-based spectroscopy technique that 
uses one or several excitation wavelengths to excite endogenous tissue fluorescence. A 
monochromatic excitation source is coupled to a flexible, fiber-optic cable(s) embedded in a 
probe. When the probe is in contact with tissue, the fluorescent molecule of interest is excited 
with a wavelength within the molecule’s absorption spectrum. The molecule will absorb this 
energy, rise to an excited state, and then relaxes back down to ground state by emitting a photon 
of a longer wavelength. Fluorescent signal is recovered by one or more adjacent fiber-optic 
probes coupled to a detector such as a spectrometer. Phantoms in fluorescence spectroscopy are 
generally used to test instrumentation response for detecting fluorescence in the presence of 
background scattering and absorbing agents (Ramanujam, 2000; Choi et al., 2011; Kanick, 
Davis, et al., 2014; Du Le et al., 2014; Gamm et al., 2014; Baran and Foster, 2013; Croce et al., 
2014; C. Y. Chang et al., 2013; Liu et al., 2011). Figure 5 shows a simple schematic of 
fluorescence spectroscopy instrumentation. Note that some of the specific research discussed in 
the following paragraphs employs modified instrumentation. 
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Figure 5. Simple schematic of fluorescence spectroscopy instrumentation 
showing a source delivering light through an excitation filter (Ex.F.) through a 
probe to a phantom. Emitted light from the phantom passes through the probe and 
emission filter (Em.F.) into a spectrometer. 
 
Optical phantoms have been developed to measure the minimum concentration of added 
fluorophore that could be detected in the presence of background scattering, absorbing, and 
autofluorescence. One set of phantoms was built using water as the substrate material with 1% 
Intralipid, 1% bovine whole blood, and protoporphyrin IX (PpIX) as the scattering, absorption, 
and fluorescent agents, respectively. 5% Tween 20 was also mixed to prevent aggregation of the 
additives. Resultant μs’ was between 10 – 50 cm-1 and blood volume fraction was between 0.5 – 
2.5%. PpIX was added in 16 increasing concentrations between 0.1 and 4000 nM. The lower 
limit of PpIX detection was shown to be 1.95 or 250 nM for 405 nm or 639 nm, respectively 
(Kanick, Davis, et al., 2014). Another group designed similar optical phantoms using deionized 
water as the substrate material, diluted 20% Intralipid as the scatterer, and manganese meso-tetra 
porphine (MnTPPS) (2-12 μM) as the absorber to simulate hemoglobin absorption. Instead of 
PpIX, doxorubicin hydrochloride (1.5-50 μM) was used as the fluorescence agent. Fluorescence 
spectra of these liquid phantoms were collected via a 0.8 mm epi-illumination probe coupled to a 
488 nm laser to recover intrinsic fluorescence and other optical properties (Baran and Foster, 
2013). These intrinsic fluorescence spectra were fit using a modified inverse MC model. 
Modified inverse MC models have been used in other cases to accurately estimate fluorophore 
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contribution in the presence of increasing non-fluorescent absorber. To validate this absorption-
corrected MC model, optical phantoms were created using PBS as the substrate material and 
20% Intralipid as the scatterer, yielding μs’ between 0.05 and 65.8 cm-1 at 405 nm. Fluorescein, 
with a negligible μa, was added as the fluorescence agent at a constant 1 μM concentration. 
Finally, increasing concentration of isolated human red blood cells were added as the absorber 
(μa = 0-26 cm-1 at 405 nm) to demonstrate that fluorescence spectra can be corrected for 
absorption using the custom, empirical MC model (Gamm et al., 2014). 
Thus far, methods of fluorescence spectroscopy have been explored that include an 
exogenous fluorophore within their optical phantom design, such as PpIX, doxorubicin 
hydrochloride, and fluorescein, to test probe sensitivity or validate MC models. Fluorescence 
spectroscopy research has also explored the endogenous fluorescence of optical phantoms 
containing no exogenous fluorophores. This research hoped to determine whether common 
scattering agents, such as Intralipid and polystyrene microspheres, contributed to background 
fluorescence in the 350-650 nm wavelength range. For this study, Intralipid-based phantoms 
were made at concentrations of 0.25%, 0.5%, 1%, 1.5%, 2%, 3%, and 5% in deionized water 
within 12 mL test tubes. Additionally, polystyrene microsphere-based phantoms were made at 
w/v concentrations of 0.72%, 0.4%, and 0.2%. Fluorescence measurements were made using a 
355 nm laser coupled to a 600 μm fiber for illumination and detection. With this knowledge of 
endogenous fluorescence from Intralipid and polystyrene microspheres, correction factors could 
be added to models to correctly extract optical properties and fluorescence from optical 
phantoms (Du Le et al., 2014).  
Additionally, optical phantoms can be designed, not only to validate modified MC 
models, but to test the depth sensitivity of a fluorescence spectroscopy probe. Depth sensitivity 
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can be quantified by creating a two-layer phantom model. In one study, two 300 μm thick 
phantom layers were constructed using water and agarose powder as the substrate material mixed 
with different types of quantum dots (Qdot) (Stanisavljevic et al., 2015). The bottom layer was 
mixed with Qdot 655 and molded into a 13 mm-diameter cylinder, 300 μm thick. The top layer 
was mixed with varying concentrations of Qdot 565 and was molded on top of the bottom layer. 
Both layers had negligible scattering and absorption. A 405 nm laser diode was coupled to a non-
contact probe and fluorescent signal from the phantoms was detected by a broadband 
spectrometer via an integrated collection fiber to quantify detection of the bottom layer (Choi et 
al., 2011). 
Optical phantoms in fluorescence spectroscopy are often used to validate MC inverse 
models, similar to those presented for reflectance spectroscopy, with modifications that account 
for fluorescence of added fluorophores. Additionally, fluorescence-based optical phantoms are 
used to test instrument sensitivity to fluorophore concentration or depth-sensitivity (Choi et al., 
2011; Kanick, Davis, et al., 2014; Du Le et al., 2014; Gamm et al., 2014; Baran and Foster, 
2013). 
3.2.6 Raman spectroscopy 
Raman spectroscopy is a non-invasive spectroscopy technique based on the principal of 
inelastic scattering. A monochromatic source injects light into the sample and target molecules 
within the sample absorb energy, generating molecule-specific vibrations. Therefore, emitted 
light from tissue undergoes a frequency shift compared to the excitation light due to the induced 
vibrational state. This shift is called a Raman shift (Kourkoumelis et al., 2015; Agenant et al., 
2014; Esmonde-White et al., 2011; Okagbare et al., "Fluorocarbon Fiber-Optic Raman Probe for 
Non-Invasive Raman Spectroscopy," 2012; Demers et al., 2012; Chen et al., 2014; Barman et 
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al., 2009; Srinivasan et al., 2008; Stone et al., 2008; Okagbare et al., 2010; Okagbare et al., 
"Polymer-Capped Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012). 
Figure 6 shows a simple schematic of Raman spectroscopy instrumentation. Note that some of 
the specific research discussed in the following paragraphs employs modified instrumentation. 
 
Figure 6. Simple schematic of Raman spectroscopy instrumentation showing a 
laser source delivering light through an excitation filter (Ex.F.), mirror (Mir.), 
dichroic mirror (D.M.), and objective lens (Obj.) through a probe to a phantom. 
Emitted light passes through the probe, objective lens (Obj.), dichroic mirror 
(D.M.), lens (Lens), and notch filter (N.F.) to a detector. 
 
Optical phantoms for Raman spectroscopy are typically solid phantoms that are used to 
simulate the optical and geometric properties of a tissue type, such as cartilage and bone. 
Additionally, phantoms have been created for other purposes such as quantifying Raman 
spectroscopy probe sampling depth and detecting blood analytes in liquid phantoms.  
One such phantom is an optical phantom that simulates a rat tibia. The rat tibia phantoms 
were made using a solid gelatin material as the substrate using a silicone rubber mold. The 
gelatin was doped with Intralipid as the scattering agent and hemoglobin as the absorber. 
Additionally, hydroxyapatite was added to simulate the chemical makeup of rat tibia. An 830 nm 
laser coupled to an illumination fiber bundle provided light to the sample and similar collection 
fibers delivered Raman signal to a spectrograph (Okagbare et al., "Fluorocarbon Fiber-Optic 
Raman Probe for Non-Invasive Raman Spectroscopy," 2012; Okagbare et al., "Polymer-Capped 
Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012; Okagbare et al., 2010). 
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A similar study constructed a cylindrical rat leg-simulating phantom (27 mm diameter) using 
agar and water as the substrate material to create a gel. Scattering and absorption were controlled 
using 1% Intralipid and 0.01% India ink to yield μs’ of 10 cm-1 and μa of 0.1 cm-1 at 830 nm. 
Teflon rods, simulating bone, at different sizes (5 and 12.5 mm diameter) were inserted into the 
agar-based phantom. Raman collection fibers were placed around the surface to collect Raman 
signal to assess the ability of creating tomographic maps of different regions within the phantom 
(Demers et al., 2012). Bone-simulating phantoms, such as these presented, have been modified 
to test another hypothesis that Raman spectroscopy of subchondral bone is attenuated due to 
optical scattering of surrounding cartilage. To test this hypothesis, a bone-simulating optical 
phantom was made by dissolving gelatin in PBS. A 5 mm thick bone layer was created with 0.2 
g/mL hydroxyapatite and 10% v/v Liposyn II. On top of the bone layer, a 6 mm thick cartilage 
layer was created with 3 mg/mL chondroitin sulfate at 0%, 10%, or 20%. The bone layer was 
cast in a Petri dish and the cartilage layer was cast on the same Petri dish once the bone layer had 
cured. The investigators took Raman spectra using 830 nm excitation laser coupled to a single, 
hand-held probe (Esmonde-White et al., 2011). Two-layer phantoms can also be used to quantify 
depth sensitivity in Raman spectroscopy probes.   
To quantify depth sensitivity, one study built a two-layer phantom in which the top layer 
consisted of 20% Intralipid in water with variable thicknesses. Thickness was controlled based 
on the volume of solution residing above the bottom layer, which was a 170 μm thick 
polyethylene terephthalate (PET) slide to mimic stromal tissue. The top layer thickness was 
increased from 0 to 1,500 μm in 50 μm increments until signal from the bottom layer was 
negligible. Both a superficial and non-superficial Raman probe were compared, and depth 
sensitivity was 200 and 300 μm, respectively (Agenant et al., 2014). 
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Presented here are liquid phantoms used in Raman spectroscopy to demonstrate a method 
to detect blood analytes within the phantom. The optical phantoms were made using distilled 
water as the substrate material with Intralipid (μs’ = 24-130 cm-1 at 830 nm) and India ink (μa = 
0.08-1.3 cm-1 at 830 nm) serving as the primer scattering and absorbing agents. Additionally, the 
blood analytes, glucose and creatinine, were pipetted into the solution at concentrations ranging 
from 4-30 mM, spanning the range from hypoglycemic to hyperglycemic levels in humans. 
Aliquots of this solution were placed in a fused silica cuvette for Raman spectroscopic analysis 
to predict a phantoms’ analyte concentration based on a custom calibration model (Barman et al., 
2009). 
Raman spectroscopy is a broadly applicable to many subfields in biomedicine and many 
investigators demonstrate their technique or characterize their instrumentation using tissue-
mimicking optical phantoms (Demers et al., 2012; Okagbare et al., 2010; Okagbare et al., 
"Polymer-Capped Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012; 
Esmonde-White et al., 2011; Agenant et al., 2014; Barman et al., 2009; Okagbare et al., 
"Fluorocarbon Fiber-Optic Raman Probe for Non-Invasive Raman Spectroscopy," 2012).  
3.3 Requirements for small endoscopic instrumentation 
The major objective of the probe-based methods outlined in the previous sections are to 
non-invasively characterize tissue based on its qualitative appearance or optical properties, most 
prevalent being μs’ and μa, among others. Optical phantoms provide a necessary step in 
evaluating parameters of these non-invasive or minimally invasive imaging and spectroscopy 
techniques. However, before such research goals can be realized, an understanding of several key 
aspects is necessary. First, it is vital to understand the type of tissue one hopes to work with, 
including its size and mechanical, chemical, and optical properties. Second, it is useful to 
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understand the models describing how light propagation through these tissues is typically 
understood. Therefore, in this next section, the biology of common epithelial structures is 
described in terms of size and optical properties, which are important for designing optical 
phantoms that mimic these tissues. Next, the sub-diffuse scattering regime will be described, a 
common physical regime within optical imaging when using small spectroscopy probes with 
small source-detector separations. 
3.3.1 Sub-diffuse scattering regime 
Light propagation in tissue can be fully described by the radiative transport equation 
(RTE). The RTE states that the total radiance for photons traveling in a specific direction through 
time and space is equal to the sum of all sources that affect (increase or decrease) radiance. 
Radiance is defined as the quantity of photons per unit volume. A more detailed description of 
the RTE can be found in numerous sources (Liemert et al., 2012; Liemert et al., 2014; Wilson et 
al., 2011). The RTE has been successfully used to model photon transport in turbid media, such 
as tissue or tissue-simulating phantoms. However, the RTE is mathematically and 
computationally intensive, and because of this, research has sought to create simpler models that 
approximate the RTE (Liemert et al., 2014; Liemert et al., 2012; Wilson et al., 2011; Kim et al., 
2006; Kim, 2004; Kim et al., 2003). 
One such simplification used in biological tissues is the diffuse approximation. The 
diffusion approximation is a method that has been used to determine μs’ and μa in tissue (Wilson 
et al., 2011; Reif et al., 2007; Gibson et al., 2005; Kim, 2004; Kim et al., 2003). However, the 
diffusion approximation is only valid in turbid media if the following requirements are met: 1) 
the μs’ must be much greater than the μa, and 2) large source-detector separations must exist 
(Reif et al., 2007). Some sources have also claimed that the diffusion approximation is not valid 
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in media that exhibit anisotropic scattering (Gibson et al., 2005). These requirements ensure that 
any collected photons have traveled through large volumes of tissue. In turn, this ensures that 
extracted optical properties represent an accurate average of the real optical properties. However, 
in many cases, investigators are interested in using small endoscopy devices, as mentioned in the 
previous section, to sample thin tissues with a small sampling depth. This is the case for 
dysplasia or cancers that are confined to the epithelium, which is only between 100-500 µm thick 
(Rajaram et al., 2008).  
Therefore, a distinction must be made between what is meant by the diffuse regime, in 
which the diffusion approximation is valid, and the sub-diffuse regime, in which the diffusion 
approximation is not valid (Reif et al., 2007; Subramanian et al., 2007; Turzhitsky, Rogers, et 
al., 2010; Turzhitsky, Radosevich, et al., 2010; Bosschaart et al., 2011; Kanick, McClatchy, et 
al., 2014). For many of the cases listed here, the validity of the diffusion approximation begins to 
fail for one of two reasons. The first reason is that μs’ is not much greater than μa (Reif et al., 
2007; Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et al., 2010; Subramanian et al., 
2007; Bosschaart et al., 2011). The μs’ is considered “not much greater” than the μa when albedo 
is less than 0.9 (Rajaram et al., 2008). Albedo is defined by Eq. 1,  
𝐴 =
(𝜇𝑠
′)
(𝜇𝑠′ − 𝜇𝑎)
 (1) 
 
where A is the albedo [unitless], µs’ is the reduced scattering coefficient [cm-1] and µa is the 
absorption coefficient [cm-1] (Rajaram et al., 2008; Bish et al., 2014; Bremmer et al., 2011). The 
second reason the diffusion approximation begins to fail is the use of small source-detector 
separations common to small endoscopic probes. A source-detector separation is considered 
“small” if it is less than approximately one reduced mean free path (Rajaram et al., 2008; 
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Subramanian et al., 2007; Bosschaart et al., 2011; Kanick, McClatchy, et al., 2014). The reduced 
mean free path is defined by Eq. 2,  
𝑀𝐹𝑃𝑟𝑒𝑑𝑢𝑐𝑒𝑑 =
1
(𝜇𝑠′ + 𝜇𝑎)
 (2) 
 
where MFPreduced is the reduced mean free path (cm), µs’ is the reduced scattering coefficient 
[cm-1], and µa is the absorption coefficient [cm
-1] (Rajaram et al., 2008; Bosschaart et al., 2011). 
Consider the case in which an investigator is using a spectroscopy probe to non-invasively 
quantify the optical properties of skin at 630 nm. Skin tends to have a µs’ of approximately 20 
cm-1 and µa of approximately 0.4 cm
-1 at 630 nm, although there is a wide range associated with 
skin optical properties (Sandell et al., 2011). If this were the case, the albedo and reduced mean 
free path would be 0.98 and 490 µm, respectively. This theoretical value for albedo satisfies the 
requirements for the diffusion approximation. However, if an investigator is using source-
detector separations less than 490 µm which is often the case, the diffusion approximation may 
begin to fail. In such a situation, we define the volume of tissue being probed to be in the “sub-
diffuse scattering regime” rather than the “diffuse scattering regime” (Rajaram et al., 2008; 
Turzhitsky, Radosevich, et al., 2010; Turzhitsky, Rogers, et al., 2010; Subramanian et al., 2007).  
The reason this distinction is important is that light in the sub-diffuse transport regime 
requires modified model-based interpretations. Mathematical models that describe light transport 
in the sub-diffuse regime require additional knowledge of the first and second Legendre 
moments, which is based on backscattering probability (Kanick, McClatchy, et al., 2014). Figure 
7 shows a three-dimensional, color-mapped representation of albedo and reduced mean free path 
as a function of μs’ and μa for visualization. Albedo increases with higher μs’ and lower μa. The 
reduced mean free path increases with lower μs’ and μa values. Both three-dimensional graphs 
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are shown for μs’ between 5-40 cm-1 and μa between 0-40 cm-1.  
 
Figure 7. This figure shows the relationship between µs’ and µa and the (a) albedo 
and (b) reduced mean free path of tissue. Notice that increasing µs’ and decreasing 
µa increases albedo. For the diffusion approximation to be valid, albedo must be 
greater than 0.9. For tissues with albedo less than 0.9, optical imaging and 
spectroscopy occurs in the sub-diffuse regime. Alternatively, notice that 
decreasing µs’ and µa increases the reduced mean free path of tissue. For the 
diffuse approximation (and thus the diffuse regime) to be valid, source-detector 
separations for spectroscopy probes must be greater than one reduced mean free 
path.  
 
3.3.2 Geometry and optical properties of epithelial tissue 
We next present a review of the geometry and optical properties of several types of 
epithelial tissues that are often the target of analysis in imaging and spectroscopy systems. Tissue 
thickness, albedo and reduced mean free path will be provided to correlate with the previous 
section. This section aims to 1) provide an organized set of relevant information regarding 
epithelial tissues, 2) guide the design of imaging and spectroscopy probes, and 3) facilitate an 
understanding of the basic optic and geometric parameters defining the “diffuse regime” and 
“sub-diffuse regime”. Understanding how the diffuse and sub-diffuse regimes are affected by 
tissue properties such as albedo and reduced mean free path and a probe’s source-detector 
separation can facilitate design of tissue-mimicking optical phantoms. 
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3.4 Considerations for thin tissue-simulating PDMS phantoms 
When considering optical imaging techniques, a primary feature of phantom development 
is the control of optical properties (reduced scattering and absorption coefficients) to mimic 
human tissue (Pogue et al., 2006; Ayers et al., 2008). Optical properties of myriad human tissues 
have previously been characterized and can provide a guideline for phantom design (Sandell et 
al., 2011). In addition, some applications are required to probe deep layers of tissues, such as the 
basement membrane or submucosa, which can exist up to 800 or more microns below the apical 
surface (Liu et al., 2006; Harris et al., 1992). In such cases, modulation of the phantom geometry 
on the scale of tens to hundreds of microns is crucial in phantom development (de Bruin et al., 
2010; Chang et al., 2012; Koschwanez et al., 2009; Guimarães et al., 2007). Therefore, the 
ability to reproducibly create thin tissue-like phantoms with tunable optical properties may be 
beneficial for a wide range of optical image techniques (de Bruin et al., 2010; Cerussi et al., 
2012; Pogue et al., 2006; Ayers et al., 2008). 
Many other groups have attempted to address this need for their applications. Bruin et al. 
demonstrated a method to produce 50 μm thick phantoms by curing PDMS between two glass 
plates. These phantoms contained either silicon or titanium dioxide as the scattering agent and 
ABS 551, a green dye, as the absorber (de Bruin et al., 2010). Saager et al. demonstrated a 
method to produce 90 μm thick phantoms by curing PDMS in a custom well plate using titanium 
dioxide as the scattering agent and either coffee, nigrosin, or India ink as the absorber (Saager et 
al., 2010). Finally, Bae et al. demonstrated a method to use a spin coater to spin epoxy down to 
ultra-thin (5 μm) layers. India ink was used as the absorber (Bae et al., 2013). Although these 
methods provided rigorous validation of tissue-simulating phantoms, all have specific limitations 
which we seek to address. Bruin et al. reported their optical properties only in terms of the 
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attenuation coefficient (μt) instead of the more conventional reduced scattering (µʹs) and 
absorption (μa) coefficients commonly used to quantify tissue optical properties (de Bruin et al., 
2010). Saager et al. thoroughly reported on the wavelength dependence of their phantoms but do 
not provide information on the dependence of these optical properties on the concentrations of 
absorbing and scattering agents (Saager et al., 2010). Finally, Bae et al. introduced a spin coating 
technique to produce ultra-thin layers. The resulting multi-layered phantoms with included 
heterogeneities were permanent, meaning thin layers cannot be easily interchanged (Bae et al., 
2013).15 We seek to combine various aspects of the phantom design procedures briefly reviewed 
here to create unique tissue-simulating optical phantoms (de Bruin et al., 2010; Saager et al., 
2010; Bae et al., 2013).         
We introduce a method to produce thin, interchangeable phantom layers with tunable 
optical properties using poly(dimethylsiloxane) (PDMS), an optically clear, silicone-based 
elastomer, to simulate epithelium (Pogue et al., 2006; Ayers et al., 2008; Sandell et al., 2011; 
Liu et al., 2006).9-12 PDMS was chosen because of its durability, optical stability over time, 
comparable refractive index to human tissue (1.4), and the easy manipulation of both layer 
thickness and optical properties through the addition of scattering and absorbing agents (de Bruin 
et al., 2010; Cerussi et al., 2012; Pogue et al., 2006).  
Phantom thickness was controlled by spinning uncured PDMS on a clean, non-patterned 
silicon wafer in a spin coater, in which the spin speed (100 to 1000 rpm) was manipulated to 
reproducibly create thin PDMS optical phantoms between 115 and 880 microns (Bae et al., 
2013; Koschwanez et al., 2009). Thicker phantoms were constructed by pouring uncured PDMS 
into a mold. Preparing phantom layers in the range of 100 to 300 microns is especially important 
to model many tissue types, such as the skin, gingivae, esophagus, and cervix, among others (de 
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Bruin et al., 2010; Harris et al., 1992; Guimarães et al., 2007; Rocha et al., 2010; Baxi et al., 
2014).   
Phantom optical properties were controlled by introducing varying concentrations of 
titanium dioxide and alcohol-soluble nigrosin as the scattering and absorbing agents, respectively 
(de Bruin et al., 2010; Pogue et al., 2006; Ayers et al., 2008; Sandell et al., 2011; Liu et al., 
2006). The reduced scattering and absorption coefficients of PDMS-based phantoms with 
increasing concentrations of titanium dioxide and alcohol-soluble nigrosin were quantified by 
spatial frequency domain imaging (SFDI) at six discrete wavelengths (591, 631, 659, 691, 731, 
and 851 nm) across the visible to near-infrared spectrum (Cuccia et al., 2009; Cuccia et al., 
2005). Optical characterization with SFDI outside this wavelength range was unreliable (data not 
shown). Based on the data presented here, lookup tables have been provided that list appropriate 
concentrations of titanium dioxide and alcohol-soluble nigrosin to use based on desired reduced 
scattering and absorption coefficients. These lookup tables may be useful for researchers 
interested in developing similar phantoms for their specific imaging applications.  
Once phantoms were characterized, individual thin phantom layers were stacked to create 
thicker, multi-layer phantoms, which can model an optically heterogeneous tissue of interest 
(Saager et al., 2010; Agrawal et al., 2013; Chang et al., 2012). Using SFDI, optical properties of 
multi-layer phantoms were compared to single-layer phantoms with identical concentrations of 
titanium dioxide and alcohol-soluble nigrosin for validation. Furthermore, multi-layered 
phantoms were imaged using OCT B-scanning for validation and qualitative purposes. 
 
 
 
153 
 
3.5 Materials and methods 
 
3.5.1 Design of thin PDMS-based optical phantom layers for thickness characterization 
 
For each thin phantom, 6.5 ± 0.1 grams of PDMS (Sylgard 184 Silicone Elastomer Kit, 
Dow Corning, USA) elastomer base was dispensed into an ARE-100 conditioning mixer cup 
(Intertronics, UK). Next, the curing agent was dispensed into a 7 mL scintillation vial (VWR, 
USA) based on a 10:1 ratio of base to curing agent. Titanium dioxide (Sigma-Aldrich, USA) and 
alcohol-soluble nigrosin (Sigma-Aldrich, USA, SKU: 211680-25G) were used to control the 
reduced scattering coefficient (µʹs) and absorption coefficient (µa), respectively. Titanium 
dioxide (TiO2) was weighed and dispensed into the 7 mL scintillation vial containing the curing 
agent. Next, a 1% w/v solution of nigrosin in ethanol was prepared and added to the scintillation 
vial. The mixture in the scintillation vial was mixed for one minute on a vortex mixer (VWR, 
USA) to disperse large particles of TiO2. Following this, the scintillation vial was placed in a 
Model 3510 sonicator (Branson Ultrasonics Corporation, USA) for 30 minutes to disperse small 
particles of TiO2 and nigrosin emulsions in the curing agent solvent. The process of vortexing for 
one minute and sonicating for 30 minutes was repeated a total of five times to ensure uniform 
scattering and absorption throughout.  
The mixture of curing agent, TiO2, and 1% w/v nigrosin/EtOH was then dispensed into 
the mixing cup containing the PDMS elastomer base. This final mixture was thoroughly mixed 
and degassed for three cycles in an ARE-100 conditioning mixer (Intertronics, UK) for a total of 
12 minutes. Immediately following mixing and conditioning in the ARE-100 conditioning mixer, 
the uncured mixture was placed in an oven at 70°C for three minutes to initiate curing. The 
PDMS mixture was removed from the oven and slowly poured onto the center of a 10 cm silicon 
wafer (University Wafer, USA) within a G3P-8 Spin Coater (SCS Spin Coating Systems, USA). 
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The spin coater was optimized to accelerate to its peak speed in four seconds, spin at 
maximum speed for 20 seconds, and then decelerate to zero RPM in four seconds. Once the spin 
coater reaches zero RPM, the silicon wafer, containing a thin film of partially cured PDMS 
mixture, was removed and placed in an oven at 70°C for two hours to complete curing. 
Thin phantoms were created at spin speeds of 100, 200, 300, 400, 500, 700 and 1000 
RPM, with three trials of each. Each phantom at a particular spin coater speed was sampled six 
times for a total of 18 thickness measurements at each speed, shown in Figure 2. Thickness was 
quantified by analyzing transmittance images of PDMS phantom layers. A transverse cut was 
made in each phantom and imaged using a wide-field microscope with a Nikon Plan Fluor 10X, 
0.30 NA objective and Nikon DS-Fi2 camera. Calibration of image scale was performed with a 
positive USAF 1951 resolution target. Images were analyzed using the MATLAB Image 
Analysis Toolbox (Mathworks, USA). 
3.5.2 Design of PDMS-based optical phantoms for characterization of reduced scattering and 
absorption coefficients 
The µʹs and µa of phantoms containing varying amounts of TiO2 and 1% w/v 
nigrosin/EtOH were quantified with spatial frequency domain imaging (SFDI) (Cuccia et al., 
2005; Cuccia et al., 2009). For analysis with SFDI, thicker phantoms (2.5 cm thick) were built 
using an ARE-100 conditioning mixer cup (Intertronics, UK) as a mold. Construction of thick 
phantoms followed the same procedure as the construction of thin phantoms up until the point 
the spin coater was introduced. Instead of using a spin coater to spin partially cured PDMS into a 
thin layer, completely mixed PDMS was placed in an oven at 70°C for two hours to complete 
curing. 16 phantoms were created using this technique. Eight phantoms (#1-8 in Table 1) 
contained a constant amount of 1% w/v nigrosin/EtOH solution with increasing concentration of 
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TiO2 in PDMS elastomer base to manipulate µʹs. Nine phantoms (#1 and 9-16 in Table 1) 
contained a constant amount of TiO2 with increasing concentration of 1% w/v nigrosin/EtOH 
solution in PDMS elastomer base to manipulate µa. As an example, since 50 grams of PDMS 
elastomer base were used to create Phantom #5, 0.25 grams of TiO2 and 25 μL of 1% w/v 
nigrosin/EtOH were added. Table 1 shows the breakdown of each phantom created for the 
quantification of optical properties by SFDI. In addition, Figure 8 shows an aerial view of all 16 
phantoms represented in Table 1. Figures 12-15 provide analysis on the resulting µʹs and µa.   
Table 1. Amounts of titanium dioxide (scattering agent) and nigrosin/ethanol solution (absorbing 
agent) per thick (2.5 cm) “semi-infinite” phantom quantified by SFDI 
 
 
 
 
 
 
 
 
Phantom  
Number 
TiO2 
[g/g] 
1% w/v 
Nigrosin/EtOH  
[µL/g] 
1 0.001 0.5 
2 0.002 0.5 
3 0.003 0.5 
4 0.004 0.5 
5 0.005 0.5 
6 0.006 0.5 
7 0.007 0.5 
8 0.008 0.5 
9 0.001 1.0 
10 0.001 2.0 
11 0.001 3.0 
12 0.001 4.0 
13 0.001 5.0 
14 0.001 7.0 
15 0.001 10.0 
16 0.001 40.0 
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Figure 8. Aerial view of the 16 phantoms used in the SFDI characterization of µʹs 
and µa, corresponding to Table 1. Phantoms used in this study are #1-4 (1st row), 
#5-8 (2nd row), #9-12 (3rd row), and #13-16 (4th row). 
 
3.5.3 Construction of multi-layer phantoms for inclusion of heterogeneities  
One multi-layer phantom was constructed, quantified by SFDI, and compared to a single-
layer, “semi-infinite” control phantom with identical concentrations of optical agents (Cuccia et 
al., 2005; Cuccia et al., 2009). The primary concern during construction of multi-layer phantoms 
was the formation of air pockets between two adjacent layers. One possible technique to avoid 
air pocket formation was directly spinning uncured PDMS over an existing base layer to build 
multi-layer tissue-simulating phantoms. While this method can successfully eliminate air pocket 
formation, it was not be suitable for creating thin layers that were easily interchangeable (Bae et 
al., 2013). Instead, our method allowed for thin PDMS layers to readily be stacked and removed, 
creating diverse sets of multi-layer phantoms for various optical imaging purposes. First, two 2.5 
cm thick “semi-infinite” phantom layers were molded and cured in an ARE-100 conditioning 
mixer cup (Intertronics, UK), containing 0.002g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per 
gram PDMS elastomer base. Then, using the described spin coating method, two 200-micron 
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layers were constructed, containing exactly the same concentrations of optical agents. After the 
two 200-micron layers finished curing, they were carefully peeled off the silicon wafer. The 
layers were cut using a scalpel into approximately 3 cm2 squares. Each thin-layer square was 
placed into a 70% ethanol/DI water solution and sonicated for 10 minutes to remove dust and 
other surface contaminants. Following this, two drops of ethanol were placed on one of the 2.5 
cm “semi-infinite” base layers. One 200-micron layer was placed directly on top of the ethanol 
drops so that no visible air bubbles remained. This two-layer phantom was placed in an oven at 
70°C for three minutes to allow evaporation of the ethanol, creating two adjacent layers without 
air pockets. These steps were repeated for the second 200-micron layer on the same multi-
layered phantom (Phantom #18 in Table 2). To the second 2.5 cm “semi-infinite” base layer, no 
thin layers were added (Phantom #17 in Table 2). Table 2 shows the geometric specifications of 
the two phantoms. 
Table 2. Thickness specifications for single-layer and multi-layer control phantoms (for all 
layers: 0.002g TiO2 and 2.0 µL 1% w/v Nigrosin/EtOH in PDMS elastomer base) 
Thickness [µm] Phantom #17 (single-layer) Phantom #18 (multi-layer) 
Top Layer N/A 200 
Middle Layer N/A 200 
Bottom Layer 25,000 25,000 
 
Both phantoms were subjected to SFDI analysis to quantify µʹs and µa at the six discrete 
wavelengths shown in Figure 16 and 17. This analysis served to validate the process of creating 
multi-layer phantoms without air pocket formation. In addition, SFDI analysis on multi-layered 
phantoms served to validate that thin (<880 µm) and thick (2.5 cm) phantoms layers with 
identical concentrations of optical agents have comparable optical properties. Because all layers 
contain identical concentrations of TiO2 and 1% w/v nigrosin/EtOH, µʹs and µa should be 
identical for both single-layer and multi-layer phantoms (Figure 16 and 17).   
Additionally, one more three-layer multi-layer phantom was constructed and imaged 
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using an OCT B-scan for qualitative purposes. First, one 2.5 cm thick phantom layer was molded 
and cured in an ARE-100 conditioning mixer cup (Intertronics, UK), containing 0.002 g titanium 
dioxide and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS elastomer base. Then, using the 
described spin coating method, two 200-micron layers were constructed. The first 200-µm layer 
contained 0.006 g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS elastomer base, tripling 
the scattering agent concentration while keeping the absorbing agent concentration constant. The 
second 200-micron layer contained 0.002g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per g PDMS 
elastomer base (identical to the base layer). The first (optically different) thin layer was placed 
between the base layer and second (optically identical) thin layer to produce a heterogeneous 
multi-layer phantom that was imaged by an OCT B-scanning technique. These phantom images 
are compared to various types of human epithelium (skin and oral mucosa) in Figure 18. Table 3 
shows the geometric and optical specifications of the heterogeneous multi-layer phantom for this 
comparative study using OCT. Optical coherence tomography (OCT) imaging was performed on 
a custom-built spectral-domain OCT platform with a center wavelength of 1325 nm, axial 
resolution of 8.0 m (in air), lateral resolution of 22.5 m, and maximum imaging depth of 3.0 
mm (in air) (Higgins et al., 2014). For phantom imaging (Figure 18), OCT cross-sections (B-
scans) contained 500 A-lines acquired over a 5 mm scan width. B-scan images were generated 
by standard SD-OCT processing (spectrometer wavelength calibration, interpolation to evenly 
spaced samples in k-space, and Fourier transformation) (Higgins et al., 2014). The OCT system 
used here operates at 1325 nm, further out into the near-infrared range than our SFDI system was 
capable of testing (591-851 nm). The majority of OCT imaging of tissues (including the 
epithelial tissues in which our phantoms seek to mimic) is done in the 1325 nm region (Higgins 
et al., 2014). Therefore, OCT B-scans were used for comparative purposes and not to 
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characterize optical properties of phantoms.    
Table 3. Thickness and optical concentration specifications for multi-layer phantom imaged by 
an OCT B-scanning technique 
Phantom #19 Layer 1 Layer 2 Layer 3 
Thickness [µm] 25,000 200 200 
TiO2 [g/g] 0.002 0.006 0.002 
1 w/v% Nigrosin/EtOH [uL/g] 2 2 2 
 
3.5.4 Semi-infinite phantom model of dysplastic progression 
Once optical property extraction and sampling depth were validated, we tested the 
capabilities of the DRS modality of the hybrid fiber-bundle in a dysplasia-mimicking phantom 
model (Zhu et al., 2011). Figure 9 (a-c) shows a simplified representation of dysplastic 
progression starting at the basement membrane and proliferating upwards into surrounding 
healthy tissue (Speight, 2007; Warnakulasuriya et al., 2008). Early dysplasia is known to 
significantly increase epithelial scattering by nearly two-fold (Arifler et al., 2003; Collier et al., 
2003; Clark et al., 2004). To simulate this phenomenon, three solid scattering-only phantoms, 
shown in Figure 9 (d-f), were created (Zhu et al., 2011). Since scattering contributes much more 
to reflectance intensity compared to absorption, the µa was held constant at 0 cm
-1 (Clark et al., 
2004). Additionally, the phantom “epithelia” was made to be 300 µm thick to approximately 
simulate the thickness of oral mucosa (Greening et al., 2015). With the understanding that the 
374 and 730 μm SDSs sample different depths, it was expected that the 374 μm SDS may be 
more sensitive to shallower, epithelial-confined scattering changes associated with early 
dysplasia.  
The three phantom models have a semi-infinite geometry, a common geometry used in 
various models of photon transport in tissues with sub-surface optical heterogeneities (Zhu et al., 
2011). The semi-infinite geometry requires an optically thick base layer (bottom gray layer in 
Figure 9 (d-f)) that can be considered infinitely thick in the z direction since no photons penetrate 
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through this layer. In this experiment, the semi-infinite base layer was 1 cm thick. Additionally, 
all layers can be considered infinite in the x and y directions since no photons penetrate laterally 
outside this plane (Zhu et al., 2011).  
 
Figure 9. A simplified representation of dysplastic proliferation arising at the 
basement membrane in the oral cavity (a-c) showing normal cells (gray with 
nuclei), dysplastic cells (light gray with nuclei), basement membrane (dark gray), 
and the stroma (gray). The associated dysplasia-mimicking phantom models (d-f) 
simulate this progression. Two SDSs (374 and 730 μm) deliver and collect 
broadband light at different depths (detected photons shown here as blue and red 
crescents, respectively). Each of thin phantom layers was 150 μm thick for a total 
phantom thickness of 300 μm to simulate the thickness of oral epithelium. 
 
Phantoms were created using poly(dimethylsiloxane) (PDMS) as the substrate material, 
and titanium dioxide (TiO2) as the scattering agent. PDMS was used because of its optical clarity 
(μs’ and μa = 0 cm-1 between 500-750 nm), comparable refractive index to human tissue (~1.4), 
optical stability over time, physical durability, and ability to form multilayer geometries 
(Greening et al., 2014). Since µs’ contributes to reflectance intensity much more than µa, no 
absorbing agent was used (Clark et al., 2004).  
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The semi-infinite layer and 150 µm thick healthy tissue-mimicking layers were designed 
with 0.25% w/w TiO2 in PDMS (2.5 mg TiO2 per 1.0 g PDMS) to yield a µs’ of ~7 cm-1 at 630 
nm which is comparable to healthy tissue (Chang et al., 2009; Greening et al., 2014). The 150 
µm thick dysplasia-mimicking layers were designed with 0.50% w/w TiO2 in PDMS (5.0 mg per 
1.0 g PDMS) to yield a µs’ of ~14 cm-1 at 630 nm (Greening et al., 2014; Chang et al., 2009). 
This represented a two-fold increase in scattering which is representative of the increased 
scattering ratio of dysplastic to healthy epithelial tissue (Collier et al., 2003; Clark et al., 2004; 
Arifler et al., 2003). For each geometry in Figure 9, two 150 µm layers were stacked to generate 
the desired phantom (Greening et al., 2014; Greening et al., 2015). The total phantom 
“epithelial” thickness was thus 300 μm, not including the “stromal” semi-infinite base layer, 
which was 1 cm thick. All thin phantom layers were created using a previously described spin 
coating technique (Greening et al., 2015; Greening et al., 2014).  
The volume-averaged µs’ was extracted between 500-750 nm for each phantom. Ten 
DRS measurements were averaged for each geometry (Phantoms 1-3) and SDS with an 
integration time of 500 ms. We hypothesized that the 374 µm SDS would show larger deviations 
in volume-averaged µs’ compared to the 730 µm SDS because the changes in scattering were 
confined to the upper 300 µm of the phantom. The 730 µm would be sampling significantly 
more into the underlying “stromal” semi-infinite layer, in which µs’ was held constant for this 
experiment. Results from this study were expected to indicate that the shorter SDS would be 
more sensitive to scattering changes associated with dysplastic epithelium. 
3.5.5 Collaboration with the Boston University Department of Biomedical Engineering: Two-
Layer Tissue-Simulating Optical Phantoms 
The following section was directly adapted from Syeda Tabassum, Vivian Pera and 
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Darren Roblyer from Boston University, with whom we provided tissue-simulating PDMS 
phantoms for their experiments (Tabassum et al., 2018). 
A set of two-layer solid silicone phantoms was fabricated to optically simulate 
subcutaneous tumors in a mouse with a range of optical properties. These phantoms were used to 
test the accuracy of Gardner LUT inversion algorithms. The phantoms consisted of a thin skin 
layer above a tumor layer. Four different two-layer phantoms were fabricated, all of which used 
the same skin layer. In all phantoms, silicone was used as the base solvent, nigrosin as the 
absorber, and titanium dioxide as the scatterer. The optical properties of the phantoms were 
adjusted by varying the amount of absorber and scatterer during fabrication as previously 
described (Ayers et al., 2008; Tabassum et al., 2018). 
The thin upper layer phantom was made by adapting a previously described technique 
(Saager et al., 2010). First, an aluminum phantom mold was fabricated by machining a well that 
was 330 μm in depth and 1.5 in. × 1.5 in. in the lateral dimensions using a computer-controlled 
milling machine (SV-2414S-M, Sharp Industries). After the phantom ingredients were mixed 
together, the liquid mixture was poured into the aluminum mold. A microtome blade was used to 
draw and spread the mixture evenly across the well, and the edges of the blade remained in 
contact with the top surface of the mold at all times. The phantom was then left to cure, 
uncovered, overnight. During curing, the silicone layer was observed to shrink in the center of 
the well. Once cured, the thin silicone layer was removed from the mold and cut to the size of 
100 × 100 to remove the uneven and thicker edge. The thickness of the phantom was confirmed 
using caliper measurements by confining the thin layer between two microscope slide coverslips 
for stability and consistency. Because the top layer phantom was too thin for accurate optical 
property measurements with diffuse imaging techniques, a much larger, 2.5-cm thick 
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homogeneous phantom was made from the same batch of material and SFDI was used to extract 
the optical properties (Tabassum et al., 2018). 
Similarly, for the bottom (tumor) layer, four homogeneous phantoms were fabricated in 
collaboration with Dr. Muldoon’s group (Greening et al., 2014) and measured with SFDI. The 
thickness of each phantom was 2.5 cm, and the μa and μ0s values of each phantom were targeted 
to span known mouse tumor optical properties. The skin layer and tumor layer phantoms were 
stacked to create the two-layer phantoms. First, the thin skin layer phantom was cleaned using an 
alcohol wipe. Then a small amount of ethanol was poured on a thick tumor layer phantom, and 
the thin layer was directly placed on top of the tumor layer, making sure that no visible air 
bubbles remained. The two-layer phantom was left under the chemical hood overnight to allow 
the ethanol to evaporate without leaving any air pockets between the layers. An example of one 
of the two-layer phantoms is shown in Figure 10(c). The procedure was repeated 4 times to 
generate the four two-layer phantoms (Tabassum et al., 2018). 
 
Figure 10. (a) Schematic of tissue model for the homogenous case, (b) schematic 
of the tissue model for the two-layer case, and (c) an example of a custom-made 
two-layer silicone phantom used to validate the accuracy of the resulting two-
layer inverse algorithm (Tabassum et al., 2018).  
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3.6 Results 
 
3.6.1 Characterization of thickness of thin PDMS-based optical phantoms 
 
Figure 11 shows the relationship between the primary, maximum 20-second spin speed 
and resulting thickness of PDMS layers. Seven different spin speeds were used (100, 200, 300, 
400, 500, 700, and 1000 rpm) to characterize the resulting thickness (between 115 and 880 µm) 
of thin PDMS-based phantoms.  
 
 
Figure 11. Relationship between thickness of thin-layer phantoms and maximum 
20-second spin speed of a spin coater. Here, phantoms were constructed between 
approximately 115 and 880 µm. The R2 value for the curve of best fit is 0.988. 
Best fit lines were generated by the MATLAB curve-fitting toolbox (power fit).  
 
3.6.2 Characterization of reduced scattering coefficient of PDMS-based optical phantoms 
 
Figure 12 shows the relationship between TiO2 (scattering agent) in PDMS elastomer 
base [g/g] and the resulting µʹs [cm-1] for six discrete wavelengths [nm] measured by SFDI (591, 
621, 659, 691, 731, and 851 nm). Eight phantoms (#1-8 in Table 1) were used in this study 
which contained a constant amount of 1% w/v nigrosin/Et/OH (absorbing agent) and increasing 
concentration of TiO2 in PDMS elastomer base [g/g]. 
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Figure 12. Relationship between µʹs [cm-1] and TiO2 concentration in PDMS 
elastomer base [g/g] measured at six discrete wavelengths (591, 621, 659, 691, 
731, and 851 nm) using spatial frequency domain imaging (SFDI) analysis. Here, 
µʹs values range between approximately 1 and 21 cm-1. R2 values for best fit lines 
from 591 to 851 nm are 0.994, 0.994, 0.994, 0.995, 0.995, and 0.998, respectively. 
Best fit lines were generated by the MATLAB curve-fitting toolbox (linear fit). 
 
In addition, µʹs was measured at increasing 1% w/v nigrosin/EtOH concentrations in 
PDMS elastomer base to determine if increasing the chosen absorbing agent would affect the 
bulk scattering properties. Figure 13 shows the relationship between 1 w/v% of nigrosin/EtOH 
concentration and the resulting µʹs [cm-1]. Results from Phantom #16 are not shown in Figure 4. 
The phantoms used in this experiment (#1, 9-15 in Table 1) all contained identical concentrations 
of the chosen scattering agent, TiO2 (0.001 g/g).  
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Figure 13. Relationship between µʹs [cm-1] and 1% w/v nigrosin/EtOH 
concentrations in PDMS elastomer base [μL/g] measured at six discrete 
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency 
domain imaging (SFDI) analysis. Best fit lines were generated by the MATLAB 
curve-fitting toolbox (linear fit). 
 
3.6.3 Characterization of absorption coefficient of PDMS-based optical phantoms 
 
Figure 14 shows the relationship between 1 w/v% of nigrosin/EtOH (absorbing agent) in 
PDMS elastomer base [μL/g] and the resulting µa [cm-1] for six discrete wavelengths measured 
by SFDI (591, 621 ,659, 691, 731, and 851 nm). Nine phantoms (#1 and 9-16 in Table 1) were 
used in this study which contained a constant amount of TiO2 (scattering agent) and increasing 
1% w/v nigrosin/EtOH concentration in PDMS elastomer base.  
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Figure 14. Relationship between µa [cm
-1] and 1% w/v nigrosin/EtOH 
concentration in PDMS elastomer base [μL/g] measured at six discrete 
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency 
domain imaging (SFDI) analysis. Here, µa values range between approximately 0 
and 1.5 cm-1. Best fit curves, generated by the MATLAB curve-fitting toolbox 
(power fit), are shown for the 591 nm (dashed) and 851 nm (dotted) wavelengths, 
respectively. 
 
In addition, µa was measured at increasing TiO2 concentrations in PDMS elastomer base 
to determine if increasing the chosen scattering agent would affect the bulk absorbing properties. 
Figure 15 shows the relationship between TiO2 concentration and the resulting µa [cm
-1]. Eight 
phantoms (#1-8 in Table 1) were used in this study which contained identical concentrations of 
the chosen absorbing agent, 1% w/v nigrosin/EtOH (0.5 µL/g). 
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Figure 15. Relationship between µa [cm
-1] and TiO2 concentration in PDMS 
elastomer base [g/g] measured at six discrete wavelengths (591, 621, 659, 691, 
731, and 851 nm) using spatial frequency domain imaging (SFDI) analysis. 
 
3.6.4 Validation of multi-layer PDMS-based optical phantoms 
 
For the two phantoms specified in Table 2 (Phantom # 17 and 18), µʹs [cm-1] and µa [cm-
1] were quantified with SFDI (Cuccia et al., 2005; Cuccia et al., 2009). Phantom #17 (square 
data points in Figure 16 and 17) consisted of only one thick 2.5 cm base layer, containing 0.002 
g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per gram PDMS elastomer base. Phantom #18 
(diamond data points in Figure 16 and 17) consisted of one thick 2.5 cm base layer with two 
overlying 200-µm layers, all containing 0.002 g TiO2 and 2.0 µL 1% w/v nigrosin/EtOH per 
gram PDMS elastomer base. This experiment attempted to validate the creation of multi-layer 
phantoms by comparing the overall optical properties (µʹs and µa) of a single-layer and multi-
layer phantoms with all layers containing identical concentrations of scattering and absorbing 
agents. Figure 16 shows the relationship between the wavelength and resulting µʹs while Figure 
17 shows the relationship between the wavelength and resulting µa for the single-layer (Phantom 
#17) and multi-layer (Phantom #18) phantoms specified in Table 2. 
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Figure 16. Comparison of µʹs [cm-1] between a single-layer and multi-layer 
phantom with identical concentrations of scattering and absorbing agents 
measured at six discrete wavelengths (591, 621, 659, 691, 731, and 851 nm) using 
spatial frequency domain imaging (SFDI) analysis. Average aggregate error was 
7.7%. 
 
 
 
Figure 17. Comparison of µa [cm
-1] between a single-layer and multi-layer phantom 
with identical concentrations of scattering and absorbing agents measured at six discrete 
wavelengths (591, 621, 659, 691, 731, and 851 nm) using spatial frequency domain 
imaging (SFDI) analysis. Average aggregate error was 10.9%. 
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Figure 18 represents an OCT B-scan comparison between multi-layered phantoms and 
several types of human epithelium from a normal volunteer (fingertip epithelium, wrist 
epithelium, and oral mucosa).  
 
 
Figure 18. Images of multi-layered PDMS-based phantoms compared to OCT B-
scans of various human epithelium. (a) OCT B-scan of a three-layer phantom. 
Thickness in layers 1 and 2 (L1 and L2) were approximately 200 µm, 
respectively. TiO2 concentration in layers 1, 2, and 3 (L3) were 0.002, 0.006, and 
0.002 [g/g], respectively. 1 w/v% nigrosin/EtOH concentration was 2.0 μL/g in all 
layers. The comparative images show OCT B-scans from a normal volunteer of 
the (b) fingertip showing the epidermis (Epid) and dermis (Der), (c) wrist 
showing the epidermis (Epid) and dermis (Der), and (d) oral mucosa showing the 
epithelium (Epit) and lamina propria (LP) Scale bars represents 500 μm. 
 
3.6.5 Lookup Tables for Optical Properties of Solid PDMS-Based Phantoms 
 
The following lookup tables can be used as a guideline to determine approximate 
concentrations of the studied absorbing agent (1% w/v Nigrosin/Ethanol) and scattering agent 
(Titanium dioxide) given a desired absorption coefficient (µa) and reduced scattering coefficient 
(µʹs) at a specific wavelength when designing PDMS-based tissue-simulating phantoms. Six 
lookup tables are included, corresponding to the six wavelengths (591, 631, 659, 691, 731, and 
851 nm) used in this study. It should be noted that individual concentrations listed in this table 
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were not explicitly measured. Instead, the individual concentrations listed here were acquired 
based on empirical mathematical models fitting the presented data. While the tables do fit the 
presented data, extensive validation of these tables was not performed. Therefore, optical 
properties should always be independently validated.  
To use these lookup tables, first choose a desired µa to obtain the correct concentration of 
1% w/v nigrosin/EtOH in PDMS elastomer base [µL/g]. Then, choose a desired µʹs and line up 
this row with the column corresponding to the chosen µa to obtain the correct concentration of 
TiO2 in PDMS elastomer base [g/g]. 
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Table 4. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 591 nm (Greening et al., 
2014).  
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.3 1.7 2.1 2.4 2.8 3.1 3.5 4.1 4.9 5.8 6.6 7.1 13.9 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.3 0.5 0.6 0.9 1.1 1.1 
2 0.5 0.5 0.6 0.6 0.7 0.7 0.8 0.9 1.0 1.2 1.6 2.2 2.6 2.6 
3 0.9 1.0 1.0 1.1 1.2 1.3 1.3 1.4 1.7 2.0 2.6 3.4 4.0 4.0 
4 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.3 2.8 3.5 4.7 5.5 5.5 
5 1.7 1.8 1.9 2.0 2.2 2.3 2.4 2.6 3.0 3.6 4.5 5.9 7.0 7.0 
6 2.2 2.3 2.4 2.5 2.7 2.8 3.0 3.2 3.6 4.4 5.4 7.2 8.4 8.4 
7 2.6 2.7 2.8 3.0 3.2 3.3 3.5 3.8 4.3 5.1 6.4 8.4 9.9 9.9 
8 3.0 3.1 3.3 3.5 3.6 3.9 4.1 4.4 4.9 5.9 7.4 9.7 11.3 11.3 
9 3.4 3.5 3.7 3.9 4.1 4.4 4.7 5.0 5.6 6.7 8.3 10.9 12.8 12.8 
10 3.8 4.0 4.2 4.4 4.6 4.9 5.2 5.5 6.2 7.5 9.3 12.2 14.2 14.2 
11 4.2 4.4 4.6 4.9 5.1 5.4 5.8 6.1 6.9 8.2 10.2 13.4 15.7 15.7 
12 4.6 4.8 5.1 5.3 5.6 5.9 6.3 6.7 7.5 9.0 11.2 14.7 17.1 17.1 
13 5.0 5.3 5.5 5.8 6.1 6.5 6.9 7.3 8.2 9.8 12.1 15.9 18.6 18.6 
14 5.4 5.7 6.0 6.3 6.6 7.0 7.4 7.9 8.8 10.6 13.1 17.2 20.0 20.0 
15 5.8 6.1 6.4 6.7 7.1 7.5 8.0 8.5 9.5 11.3 14.1 18.4 21.5 21.5 
16 6.3 6.5 6.9 7.2 7.6 8.0 8.5 9.0 10.2 12.1 15.0 19.7 22.9 22.9 
17 6.7 7.0 7.3 7.7 8.1 8.6 9.1 9.6 10.8 12.9 16.0 20.9 24.4 24.4 
18 7.1 7.4 7.8 8.2 8.6 9.1 9.6 10.2 11.5 13.7 16.9 22.2 25.8 25.8 
19 7.5 7.8 8.2 8.6 9.1 9.6 10.2 10.8 12.1 14.5 17.9 23.4 27.3 27.3 
20 7.9 8.3 8.7 9.1 9.6 10.1 10.7 11.4 12.8 15.2 18.8 24.7 28.7 28.7 
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Table 5. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 631 nm (Greening et al., 
2014).  
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.4 1.7 2.1 2.5 2.9 3.2 3.6 4.2 5.1 5.9 6.8 7.3 14.5 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.4 0.4 0.6 0.7 1.0 1.1 1.1 
2 0.7 0.7 0.7 0.8 0.8 0.9 1.0 1.0 1.2 1.4 1.8 2.3 2.5 2.5 
3 1.1 1.2 1.3 1.3 1.4 1.5 1.6 1.7 1.9 2.3 2.8 3.6 3.9 3.9 
4 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.4 2.6 3.1 3.8 4.9 5.3 5.3 
5 2.1 2.2 2.3 2.4 2.5 2.7 2.8 3.0 3.4 4.0 4.9 6.2 6.7 6.7 
6 2.5 2.7 2.8 2.9 3.1 3.3 3.5 3.7 4.1 4.8 5.9 7.5 8.1 8.1 
7 3.0 3.1 3.3 3.5 3.7 3.9 4.1 4.3 4.8 5.7 6.9 8.8 9.5 9.5 
8 3.5 3.6 3.8 4.0 4.2 4.4 4.7 5.0 5.6 6.6 8.0 10.1 10.9 10.9 
9 3.9 4.1 4.3 4.5 4.8 5.0 5.3 5.7 6.3 7.4 9.0 11.4 12.3 12.3 
10 4.4 4.6 4.8 5.1 5.3 5.6 6.0 6.3 7.0 8.3 10.0 12.7 13.7 13.7 
11 4.9 5.1 5.3 5.6 5.9 6.2 6.6 7.0 7.8 9.1 11.1 14.0 15.1 15.1 
12 5.4 5.6 5.9 6.1 6.5 6.8 7.2 7.6 8.5 10.0 12.1 15.3 16.4 16.4 
13 5.8 6.1 6.4 6.7 7.0 7.4 7.8 8.3 9.2 10.8 13.1 16.6 17.8 17.8 
14 6.3 6.6 6.9 7.2 7.6 8.0 8.4 9.0 10.0 11.7 14.1 17.9 19.2 19.2 
15 6.8 7.1 7.4 7.8 8.2 8.6 9.1 9.6 10.7 12.6 15.2 19.1 20.6 20.6 
16 7.2 7.6 7.9 8.3 8.7 9.2 9.7 10.3 11.4 13.4 16.2 20.4 22.0 22.0 
17 7.7 8.0 8.4 8.8 9.3 9.8 10.3 10.9 12.2 14.3 17.2 21.7 23.4 23.4 
18 8.2 8.5 8.9 9.4 9.8 10.4 10.9 11.6 12.9 15.1 18.3 23.0 24.8 24.8 
19 8.6 9.0 9.4 9.9 10.4 11.0 11.6 12.3 13.6 16.0 19.3 24.3 26.2 26.2 
20 9.1 9.5 10.0 10.4 11.0 11.5 12.2 12.9 14.4 16.8 20.3 25.6 27.6 27.6 
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Table 6. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 659 nm (Greening et al., 
2014). 
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.4 1.8 2.2 2.6 3.0 3.3 3.7 4.4 5.2 6.0 6.8 7.5 12.6 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.5 0.7 0.8 1.0 1.1 1.1 
2 0.8 0.8 0.9 0.9 1.0 1.1 1.1 1.2 1.4 1.6 1.9 2.3 2.4 2.4 
3 1.3 1.4 1.5 1.5 1.6 1.7 1.8 1.9 2.2 2.5 2.9 3.6 3.8 3.8 
4 1.8 1.9 2.0 2.1 2.2 2.4 2.5 2.6 3.0 3.4 4.0 4.8 5.1 5.1 
5 2.4 2.5 2.6 2.7 2.9 3.0 3.2 3.4 3.8 4.3 5.1 6.1 6.5 6.5 
6 2.9 3.0 3.2 3.3 3.5 3.7 3.9 4.1 4.6 5.3 6.1 7.4 7.8 7.8 
7 3.4 3.6 3.7 3.9 4.1 4.3 4.6 4.8 5.4 6.2 7.2 8.7 9.2 9.2 
8 3.9 4.1 4.3 4.5 4.7 5.0 5.3 5.6 6.2 7.1 8.3 9.9 10.5 10.5 
9 4.5 4.7 4.9 5.1 5.4 5.6 5.9 6.3 7.0 8.0 9.4 11.2 11.9 11.9 
10 5.0 5.2 5.4 5.7 6.0 6.3 6.6 7.0 7.8 8.9 10.4 12.5 13.2 13.2 
11 5.5 5.8 6.0 6.3 6.6 6.9 7.3 7.7 8.6 9.8 11.5 13.8 14.6 14.6 
12 6.0 6.3 6.6 6.9 7.2 7.6 8.0 8.5 9.4 10.8 12.6 15.0 15.9 15.9 
13 6.6 6.8 7.2 7.5 7.9 8.3 8.7 9.2 10.2 11.7 13.6 16.3 17.3 17.3 
14 7.1 7.4 7.7 8.1 8.5 8.9 9.4 9.9 11.0 12.6 14.7 17.6 18.6 18.6 
15 7.6 7.9 8.3 8.7 9.1 9.6 10.1 10.6 11.8 13.5 15.8 18.9 20.0 20.0 
16 8.1 8.5 8.9 9.3 9.7 10.2 10.8 11.4 12.6 14.4 16.8 20.1 21.3 21.3 
17 8.7 9.0 9.4 9.9 10.3 10.9 11.5 12.1 13.4 15.4 17.9 21.4 22.7 22.7 
18 9.2 9.6 10.0 10.5 11.0 11.5 12.1 12.8 14.2 16.3 19.0 22.7 24.0 24.0 
19 9.7 10.1 10.6 11.1 11.6 12.2 12.8 13.6 15.0 17.2 20.0 24.0 25.4 25.4 
20 10.2 10.7 11.1 11.7 12.2 12.8 13.5 14.3 15.9 18.1 21.1 25.2 26.7 26.7 
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Table 7. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 691 nm (Greening et al., 
2014). 
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.4 1.8 2.3 2.7 3.1 3.5 3.9 4.7 5.4 6.1 6.8 7.3 9.1 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.4 0.4 0.5 0.5 0.5 0.5 0.6 0.6 0.7 0.8 0.9 1.0 1.1 1.1 
2 1.0 1.0 1.1 1.1 1.2 1.2 1.3 1.4 1.5 1.7 1.9 2.2 2.3 2.3 
3 1.6 1.6 1.7 1.8 1.9 1.9 2.0 2.2 2.4 2.6 3.0 3.4 3.5 3.5 
4 2.1 2.2 2.3 2.4 2.5 2.6 2.8 2.9 3.2 3.6 4.0 4.6 4.7 4.7 
5 2.7 2.8 2.9 3.0 3.2 3.3 3.5 3.7 4.1 4.5 5.0 5.7 5.9 5.9 
6 3.3 3.4 3.5 3.7 3.9 4.0 4.2 4.5 4.9 5.4 6.1 6.9 7.2 7.2 
7 3.8 4.0 4.1 4.3 4.5 4.7 5.0 5.2 5.7 6.4 7.1 8.1 8.4 8.4 
8 4.4 4.6 4.8 5.0 5.2 5.4 5.7 6.0 6.6 7.3 8.2 9.3 9.6 9.6 
9 5.0 5.2 5.4 5.6 5.9 6.1 6.4 6.8 7.4 8.2 9.2 10.4 10.8 10.8 
10 5.5 5.7 6.0 6.2 6.5 6.8 7.2 7.5 8.3 9.2 10.2 11.6 12.0 12.0 
11 6.1 6.3 6.6 6.9 7.2 7.5 7.9 8.3 9.1 10.1 11.3 12.8 13.2 13.2 
12 6.7 6.9 7.2 7.5 7.9 8.2 8.6 9.1 10.0 11.0 12.3 14.0 14.5 14.5 
13 7.2 7.5 7.8 8.2 8.5 8.9 9.4 9.8 10.8 12.0 13.4 15.2 15.7 15.7 
14 7.8 8.1 8.4 8.8 9.2 9.6 10.1 10.6 11.6 12.9 14.4 16.3 16.9 16.9 
15 8.4 8.7 9.0 9.4 9.9 10.3 10.8 11.4 12.5 13.8 15.4 17.5 18.1 18.1 
16 8.9 9.3 9.7 10.1 10.5 11.0 11.6 12.1 13.3 14.7 16.5 18.7 19.3 19.3 
17 9.5 9.9 10.3 10.7 11.2 11.7 12.3 12.9 14.2 15.7 17.5 19.9 20.6 20.6 
18 10.1 10.5 10.9 11.4 11.9 12.4 13.0 13.7 15.0 16.6 18.6 21.0 21.8 21.8 
19 10.6 11.0 11.5 12.0 12.5 13.1 13.7 14.5 15.9 17.5 19.6 22.2 23.0 23.0 
20 11.2 11.6 12.1 12.6 13.2 13.8 14.5 15.2 16.7 18.5 20.6 23.4 24.2 24.2 
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Table 8. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 731 nm (Greening et al., 
2014). 
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.5 1.9 2.4 2.8 3.3 3.8 4.3 5.1 5.8 6.5 7.3 9.3 17.3 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.5 0.5 0.5 0.6 0.6 0.6 0.7 0.7 0.8 0.9 1.0 1.0 1.0 1.0 
2 1.1 1.2 1.2 1.3 1.3 1.4 1.4 1.5 1.7 1.8 2.0 2.2 2.2 2.2 
3 1.7 1.8 1.9 1.9 2.0 2.1 2.2 2.4 2.6 2.8 3.1 3.4 3.4 3.4 
4 2.3 2.4 2.5 2.6 2.7 2.9 3.0 3.2 3.5 3.8 4.2 4.5 4.5 4.5 
5 2.9 3.1 3.2 3.3 3.5 3.6 3.8 4.0 4.4 4.8 5.3 5.7 5.7 5.7 
6 3.6 3.7 3.8 4.0 4.2 4.4 4.6 4.9 5.3 5.8 6.4 6.8 6.8 6.8 
7 4.2 4.3 4.5 4.7 4.9 5.1 5.4 5.7 6.2 6.8 7.5 8.0 8.0 8.0 
8 4.8 5.0 5.2 5.4 5.6 5.9 6.1 6.5 7.1 7.7 8.5 9.2 9.2 9.2 
9 5.4 5.6 5.8 6.1 6.3 6.6 6.9 7.4 8.0 8.7 9.6 10.3 10.3 10.3 
10 6.0 6.2 6.5 6.8 7.0 7.4 7.7 8.2 8.9 9.7 10.7 11.5 11.5 11.5 
11 6.6 6.9 7.1 7.4 7.8 8.1 8.5 9.0 9.8 10.7 11.8 12.6 12.6 12.6 
12 7.2 7.5 7.8 8.1 8.5 8.9 9.3 9.9 10.7 11.7 12.9 13.8 13.8 13.8 
13 7.9 8.1 8.5 8.8 9.2 9.6 10.1 10.7 11.6 12.7 13.9 15.0 15.0 15.0 
14 8.5 8.8 9.1 9.5 9.9 10.4 10.8 11.5 12.5 13.6 15.0 16.1 16.1 16.1 
15 9.1 9.4 9.8 10.2 10.6 11.1 11.6 12.3 13.4 14.6 16.1 17.3 17.3 17.3 
16 9.7 10.1 10.5 10.9 11.3 11.9 12.4 13.2 14.3 15.6 17.2 18.4 18.4 18.4 
17 10.3 10.7 11.1 11.6 12.1 12.6 13.2 14.0 15.2 16.6 18.3 19.6 19.6 19.6 
18 10.9 11.3 11.8 12.3 12.8 13.3 14.0 14.8 16.1 17.6 19.4 20.8 20.8 20.8 
19 11.5 12.0 12.4 12.9 13.5 14.1 14.8 15.7 17.0 18.6 20.4 21.9 21.9 21.9 
20 12.1 12.6 13.1 13.6 14.2 14.8 15.5 16.5 17.9 19.5 21.5 23.1 23.1 23.1 
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Table 9. Lookup table to determine the required concentrations of absorbing and scattering 
agents from desired absorption and reduced scattering coefficients at 851 nm (Greening et al., 
2014). 
Absorption Coefficient µa [cm-1] 
Concentration of 1% w/v Nigrosin/EtOH to PDMS elastomer base [µL/g] 
 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 
1.0 1.7 2.4 3.1 3.8 4.4 5.2 5.9 6.7 7.7 9.6 12.9 18.4 27.4 
Reduced Scattering Coefficient µʹs [cm-1] 
Concentration of Titanium Dioxide to PDMS elastomer base [g/g] x10-3 
1 0.6 0.6 0.7 0.7 0.7 0.7 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 
2 1.4 1.4 1.4 1.5 1.5 1.6 1.6 1.7 1.8 1.8 1.8 1.8 1.8 1.8 
3 2.1 2.1 2.2 2.3 2.4 2.4 2.5 2.6 2.7 2.8 2.8 2.8 2.8 2.8 
4 2.8 2.9 3.0 3.1 3.2 3.3 3.4 3.5 3.7 3.7 3.7 3.7 3.7 3.7 
5 3.6 3.7 3.8 3.9 4.0 4.1 4.3 4.4 4.6 4.7 4.7 4.7 4.7 4.7 
6 4.3 4.4 4.5 4.7 4.8 5.0 5.2 5.4 5.6 5.7 5.7 5.7 5.7 5.7 
7 5.0 5.2 5.3 5.5 5.7 5.8 6.0 6.3 6.5 6.6 6.6 6.6 6.6 6.6 
8 5.8 5.9 6.1 6.3 6.5 6.7 6.9 7.2 7.5 7.6 7.6 7.6 7.6 7.6 
9 6.5 6.7 6.9 7.1 7.3 7.5 7.8 8.1 8.4 8.6 8.6 8.6 8.6 8.6 
10 7.2 7.4 7.7 7.9 8.1 8.4 8.7 9.0 9.4 9.5 9.5 9.5 9.5 9.5 
11 8.0 8.2 8.4 8.7 9.0 9.2 9.6 9.9 10.3 10.5 10.5 10.5 10.5 10.5 
12 8.7 9.0 9.2 9.5 9.8 10.1 10.4 10.8 11.3 11.4 11.4 11.4 11.4 11.4 
13 9.4 9.7 10.0 10.3 10.6 10.9 11.3 11.7 12.2 12.4 12.4 12.4 12.4 12.4 
14 10.2 10.5 10.8 11.1 11.4 11.8 12.2 12.7 13.2 13.4 13.4 13.4 13.4 13.4 
15 10.9 11.2 11.6 11.9 12.3 12.6 13.1 13.6 14.1 14.3 14.3 14.3 14.3 14.3 
16 11.6 12.0 12.3 12.7 13.1 13.5 14.0 14.5 15.1 15.3 15.3 15.3 15.3 15.3 
17 12.4 12.7 13.1 13.5 13.9 14.3 14.8 15.4 16.0 16.3 16.3 16.3 16.3 16.3 
18 13.1 13.5 13.9 14.3 14.7 15.2 15.7 16.3 17.0 17.2 17.2 17.2 17.2 17.2 
19 13.9 14.2 14.7 15.1 15.6 16.0 16.6 17.2 17.9 18.2 18.2 18.2 18.2 18.2 
20 14.6 15.0 15.4 15.9 16.4 16.9 17.5 18.1 18.8 19.2 19.2 19.2 19.2 19.2 
 
3.6.6 Extraction of sampling depth from semi-infinite phantom model of dysplastic 
progression 
 
Three different phantom geometries, simulating the progression from healthy tissue to 
severe dysplasia, underwent DRS evaluation using both SDSs (374 and 730 µm). Figure 19 
shows that the extracted µs’ for phantom 1 (blue line) was approximately 7 cm-1 at 630 nm, as 
expected from the phantom generation protocol (Greening et al., 2014). As the higher scattering 
(µs’ = 14 cm-1) layers proliferated upwards towards the probe tip (phantoms 2 and 3), an increase 
in volume-averaged µs’ occurred for both SDSs, although more so for the shorter SDS, as 
expected. For the shorter SDS, there was a significant increase in volume-averaged µs’ from 
phantoms 1 to 2 and 2 to 3. However, for the longer SDS, there was only a significant increase in 
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volume-averaged µs’ from phantoms 2 to 3. This indicates the 374 µm SDS is more sensitive to 
scattering heterogeneities at upper layers compared to the 730 µm SDS.  
This phenomenon is further quantified in Table 10 by the percent increase in volume-
averaged µs’ at 630 nm for Phantoms 1-3 for each SDS. The data indicates that the µs’ percent 
increase for the 374 µm SDS is significantly greater compared to the 730 µm SDS. This is 
because the shorter SDS has a decreased sampling depth, and therefore scattering is mostly 
affected by more superficial heterogeneities, as seen in early dysplasia, compared to the longer 
SDS. However, it is important to note that the 374 µm SDS still does not exclusively sample the 
upper layers, as indicated by the fact that the volume-averaged µs’ of phantom 3 (300 µm thick 
heterogeneity) is approximately 9 cm-1 rather than 14 cm-1 at the reference 630 nm. Additionally, 
sampling depth of the 374 µm SDS at a µs’ of 14 cm-1 is ~400 µm, indicating a sampling depth 
deeper than the 300 µm scattering heterogeneity. These results demonstrate the value of 
including a shorter SDS for detection of more superficial scattering changes. The value of 
including an additional longer SDS was shown in the following section describing in vivo results 
from healthy human oral mucosa. 
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Figure 19. The volume-averaged µs’ (a, b) increased as the proliferating 
scattering heterogeneity moved upwards towards the phantom surface (going 
from P1 to P3) showing a vertical line at 630 nm, in which percent increase in 
volume-averaged µs’ was measured from. There was a significantly greater µs’ 
increase in these values for the 374 µm SDS compared to the 730 µm SDS, 
indicating that the shorter SDS is more sensitive to superficial scattering changes 
associated with early epithelial dysplasia. 
 
Table 10. Paired t-test statistics for percent increases in µs’ (λ = 630 nm) for dysplasia-
mimicking phantom model 
Phantom 
Comparison 
374 μm SDS (n=10) 730 μm SDS (n=10) 
P-Value 
Significance 
(Y/N), α=0.01 Mean Std. Dev. Mean Std. Dev. 
P1 to P2 (%) 4.97 0.40 1.42 1.93 1.7x10-4 Y 
P2 to P3 (%) 16.18 5.95 9.19 1.54 4.6x10-3 Y 
P1 to P3 (%) 21.96 6.42 10.72 0.93 1.2x10-4 Y 
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3.6.7 Collaboration with the Boston University Department of Biomedical Engineering: two-
layer LUT improves the accuracy of tumor layer optical property extractions using SFDI 
The following section was directly adapted from Syeda Tabassum, Vivian Pera and 
Darren Roblyer from Boston University, with whom we provided tissue-simulating PDMS 
phantoms for their experiments (Tabassum et al., 2018). 
Experimental measurements were conducted to determine if the Gardner two-layer LUT 
inversion algorithm improves the accuracy of tumor layer optical property extractions compared 
to the Gardner homogeneous LUT. This accuracy test utilized the four two-layer phantoms 
described in Section 3.5.5. Each of the two-layer phantoms used the same top (skin) layer. The 
measured thickness of the skin layer was 310 μm at its center, which is within 0.8% of the skin 
layer thickness defined in the MC simulations used to generate the Gardner two-layer LUT. 
Absorption of the skin layer was 0.0936 mm−1 at 659 nm, which is within 2.52% of the MC 
absorption parameter, and the μ0s value was 0.780 mm−1 at 659 nm, which is within 0.063% of 
the MC value. For the tumor layer, four different pairs of optical properties were utilized, 
spanning a range of optical properties observed in our prior work, in which we monitored 
PC3/2G7 mouse xenografts over 45 days using SFDI (Tabassum et al., 2016). These pairs are 
labeled as tumor 1 through tumor 4 in Figure 10. The optical property pairs, reported at 659 nm, 
are as follows: for tumor 1: μa ¼ 0.0244 mm−1 and μ0 s ¼ 2.054 mm−1; tumor 2: μa ¼ 0.002 
mm−1 and μ0s ¼ 2.314 mm−1; tumor 3: μa ¼ 0.0039 mm−1 and μ0s ¼ 0.714 mm−1; and tumor 
4: μa ¼ 0.0301 mm−1 and μ0s ¼ 0.676 mm−1.  
Each two-layer phantom was measured with SFDI, and the bottom (tumor) layer optical 
properties were extracted using both the Gardner homogeneous and Gardner two-layer LUTs. 
Since these phantoms have flat surfaces, no corrections for height or angle were implemented. 
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The absolute differences between the measured and true μa for the tumor layer are shown in 
Figures 10(a) and 10(b). The absolute differences between the measured and true μ0s for the 
tumor layer are shown in Figures 5(c) and 5(d). In both cases, Figures 10(b) and 10(d) 
recapitulates the data in Figures 10(a) and 10(c) but with a zoomed-in y-axis to allow 
visualization of the small error values obtained for some phantoms. In the worst-case, the μa and 
μ0 s extraction errors were 20.33% and 10.87% for the two-layer LUT.  
In all cases, the error in tumor layer optical property extraction is substantially lower for 
the two-layer LUT versus the homogeneous LUT. This effect is not as pronounced in μ0s for 
tumors 3 and 4, as μ0s values in these tumors are very similar to that of the skin layer (μ0 s ¼ 
0.78 mm−1). Note that the decrease in error by the two-layer LUT is between 7 and 256 times 
for μa and between 2 and 24 times for μ0s. Taken together, these results confirm that the two-
layer LUT provides a better estimate of the true tumor layer optical properties than the 
homogeneous LUT (Tabassum et al., 2018). 
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Figure 20. Comparisons in bottom (tumor) layer optical property extraction errors 
for the Gardner homogeneous and Gardner two-layer LUT inversion algorithms. 
Diffuse reflectance measurements of four two-layer tissue-simulating optical 
phantoms were made with SFDI, and both inversion models were used to extract 
the bottom (tumor) layer optical properties (labeled as tumors 1 to 4). (a) The 
absolute extraction error compared with the known tumor layer μa. (b) The same 
data but with a zoomed-in y-axis so that small extraction errors can be visualized. 
(c) Absolute errors in tumor layer μ0s extractions and (d) the same data with a 
zoomed-in y-axis. Optical properties were measured at 659 nm (Tabassum et al., 
2018). 
 
3.7 How-to guide: solid phantoms as tools for simulating epithelial structure 
Presented in this section is a tutorial for constructing solid phantoms. These phantoms 
can be used to simulate thin epithelial tissue 100’s of microns thick. Thin layers can be stacked 
to mimic the geometry of layered epithelia, such as in the epidermis and dermis of skin. Different 
types of scattering and absorbing agents can be added to the solid phantoms to mimic an array of 
μs’ and μa. Furthermore, these solid optical phantoms can easily be molded into a variety of 
thicker shapes and inclusions/heterogeneities can be added for various purposes. Therefore, these 
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phantoms are a robust, multipurpose tool for a variety of imaging and spectroscopy applications.   
3.7.1 Constructing the PDMS-based mix 
The substrate material used to construct the following optical phantoms is 
polydimethylsiloxane (PDMS), a thermoset polymer. PDMS-based phantoms have been used by 
investigators for various purposes including epithelial tissue simulation (Greening et al., 2014; 
Wang et al., 2011), retina-simulating phantoms (Fogli et al., 2014), aorta models (Schlicht et al., 
2013), and other soft tissues (Avigo et al., 2015) for various imaging purposes.  
To construct these PDMS-based phantoms, an aliquot of PDMS elastomer base 
(Sylgard® 184 Silicone Elastomer Base) is poured into a plastic mixing cup. Depending on the 
application, less volume of elastomer base is needed for thinner layers (~150-300 μm) versus 
slightly thicker layers (300+ μm). After dispensing the PDMS elastomer base, the scattering and 
absorbing agents can be added. Scattering agents can be a variety of substances, such as TiO2 or 
polystyrene microspheres. Absorbing agents can also be a variety of substances including dyes 
and inks. The examples for this tutorial will use TiO2 (14021, Sigma Aldrich, USA) and water-
soluble nigrosin (N4763, Sigma Aldrich, USA) as the scattering and absorbing agents, 
respectively. Before adding the curing agent, it is important to thoroughly mix the elastomer base 
and optical agents. Mixing can be done by hand or in an appropriate automated mixing machine. 
Once mixed, the appropriate amount of curing agent (Sylgard® 184 Silicone Elastomer Curing 
Agent) should be added to the mix. The amount of curing agent needed is a 1:10 mass-to-mass 
ratio of curing agent to elastomer base (Greening et al., 2014). It is recommended to use a 
reliable micropipette to add in the appropriate amount of curing agent to the mix. Immediately 
following addition of curing agent, the curing process will begin. Therefore, it is imperative to 
mix the curing agent into the PDMS elastomer base immediately either by hand or with an 
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automated mixing machine. Some mixing machines contain a “degassing” feature, in which the 
recovered mixed product is free of air bubbles. If mixing the elastomer base, curing agent, and 
scattering and absorbing agents by hand, the resultant mix must be fully degassed using a 
vacuum for at least 90-120 minutes. Furthermore, the PDMS must always be vacuumed to create 
a spatially homogenous solution free of air bubbles after dispensing into a mold. 
Curing PDMS at room temperature takes between 48-72 hours. Curing can be accelerated 
by placing the fully mixed and degassed solution into an oven. Placing the mix inside an oven at 
70°C will cure the mix in 2 hours. Furthermore, if needed, curing can be halted by placing the 
mix in a sub-0°C freezer.  
Figure 21 shows the process for creating bulk PDMS-based phantoms, including the 
viscous, pre-cured PDMS elastomer base, the addition of TiO2 as the scattering agent and water 
soluble nigrosin as the absorbing agent.  
 
Figure 21. A demonstration of the process to create PDMS-based phantoms with 
TiO2 and water-soluble nigrosin. The figure shows (a) PDMS elastomer base with 
no mixed components, (b) TiO2 mixed in the PDMS elastomer base, and (c), 
water-soluble nigrosin mixed in the PDMS elastomer base.  
 
Since PDMS is a viscous polymer prior to curing into a permanent solid polymer, it can 
be molded into a variety of shapes and sizes. Figure 22 shows an example of a PDMS-based 
phantom, containing TiO2 and water-soluble nigrosin, molded into a cylinder 28 mm in diameter 
and 50 mm in height. The cylinder had a μs’ of 4.75 cm-1 and μa of 0.25 cm-1 at a reference of 
633 nm. One 6.35-diameter hole was drilled into the top of the phantom 30 mm deep. The drilled 
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hole was filled with PDMS-based phantom mix with a μs’ of 4.75 cm-1 and μa of 5.0 cm-1, so that 
scattering was constant, and absorption was increased by a factor of 20. This demonstration 
shows that heterogeneities or inclusions can be added to a solid-PDMS phantom to potentially 
simulate a variety of tissue types for different imaging or spectroscopic applications.  
 
Figure 22. PDMS-based phantoms molded into three-dimensional structures. The 
figure shows (a) PDMS molded into the shape of a finger, (b) a PDMS optical 
phantom with 5 mm-diameter holes drilled 5 cm deep for the addition of optical 
inclusions, and (c) a block of PDMS containing TiO2 and water-soluble nigrosin 
that can be used as a “semi-infinite” layer in which thin PDMS phantom layers 
can be stacked.  
 
3.7.2 Spin coating technique for creation of thin phantoms 
In addition to using PDMS to create bulk tissue phantoms, thin phantoms, down to 
approximately 100 μm or thinner, can also be constructed (Greening et al., 2014; Koschwanez et 
al., 2009). These thin phantoms can be stacked to create semi-permanent multilayer phantoms. 
These multilayer phantoms are semi-permanent because each individual layer is optically stable 
over time, but each layer can be switched out for additional layers. This gives investigators the 
freedom to mix and match stable layers of varying optical properties and thicknesses.  
Optical properties of these PDMS-based phantoms are controlled with the addition of 
scattering and absorbing agents. The scattering properties can be controlled by obtaining a LUT 
showing μs’ as a function of scattering agent concentration, other empirical methods presented in 
literature, or Mie Theory. The absorbing properties can be controlled by evaluating the μa of 
dilute solutions of the absorbing agent using a spectrophotometer and Beer’s Law.  
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Layer thickness is controlled using a custom spin coating technique. Immediately after 
the PDMS-reagent mixture has completed the mixing and degassing steps outlined in the 
previous section, a quarter-sized amount is transferred to an unmodified silicon wafer. These 
wafers are 500 microns in depth, with a diameter of 100 millimeters. The wafer is then placed 
within a spin coating machine and spun at an appropriate rotational speed (RPM) to yield the 
desired layer thickness. For our purposes, the spin coater spins the silicon wafer at maximum 
speed for 20 seconds, with a 2 second acceleration and deceleration period. Immediately after 
curing, the still-viscous spun layer of PDMS is transferred to a 70°C oven where it is allowed to 
complete the curing process for 2 hours. Several groups have used spin coating methods to 
produce thin phantom layers and their specific target thicknesses can be found elsewhere 
(Koschwanez et al., 2009; Greening et al., 2014). 
For this tutorial, it is important to note the parameters that affect layer thickness using a 
spin coater. First, maximum speed affects layer thickness. The faster the silicon wafer spins the 
PDMS mix, the thinner the resultant layer. Second, duration of speed affects layer thickness. A 
shorter spin duration increases layer thickness whereas a longer spin duration decreases layer 
thickness. Third, the temperature of the PDMS mix prior to mixing affects resultant layer 
thickness. Since PDMS is a thermoset, the higher the temperature prior to spinning, the thicker 
the layer since the polymer will begin to resist mechanical forces throughout curing. A colder 
pre-spun mix will result in thinner layers. Fourth, the post-spinning curing temperature will 
affect thickness. Since the PDMS will not have fully cured after spinning, it will continue to 
slightly settle and spread out post-spinning. Therefore, the higher the temperature post spinning, 
the thicker the resultant layer. Fifth, additives to the PDMS mix will affect layer thickness. One 
group has shown that adding in a type of alcohol results in thinner layers when holding all other 
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variables constant (Koschwanez et al., 2009). Additionally, adding in varying amounts of 
scattering and absorbing agents may affect resultant thickness, although this has not been 
extensively investigated at this time. The next few factors are timing factors, since the curing 
process is time sensitive. In all cases, increased time between steps results in thicker layers. 
These factors include the time between mixing the curing agent with the elastomer base and 
spinning with the spin coater, and the time between mixing with the spin coater and placing in 
the oven to finalize the curing process.  
The spin coating method for creating phantoms is extremely useful and important. It is, 
for this process, what allows there to be multiple layer thicknesses to simulate different depths 
within epithelial tissues. It also allows for a simple way of creating multi-layer phantoms to 
quickly and easily vary a simulation of different depths within epithelial tissues by stacking a 
pre-made, set number of individual thin phantoms (Greening et al., 2014).  
Figure 23 shows the process of creating thin PDMS-based phantoms. The uncured 
viscous PDMS-phantom mix, with μs’ of 4.75 cm-1 and μa of 0.25 cm-1 at a reference of 633 nm, 
is poured onto a silicon wafer. The silicon wafer is placed into a spin coating machine which 
spins the uncured PDMS at a user-specified speed. The uncured PDMS spreads out, becoming 
thinner. The uncured, thinned PDMS-phantom is then placed in an oven to finish curing, and 
afterwards a piece can be cut to various geometries. In this example, the resultant cured phantom 
was 300 µm and approximately 2 cm2. 
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Figure 23. The process of creating thin PDMS-based optical phantoms. The 
figure shows the (a) silicon wafer with uncured the uncured PDMS mix (scale bar 
=3 cm), (b) silicon wafer inside the spin coating machine, (c) uncured PDMS mix 
after being spun down in the spin coating machine (scale bar =3 cm), and (d) 
cured 300 µm thick phantom cut to a 2 cm2 square with μs’ of 4.75 cm-1 and μa of 
0.25 cm-1 at a reference of 633 nm to simulate Caucasian epidermal tissue (scale 
bar = 7.5 mm).  
 
Figure 24 shows more examples of thin PDMS-based optical phantoms. Figure 24(a) 
shows three 270 μm thick phantoms with increasing concentration of TiO2, corresponding to μs’ 
values of 4.6, 8.2, and 21.5 cm-1 and a μa of 0 cm-1 at 633 nm. Figure5(b) shows an image of a 
large base phantom layer with μs’ and μa of 4.75 cm-1 and 0.25 cm-1 at 633 nm. One top of this 
base layer are four optically heterogeneous 100 μm-thick PDMS-based phantoms with μs’ and μa 
of 4.75 cm-1 and 5.00 cm-1 at 633 nm. To demonstrate the ability to create semi-permanent 
multilayer phantoms, the four optical heterogeneous layers have either zero, one, two, or three 
100 μm-thick layers that have identical optical properties to the base layer (μs’ = 4.75 cm-1 and μa 
= 0.25 cm-1 at 633 nm). This demonstrates the ability of thin PDMS-based phantom layers to be 
stacked in various arrangements to create multilayer phantoms with optical heterogeneities. In 
this case, the optical heterogeneities had a 20x increase in absorption for demonstrative purposes, 
although in real tissue, heterogeneities may not be as optically different (Greening et al., 2014; 
Salomatina et al., 2006). 
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Figure 24. This figure shows (a) three non-absorbing 270 µm thick phantom 
layers, each approximately 1.5 cm2, with increasing µs’ (4.6, 8.2, and 21.5 cm-1) 
due to increased concentrations of titanium dioxide (TiO2) and μa = 0 cm-1, and 
(b) a 6 cm-diameter “semi-infinite” layer (μs’ = 4.75 cm-1, μa = 0.25 cm-1 at 633 
nm) with various thin stacked phantoms on top. At each quadrant, there exists a 
highly absorbing inclusion (μs’ = 4.75 cm-1, μa = 5.00 cm-1 at 633 nm) with either 
0, 1, 2, or 3 overlying 100 μm thick layers with optical properties (μs’ = 4.75 cm-1, 
μa = 0.25 cm-1 at 633 nm) matching that of the underlying “semi-infinite” layer.  
 
3.8 Discussion 
 
3.8.1 PDMS as a substrate material 
 
We have demonstrated a reproducible method for creating thin PDMS-based phantoms 
with tunable thickness and optical properties (reduced scattering and absorption coefficients) (de 
Bruin et al., 2010; Saager et al., 2010; Pogue et al., 2006; Ayers et al., 2008; Sandell et al., 
2011; Liu et al., 2006; Bae et al., 2013). PDMS, a silicone based polymer, was chosen as the 
substrate material due to its relatively long optical stability when compared to other commonly 
used substrates (de Bruin et al., 2010; Pogue et al., 2006). Bruin et al. demonstrated that optical 
properties of PDMS-based phantoms using TiO2 as a scattering agent remained stable over a six 
month testing period (de Bruin et al., 2010). Pogue et al. reports that silicone-based phantoms 
with TiO2 and various inks should have an optical stability of at least one year (Pogue et al., 
2006). Furthermore, PDMS is optically clear, easily moldable, and has a comparable refractive 
index (1.4) to human tissue (de Bruin et al., 2010; Saager et al., 2010; Pogue et al., 2006). 
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3.8.2 Spin coating to produce individual thin layers 
 
We demonstrated an ability to create both thin phantom layers (between 115 and 880 μm) 
and thick phantom layers (approximately 2.5 cm thick). Thick phantoms could be made at other 
thicknesses as well by varying the volume dispensed into the ARE-100 conditioning mixer cup 
(Intertronics, UK) mold.    
To create thin phantom layers, a spin coating technique was used to spin partially cured 
PDMS down to reproducible thicknesses as shown in Figure 11 (Bae et al., 2013; Koschwanez et 
al., 2009). Koschwanez et al. have previously outlined a spin coating technique to create multi-
layered PDMS phantoms by spinning uncured PDMS over an already cured layer. However, 
their thin phantoms ranged between 2 and 30 μm, much thinner than our intended range (100-
300 μm) for mimicking epithelial tissue thickness (Harris et al., 1992; Chang et al., 2012; 
Guimarães et al., 2007; Rocha et al., 2010). Furthermore, our method allowed for thin layers to 
be used interchangeably and non-permanently to rapidly test multiple configurations. In our 
studies, the relationship between the maximum 20 second spin speed of the spin coater and the 
resulting thickness of cured, individual PDMS layers containing varying amounts of TiO2 and 
1% w/v nigrosin/EtOH can be seen in Figure 11. Spin speeds of 100 rpm produced phantoms 
with an average thickness of 880 µm and standard deviation of 34 µm. Spin speeds of 1000 µm 
produced phantoms with an average thickness of 115 µm and standard deviation of 4 µm. As 
spin speed increased, thickness decreased, and standard deviation tended to decrease. For 
researchers interested in using this technique, the following inverse equation (Eq. 3), based on 
data presented here, can be used as a guideline to estimate the necessary spin speed [rpm] given a 
desired thickness with relative accuracy, 
𝑠 = 115,900 ∙ (𝑡−0.9985) − 15.09 (3) 
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where t is the desired thickness [µm] and s is the resulting spin speed [rpm]. The R2 value for 
this equation is 0.988 for the data presented in this manuscript. This equation (Eq. 3) was 
generated by the MATLAB curve fitting toolbox using a 2-term power model.  
One consideration when using this spin coating technique is the potential non-uniformity 
of absorbing and scattering agents within the PDMS material. Heterogeneities in these materials 
may result at increasing radial distances due to the rotational acceleration of the spin coater 
(Saager et al., 2010). This may also mean that thin phantoms of identical concentrations of 
optical agents, but different thicknesses may have slightly different optical properties. Since 
SFDI required thick phantoms (> 2.5 cm) for characterization, optical properties of thin layers 
were not explicitly measured (Cuccia et al., 2009). However, from data presented in Figure 16 
and 17, we are reasonably confident that thin layers have bulk scattering and absorbing 
properties comparable to the thicker layers characterized by SFDI. To definitively validate thin 
layer uniformity, methods capable of characterizing optical properties of thin layers, such as 
integrating spheres and Inverse Adding-Doubling (IAD) methods, must be further explored 
(Prahl et al., 1993; Pickering et al., 1993). Another limitation to this procedure was creating 
phantoms with a lower limit of approximately 115 μm. While thinner layers could potentially be 
produced using our spin coating technique, such thin layers were increasingly difficult to work 
with by hand and could no longer be considered interchangeable with regards to creating 
multilayered phantoms. Therefore, applications in need of phantoms thinner than 115 μm, such 
as retinal imaging, may benefit from other spin coating techniques such as those presented by 
Bae et al. or Koschwanez et al. that can produce much thinner layers (Bae et al., 2013; Chang et 
al., 2012; Baxi et al., 2014).  
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3.8.3 Alcohol-soluble nigrosin as an absorbing agent 
 
The absorption coefficient (µa) of PDMS phantoms was manipulated by using alcohol-
soluble nigrosin as the absorbing agent (Saager et al., 2010; Liu et al., 2006). A 1% w/v solution 
of nigrosin/ethanol was prepared and added to phantoms at increasing concentrations as seen in 
Figure 14. Figure 15 shows that µa was independent of TiO2 concentrations. However, µa was 
shown to be wavelength dependent when using 1% w/v nigrosin/EtOH for the absorbing agent. 
This can be seen in Figure 14 in the difference between the best fit curves for the 591 nm 
(dashed) and 851 nm (dotted) wavelengths, respectively. As wavelength increased, µa tended to 
decrease. This observation is comparable to results on similar phantoms created by Saager et al 
(Saager et al., 2010). In addition, µa was strongly dependent on concentration of 1% w/v 
nigrosin/EtOH as expected. Figure 14 shows that a more linear region exists between 1% w/v 
nigrosin/EtOH concentrations from 0 to 7 µL/g PDMS elastomer base, corresponding to µa 
values between approximately 0 and 0.9-1.2 cm-1 depending on the measured wavelengths. 
Increases in µa began to level off for 1% w/v nigrosin/EtOH concentrations between 7 to 40 µL/g 
PDMS elastomer base, corresponding to µa values between approximately 0.9-1.2 and 1.5 cm
-1.  
Just as in the case of the previous thickness-spin speed relationship (Eq. 3), a useful 
inverse equation would be one that estimates the necessary concentration of 1% w/v 
nigrosin/EtOH in PDMS given a desired µa. Because µa was shown to be dependent on both 
absorbing concentration and wavelength, a simple inverse equation was not found. Instead, the 
relationship between absorbing agent concentration and desired µa was modeled by a piecewise 
function for each of the six studied wavelengths (591, 631, 659, 691, 731, and 851 nm). This set 
of equations, generated by the MATLAB curve-fitting toolbox, was used to create the lookup 
tables found in the appendix. However, it should be noted that these equations and corresponding 
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lookup tables, generated from our limited sample size of 16 PDMS-based phantoms (Table 1), 
should just be used as guidelines. Exact µa values cannot be accurately predicted due to our lack 
of extensive validation testing so optical properties should always be independently validated.  
One of the major drawbacks to using alcohol-soluble nigrosin as the absorber was its 
hydrophilic nature. The alcohol-soluble nigrosin did not mix easily with the silicone base 
material used to produce PDMS. To account for this, Bisaillon et al. and Bruin et al. both suggest 
mixing hexane with PDMS (de Bruin et al., 2010; Bisaillon et al., 2008). However, Koschwanez 
et al. suggested that adding hexane swells the PDMS substrate, and instead mixed tert-butyl 
alcohol with PDMS (Koschwanez et al., 2009). Using a certain percent tert-butyl alcohol within 
the PDMS substrate may aid in more efficient mixing of alcohol-soluble nigrosin and should be 
explored in future studies. If this is to be done, however, new thickness-spin speed curves (see 
Figure 11) would need to be generated between 100 and 1000 rpm for tert-butyl alcohol infused 
PDMS (Koschwanez et al., 2009). However, our described procedure accounted for mixing 
difficulties by thoroughly mixing 1% w/v nigrosin/EtOH in PDMS with a sonicator, vortex 
mixer, and an ARE-100 conditioning mixer. Another limitation for the phantoms presented here 
was a characteristic peak in absorption in the 870-930 nm range when using nigrosin-silicone 
based tissue phantoms (Saager et al., 2010). Because our SFDI analysis only covered a 
wavelength range up to 851 nm, this phenomenon was not observed. Therefore, for our purposes, 
the procedure presented here to manipulate µa using alcohol-soluble nigrosin is sufficient. 
Finally, other absorbing agents such as whole blood, inks, dyes, or fluorophores may be 
investigated either as the single absorber or in combination with each other in the outlined 
procedure for phantom construction (Saager et al., 2010; Pogue et al., 2006).     
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3.8.4 Titanium dioxide as a scattering agent 
 
The reduced scattering coefficient (µʹs) of PDMS phantoms was manipulated by using 
titanium dioxide (TiO2) as the scattering agent (Saager et al., 2010). The µʹs of PDMS phantoms 
was shown to be dependent on TiO2 concentration (Figure 12), wavelength (Figure 12), and 1% 
w/v nigrosin/EtOH concentration (Figure 13). The dependence of µʹs on scattering agent 
concentration and wavelength has been demonstrated in previous phantom studies (de Bruin et 
al., 2010; Saager et al., 2010). Depending on the wavelength, Figure 12 shows that phantoms 
were produced with reduced scattering coefficients between approximately 1 and 20 cm-1. 
However, Figure 13 shows that as 1% w/v nigrosin/EtOH concentration increased, µʹs decreased 
in phantoms with identical concentrations of TiO2 (Phantoms #1, 9-15 in Table 1). Furthermore, 
the decline of µʹs due to increased concentration of 1% w/v nigrosin/EtOH was greater at lower 
wavelengths (591 and 621 nm) when compared to higher wavelengths (731 and 851 nm). 
Furthermore, in Figure 13, once a certain concentration of 1% w/v nigrosin/EtOH was reached 
(around 7 µL/g), further changes in wavelength and concentration did not affect µʹs. 
The roughly linear relationship between µʹs and absorbing agent concentration over the 
tested wavelengths (Figure 13) implies there may exist an empirically determined correction 
factor that could account for all variables (TiO2 concentration, wavelength, and 1% w/v 
nigrosin/EtOH concentration) that affect µʹs. Thus, given a desired wavelength, µa, and µʹs, the 
necessary TiO2 concentration was analytically determined. Therefore, for researchers interested 
in manipulating µʹs within PDMS phantoms, the provided lookup tables can predict TiO2 
concentration based on data presented in this paper. Of note, however, in Figure 13, the 
phenomenon that increasing 1% w/v nigrosin/EtOH concentration reduced µʹs was only observed 
in phantoms with minimal TiO2 concentration (0.001 g TiO2/g PDMS elastomer base). Further 
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studies will need to be completed to validate the lookup tables presented here and determine 
whether this phenomenon is prevalent in phantoms with much higher TiO2 concentrations, such 
as 0.007 or 0.008 g TiO2/g PDMS elastomer base. It should also be noted that the lookup tables 
assume a linear relationship in µʹs and TiO2 concentration beyond the tested limits (0.001 – 0.008 
g/g). Further SFDI analysis will be needed to validate these values within the lookup table. 
Finally, it is possible to expand this approach by using scattering agents other than TiO2. 
Scattering materials such as polystyrene beads, silicon dioxide, aluminum oxide powders or 
other types of microspheres have been successfully demonstrated by other investigators and 
could potentially be applied using our spin coater approach (de Bruin et al., 2010; Pogue et al., 
2006; Kanick et al., 2012; Passos et al., 2005). 
3.8.5 Multi-layered phantoms to simulate heterogeneities 
 
Generally, the purpose of multi-layered phantoms is to introduce geometrical and optical 
heterogeneities in phantoms to simulate the layered structure of epithelial tissue (de Bruin et al., 
2010; Pogue et al., 2006). A multi-layered phantom (Table 2, Phantom #18) with two thin layers 
(200 µm) was compared to a control phantom (Table 2, Phantom #17) with identical 
concentrations of optical agents. The µʹs and µa for the two phantoms were compared in Figure 
16 and 17. Only slight differences were present between the two phantoms across the six 
measured wavelengths. Figure 16, comparing µʹs, shows an average aggregate error of 7.7%. 
Figure 17, comparing µa, shows an average aggregate error 10.9%. We believe these differences 
were due to random error in dispensing the precise amounts of TiO2 and 1% w/v nigrosin/EtOH 
solution rather than being due to air pockets between layers. This assumption was further 
validated in Figure 18, which compares multi-layered phantoms to human epithelium using an 
OCT B-scan technique. OCT instrumentation, operating at 1325 nm (outside the wavelength 
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range of our SFDI equipment), was used for comparative purposes and was not meant to validate 
optical properties of phantoms. The multi-layered phantom (Figure 18) shows no visible air 
pockets between adjacent layers. These validations give us good reason to believe that creating 
PDMS-based multi-layered phantoms using our procedure can serve as appropriate models of 
various epithelium. In addition to providing evidence for the absence of air pockets, B-scans in 
Figure 18 were used for visually comparing thicknesses of phantoms to several types of 
epithelium (Higgins et al., 2014). 
The comparative images shown in Figure 18 as well as the data from Figure 11 show that 
the thickness of individual PDMS layers accurately modeled the thickness of several types of 
human epithelium (skin from the finger or wrist and oral mucosa). In addition, we believe that 
the phantom procedure presented here could potentially model the thickness of other epithelial 
tissue types, such as tongue and gingivae (100-200 μm thick, cervical epithelium (180 μm thick), 
and esophageal epithelium (250 μm thick) (Harris et al., 1992; Guimarães et al., 2007; Rocha et 
al., 2010).  
3.9 Conclusion 
To design these phantoms, lookup tables (Tables 4-9) have been provided to guide 
researchers in selecting the appropriate concentrations of scattering and absorbing agents (TiO2 
and 1% w/v Nigrosin/EtOH). Thick or thin (between 115 and 880 µm) phantoms can be created 
by either directly molding uncured PDMS or by using the described spin coating technique. Eq. 
3 provides guidance in selecting an appropriate spin speed based on a desired phantom layer 
thickness. Thick and thin layers can be combined to form multi-layered phantoms to simulate 
optical heterogeneities seen in tissue (Figure 16-18). In addition, individual thin layers may be 
used interchangeably to test multiple configurations (Saager et al., 2010). These PDMS-based 
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tissue-simulating phantoms may be used by researchers as optically stable calibration devices for 
various optical imaging techniques including, but not limited to, optical coherence tomography 
(OCT), diffuse optical spectroscopic imaging (DOSI), endoscopy, or microendoscopy (de Bruin 
et al., 2010; Saager et al., 2010; Cerussi et al., 2012; Pogue et al., 2006; Higgins et al., 2014). 
Using the provided lookup tables, these phantoms have the potential to mimic the optical 
properties of common types of epithelium including breast, skin, colon, oral, cervical, and 
esophagus, among others (Sandell et al., 2011; Harris et al., 1992; Guimarães et al., 2007; Rocha 
et al., 2010).  
A semi-infinite phantom model was used to simulate dysplastic progression in the oral 
mucosa (Figure 9) (Zhu et al., 2011; Speight, 2007; Warnakulasuriya et al., 2008). Results 
confirmed that the longer 374 μm SDS was more sensitive to the scattering heterogeneity at 
superficial layers (Figure 19), where epithelial dysplasia is known to have a profound effect on the 
scattering properties in such layers (Collier et al., 2003; Clark et al., 2004; Arifler et al., 2003). 
These experiments demonstrate the potential for monitoring scattering changes associated with 
early epithelial dysplasia which is often confined above the basement membrane (Warnakulasuriya 
et al., 2008; Zhu et al., 2011; Speight, 2007; Bouquot et al., 2006). 
3.10 Acknowledgements  
This material is based on work supported by the National Institutes of Health 
(1R15CA202662-01), the National Science Foundation Graduate Research Fellowship Program 
(G.G., DGE-1450079), the Arkansas Biosciences Institute, and the University of Arkansas 
Doctoral Academy Fellowship. Any opinions, findings, and conclusions or recommendations 
expressed in this material are those of the authors and do not necessarily reflect the views of the 
acknowledged funding agencies. I wish to thank Haley James for her contribution to our SPIE 
198 
 
Spotlights eBook discussing phantom design in optical systems. Additionally, I wish to thank 
Raeff Istfan and Darren Roblyer from Boston University and Laura Higgin and Mark Pierce from 
Rutgers University for their contributions to this chapter. 
3.11 Disclosures 
The authors declare that there are no conflicts of interest related to this chapter.  
 
References 
Agenant, M., et al. "Clinical Superficial Raman Probe Aimed for Epithelial Tumor Detection: 
Phantom Model Results." Biomedical Optics Express 5.4 (2014). 
Agrawal, A., et al. "Multilayer Thin-Film Phantoms for Axial Contrast Transfer Function 
Measurement in Optical Coherence Tomography." Biomed Opt Express 4.7 (2013): 1166-75. 
Alerstam, E., et al. "Improved Accuracy in Time-Resolved Diffuse Reflectance Spectroscopy." 
Optics Express 16.14 (2008). 
Ansari, M.A., et al. "Difuse Optical Tomography: Image Reconstruction and Verification." 
Journal of Lasers in Medical Sciences 5.1 (2014). 
Arifler, D., et al. "Light Scattering from Normal and Dysplastic Cervical Cells at Different 
Epithelial Depths: Finite-Difference Time-Domain Modeling with a Perfectly Matched Layer 
Boundary Condition." Journal of Biomedical Optics 8.3 (2003): 484-94. 
Avigo, C., et al. "Organosilicon Phantom for Photoacoustic Imaging." Journal of Biomedical 
Optics 20.4 (2015). 
Fabrication and Characterization of Silicone-Based Tissue Phantoms with Tunable Optical 
Properties in the Visible and near Infrared Domain. SPIE BiOS. 2008. SPIE. Print. 
Bae, Y., et al. "Fabrication of a Thin-Layer Solid Optical Tissue Phantom by a Spin-Coating 
Method: Pilot Study." J Biomed Opt 18.2 (2013): 25006. 
Baran, T.M., et al. "Determination of Optical Properties by Interstitial White Light Spectroscopy 
Using a Custom Fiber Optic Probe." Journal of Biomedical Optics 18.10 (2013). 
 
199 
 
Baran, T.M., and T.H. Foster. "Recovery of Intrinsic Fluorescence from Single-Point Interstitial 
Measurements for Quantification of Doxorubicin Concentration." Lasers in Surgery and 
Medicine 45.8 (2013). 
Barman, I., et al. "Turbidity Corrected Raman Spectroscopy for Blood Analyte Detection." 
Analytical Chemistry 81.11 (2009). 
Baxi, J., et al. "Retina-Simulating Phantom for Optical Coherence Tomography." J Biomed Opt 
19.2 (2014): 21106. 
Bedard, N., et al. "Real-Time Video Mosaicing with a High-Resolution Microendoscope." 
Biomedical Optics Express 3.10 (2012). 
Bender, J.E., et al. "A Robust Monte Carlo Model for the Extraction of Biological Absorption 
and Scattering in Vivo." IEEE Transactions on Biomedical Engineering 56.4 (2009). 
Bi, B., et al. "Image Reconstruction for Diffuse Optical Tomography Based on Radiative 
Transfer Equation." Computational and Mathematical Methods in Medicine 2015 (2015). 
Bisaillon, C. E., et al. "Deformable and Durable Phantoms with Controlled Density of 
Scatterers." Phys Med Biol 53.13 (2008): N237-47. 
Bish, S.F., et al. "Handheld Diffuse Reflectance Spectral Imaging (Drsi) for in-Vivo 
Characterization of Skin." Biomedical Optics Express 5.2 (2014): 573-86. 
Bosschaart, N., et al. "Optical Properties of Neonatal Skin Measured in Vivo as a Function of 
Age and Skin Pigmentation." Journal of Biomedical Optics 16.9 (2011). 
Bouquot, J.E., et al. "Epithelial Dysplasia of the Oral Mucosa—Diagnosticproblems and 
Prognostic Features." Current Diagnostic Pathology 12 (2006): 11-21. 
Bremmer, R.H., et al. "Non-Contact Spectroscopic Determination of Large Blood Volume 
Fractions in Turbid Media." Biomedical Optics Express 2.2 (2011). 
Bremmer, R.H., et al. "Diffuse Reflectance Relations Based on Diffusion Dipole Theory for 
Large Absorption and Reduced Scattering." Journal of Biomedical Optics 18.8 (2013). 
Bydlon, T.M., et al. "Performance Metrics of an Optical Spectral Imaging System for Intra-
Operative Assessment of Breast Tumor Margins." Optics Express 18.8 (2010). 
Campbell, A.P., et al. "Flexible Cochlear Microendoscopy in the Gerbil." Laryngoscope 120.8 
(2010). 
200 
 
Cerussi, A. E., et al. "Tissue Phantoms in Multicenter Clinical Trials for Diffuse Optical 
Technologies." Biomed Opt Express 3.5 (2012): 966-71. 
Chang, C.Y., et al. "Fluorescence Intrinsic Characterization of Excitation-Emission Matrix Using 
Multi-Dimensional Ensemble Empirical Mode Decomposition." International Journal of 
Molecular Sciences 14.11 (2013). 
Chang, R. C., et al. "Fabrication and Characterization of a Multilayered Optical Tissue Model 
with Embedded Scattering Microspheres in Polymeric Materials." Biomed Opt Express 3.6 
(2012): 1326-39. 
Chang, S.S., et al. "High Resolution Microendoscopy for Classification of Colorectal Polyps." 
Endoscopy 45.7 (2013): 553-9. 
Chang, V.T., et al. "Quantitative Physiology of the Precancerous Cervix in Vivo through Optical 
Spectroscopy." Neoplasia 11.4 (2009): 325-32. 
Chang, V.T., et al. "Towards a Field-Compatible Optical Spectroscopic Device for Cervical 
Cancer Screning in Resource-Limited Settings: Effects of Calibration and Pressure." Optics 
Express 19.19 (2011). 
Chen, S., et al. "Recovery of Raman Spectra with Low Signal-to-Noise Ratio Using Wiener 
Estimation." Optics Express 22.10 (2014). 
Choi, H.Y., et al. "Microlensed Dual-Fiber Probe for Depth-Resolved Fluorescence 
Measurements." Optics Express 19.15 (2011). 
Clark, A.L., et al. "Detection and Diagnosis of Oral Neoplasia with an Optical Coherence 
Microscope." Journal of Biomedical Optics 9.6 (2004): 1271-80. 
Collier, T., et al. "Determination of Epithelial Tissue Scattering Coefficient Using Confocal 
Microscopy." IEEE Journal of Selected Topics in Quantum Electronics 9.2 (2003): 307-13. 
Croce, A.C., and G. Bottiroli. "Autofluorescence Spectroscopy and Imaging: A Tool for 
Biomedical Research and Diagnosis." European Journal of Histochemistry 58.4 (2014). 
Cuccia, D. J., et al. "Modulated Imaging: Quantitative Analysis and Tomography of Turbid 
Media in the Spatial-Frequency Domain." Opt Lett 30.11 (2005): 1354-6. 
Cuccia, D.J., et al. "Quantitation and Mapping of Tissue Optical Properties Using Modulated 
Imaging." Journal of Biomedical Optics 14.2 (2009). 
 
201 
 
de Bruin, D.M., et al. "Optical Phantoms of Varying Geometry Based on Thin Building Blocks 
with Controlled Optical Properties." Journal of Biomedical Optics 15.2 (2010). 
Dehghani, H., et al. "Numerical Modelling and Image Reconstruction in Diffuse Optical 
Tomography." Philosophical Transactions of the Royal Society A 367 (2009). 
Demers, J.H., et al. "Multichannel Diffuse Optical Raman Tomography for Bone 
Characterization in Vivo: A Phantom Study." Biomedical Optics Express 3.9 (2012). 
Dhar, S., et al. "A Diffuse Reflectance Spectral Imaging System for Tumor Margin Assessment 
Using Custom Annular Photodiode Arrays." Biomedical Optics Express 3.12 (2012). 
Du Le, V.N., et al. "Measurements of Extrinsic Fluorescence in Intralipid and Polystyrene 
Microspheres." Biomedical Optics Express 5.8 (2014). 
Esmonde-White, K.A., et al. "Fiber-Optic Raman Spectroscopy of Joint Tissues." Analyst 136.8 
(2011). 
Fogli, G., et al. "New Eye Phantom for Ophthalmic Surgery." Journal of Biomedical Optics 19.6 
(2014). 
Fu, H.L., et al. "A Low-Cost, Portable, and Quantitative Spectral Imaging System for 
Application to Biological Tissues." Optics Express 18.12 (2010): 12630-45. 
Gamm, U.A., et al. "Extraction of Intrinsic Fluorescence from Single Fiber Fluorescence 
Measurements on a Turbid Medium: Experimenal Validation." Biomedical Optics Express 5.6 
(2014). 
Gibson, A.P., et al. "Recent Advances in Diffuse Optical Imaging." Physics in Medicine and 
Biology 50 (2005). 
Glennie, D.L., et al. "Inexpensive Diffuse Reflectance Spectroscopy System for Measuring 
Changes in Tissue Optical Properties." Journal of Biomedical Optics 19.10 (2014): 105005. 
Gonzalez-Rodriguez, P., and A.D. Kim. "Diffuse Optical Tomography Using the One-Way 
Radiative Transfer Equation." Biomedical Optics Express 6.6 (2015). 
Greening, G.J., et al. "Characterization of Thin Poly (Dimethylsiloxane)-Based Tissue 
Simulating Phantoms with Tunable Reduced Scattering and Absorption Coefficients at Visible 
and Nearinfrared Wavelength." Journal of Biomedical Optics 19.11 (2014): 115002. 
Greening, G.J., et al. Optical Phantoms: Diffuse and Sub-Diffuse Imaging and Spectroscopy 
Validation. Bellingham, Washington: SPIE Spotlights, 2015. 
202 
 
Gu, M., et al. "Cancer-Cell Microsurgury Using Nonlinear Optical Endomicroscopy." Journal of 
Biomedical Optics Letters 15.5 (2010). 
Gu, R. Y., et al. "Variable-Sized Bar Targets for Characterizing Three-Dimensional Resolution 
in Oct." Biomed Opt Express 3.9 (2012): 2317-25. 
Guggenheim, J.A., et al. "Multi-Modal Molecular Diffuse Optical Tomography System for 
Small Animal Imaging." Measurement Science and Technology 24.10 (2013). 
Guimarães, J.V., et al. "Thickness of the Cervical Epithelium of Autopsied Patients with 
Acquired Immunodeficiency Syndrome." Annals of Diagnostic Pathology 11.4 (2007). 
Harris, D., and J. R. Robinson. "Drug Delivery Via the Mucous Membranes of the Oral Cavity." 
J Pharm Sci 81.1 (1992): 1-10. 
Higgins, L. M., and M. C. Pierce. "Design and Characterization of a Handheld Multimodal 
Imaging Device for the Assessment of Oral Epithelial Lesions." J Biomed Opt 19.8 (2014): 
086004. 
Kanick, S. C., et al. "Scattering Phase Function Spectrum Makes Reflectance Spectrum 
Measured from Intralipid Phantoms and Tissue Sensitive to the Device Detection Geometry." 
Biomed Opt Express 3.5 (2012): 1086-100. 
Kanick, S.C., et al. "Dual-Channel Red/Blue Fluorescence Dosimetry with Broadband 
Reflectance Spectroscopic Correction Measures Protoporphyrin Ix Production During 
Photodynamic Therapy of Actinic Keratosis." Journal of Biomedical Optics 19.7 (2014). 
Kanick, S.C., et al. "Sub-Diffusive Scattering Parameter Maps Recovered Using Wide-Field 
High-Frequency Structured Light Imaging." Biomedical Optics Express 5.10 (2014): 3376-90. 
Keahey, P.A., et al. "Optimizing Modulation Frequency for Structured Illumination in a Fiber-
Optic Microendoscope to Image Nuclear Morphometry in Columnar Epithelium." Biomedical 
Optics Express 6.3 (2015): 870-80. 
Kim, A.D. "Transport Theory for Light Propagation in Biological Tissue." Journal of the Optical 
Society of America: Optics, Image Science, and Vision 21.5 (2004). 
Kim, A.D., et al. "Estimating Optical Properties in Layered Tissues by Use of the Born 
Approximation of the Radiative Transport Equation." Optics Letters 15.31 (2006). 
Kim, A.D., and J.B. Keller. "Light Propagation in Biological Tissue." Journal of the Optical 
Society of America: Optics, Image Science, and Vision 20.1 (2003). 
203 
 
Koschwanez, J.H., et al. "Thin Pdms Films Using Long Spin Times or Tert-Butyl Alcohol as a 
Solvent." PLOS One 4.2 (2009). 
Koucky, M.H., and M.C. Pierce. "Axial Response of High-Resolution Microendoscopy in 
Scattering Media." Biomedical Optics Express 4.10 (2013). 
Kourkoumelis, N., et al. "Advances in the in Vivo Raman Spectrosscopy of Malignant Skin 
Tumors Using Portable Instrumentation." International Journal of Molecular Sciences 16 
(2015). 
Kyrish, M., et al. "Needle-Based Fluorescence Endomicroscopy Via Structured Illumination 
with a Plastic, Achromatic Objective." Journal of Biomedical Optics 18.9 (2013). 
Lamouche, G., et al. "Review of Tissue Simulating Phantoms with Controllable Optical, 
Mechanical and Structural Properties for Use in Optical Coherence Tomography." Biomedical 
Optics Express 3.6 (2012). 
Liemert, A., and A. Kienle. "Explicit Solutions of the Radiative Transport Equation in the P3 
Approximation." Medical Physics 41.11 (2014). 
---. "Light Transport in Three-Dimensional Semi-Infinite Scattering Media." Journal of the 
Optical Society of America: Optics, Image Science, and Vision 29.7 (2012). 
Liu, Q., et al. "Compact Point-Detection Fluorescence Spectroscopy System for Quantifying 
Intrinsic Fluorescence Redox Ratio in Brain Cancer Diagnostics." Journal of Biomedical Optics 
16.3 (2011). 
Liu, Q., and N. Ramanujam. "Sequential Estimation of Optical Properties of a Two-Layered 
Epithelial Tissue Model from Depth-Resolved Ultraviolet-Visible Diffuse Reflectance Spectra." 
Appl Opt 45.19 (2006): 4776-90. 
Louie, J.S., et al. "Applications and Advancements in the Use of High-Resolution 
Microendoscopy for Detection of Gastrointestinal Neoplasia." Clinical Gastroenterology and 
Hepatology 12.11 (2014): 1789-92. 
Lu, G., and G. Fei. "Medical Hyperspectral Imaging: A Review." Journal of Biomedical Optics 
19.1 (2014). 
Lue, N., et al. "Portable Optical Fiber Probe-Based Spectroscopic Scanner for Rapid Cancer 
Diagnosis: A New Tool for Intraoperative Margin Assessment." PLOS One 7.1 (2012). 
Maitland, K.C., et al. "Single Fiber Confocal Microscope with a Two-Axis Gimbaled Mems 
Scanner for Cellular Imaging." Optics Express 14.19 (2006). 
204 
 
Makhlouf, H., et al. "Dual Modality Fluorescence Confocal and Spectral-Domain Optical 
Coherence Tomography Microendoscope." Biomedical Optics Express 2.3 (2011). 
Moffitt, T., et al. "Preparation and Characterization of Polyurethane Optical Phantoms." J 
Biomed Opt 11.4 (2006): 041103. 
Mora, A.D., et al. "Towards Next-Generation Time-Domain Diffuse Optics for Extreme Depth 
Penetration and Sensitivity." Biomedical Optics Express 6.5 (2015). 
Muldoon, T.J., et al. "High-Resolution Imaging in Barrett's Esophagus: A Novel, Low-Cost 
Endoscopic Microscope." Gastrointestinal Endoscopy 68.4 (2008): 737-44. 
Muldoon, T.J., et al. "Subcellular-Resolution Molecular Imaging within Living Tissue by Fiber 
Microendoscopy." Optics Express 15.25 (2007): 16413-23. 
Muldoon, T.J., et al. "Noninvasive Imaging of Oral Neoplasia with a High-Resolution Fiber-
Optic Microendoscope." Head & Neck 34.3 (2011): 305-12. 
Nichols, B.S., et al. "Performance of a Lookup Table-Based Approach for Measuring Tissue 
Optical Properties with Diffuse Optical Spectroscopy." Journal of Biomedical Optics 17.5 
(2012): 057001. 
Okagbare, P.I., et al. "Development of Non-Invasive Raman Spectroscopy for in-Vivo 
Evaluation of Bone Graft Osseointegration in a Rat Model." Analyst 135.12 (2010). 
Okagbare, P.I., and M.D. Morris. "Fluorocarbon Fiber-Optic Raman Probe for Non-Invasive 
Raman Spectroscopy." Applied Spectroscopy 66.6 (2012). 
---. "Polymer-Capped Fiber Optic Raman Probe for Non-Invasive Raman Spectroscopy." Analyst 
137.1 (2012). 
Parikh, N., et al. "In Vivo Diagnostic Accuracy of High Resolution Microendoscopy in 
Differentiating Neoplastic from Non-Neoplastic Colorectal Polyps: A Prospective Study." The 
American Journal of Gastroenterology 109.1 (2014): 68-75. 
Passos, D., et al. "Tissue Phantom for Optical Diagnostics Based on a Suspension of 
Microspheres with a Fractal Size Distribution." J Biomed Opt 10.6 (2005): 064036. 
Pickering, J. W., et al. "Double-Integrating-Sphere System for Measuring the Optical Properties 
of Tissue." Appl Opt 32.4 (1993): 399-410. 
Pierce, M.C., et al. "A Pilot Study of Low-Cost, High-Resolution Microendoscopy as a Tool for 
Identifying Women with Cervical Precancer." Cancer Prevention Research 5.11 (2012): 1273-9. 
205 
 
Pierce, M.C., et al. "Accuracy of in Vivo Multi-Modal Optical Imaging for Detection of Oral 
Neoplasia." Cancer Prevention Research 5.6 (2012). 
Pierce, M.C., et al. "High-Resolution Fiber-Optic Microendoscopy for in Situ Cellular Imaging." 
Journal of Visualized Experiments 47 (2011). 
Pogue, B.W., and M.S. Patterson. "Review of Tissue Simulating Phantoms for Optical 
Spectroscopy, Imaging and Dosimetry." Journal of Biomedical Optics 11.4 (2006). 
Prahl, S. A., et al. "Determining the Optical Properties of Turbid Mediaby Using the Adding-
Doubling Method." Appl Opt 32.4 (1993): 559-68. 
Prieto, S.P., et al. "Qualitative and Quantitative Comparison of Colonic Microendoscopy Image 
Features to Histopathology." Proceedings of SPIE 9328 (2015). 
Puszka, A., et al. "Time-Resolved Diffuse Optical Tomography Using Fast-Gated Single-Phton 
Avalanche Diodes." Biomedical Optics Express 4.8 (2013). 
Quinn, M.K., et al. "High-Resolution Microendoscopy for the Detection of Cervical Neoplasia in 
Low-Resource Settings." PLOS One 7.9 (2012). 
Rajaram, N., et al. "Design and Validation of a Clinical Instrument for Spectral Diagnosis of 
Cutaneous Malignancy." Applied Optics 49.2 (2010): 142-52. 
Rajaram, N., et al. "Experimental Validation of the Effects of Microvasculature Pigment 
Packaging on in Vivo Diffuse Reflectance Spectroscopy." Lasers in Surgery and Medicine 42.7 
(2010): 680-8. 
Rajaram, N., et al. "Lookup Table-Based Inverse Model for Determining Optical Properties of 
Turbid Media." Journal of Biomedical Optics 13.5 (2008): 050501. 
Rajaram, N., et al. "Pilot Clinical Study for Quantitative Spectral Diagnosis of Non-Melanoma 
Skin Cancer." Lasers in Surgery and Medicine 42.10 (2010): 716-27. 
Ramanujam, N. "Fluorescence Spectroscopy of Neoplastic and Non-Neoplastic Tissues." 
Neoplasia 2.1-2 (2000). 
Reif, R., et al. "Analytical Model of Light Reflectance for Extraction of the Optical Properties in 
Small Volumes of Turbid Media." Applied Optics 46.29 (2007). 
Rocha, L. , et al. "Esophageal Epithelium of Women with Aids: Thickness and Local Immunity." 
Pathology - Research and Practice 206.4 (2010). 
206 
 
Rogers, J.D., et al. "Imaging Performance of a Miniature Integrated Microendoscope." Journal 
of Biomedical Optics 13.5 (2008). 
Saager, R.B., et al. "Multi-Layer Silicone Phantoms for the Evaluation of Quantitative Optical 
Techniques in Skin Imaging." Proceedings of SPIE 7567 (2010). 
Saikia, M.J., et al. "High-Speed Gpu-Based Fully Three-Dimensional Diffuse Optical 
Tomographic System." International Journal of Biomedical Imaging 2014 (2014). 
Salomatina, E., et al. "Optical Properties of Normal and Cancerous Human Skin in the Visible 
and near-Infrared Spectral Range." Journal of Biomedical Optics 11.6 (2006). 
Sandell, J.L., and T.C. Zhu. "A Review of in-Vivo Optical Properties of Human Tissues and Its 
Impact on Pdt." Journal of Biophotonics 4.11 (2011): 773-87. 
Schlicht, M.S., et al. "Experimental Foundation for in Vivo Measurement of the Elasticity of the 
Aorta in Computed Tomography Angiography." European Journal of Vascular and 
Endovascular Surgery 46.4 (2013). 
Shahmoon, A., et al. "In Vivo Minimally Invasive Interstitial Multi-Functional 
Microendoscopy." Scientific Reports 3 (2013). 
Sharikova, A.V., et al. "Diffuse Optical Tomography Using Multichannel Robotic Platform for 
Interstitial Pdt." Proceedings of SPIE 8931 (2014). 
Sharma, M., et al. "Design and Characterization of a Novel Multimodal Fiber-Optic Probe and 
Spectroscopy System for Skin Cancer Applications." Review of Scientfic Instruments 85 (2014): 
083101. 
Shin, D., et al. "Quantitative Analysis of High-Resolution Microendoscopic Images for 
Diagnosis of Esophageal Squamous Cell Carcinoma." Clinical Gastroenterology and 
Hepatology 13 (2015): 272-79. 
Shukla, R., et al. "Endoscopic Imaging: How Far Are We from Real-Time Histology?" World 
Journal of Gastroenterology 3.10 (2011): 183-94. 
Sokolov, K., et al. "Real Time Vital Imaging of Pre-Cancer Using Anti-Egfr Antibodies 
Conjugated to Gold Nanoparticles." Cancer Research 63 (2003). 
Speight, P.M. "Update on Oral Epithelial Dysplasia and Progression to Cancer." Head and Neck 
Pathology 1.1 (2007): 61-6. 
 
207 
 
Srinivasan, S., et al. "Image-Guided Raman Spectroscopic Recovery of Canine Cortical Bone 
Contrast in Situ." Optics Express 16.16 (2008). 
Stanisavljevic, M., et al. "Quantum Dots-Fluorescence Resonance Energy Transfer-Based 
Nanosensors and Their Application." Biosensors and Bioelectronics 74 (2015). 
Stone, N., and P. Matousek. "Advanced Transmission Raman Spectroscopy: A Promising Tool 
for Breast Disease Diagnosis." Cancer Research 68.11 (2008). 
Subramanian, H., et al. "Penetration Depth of Low-Coherence Enhanced Backscattered Light in 
Subdiffusion Regime." Physical Review E: Statistical, Nonlinear, and Soft Matter Physics 75.4 
(2007): 041914. 
Tabassum, S., et al. "Two-Layer Inverse Model for Improved Longitudinal Preclinical Tumor 
Imaging in the Spatial Frequency Domain." J Biomed Opt 23.7 (2018): 1-12. 
Tabassum, S., et al. "Feasibility of Spatial Frequency Domain Imaging (Sfdi) for Optically 
Characterizing a Preclinical Oncology Model." Biomed Opt Express 7.10 (2016): 4154-70. 
Tavakoli, B., and Q. Zhu. "Depth-Correction Algorithm That Improves Optical Quantification of 
Large Breast Lesions Imaged by Diffuse Optical Tomography." Journal of Biomedical Optics 
16.5 (2011). 
Tseng, T., et al. "Quantification of the Optical Properties of Two-Layered Turbid Media by 
Simultaneously Analyzing the Spectral and Spatial Information of Steady-State Diffuse 
Reflectance Spectroscopy." Biomedical Optics Express 2.4 (2011). 
Turzhitsky, V., et al. "A Predictive Model of Backscattering at Subdiffusion Length Scales." 
Biomedical Optics Express 1.3 (2010): 1034-46. 
Turzhitsky, V., et al. "Characterization of Light Transport in Scattering Media at Sub-Diffusion 
Length Scales with Low-Coherence Enhanced Backscattering." IEEE Journal of Selected Topics 
in Quantum Electronics 16.3 (2010): 619-26. 
Valim, N., et al. "The Effect of Temporal Impulse Response on Experimental Reduction of 
Photon Scatter in Time-Resolved Diffuse Optical Tomography." Physics in Medicine and 
Biology 58.2 (2013). 
Wang, T., et al. "Comparison of Pulsed Photothermal Radiometry, Optical Coherence 
Tomography and Ultrasound for Melanoma Thickness Measurement in Pdms Tissue Phantoms." 
Journal of Biophotonics 4.5 (2011). 
 
208 
 
Warnakulasuriya, S., et al. "Oral Epithelial Dysplasia Classification Systems: Predictive Value, 
Utility, Weaknesses and Scope for Improvement." Journal of Oral Pathology & Medicine 37.3 
(2008): 127-33. 
Wilson, R.H., and M.A. Mycek. "Models of Light Propagation in Human Tissue Applied to 
Cancer Diagnostics." Technology in Cancer Research and Treatment 10.2 (2011). 
Wu, X., et al. "Quantitative Evaluation of Atlas-Based High-Density Diffuse Optical 
Tomography for Imaging of the Human Visual Cortex." Biomedical Optics Express 5.11 (2014). 
Xu, R.X., et al. "Developing Digital Tissue Phantoms for Hyperspectral Imaging of Ischemic 
Wounds." Biomedical Optics Express 3.6 (2012). 
Zhu, C., and Q. Liu. "Validity of the Semi-Infinite Tumor Model in Diffuse Reflectance 
Spectroscopy for Epithelial Cancer Diagnosis: A Monte Carlo Study " Optics Express 19.18 
(2011): 17799-812. 
Zonios, G., et al. "Diffuse Reflectance Spectroscopy of Human Adenomatous Colon Polyps in 
Vivo." Applied Optics 38.31 (1999): 6628-37. 
 
209 
 
Chapter 4 (Specific Aim 3): Sampling depth of a diffuse reflectance spectroscopy probe for 
in vivo physiologic quantification of murine subcutaneous tumor allografts 
 
4.1 Introduction 
Diffuse reflectance spectroscopy (DRS) is a non-invasive, spectral biopsy technique that 
is used to indirectly estimate tissue optical properties and differentiate tissue types (Valdés et al., 
2017; Baltussen et al., 2017). The fundamental tissue optical properties are reduced scattering 
coefficient (μs’) and absorption coefficient (μa) (Novikova, 2017). The μs’ morphologically 
depends on the size, density, and orientation of scattering particles in tissue, such as the cell 
membrane, cell nuclei, mitochondria, lysosomes, and collagen fibers, among others (Sandell et 
al., 2011; Arifler et al., 2007). In amelanotic tissues, the μa in the visible and near infrared 
spectral range functionally depends on total hemoglobin concentration and tissue oxygen 
saturation (Novikova, 2017). Changes in these fundamental optical properties have been shown 
to occur in neoplastic and cancerous tissue because of angiogenesis, degradation of stromal 
collagen, and altered morphology of epithelial cells (Arifler et al., 2007; Arifler et al., 2003; 
Lister et al., 2012). Therefore, DRS has shown promise for early cancer diagnostics, tracking 
tissue response to therapy, and in intraoperative surgical guidance (Yu et al., 2014; Valdés et al., 
2017; Baltussen et al., 2017; Spliethoff et al., 2016; Spliethoff et al., 2014; Lin et al., 2000; Hu 
et al., 2016). 
Spliethoff et al. used DRS to track changes in optical parameters over time in a mouse 
xenograft model of hereditary breast cancer in response to cisplatin chemotherapy. They showed 
that treated tumors had increased StO2 compared to non-treated tumors, and concluded that DRS 
provided valuable functional tissue information that correlated well with tumor treatment 
210 
 
response (Spliethoff et al., 2014). This group also evaluated their fiber-optic needle-based DRS 
system on human lung cancer patients undergoing a diagnostic image-guided transthoracic 
needle biopsy procedure, and concluded that spectroscopic guidance enabled more accurate 
needle positioning for lung biopsies (Spliethoff et al., 2016). DRS has also been clinically 
applied to neurosurgery, in which Lin et al. performed DRS measurements on in vitro brain 
tumors and developed a discrimination algorithm, primarily based on scattering from white 
matter, with a sensitivity and specificity of 96% and 93%, respectively (Lin et al., 2000). 
Recently, Hu et al. used DRS to measure tissue hypoxia in a subcutaneous mouse xenograft 
model of human pharynx squamous cell carcinoma treated with radiation and found that higher 
doses of radiation yielded a quicker increase in tumor oxygenation (Hu et al., 2016).  
DRS probes vary greatly in terms physical geometry and sampling depth depending on 
the tissue-of-interest. Physical geometry can differ in terms of probe length, probe tip diameter, 
number and type of integrated optical fibers, and degree of invasiveness. For example, most DRS 
probes contact the tissue surface and are considered non-invasive but contact probes have limited 
sampling depth. Some groups have overcome this sampling depth limitation by creating 
minimally invasive, fiber-optic needle-based DRS systems (Spliethoff et al., 2014). However, 
these systems sacrifice non-invasiveness and may induce bleeding at the tip of the needle, 
potentially affecting accuracy when quantifying total hemoglobin content. In non-invasive, 
contact-based DRS systems, sampling depth depends on source-detector separation (SDS), or the 
distance between the optical fibers delivering and collecting light. In general, as SDS increases, 
sampling depth increases-due to the increased overall path length travel of the remitted photons 
at a cost of progressively decreasing signal-to-noise ratio (Kanick et al., 2009; Hennessy et al., 
2014; Hennessy et al., 2013). Thus, sampling depth can be fine-tuned to collect light primarily 
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from specific tissue layers, such as epithelial, stromal, or subcutaneous tumor layers. Therefore, a 
relationship between raw diffuse reflectance, μs’, μa, and sampling depth must be established for 
each SDS channel.  
Specifically, DRS can be used in subcutaneous murine tumors, which are used for a 
variety of research purposes including investigating the effects of potential therapies (He, Tian, 
Li, et al., 2015). The central research question in this paper is: How can a DRS probe be 
optimally designed for evaluating tissue physiological parameters in subcutaneous murine 
tumors?  At present, there have been no studies simultaneously quantifying wavelength- and 
SDS-dependent sampling depth in DRS probes with multiple channels to sample murine 
subcutaneous tumor allografts. The present study fills this knowledge gap by elaborating on 
methods to quantify wavelength-dependent sampling depth and demonstrating our capability to 
quantify physiologically-relevant parameters such as total hemoglobin concentration (THC) and 
tissue oxygen saturation (StO2), in subcutaneous murine tumors models. Experimental methods 
presented here are scalable for a variety of application-specific constraints, such as using small 
SDSs for endoscopically-deployable probes within the sub-diffuse regime, where the diffuse 
approximation is limited (Kanick et al., 2014). 
A DRS probe was designed to interrogate subcutaneous murine tumors at increasing 
sampling depths and quantify the associated optical properties. The relationship between diffuse 
reflectance, μs’, μa, and SDS was experimentally established by measuring a set of tissue-
simulating calibration phantoms to create lookup tables (LUTs). Then, the LUT was used as an 
inverse model to fit measured spectral data and extract optical properties (Greening, James, et 
al., 2016; Greening, James, Powless, et al., 2015; Greening, Rajaram, et al., 2016). DRS data at 
each SDS represents a weighted average of physiological parameters collected at increasing 
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depths. Therefore, a one-layer inverse experimental model was chosen to quantity volume-
averaged, rather than layer-specific, physiological parameters without assuming precise 
thickness of overlying skin layers (Sharma et al., 2013). The accuracy of the probe in extracting 
optical properties was determined using a second set of hemoglobin-based tissue-simulating 
phantoms. Following this, the relationship between sampling depth, μs’, μa, and SDS was 
experimentally established by detecting an embedded, highly-absorbing, optical heterogeneity 
within tissue-simulating phantoms at incremental distances. Finally, the DRS technique was 
applied to a Balb/c murine allograft model of CT26 colon carcinoma as a model for 
subcutaneous mouse tumors. The µs’, µa, THC, StO2, and sampling depths were compared for 
normal and tumor tissue. The central hypothesis was that this probe would simultaneously 
sample the overlying epithelial skin layer as well as the subcutaneous Balb/c-CT26 tumor and 
accurately extract physiologically-relevant optical parameters from each.  
4.2 Materials and methods 
4.2.1 Instrumentation 
The DRS probe (FiberTech Optica, Kitchener, ON, Canada) consists of a brass ferrule tip 
6.35 mm in diameter and 50 mm in length (Figure 1). Five multimode optical fibers (NA = 0.22 
± 0.02, high-OH for wavelength range 190-1200 nm) are arranged in a slit line along the tip of 
the brass ferrule, with one fiber serving as the source fiber and the remaining four fibers serving 
as the detector fibers. SDSs are 0.75, 2.00, 3.00, and 4.00 mm. These optical fibers were 
included to sample into the subcutaneous murine tumor at increasing sampling depths The source 
fiber, as well as the 2.00, 3.00, and 4.00 SDS fibers (FiberTech Optica, SUV400/440PI) consist 
of a 400/440 μm ± 2% silica core/cladding with a 470 μm ± 5% polyimide jacket. The 0.75 mm 
SDS fiber (FiberTech Optica, SUV200/220PI) consists of a 200/220 μm ± 2% silica 
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core/cladding with a 245 μm ± 5% polyimide jacket.  
The total length of the DRS probe is 1.00 m. The distal (common) end of the probe, is 
0.67 m long, and fibers are secured within a 4.8 mm outer diameter black PVC coating monocoil. 
The proximal (legs) end of the probe is 0.33 m in length, and each individual fiber is secured 
within a 3.0 mm outer diameter black PVC monocoil terminating in Subminiature version A 
(SMA) connectors, reinforced with strain relief, to be attached to the lamp or spectrometers. 
A 20W tungsten-halogen lamp (Ocean Optics, HL-2000-HP) provided broadband light 
(360-2400 nm) to the 400-μm core source fiber. One spectrometer (Ocean Optics, 
USB2000+VIS-NIR-ES) with a Sony ILX511B 2048-element linear silicon CCD array collected 
diffusely reflected light from the 0.75 and 2.00 mm SDSs. A second spectrometer (Ocean Optics, 
FLAME-S) with a Sony ILX511B 2048-element linear silicon CCD array collected diffusely 
reflected light from the 3.00 and 4.00 mm SDSs. The spectral resolution of the system (Eq. 1) 
was calculated by  
𝑅𝑠𝑝𝑒𝑐𝑡𝑟𝑎𝑙(𝑛𝑚) = [
𝑅𝑎𝑛𝑔𝑒𝑠𝑝𝑒𝑐𝑡𝑟𝑎𝑙(𝑛𝑚)
𝐸𝑙𝑒𝑚𝑒𝑛𝑡𝑠𝑝𝑖𝑥𝑒𝑙(𝑝𝑖𝑥𝑒𝑙𝑠)
] × 𝑅𝑝𝑖𝑥𝑒𝑙(𝑝𝑖𝑥𝑒𝑙𝑠) (1) 
 
where Rspectral is the spectral resolution in nm, Rangespectral is the spectral range which equaled 
667 nm based on each spectrometer having a grating of 600 lines/nm, Elementspixel is the number 
of pixel elements which equaled 2048, and Rpixel is the pixel resolution which equaled 6.5 pixels 
based on a 50 μm diameter laser cut slit within the round SMA connector (Ocean Optics, 
INTSMA-KIT). This resulted in a spectral resolution of 2.1 nm. No binning was performed. 
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Figure 1. The diffuse reflectance spectroscopy probe showing (a) distal optics, 
(b) dimenstions of the optical fibers within the probe tip, and (c) proximal optics 
showing several legs of the DRS probe, spectrometers and lamp. 
 
4.2.2 Animal model 
The study was approved by the University of Arkansas Institutional Animal Care and Use 
Committee (IACUC #18060). CT26 (ATCC®, CRL-2638TM), a murine colon carcinoma cell line 
derived from the Balb/c mouse strain, was maintained in Roswell Park Memorial Institute 
(RPMI)-1640 medium (ATCC®, 30-2001TM) supplemented with 10% fetal bovine serum 
(ATCC®, 30-2020), 1% antibiotic antimycotic solution (Sigma-Aldrich, A5955-100ML), and 
0.2% amphotericin B/gentamicin (Thermo Fisher Scientific, R015010). Third passage (P3) CT26 
cells were used throughout the study (Castle et al., 2014).  
Ten female Balb/c mice were (strain: 000651, The Jackson Laboratory, ME, USA) aged 
nine weeks were housed in groups of three in three cages in the Small Animal Facility at the 
University of Arkansas. The facility was maintained at 23°C ± 1°C and 40-60% humidity on a 
12:12 hour light-dark cycle. Food (8640, Teklad) and water was provided ad libitum. All nine 
mice acclimated for seven days after arrival prior to the study start. After one week of 
acclimation, the left flanks of the 10-week old Balb/c mice were shaved, and Nair was applied 
for one minute to locally remove hair. Then, 1x105 CT26 cells in sterile saline were injected 
subcutaneously into the left flank (Zhang et al., 2013; Tongu et al., 2015; Malvicini et al., 2011). 
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Tumor allografts grew until they reached a volume of 200 mm3, after which the tumor underwent 
DRS measurements.  
4.2.3 Tumor allograft geometry 
After performing DRS measurements of Balb/c-CT26 tumor allografts at a volume of 200 
± 50 mm3, mice were euthanized via cervical dislocation under 4.0% isoflurane and 1 L/min 
oxygen. Tumors were dissected, placed in OCT and flash frozen in isopentane in liquid nitrogen, 
and stored at -80°C for up to one week. Tumors cut into 6-μm sections using a cryostat (Leica 
Biosystems CM1860) and stained with hematoxylin (VWR 100504-404) and eosin (VWR 
10143-130) (H&E). H&E-stained tissue sections were imaged with a microscope (Nikon Eclipse 
Ci) with a 4X/0.25 NA objective and field-of-view (FOV) of 2.9 x 2.2 mm. Tumors often 
exceeded this FOV (i.e. a perfectly spherical tumor at a volume of 200 mm3 would have a 
diameter of ~7.4 mm). Therefore, images were taken of the entire tumor cross section and 
stitched together using a commercial panoramic image stitching software (Microsoft, Image 
Composite Editor) (Figure 2). Thickness of the epidermis, dermis/hypodermis, and fascia were 
calculated from H&E images calibrated to a 1951 USAF resolution test target (Thorlabs, 
R1DS1P). All nine CT26 tumors were measured to determine average and standard deviation. 
Calculating tissue thickness overlying the subcutaneous tumor was important to determine which 
layers were sampled by each SDS of the DRS probe (Figure 2).   
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Figure 2. The subcutanous Balb/c-CT26 colon tumor allograft showing (a) the 
DRS probe in contact with the tumor (b) an H&E-stained transverse section of 
tumor with overlying tissue layers (scale bar = 1 mm, E=epidermis, D=dermis, 
F=fascia, T=tumor), and (c) a representation of light transport through the murine 
subcutaneous tumor allograft at each of the four SDSs (0.75, 2.00, 3.00, and 4.00) 
 
4.2.4 Optical phantoms 
To establish a relationship between optical properties, diffuse reflectance, and sampling 
depth in the LUT model, liquid calibration phantoms were generated with known µs’ and µa. 
Calibration phantoms were constructed using distilled water as the solvent. The scattering agent 
was 1.00 µm-diameter polystyrene microspheres (07310-15, Polysciences, USA) and the 
associated µs’ was calculated using Mie theory. The absorbing agent was teal India ink (11BY, 
Salis International, USA). The µa was calculated by measuring a diluted solution of teal India ink 
in distilled water using a spectrophotometer (5102-00, PerkinElmer, USA) and the Beer-Lambert 
Law (Greening, James, et al., 2016; Greening, Rajaram, et al., 2016; Greening, James and 
Muldoon, 2015; Greening, James, Powless, et al., 2015).  
A 5 x 3 (15 total) set of calibration phantoms was created, corresponding to five 
scattering ranges and three absorbing ranges (Figure 3). Five of the 15 phantoms were 
considered “scattering-only” and contained only polystyrene microspheres without India ink. 
Distilled water and polystyrene microspheres were mixed inside 7 mL scintillation vials (66022-
300, VWR, USA) to yield a µs’ of 2.7, 3.8, 5.4, 7.6, and 10.9 cm-1 at a reference of 630 nm to 
span a µs’ range of 2-15 cm-1 from 450-900 nm. The remaining ten calibration phantoms 
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contained both polystyrene spheres and teal India Ink. Five of the 12 phantoms had a peak µa
 of 
3.0 cm-1 at 632 cm-1 and the final five phantoms had a peak µa of 10 cm
-1 at 632 cm-1. Thus, 
calibration phantoms spanned a µs’ range of 2-15 cm-1 and a µa range of 0-10 cm-1 from 450-900 
nm. These ranges span the optical property range of interest for subcutaneous Balb/c-CT26 
tumor allografts (Sabino et al., 2016; Spliethoff et al., 2014; Honda et al., 2011). 
To validate the relationship between optical properties and diffuse reflectance in the LUT 
model, liquid validation phantoms were generated with known µs’ and µa. Using these validation 
phantoms, accuracy of the LUT model could be established by comparing known µs’ and µa 
(expected values) to the µs’ and µa generated by the LUT model (experimental). Validation 
phantoms were constructed similar to calibration phantoms, but used bovine hemoglobin 
(H2625, Sigma-Aldrich, USA) as the absorbing agent. Bovine hemoglobin was used to better 
simulate biological tissue absorption.  
A 3 x 3 (9 total) set of validation phantoms was created, corresponding to three scattering 
ranges and three absorbing ranges (Figure 3). Polystyrene microspheres were added such that 
phantoms yielded a µs’ of 5.2, 8.5, and 13.5 cm-1 at a reference of 630 nm to span a µs’ range of 
4-19 cm-1 from 450-900 nm. Bovine hemoglobin was added such that phantoms yielded a µa of 
0-1.8 cm-1, 0-3.6 cm-1, and 0-8.1 cm-1, respectively.  
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Figure 3. Calibration phantoms were made with distilled water, polystyrene 
microspheres, and teal India ink to span µs’ and µa ranges between (a) 2-15 cm-1 
and (b) 0-10 cm-1, respectively, while validation phantoms were made with 
distilled water, polystyrene microspheres, and bovine hemoglobin to span µs’ and 
µa ranges between (c) 4-19 cm
-1 and (d) 0-8 cm-1, respectively. 
 
4.2.5 Lookup tables for diffuse reflectance 
The DRS probe was placed in each liquid calibration phantom, so it was completely 
submerged at 2 cm from the bottom of the 7 mL scintillation vial. Broadband DRS data (450-900 
nm) were recorded at each SDS (0.75, 2.00, 3.00, and 4.00 mm) with integration times of 100, 
200, 300, and 400 ms, respectively, to yield a signal-to-noise ratio (SNR) of at least 15 dB. Five 
spectra were averaged for all measurements. Spectra were converted to absolute diffuse 
reflectance values (Sharma et al., 2013) by calibrating with a Spectralon® 20% diffuse 
reflectance standard (SRS-20-010, Labsphere, USA), which accounts for the spectral shape and 
daily intensity fluctuations of the halogen lamp. Diffuse reflectance calibration (Eq. 2) was 
calculated by  
𝑅(𝜆) =
𝐼𝑠𝑎𝑚𝑝𝑙𝑒(𝜆) − 𝐼𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑(𝜆)
[𝐼𝑠𝑡𝑑(𝜆) − 𝐼𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑(𝜆)] × 100 𝑅𝑠𝑡𝑑⁄
 (2) 
 
where ( )R   is absolute diffuse reflectance, ( )sampleI   is the intensity of the raw, uncorrected 
spectra from phantoms or tissue, ( )backgroundI   is the inherent background noise (spectra 
collected without excitation from the light source), ( )stdI   is the spectral intensity of the 
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Spectralon® 20% diffuse reflectance standard, and 100 stdR  accounts for the reflectance level 
(20%) of the Spectralon® diffuse reflectance standard. All intensity measurements per SDS were 
acquired with equal integration time.  
LUTs were generated for each SDS by plotting absolute diffuse reflectance (R) against 
µs’ and µa and then interpolating between raw data points to create a smooth mesh for µs’ 
between 4-12 cm-1 and µa between 0-8 cm
-1 (Figure 4). This optical property range accounts for 
all expected μs’ and μa in murine tissue in the wavelength range of interest (450-900 nm) (Sabino 
et al., 2016). 
 
Figure 4. (a-d) LUTs were created for each SDS (0.75, 2.00, 3.00, and 4.00 mm) 
using diffuse reflectance spectra from calibration phantoms which were then (e-h) 
interpolated to create a continuous mesh for µs’ values between 4-12 cm-1 and µa 
values between 0-8 cm-1. 
 
4.2.6 Validation of lookup table inverse model 
Once LUTs were constructed (Figure 4), the accuracy of the LUTs needed to be 
quantified. In other words, for a single spectrum, how closely do the experimental optical 
properties (determined by the LUT model) match the expected optical properties?  
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The DRS probe was placed in each liquid bovine Hb-based validation phantom, so it was 
completely submerged 2 cm from the bottom of the 7 mL scintillation vial. Broadband DRS data 
(450-900 nm) were recorded at each SDS (0.75, 2.00, 3.00, and 4.00 mm) with integration times 
of 100, 200, 300, and 400 ms, respectively, to yield an SNR of at least 15 dB. Five spectra were 
averaged for all measurements. Spectra were converted to absolute diffuse reflectance values by 
calibrating with a Spectralon® 20% diffuse reflectance standard and background noise 
subtraction as previously described. 
Experimental μs’ and μa were calculated using the damped least-squares nonlinear fitting 
method, appropriate for least squares curve fitting. This method will be henceforth referred to as 
the LUT inverse model fit and was based on the constraining equation for μs’ (Eq. 3) and μa (Eq. 
4). The constraining equation for μs’ is 
𝜇𝑠
′(𝜆) = 𝜇𝑠
′(𝜆0) × [
𝜆
𝜆𝑜
]
−𝐵
 (3) 
 
where μs’(λ) is the reduced scattering coefficient, μs’(λ0) is the reduced scattering coefficient at a 
reference of 630 nm, λ is all wavelengths, λ0 is 630 nm, and B is the scattering exponent, which 
relates to the size of tissue scatterers; smaller values of B correspond to larger scatterer sizes 
(Greening, James, et al., 2016; Zonios et al., 2008). Zonios et al. describes an in-depth method to 
calculate spherical scatterer diameter based on B, which can range between 0.2 and 4.0 in tissue 
(Zonios et al., 2008). On the other hand, the constraining equation for μa is  
𝜇𝑎(𝜆) = 𝐶 × 𝜇𝑎,𝑠𝑡𝑜𝑐𝑘(𝜆) (4) 
 
where μa(λ) is the absorption coefficient, μa, stock(λ) is the absorption coefficient of the bovine-Hb 
stock solution, and C is the volume fraction of bovine-Hb stock solution in the phantom. The μa 
of the bovine-Hb stock solution was determined via a spectrophotometer and the Beer-Lambert 
Law. These constraining equations required initial and boundary conditions, listed in Table 1. 
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Bounds for μs’ at 630 nm were set based on the μs’ limits of the calibration phantoms used to 
create the LUTs. Bounds for B were set to exceed values commonly observed (~0.9-1.2) in tissue 
(Semeniak, 2017). Bounds for C were set to be the minimum and maximum values for volume 
fraction (Greening et al., 2018). Initial conditions did not affect outcomes as long as they were 
between the lower and upper bounds. Initial and boundary conditions were constant for all 
validation phantoms and for all SDSs.  
Table 1. Boundary conditions for quantifying optical properties of validation phantoms 
Variable Lower 
Bound 
Upper 
Bound 
μs’ (λ0) 2.0 cm-1 15.0 cm-1 
B 0.0 4.0 
C 0.0% 100% 
 
After initial conditions were set, the LUT inverse model fit performed up to 1x104 
iterations until the sum of squares (2) was minimized (Sharma et al., 2013) between the fitted 
reflectance and measured reflectance. All phantom DRS spectra underwent a final quality control 
step. If 2 was greater than 5%, data was discarded (Figure 5). 
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Figure 5. The LUT inverse model of diffuse reflectance fit is based on the 
damped least-squares nonlinear fitting method, with the goal of outputting μs’ and 
μa, as well as contributing parameters from the constraining equations such as 
scattering exponent and absorber concentration.   
 
Percent errors for μs’ and μa were calculated by comparing the expected optical properties 
derived from Mie Theory and the Beer-Lambert Law to experimental optical properties derived 
from the LUT inverse model fit. Average percent error was then calculated by averaging the 
percent error at each wavelength (450-900 nm) for each validation phantom (9 phantoms). 
Percent errors were always positive values; thus, overestimating and underestimating optical 
properties produced positive errors that did not cancel out. The LUT was considered accurate 
when average percent errors for μs’ and μa were each less than 10%, a standard cutoff across 
literature (Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011; Greening, 
James, et al., 2016; Greening, Rajaram, et al., 2016). 
4.2.7 Optical properties from Balb/c-CT26 tumor allografts 
After validation of the LUTs, spectra were collected from Balb/c-CT26 tumor allografts 
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200 ± 50 mm3 in diameter (n=9), as well as immediately adjacent tissue from the same mouse. 
Mice were not anesthetized during data collection. The DRS probe was placed in direct contact 
with the tissue. Broadband DRS data (450-900 nm) were recorded at each SDS (0.75, 2.00, 3.00, 
and 4.00 mm) with integration times of 100, 200, 300, and 400 ms, respectively, to yield an SNR 
of at least 15 dB. Five spectra were averaged for all measurements. Spectra were converted to 
absolute diffuse reflectance values by calibrating with a Spectralon® 20% diffuse reflectance 
standard and background noise subtraction as previously described. 
The optical properties were quantified in a similar manner to validation phantoms, using 
the LUT inverse model fit based on the damped least-squares nonlinear fitting method (Nichols 
et al., 2012). Quantifying in vivo μs’ relied on the same constraining equation as validation 
phantoms (Eq. 3). Next, assuming hemoglobin as the only in vivo absorber from 450-900 nm, the 
constraining equation (Eq. 5) for μa was expressed as 
𝜇𝑎,𝑖(𝜆) = 𝑇𝐻𝐶 × [𝛼𝜀𝐻𝑏𝑂2(𝜆) + (1 − 𝛼)𝜀𝐻𝑏(𝜆)] (5) 
 
where, μa,i is the initial tissue absorption coefficient, THC is the total hemoglobin concentration 
in tissue, α is the tissue oxygen saturation (StO2), and 𝜀𝐻𝑏𝑂2(𝜆) and 𝜀𝐻𝑏(𝜆) are the extinction 
coefficients of oxyhemoglobin and deoxyhemoglobin, respectively. Next, the final version of the 
constraining equation for μa (Eq. 6) incorporated the standard pigment-packaging correction 
factor, described in depth by Rajaram et al. (Rajaram, Gopal, et al., 2010). The corrected 
absorption equation is expressed as  
𝜇𝑎,𝑓(𝜆) = 𝜇𝑎,𝑖(𝜆) × [
1 − 𝑒−2∙𝜇𝑎,𝑏𝑙(𝜆)∙𝑟𝑣𝑒𝑠𝑠
2 ∙ 𝜇𝑎,𝑏𝑙(𝜆) ∙ 𝑟𝑣𝑒𝑠𝑠
] 
(6) 
 
where μa,f is the final tissue absorption coefficient, μa,i is the initial absorption coefficient, μa,bl is 
the absorption coefficient of whole blood assuming a hemoglobin concentration of 150 mg/mL, 
and rvess is the average blood vessel radius in the sampled tissue. Including the pigment-
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packaging correction factor accounts for hemoglobin in tissue being confined to blood vessels, 
which is a small fraction of the total volume sampled by light. This phenomenon differs from the 
homogenous tissue-simulating phantoms. However, like the homogenous tissue-simulating 
phantoms, the constraining equations for in vivo measurements of Balb/c-CT26 allografts 
required initial and boundary conditions, listed in Table 2. Bounds for μs’ at 630 nm were set 
based on the μs’ limits of the calibration phantoms used to create the LUTs. Bounds for B were 
set to exceed values commonly observed (~0.9-1.2) in tissue (Semeniak, 2017). Bounds for THC 
were set such that the maximum could not exceed the hemoglobin concentration found in whole 
blood (150 mg/mL). Bounds for StO2 were set such that the maximum could not exceed the StO2 
found in fully oxygenated tissue (100%). For rvess, average capillary radius is approximately 2.5 
μm (Potter et al., 1983), whereas average arteriole radius is approximately 10-15 μm (Burrows et 
al., 1981). Bounds for rvess were set to significantly exceed these averages. Initial conditions 
(Figure 5) did not affect outcomes as long as they were between the lower and upper bounds. 
Initial and boundary conditions were constant for all in vivo measurements and for all SDSs.  
Table 2. Boundary conditions for quantifying optical properties of Balb/c-CT26 tissue 
Variable Lower 
Bound 
Upper 
Bound 
μs’ (λ0) 2.0 cm-1 15.0 cm-1 
B 0.0 4.0 
THC 0 mg/mL 150 mg/mL 
StO2 0.0% 100% 
rvess 0 μm 100 μm 
 
After initial conditions were set, the LUT inverse model fit performed up to 1x104 
iterations until the sum of squares (2) was minimized between the fitted reflectance and 
measured reflectance. Using the constraining equations for in vivo tissue, μs’ at 630 nm, THC, 
and StO2 were quantified as a function of tissue type (normal vs. tumor) and SDS. Optical 
properties were compared between normal and tumor tissue for each SDS. The significance 
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threshold was set at 0.05. All in vivo DRS spectra underwent a final quality control step. If 2 
was greater than 5%, data was discarded (Figure 5). Artifacts due to mouse movement during 
data collection could potentially cause a high 2 between the fitted reflectance and measured 
reflectance. Significance of optical properties between tissue type (healthy and tumor) and SDS 
(0.75, 2.00, 3.00, 4.00) was determined using two-way mixed ANOVA. The significance level 
was set at 0.05. 
4.2.8 Sampling depth of DRS probe into tissue 
The next goal was to quantify sampling depth for each SDS as a function of μs’ and μa. In 
other words, once μs’ and μa have been quantified via the LUT inverse model, at what depth into 
tissue are these optical properties being measured?  
To quantify sampling depth, a 5 x 3 (15 total) set of calibration phantoms were 
constructed (Greening, James, et al., 2016). Each of these phantoms was placed into a 5 mL 
beaker (Figure 6) with a highly absorbing (μa > 100 cm-1) black phantom layer, made with 
(poly)-dimethylsiloxane (PDMS) and black India ink at the bottom. It was assumed that any 
photon contacting this layer would be attenuated. The μa of the black layer was calculated using 
a spectrophotometer and the Beer-Lambert Law. Additionally, the black layer contained no 
scattering agent. Contributions from specular reflection at the interface between the black layer 
and calibration phantoms were negligible (data not shown) since there is a minimal mismatch 
between the PDMS and liquid phantoms (Greening, James, et al., 2016; Hennessy et al., 2014). 
The probe was placed in direct contact with the black layer (Figure 6(a-d)). Using a 
mechanical translation stage equipped with a micrometer scale (LNR25M, Thorlabs, USA), the 
probe was raised from the black layer in 50 μm increments from 0 to 3 mm. DRS measurements, 
from 450-900 nm, were taken at each 50 μm step at each SDS of 0.75, 2.00, 3.00, and 4.00 mm 
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at integration times of 100, 200, 300, and 400 ms, respectively, to yield an SNR of at least 15 dB. 
Since the optical properties of the calibration phantoms were known, a relationship was 
established between μs’, μa, and reflectance at various sampling depths. As the probe increased in 
distance from the black layer, reflectance increased, then leveled (Figure 6(e)). At each 
wavelength, the probe was most sensitive to changes in optical properties when 50% of photons 
reached the black layer (Figure 6(f)). When this process was repeated at each wavelength, a 
relationship between sampling depth and wavelength was established (Figure 6 (g)). Therefore, 
sampling depth(λ) was defined at the most sensitive 50-μm increment.  
Three-dimensional plots were generated for each SDS by plotting sampling depth (D) 
against µs’ and µa and then interpolating between raw data points to create a smooth mesh for µs’ 
between 4-12 cm-1 and µa between 0-8 cm
-1. This optical property range accounts for all 
expected μs’ and μa in murine tissue in the wavelength range of interest (450-900 nm). Once 
optical properties were calculated using the LUT inverse model, sampling depth was quantified. 
Significance of sampling depth between tissue type (healthy and tumor) and SDS (0.75, 2.00, 
3.00, 4.00) was determined using two-way mixed ANOVA. The significance level was set at 
0.05.  
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Figure 6. Sampling depth was quantified by (a-d) taking DRS measurements of 
calibration phantoms at 50 μm increments between 0-3 mm from a highly 
absorbing (μa > 100 cm-1) phantom layer. (e) Reflectance (R) increased as 
distance between the probe and black layer increased, shown for calibration 
phantom #7 at the 3.00 mm SDS as an example. (f) Sampling depth (D) was 
defined when the SDS is most sensitive to the black layer, which occurs when 
50% of photons reach the black layer. (g) Sampling depth (D) was then quantified 
at the 50 μm increment at each wavelength. 
 
4.3 Results 
4.3.1 Tumor allograft geometry by tissue type 
Tumors were dissected, cut into 6 μm sections, and H&E stained. Three primary tissue 
types were visualized above the subcutaneous tumor (Figure 7): the epidermis, 
dermis/hypodermis, and fascia. In female Balb/c-CT26 tumor allografts (n=9), the epidermis was 
0.22 ± 0.05 mm thick, the base of the dermis was 0.71 ± 0.11 mm from the surface, and the base 
of the fascia was 1.00 ± 0.15 mm from the surface. 
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Figure 7. To acquire optical properties from the subcutaneous tumor, broadband 
light from the DRS probe needed to penetrate past the fascia, located 1.00 ± 0.15 
mm from the surface. Values are mean ± SD. (scale bar = 1 mm) 
 
4.3.2 Validation of lookup table inverse model 
The reflectance from each validation phantom at each SDS, with known μs’ and μa, was 
plotted against the LUT created from the calibration phantoms (Figure 8). Percent errors were 
acceptable if less than 10% for both μs’ and μa. 
 
Figure 8. Reflectance from bovine Hb-based validation phantoms (red) was 
plotted against the LUTs (grayscale grid) for each SDS of a) 0.75 mm, b) 2.00 
mm, c) 3.00 mm, and d) 4.00 mm.   
 
Average percent errors for μs’ were 2.9%, 4.7%, 2.2%, and 2.8% for the 0.75, 2.00, 3.00, 
and 4.00 mm SDSs, respectively. Average percent errors for μa were 9.1%, 9.6%, 9.6%, and 
9.2% for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively. Thus, all percent errors were 
below 10% (Figure 9). 
229 
 
 
Figure 9. Percent errors for comparing experimental optical properties (from 
LUT inverse model fit) and expected (known) optical properties were below 10% 
for all SDS of (a,e) 0.75 mm, (b,f) 2.00 mm, (c,g) 3.00 mm, and (d,h) 4.00 mm. 
The LUT inverse model fit more accurately extracted (a-d) μs’ (percent errors < 
5%) compared to (e-h) μa. Black dots represent raw data. Red lines indicate a 
perfect fit with 0% error. Gray background represents the acceptable 10% error.  
 
4.3.3 Sampling depth in Balb/c-CT26 allografts 
Following DRS measurements of calibration phantoms overlying a highly absorbing 
PDMS layer, three-dimensional plots were generated for each SDS by plotting sampling depth 
(D) against µs’ and µa and then interpolating between raw data points to create a smooth mesh. 
Sampling depths were valid for µs’ between 4-12 cm-1 and µa between 0-8 cm-1 (Figure 10). 
Lowest sampling depth occurred at highest optical properties (μs’ = 12 cm-1, μa = 8 cm-1) and 
highest sampling depth occurred at lowest optical properties (μs’ = 4 cm-1, μa = 0 cm-1). Based on 
this, sampling depths ranged between 0.37 to 1.10 mm, 0.72 to 1.76 mm, 0.92 to 2.08 mm, and 
1.16 to 2.25 mm for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively, indicating sampling 
depth increased as SDS increased. Subcutaneous tumors were located 1.00 ± 0.15 mm or deeper 
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below the skin surface; thus, broadband light from the DRS probe needed to penetrate at least 
1.15 mm into tissue to sample tumor optical properties. With regards to the colormap in Figure 
10, red coloring indicates sampling depth ≤ 1.15 mm, which was the average thickness, plus one 
standard deviation, of the overlying skin and fascia of the subcutaneous Balb/c-CT26 tumor. 
Yellow coloring indicates sampling depth between 1.15 and 1.45 mm, with peak yellow 
occurring at 1.30 mm, which was the average thickness, plus two standard deviations. Green 
coloring indicates sampling depth ≥ 1.45 mm, which was the average thickness plus three 
standard deviations. Thus, yellow and green coloring represent optical properties in which tumor 
tissue was sampled.  
 
Figure 10. Raw sampling depth data (a-d) was plotted for each SDS and then (e-
h) interpolated into a mesh. Sampling depth increased as SDS increased.  
 
4.3.4 Balb/c-CT26 allograft wavelength-dependent optical properties 
Next, DRS measurements were collected from Balb/c-CT26 tumor allografts (n=9) 200 ± 
50 mm3 in diameter, as well as immediately adjacent normal flank tissue from the same mouse. 
The LUT inverse model fit analyzed the spectra to output μs’(λ) and μa(λ) (Figure 11). Based on 
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the relationship between μs’, μa, and sampling depth (Figure 10), sampling depth was quantified 
as a function of wavelength. In general, as SDS increased, μs’(λ) decreased, μa(λ) increased, and 
sampling depth increased for both normal and tumor tissue.  
 
Figure 11. Average optical properties and sampling depth for (a-c) normal Balb/c 
flank tissue and (d-f) subcutaneous Balb/c-CT26 tumor allografts showing (a, d) 
μs’, (b, e) μa, and (c, f) sampling depth. As SDS increased, μs’ decreased, μa 
increased, and sampling depth increased for both tissue types. Values are mean ± 
SD. 
 
4.3.5 Balb/c-Ct26 allograft DRS-derived physiological parameters 
After comparing wavelength-dependent optical properties as a function of SDS, key 
physiological optical parameters were extracted and compared for normal and tumor tissue 
(Figure 12).  
The μs’ at 630 nm decreased as SDS increased (Figure 12(a)), as observed in Figure 11. 
For the 0.75, 3.00, and 4.00 mm SDSs, differences in μs’ were insignificant between normal and 
tumor tissue. In the 2.00 mm SDS, μs’ was significantly lower in tumor tissue (p=0.02) compared 
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to normal tissue, but only by 0.49 cm-1. 
The THC, measured in mg/mL, increased as SDS increased (Figure 12(b)). This was also 
indicated by the observed increased μa(λ) magnitude observed in Figure 11. For the 0.75, 2.00, 
and 4.00 mm SDSs, differences in THC were insignificant between normal and tumor tissue. In 
the 3.00 mm SDS, THC was significantly lower in normal tissue (p=0.03) compared to tumor 
tissue, but only by 0.64 mg/mL. The THC rose from approximately 1.4 mg/mL in the 0.75 mm 
SDS to approximately 6.8 mg/mL in the 4.00 mm SDS for both tissue types.  
The StO2 remained constant as SDS increased in normal tissue (Figure 12(c)). However, 
StO2 decreased as SDS increased in tumor tissue, indicating increasing hypoxia at increased 
depths within the tumor microenvironment. The StO2 quantified by the short 0.75 mm SDS was 
significantly higher (p<0.01) than the StO2 quantified by all longer SDSs. Furthermore, there 
was no significant difference in StO2 between normal and tumor tissue in the 0.75 mm SDS. 
However, tumor tissue expressed significantly decreased StO2 compared to normal tissue for 
SDSs of 2.00, 3.00, and 4.00 mm.  
In Figure 12(d), sampling depth was quantified at the first Q-band of hemoglobin at 542 
nm, where the lowest sampling depth would occur. In normal tissue, sampling depth was 
0.66±0.04, 1.22±0.11, 1.55±0.12, and 1.64±0.12 mm at 542 nm for the 0.75, 2.00, 3.00, and 4.00 
mm SDSs, respectively. In tumor tissue, sampling depth was 0.66±0.03, 1.30±0.09, 1.49±0.14, 
and 1.65±0.05 mm at 542 nm for the 0.75, 2.00, 3.00, and 4.00 mm SDSs, respectively. There 
was no significant difference (p > 0.05) comparing sampling depth in normal vs. tumor tissue. 
For both normal and tumor tissue, sampling depth increased significantly (p<0.01) at longer 
SDSs of 2.00, 3.00, and 4.00 mm compared to the shorter 0.75 mm SDS. 
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Figure 12. Average (a) μs’ at 630 nm, (b) THC, (c), StO2, and (d) sampling depth 
for normal (dark gray) and tumor (light gray) tissue. The μs’ was comparable 
between normal and tumor tissue and decreased as SDS increased. The THC was 
comparable between normal and tumor tissue and increased as SDS increased. 
The StO2 in tumor tissue was significantly decreased compared to normal tissue 
for SDSs longer than 0.75 mm. Additionally, StO2 decreased as SDS decreased. 
The sampling depth was comparable between normal and tumor tissue and 
increased as SDS increased. Values are mean ± SD. Significance is indicated by 
*(p<0.05).  
 
4.4 Discussion 
A diffuse reflectance spectroscopy (DRS) probe was designed to acquire optical 
properties of subcutaneous murine tumor allografts and was applied specifically in Balb/c-CT26 
colon tumor allografts. In this paper, a complete validation of the DRS probe in this context was 
presented. Raw data from DRS is reflectance intensity as a function of wavelength. This paper 
explicitly describes a method to post-process raw spectra into the associated optical properties, 
µs’ and µa, physiological perfusion parameters including THC and StO2, and sampling depth 
(Hennessy et al., 2014; Rajaram et al., 2008). The central hypothesis was that this DRS probe 
would simultaneously sample the overlying epithelial skin layer as well as the subcutaneous 
tumor allograft by including multiple discrete source-detector separations (SDSs) and extract 
optical parameters from increasing depths (He, Tian and He, 2015; Hennessy et al., 2014). DRS 
data at each SDS represents a weighted average of physiological parameters collected from 
increasing sampling depths. In the female Balb/c-CT26 colon tumor allograft model, the skin, 
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consisting of the epidermis, dermis, and hypodermis was 0.71 ± 0.11 mm thick, and the 
underlying fascia resulted in 1.00 ± 0.15 mm of total tissue above the underlying subcutaneous 
tumor. These values are expected to vary based on mouse strain, subcutaneous tumor location, 
sex, and age, and should be independently confirmed by investigators performing similar studies 
(Azzi et al., 2005; Calabro et al., 2011; Sabino et al., 2016). Thus, the DRS probe needed to 
sufficiently sample beyond the 1.00 mm skin layer and into the subcutaneous tumor. 
A lookup-table (LUT)-based inverse model, an established method, was chosen as the 
method to relate diffuse reflectance with µs’ and µa (Rajaram et al., 2008; Greening, James, 
Powless, et al., 2015; Greening, James, et al., 2016; Nichols et al., 2012). Other methods exist to 
perform this task such as Monte Carlo-based simulations (Hennessy et al., 2014; Hennessy et al., 
2013; Zhong et al., 2014), but the LUT-based inverse model was chosen because it is based on 
experimental values that necessarily account for our specific system response (Nichols et al., 
2012). To generate a LUT, a set of calibration phantoms with known optical properties was used. 
As of the current report, the LUTs for each SDS are valid for µs’ between 4-12 cm-1 at 630 nm 
and for µa between 0-8 cm
-1. This optical property range effectively encompasses expected 
optical properties found in murine skin and subcutaneous tumors between 450-900 nm (Sabino et 
al., 2016). This wavelength range was chosen because of the absorption properties of 
hemoglobin, with specific absorption peaks (Q-bands) at 542 and 576 nm that indicate THC and 
StO2 and negligible absorption (µa < 0.5 cm
-1 for both oxygenated and deoxygenated hemoglobin 
in whole blood) between 600-900 nm (Prahl, 2015). Therefore, reflectance in the 600-900 nm 
wavelength range necessarily indicates µs’ (Sharma et al., 2013). It is common in literature to 
report µs’ at a reference of 630 nm, so this convention was used here (Sharma et al., 2013; 
Rajaram, Aramil, et al., 2010; Rajaram, Gopal, et al., 2010; Hennessy et al., 2015). 
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Since the LUTs were generated with dye-based calibration phantoms, a set of bovine 
hemoglobin-based phantoms, which more closely simulate physiological conditions, with known 
optical properties was used to validate the LUTs (Greening, James, et al., 2016). Within the LUT 
optical property range, it was shown that average percent errors for extracting µs’ and µa were 
below 10% for all SDSs, indicating it is reasonable to assume that measured tissue optical 
properties and physiological perfusion metrics are accurate within 10%. Average percent errors 
below 10% are considered acceptable and are comparable to many other DRS studies 
(Vishwanath et al., 2011; Yu et al., 2008; Yu et al., 2010; Bish et al., 2011). However, it was not 
uncommon for percent errors in several experimental optical property observations to exceed 
10% (Figure 9). Despite this, there was no relationship between percent error and magnitude of 
µs’ and µa, indicating that while some in vivo measurements of murine tissue may indeed exceed 
10%, on average the percent errors will be within 10% regardless of magnitude of µs’ and µa. 
Additionally, percent errors did not significantly change with respect to SDS. Since SDS is 
related to sampling depth (Hennessy et al., 2014), this indicates that measuring optical properties 
of deeper tumor tissue was no less accurate than measuring optical properties of shallower skin 
tissue. It should be noted that average percent errors for extracting µa were greater (~9%) 
compared to extracting µs’ (~3%), a common observation in existing literature (Rajaram, Aramil, 
et al., 2010). Finally, since LUT validation was performed with bovine hemoglobin-based 
phantoms, it was extraneous to perform additional validation via Monte Carlo simulations.  
Once the relationship between diffuse reflectance, µs’ and µa was established and 
validated, the same set of calibration phantoms was used to establish a relationship between 
sampling depth, µs’ and µa. As of the current report, the sampling depth relationship for each 
SDS are valid for µs’ between 4-12 cm-1 at 630 nm and for µa between 0-8 cm-1. We employed a 
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method to quantify sampling depth similar to that pioneered by Hennessey et al. (Hennessy et al., 
2014), in which sampling depth as a function of wavelength was quantified based on the depth at 
which the SDS was most sensitive to an optical heterogeneity (Figure 6). It is important to note 
that, even at lower and higher depths, the probe was still sensitive to the optical heterogeneity 
(Figure 6(f)), similar to other studies (Hennessy et al., 2014). This shows that stating the probe 
has a single sampling depth at specific optical properties is an oversimplification. Instead, the 
depth sampled by our DRS probe represents a wide range, a phenomenon described explicitly by 
Kanick et al. (Kanick et al., 2009). However, for simplicity, we report sampling depth as a single 
value at which the SDS was most sensitive to the heterogeneity. Figure 10 shows that sampling 
depth increased with increasing SDS, and decreased with increasing µs’ and µa, as expected 
(Hennessy et al., 2014; Kanick et al., 2009).  
There was a decrease in sampling depth at the Soret band (< 500 nm) and Q-bands (542 
and 576 nm) of hemoglobin. It is these peaks that most heavily influence extracted THC and 
StO2 in the LUT inverse model. Thus, even though sampling depth is higher at longer 
wavelengths, we explicitly report sampling depth at the first Q-band of hemoglobin, where 
sampling depth is lowest in our wavelength range (450-900 nm). From Figure 12(d), we can 
conclude that the 0.75 mm SDS only samples the skin layer since its sampling depth was 
0.66±0.04 mm and 0.66±0.03 mm for normal and tumor tissue, respectively, shallower than the 
1.00 ± 0.15 mm normal tissue above the subcutaneous tumor. Further evidence for the 0.75 mm 
SDS sampling only the overlying skin layer is shown from Figure 12(a-c), in which there were 
insignificant differences between normal vs. tumor tissue with respect to µs’, THC, and StO2. 
The tumor begins to be sampled at the 2.00, 3.00, and 4.00 mm SDSs, indicated by the sampling 
depths at the first Q-band to be 1.30±0.09, 1.49±0.14, and 1.65±0.05 mm, respectively. As such, 
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since the subcutaneous tumor is relatively hypoxic (Shay et al., 2014), there was a significant 
difference in StO2 between normal and tumor tissue at these sampling depths (Figure 12(c)). 
Furthermore, in tumor tissue, StO2 decreased steadily from 44±11% to 22±7% as SDS increased. 
It is important to note that the observed decreasing StO2 with increasing sampling depth does not 
necessarily indicate the tumor was more hypoxic at increased depths but is most likely due to 
more overall tumor tissue contributing to the volume-averaged physiological parameters. It is 
common for DRS-derived StO2 of keratinized epithelia, such as the skin, to be much less than 
100% (Spliethoff et al., 2014). DRS studies reporting in non-keratinized epithelia tend to extract 
much higher StO2 values upwards of 95% (Greening, James, et al., 2016). Additionally, the StO2 
presented in this study does not necessarily correlate to arterial oxygen saturation, which would 
be more accurately measured using pulse oximetry (Bashkatov et al., 2014). Interestingly, µs’ 
and THC were mostly comparable between normal and tumor tissue, indicating StO2 may be a 
key physiological parameter to evaluate murine tissue health via DRS, a sentiment held by other 
research groups (Spliethoff et al., 2014; Spliethoff et al., 2016; Sircan-Kucuksayan et al., 2015). 
Figures 11 and 12 show that increasing sampling depth resulted in decreased µs’ and 
increased µa in both normal and tumor tissue. In the skin, scattering from the epidermis (0 to 0.22 
mm) is primarily caused by keratin, a filamentous protein, as well as cell nuclei and lipid 
membranes. In the dermis and hypodermis, (0.22 to 0.71 mm) scattering is primarily caused by 
collagen, which accounts for approximately 25% of the dermal volume, other cellular 
constituents (Lister et al., 2012; Arifler et al., 2007; Arifler et al., 2003), and lipids confined to 
adipocytes in the hypodermis. In the superficial fascia (0.71 to 1.00 mm), an areolar connective 
tissue (Arifler et al., 2007; Kumka et al., 2012), scattering is primarily caused by collagenous, 
elastic, and reticular fibers. Finally, scattering in the CT26 cell layer (an epithelial cell type) is 
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caused by cellular constituents. Measurements in similar tissue in literature have suggested that 
epithelial tumors have lower light scattering (Collier et al., 2003) compared to skin, whose 
scattering properties are dominated by the dermis (Lister et al., 2012), although a direct 
comparison of µs’ between subcutaneous CT26 allografts and skin has not been exclusively 
studied. The µs’ presented here were comparable to other studies (Sabino et al., 2016). On the 
other hand, increased µa, associated with increased THC, increased with sampling depth. The 
epidermis contains no blood vessels, which are situated in deeper dermal layers (Sabino et al., 
2016). In Balb/c mice, which are albino, hemoglobin is the only significant absorber. It is 
important to note that the observed increasing THC with increasing sampling depth does not 
necessarily indicate higher THC in the tumor but is most likely due to reduced contribution of 
the epidermis to the volume-averaged optical properties of the subcutaneous tumor model. The 
µa and THC presented here were comparable to other studies (Lister et al., 2012; Rajaram, 
Reichenberg, et al., 2010; Bremmer et al., 2011; Sabino et al., 2016). 
This work has several limitations. First, contact-based, non-invasive DRS cannot sample 
into the center of a subcutaneous tumor 200 ± 50 mm3 in diameter. Sampling into the tumor 
center may be difficult even for small tumors, since even at the 4.00 mm SDS, sampling depth 
only reached 1.65±0.05 mm Therefore, considering the spatial heterogeneity of the tumor 
microenvironment (Yuan, 2016),  DRS may not provide representative data for the entire tumor. 
Spliethoff et al. overcame this limitation by using a minimally-invasive biopsy needle with 
integrated optical fibers for intratumoral DRS measurements in subcutaneous murine xenografts 
(Spliethoff et al., 2014). Secondly, extracted optical properties are volume-averaged, meaning 
that fine spatial resolution of µs’ and µa is lost (Kanick et al., 2009; Saager et al., 2011). 
Moreover, even at long SDSs designed to sample deeper into the subcutaneous tumor allograft, 
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extracted optical properties are a volume-averaged measurement of both tumor and skin. To 
overcome this limitation, the 0.75 mm SDS was integrated into the DRS probe design to 
simultaneously and exclusively sample overlying skin. This way, fluctuations in optical 
properties and physiological parameters over time could be attributed to either changes in the 
tumor itself, or changes in the skin, and assumptions could be limited. Saager et al. mitigated this 
volume-average limitation by implementing a depth-resolved quantification based on a two-layer 
Monte Carlo model (Saager et al., 2011). Additionally, due to the thin nature of skin, we expect 
overall optical contributions on tumor physiological parameters to be relatively small (Muldoon 
et al., 2012). Finally, future work must correlate DRS-derived perfusion metrics with 
immunohistochemical analysis. For example, pimonidazole is a dye that stains for hypoxia 
(Aguilera et al., 2014), and can be used to correlate end-point hypoxic fraction of tumor sections 
with in-vivo StO2 measurements via DRS.  
4.5 Conclusion 
Diffuse reflectance spectroscopy is a non-invasive spectral biopsy tool that has shown 
promise in early cancer diagnostics, tracking tissue response to therapy, and in intraoperative 
surgical guidance. This paper provides an outline for a general method for quantifying tissue 
optical properties, as well as physiologically relevant perfusion parameters, such as hemoglobin 
concentration and tissue oxygen saturation, that can be used by investigators hoping to 
implement diffuse reflectance spectroscopy for cancer research. Experimental methods presented 
here are scalable for smaller probe sizes (within the sub-diffuse regime) for endoscopically-
deployable spectroscopy probes, where the diffuse approximation is limited. 
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Chapter 5 (Specific Aim 3): Effects of isoflurane anesthesia on physiological parameters in 
murine tumor allografts measured via diffuse reflectance spectroscopy 
 
5.1 Introduction 
Diffuse reflectance spectroscopy (DRS) is a non-invasive method which can be used to 
quantify volumetric total hemoglobin concentration (THC), tissue oxygen saturation (StO2), and 
tissue scattering at or within accessible tissue sites (Rajaram et al., 2010; Glennie et al., 2015; 
Yu et al., 2014; Glennie et al., 2014; Chin et al., 2017; Fong et al., 2017; Greening, James and 
Muldoon, 2015; Greening et al., 2016; Hennessy et al., 2014; Karsten et al., 2013). This 
technique has been adapted for studies of tumor perfusion and response to therapy, since THC 
and StO2 can be used to differentiate therapeutic responders from non-responders over the course 
of treatment (Yu et al., 2017; Thong et al., 2017; Schaafsma et al., 2015). DRS is widely used in 
murine studies in which subcutaneous or orthotopic tumor models are treated with anti-cancer 
agents or radiation therapy and tumor perfusion is monitored longitudinally over time (Turley et 
al., 2012; Spliethoff et al., 2014; Hu et al., 2016; Vishwanath, Klein, et al., 2009; Palmer et al., 
2009). For example, Turley et al. used a handheld DRS probe to show that Bevacizumab, an anti-
VEGF monoclonal antibody, decreased oxyhemoglobin (THC * StO2) in melanoma tumor 
xenografts over a 7-day study (Turley et al., 2012). Spliethoff et al. used DRS to show that 
cisplatin, a chemotherapy drug, caused an increase in tumor StO2 in an orthotopic model of 
mammary tumors over a 7-day study (Spliethoff et al., 2014). Finally, Hu et al. used DRS to 
show that oxygenation kinetics of pharynx squamous cell carcinoma xenografts changed prior to 
tumor volume changes in response to radiation therapy (Hu et al., 2016). These studies indicate 
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that DRS provides clinically relevant, quantitative, and functional information that can be used to 
monitor tumor response to various types of chemotherapy, radiation therapy, or immunotherapy. 
Anesthesia is typically used in murine studies because it reduces the animals’ stress, 
enables easy manipulation of the mice, allows for injections of cancer cells and anti-cancer 
agents, and allows for accompanying surgical procedures. Anesthetic agents used in mouse 
studies can be delivered via inhalational (isoflurane or sevoflurane) or injected (pentobarbital or 
ketamine/xylazine) routes (Gargiulo et al., 2012). According to the American Veterinary 
Medical Association (AVMA), the Institute for Laboratory Animal Research (ILAR), and the 
Cornell University Institutional Animal Care and Use Committee (IACUC), the most common 
and recommended anesthesia technique for mice is inhaled isoflurane, a halogenated anesthetic 
gas supplemented with either 21% (i.e. room air equivalent) or 100% oxygen (O2) (Gargiulo et 
al., 2012; Leary et al., 2013; Bliss, 2017). The minimum alveolar concentration (MAC), which is 
the anesthesia required to prevent movement in response to surgical stimuli in 50% of subjects, is 
1.4% for mice under isoflurane anesthesia (Gargiulo et al., 2012). Therefore, the most common 
practice in DRS studies is placing mice in an induction chamber where anesthesia is quickly 
induced at 3.0-5.0% isoflurane, and then transferred to a nose cone where anesthesia is 
maintained at 1.5-3.0% isoflurane, with a constant gas flow rate of 1 L/min (Leung et al., 2015; 
Spliethoff et al., 2014; Turley et al., 2012; Hu et al., 2016; Vishwanath, Klein, et al., 2009; 
Gargiulo et al., 2012; Wang et al., 2004; Vishwanath, Yuan, et al., 2009; Guoqiang et al., 2005). 
Isoflurane is a respiratory and myocardial depressant, which causes increased partial pressure of 
carbon dioxide and bicarbonate levels in arterial blood (Cesarovic et al., 2010; Thal et al., 2007). 
Thus, even in the presence of O2 delivery via nose cone, isoflurane results in tissue O2 
desaturation, which may be a confounding variable when studying tissue perfusion of 
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subcutaneous murine models in response to therapy. Additionally, some therapies, such as 
chemotherapy or immunotherapy, depend on adequate tissue perfusion and O2 saturation to be 
effective (Ueda et al., 2013). DRS can quantify these perfusion metrics and help understand if 
limitations exist for emerging cancer therapies (Huang et al., 2013). However, there have been 
no studies analyzing the effects of isoflurane anesthesia on DRS-derived physiological 
parameters of murine tissue. 
The present study fills this knowledge gap by monitoring DRS-derived physiological 
parameters of murine tissue while mice were under various anesthesia conditions. Physiological 
parameters studied include THC, StO2, tissue oxyhemoglobin (HbO2), and reduced scattering 
coefficient (μs’). It should be noted that DRS quantifies average StO2 sampled by light, rather 
than arterial oxygen saturation (SaO2), venous oxygen saturation (SvO2), or peripheral oxygen 
saturation (SpO2) (Teng et al., 2008; Sircan-Kucuksayan et al., 2015). StO2 linearly correlates 
with the average of SaO2 and SvO2; thus, StO2 values are significantly lower than SaO2 (Hueber 
et al., 2001). HbO2 is the product of THC and StO2, and describes the concentration of O2-bound 
hemoglobin in circulation (Chung et al., 2010; Lee et al., 2007). This study was divided into four 
aims: 1) examine the effects of isoflurane anesthesia on DRS-derived physiological parameters 
of normal immunocompetent mouse tissue, 2) determine optimal anesthetic conditions for 
performing DRS while adhering to AVMA and IACUC standards (Gargiulo et al., 2012; Bliss, 
2017; Leary et al., 2013), 3) characterize the time-dependent response of physiological 
parameters while maintaining mice on 1.5% isoflurane after induction with either 1.5% or 4.0% 
isoflurane, and 4) validate findings in a subcutaneous murine allograft model of colon 
carcinoma. An allograft model of colon carcinoma was chosen because they are well-established 
models in literature but are understudied regarding DRS. For the first aim, physiological 
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parameters were quantified after manipulating two variables including metabolic gas type (O2 vs. 
medical air) and isoflurane concentration (1.5% to 4.0%). For the second aim, optimal anesthetic 
conditions were determined based on least significant differences between control (no-
anesthesia) and experimental groups. For the third aim, mice were anesthetically induced with 
either 4.0% isoflurane for one minute or 1.5% isoflurane for four minutes. Following induction, 
mice were transferred to a nose cone and maintained on 1.5% isoflurane for 15 minutes to 
determine how initial induction conditions affect physiological properties over time. 
Physiological parameters were monitored via DRS every minute. Finally, for the fourth aim, an 
allograft model of murine colon carcinoma was used to demonstrate expected changes in DRS-
derived tumor physiological parameters during isoflurane anesthesia. 
The central hypothesis was that DRS can accurately monitor physiological changes 
associated with isoflurane anesthesia. Specially, isoflurane anesthesia was expected to yield 
experimentally-induced low StO2 and HbO2, but insignificant changes in THC and μs’, for both 
normal and subcutaneous tumor sites. Optimal anesthesia conditions were expected to occur at 
the lowest tested isoflurane concentration (1.5%) with 100% O2. Furthermore, StO2 and HbO2 
were expected to change over time in response to anesthesia. This work aims to guide 
investigators in eliminating, limiting, or managing anesthesia-induced physiological changes in 
DRS studies in mouse models. 
5.2 Materials and methods 
5.2.1 Murine models 
The study was approved by the University of Arkansas Institutional Animal Care and Use 
Committee (IACUC #18060). Fifteen female Balb/c mice (strain: 000651, The Jackson 
Laboratory, ME, USA) aged nine weeks were purchased. Balb/c mice were housed in groups of 
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three in five cages at 23°C ± 1°C and 50% ± 10% humidity on a 12:12 hour light-dark cycle. 
Food (8640, Teklad) and water was provided ad libitum. All 15 mice acclimated for seven days, 
including daily handling (2 minutes) for adaptation to future measurements, after arrival prior to 
the start of the study. After one week of acclimation, left flanks of the 10-week old Balb/c mice 
were shaved and Nair depilatory was applied for one minute to locally remove fur. 
5.2.2 Cell line for allograft model of colon carcinoma 
Five of the 15 Balb/c mice were randomly selected for tumor allotransplantation. CT26 
(ATCC®, CRL-2638TM), a colon carcinoma cell line derived from the Balb/c mouse strain, was 
maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (ATCC®, 30-2001TM) 
supplemented with 10% fetal bovine serum (ATCC®, 30-2020), 1% antibiotic antimycotic 
solution (Sigma-Aldrich, A5955-100ML), and 0.2% amphotericin B/gentamicin (Thermo Fisher 
Scientific, R015010) at 37°C and 5% CO2. CT26 cells were brought to the third passage (P3). 
Then, 1x105 CT26 cells in sterile saline were injected subcutaneously into the left flank. Tumor 
allografts grew until they reached a volume of 100 mm3, measured via 𝑉 = (𝐿 ∙ 𝑊2)/2, which 
took 14.4 ± 2.2 days, upon which tumor underwent DRS measurements. Then, tumor allografts 
continued to grow until they reached 500 mm3, approximately 18.1 ± 1.2 days following 
implantation, upon which additional DRS measurements were taken to compare physiological 
parameters at different tumor sizes in response to isoflurane anesthesia. For controls, adjacent 
healthy flank tissue was measured. 
5.2.3 Diffuse reflectance spectroscopy instrumentation 
The custom, handheld DRS probe (FiberTech Optica, Kitchener, ON, Canada) was used 
in direct contact with tissue to perform all spectroscopy measurements. The brass probe tip is 
cylindrical with a diameter of 6.35 mm. The probe includes a 400 μm-core source fiber 
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(FiberTech Optica, SUV400/440PI, 0.22 ± 0.02 NA) which delivers broadband light (450-900 
nm) from a 20W tungsten-halogen lamp (Ocean Optics, HL-2000 HP) into tissue, and an 
adjacent 400-μm core detector fiber (FiberTech Optica, SUV400/440PI, 0.22 ± 0.02 NA) which 
transfers diffusely reflected light to a spectrometer (Ocean Optics, FLAME-S) with an optical 
resolution of 2.1 nm. The center-to-center source-detector separation (SDS) between these two 
optical fibers was 3.00 mm. All DRS measurements were performed in a dark environment. 
The four physiological parameters were quantified by inputting raw DRS spectra into an 
experimental lookup-table (LUT)-based post-processing software with a priori values for 
oxygenated and deoxygenated hemoglobin extinction coefficients (Greening et al., 2016; Prahl, 
2015; Greening, James, Powless, et al., 2015). The software performed an iterative model fit, 
based on a standard damped least-squares nonlinear fitting method, on raw DRS data to quantify 
THC, StO2, HbO2, and μs’ (Greening et al., 2016). Additionally, the chi-squared (Χ2) value 
indicated goodness-of-fit between the model fit and raw DRS data; for this study, if Χ2 values 
exceeded 1.0, data was rejected and re-acquired as this was likely due to user-induced movement 
artifacts during data collection (i.e. discarding data taken with small air gaps between probe and 
skin). Finally, the software is based on a fitting range (i.e. boundary conditions) for all four 
physiological parameters, as shown in table 1. Lower and upper bounds were set to encompass a 
wide range of potential physiological parameters in murine skin and tumor tissue (Sabino et al., 
2016; Prahl, 1999). The wavelength range used to fit the data was between 450 to 900 nm. 
Table 1. Boundary conditions for quantifying in vivo physiological parameters 
Physiological 
parameter 
Lower 
Bound 
Upper 
Bound 
THC 0 mg/mL 150 mg/mL 
StO2 0% 100% 
HbO2 0 mg/mL 150 mg/mL 
μs’ (750 nm) 3 cm-1 12 m-1 
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5.2.4 Controlling for confounding variables in mouse diffuse reflectance spectroscopy  
Positioning of the mice during DRS measurements could potentially affect results by 
changing venous blood distribution. Therefore, for DRS measurements of mice under isoflurane 
anesthesia, mice were placed in the prone position. For DRS measurements of non-anesthetized 
mice, mice sat in the operator’s hand. Thus, the tumor and adjacent healthy skin were identically 
oriented during measurements in both anesthesia and non-anesthesia cases. 
Next, the method of restraining non-anesthetized animals during measurements could 
affect results by increasing stress leading to altered hemodynamic and tissue blood volume levels 
(Sikora et al., 2016; Zhao et al., 2011). Mice were restrained by holding the base of the tail 
between index and middle fingers and allowing the mouse to rest in the palm, or, for the 
anesthesia conditions, in the prone position with a nose cone delivering isoflurane and metabolic 
gas. Stress was accounted for in two ways. First, all mice were handled daily for 2 minutes 
during the 7-day acclimation period to allow the mouse to adapt to DRS measurement 
procedures and provide reproducible results (Zhao et al., 2011). Additionally, mouse respiration 
rate was monitored during experiments. During DRS measurements of anesthetized animals, 
respiration rate was monitored visually by an operator not performing measurements. Safe 
respiration rate under anesthesia is 55-70 breaths per minute (Ewald et al., 2011). During DRS 
measurements of non-anesthetized animals, breath rate was not to exceed 150 breaths per minute 
(BPM) or a 10% increase from baseline prior to handling (Ewald et al., 2011). If BPM did not 
fall within these stress-related criteria, DRS measurements were not taken. 
Finally, previous research has shown that absorption due to THC and StO2 decreases with 
both increasing probe-tissue pressure and time since the probe may physically compress blood 
out of the tissue site and impede the sampled tissue site from receiving replacement oxygenated 
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blood (Lim et al., 2011). Although probe-pressure effects were not directly measured in this 
study, probe-pressure effects have been shown to be nearly negligible (< 5% error) within a 
range of probe-skin pressures between 9 to 152 mN/mm2 (1.3 to 22.0 PSI) using a similar 6.35 
mm-diameter DRS probe in short (< 2 s) contact durations. Normal probe-skin pressure tends to 
be less than 9 mN/mm2, and, for our setup, a contact time less than 1 s, justifying the non-use of 
an integrated pressure sensor (Lim et al., 2011).  
5.2.5 Effect of isoflurane concentration on physiological tissue parameters 
The aim of this experiment was to examine the effect of inhaled isoflurane anesthesia 
physiological parameters of murine tissue, measured by DRS, and determine optimal anesthetic 
conditions for DRS. 
The normal, exposed left flank of Balb/c mice (n=10) underwent DRS with varying 
anesthesia conditions. The control group received no anesthesia. Subsequent groups received 
isoflurane anesthesia (Henry Schein Animal Health, 1169567762) using a tabletop laboratory 
animal anesthesia system (VWR, 89012-492). Metabolic gas was varied between pure O2 (100% 
O2, Airgas, OX USP200) and medical air (21% O2, Airgas, AI USP200), with a constant flow 
rate of 1 L/min. Isoflurane concentration was varied between 1.5%, 2.0%, 3.0%, and 4.0%. Mice 
were induced and maintained on the same isoflurane concentration.  Concentrations below 1.5% 
were not tested because such concentrations would be below the MAC value (1.4%) for 
isoflurane in mice (Gargiulo et al., 2012). Isoflurane concentrations above 4.0% were not tested 
since higher values are usually only used for isoflurane-induced euthanasia according to AVMA 
(Leary et al., 2013). Furthermore, investigators generally do not exceed 4.0% isoflurane during 
anesthetic induction (Turley et al., 2012; Spliethoff et al., 2014; Hu et al., 2016; Vishwanath, 
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Klein, et al., 2009; Gargiulo et al., 2012; Leung et al., 2015; Wang et al., 2004; Vishwanath, 
Yuan, et al., 2009; Guoqiang et al., 2005). 
Mice were placed in a 2L induction chamber with an input connected to the isoflurane-
gas mix and output connected to a disposable charcoal filter (VWR, 89012-608) housed in an 
externally ventilating chemical fume hood. Mice were anesthetically induced until they had no 
pedal reflex (firm toe pinch). Mice were then transferred to a second independent anesthesia 
circuit consisting of a 9 mm-diameter nose cone with an input connected to the isoflurane-gas 
mix and output connected to a disposable charcoal filter. To maintain body temperature, mice 
were placed on a water-based warming pad (Stryker, #TP12E) controlled by a warming pump 
(Stryker, #TP700) set to 42°C (107°F), as recommended by the Cornell University IACUC 
(Bliss, 2017). 
The DRS probe was placed in direct contact with the exposed skin of the left flank. DRS 
measurements were taken with an integration time of 75 ms, and the probe was in direct contact 
with skin for less than 1 s to mitigate probe-pressure effects. Ten DRS measurements were 
averaged over the course of 30 seconds per mouse, with the probe being completely removed 
from the skin between each data take. Total time under anesthesia was less than 5 minutes in all 
cases. Paired t-tests were used to compare groups since each mouse was subject to all groups. 
Figure 1 shows the experimental setup.  
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Figure 1. Balb/c mice in experimental groups underwent isoflurane induction for 
less than 3 minutes, depending on concentration (1.5%, 2.0%, 3.0%, or 4.0%), 
using either 1 L/min of 100% or 21% O2 (a). Then, mice underwent less than 30 
seconds of 10 consecutive DRS measurements on healthy tissue of the exposed 
left flank in either control (b), or experimental (1.5%, 2.0%, 3.0%, or 4.0% 
isoflurane) groups (c). During maintenance, mice were maintained on a warming 
pad.   
 
5.2.6 Temporal effects of isoflurane anesthesia on physiological tissue parameters 
The aim of this experiment was to characterize the time-dependent physiological 
parameter response while maintaining the mouse on 1.5% isoflurane after isoflurane induction. 
DRS measurements were taken on left flank of conscious mice (n=10) every minute for 
five minutes with no isoflurane anesthesia as a baseline. Mice were restrained within the palm of 
the hand gently holding the tail, held no more than three inches above the work surface.  
Then, mice were placed into the 2L induction chamber supplied with either 4.0% 
isoflurane for one minute or 1.5% isoflurane for four minutes with 1 L/min O2. No DRS 
measurements occurred during induction. Mice were then transferred to a nose cone and 
maintained on 1.5% isoflurane and 1 L/min O2 for 15 minutes, with DRS measurements taken 
every minute. A maximum of 15 minutes was chosen since it takes approximately 10-15 minutes 
for mice to fully respond to a change in isoflurane concentration (Ewald et al., 2011). Therefore, 
to control for intergroup and intragroup variation, DRS measurements must occur only after the 
mouse has presumably fully responded to such change. Throughout DRS measurements under 
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anesthesia, mice were maintained on a water-based warming pad (Stryker, #TP12E) controlled 
by a warming pump (Stryker, #TP700) set to 42°C (107°F). 
Following 15 minutes of isoflurane maintenance, mice were removed from anesthesia 
and DRS measurements were taken every minute for 5 minutes. DRS measurements were taken 
with an integration time of 75 ms. Figure 2 visualizes the experimental set-up.  
 
Figure 2. Conscious Balb/c mice underwent DRS for 5 minutes. Then, mice were 
anesthetically induced for 1 or 4 minutes with 4.0% or 1.5% isoflurane (Iso), 
respectively, and 1 L/min O2. Following induction, mice were transferred to a 
nose cone and underwent DRS for 15 minutes at 1.5% isoflurane and 1 L/min O2. 
Finally, mice were removed from the nose cone and the left flank underwent DRS 
for 5 minutes.  
 
For each mouse, physiological parameters (THC, StO2, HbO2, and μs’) were normalized 
to the highest value over the 25-minute data acquisition period. Then, normalized values of all 
mice were averaged as a function of time. Both normalized and non-normalized data are 
presented.  
5.2.7 Physiological parameters of CT26 colon carcinoma allografts 
A second cohort of Balb/c mice (n=5) with CT26 murine colon carcinoma allografts 
underwent DRS as a representative model of subcutaneous tumor allografts. Measurements with 
(1.5% isoflurane and 1 L/min O2) and without anesthesia were performed on allografts at 
volumes of 100 mm3 and 500 mm3 and an immediately adjacent normal site. Mice were placed 
in the 2L induction chamber (1.5% isoflurane and 1 L/min O2) until loss of pedal reflex and 
transferred to the nose cone. Ten DRS measurements were averaged per site at an integration 
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time of 75 ms per spectra to minimize motion artifacts. Figure 3 visualizes the experimental set-
up. 
 
Figure 3. DRS was performed on Balb/c mouse (10 weeks old) to quantify 
physiological parameters (THC, StO2, HbO2, and μs’) in subcutaneous CT26 
tumor allografts at a volume of 100 mm3 (b, e), 500 mm3 (c, f), and adjacent 
normal tissue (a, d) both with (d, e, f) and without isoflurane anesthesia (a, b, c). 
Anesthesia was constant at 1.5% isoflurane and 1 L/min O2. 
 
5.3 Results 
5.3.1 Effect of isoflurane concentration on physiological tissue parameters 
The left flank of Balb/c mice (n=10) underwent DRS measurements while varying 
isoflurane concentration between 0.0% (control, no anesthesia) and 4.0%, and varying metabolic 
gas between 21% O2 and 100% O2.  
For THC (Figure 4a), there were no significant differences between using O2 or air. 
However, there was a significant decrease in THC compared to control as isoflurane exceeds 
2.0% (p < 0.01). At 4.0% isoflurane, THC dropped to 68% (p < 0.01) and 67% (p < 0.01) 
compared to the control in O2 and air, respectively.  
For StO2 (Figure 14b), there were no significant differences between using O2 or air, 
although average values for StO2 tended to be higher when using O2. Unlike THC, StO2 
decreases rapidly, even at the minimum 1.5% isoflurane. For example, at 1.5% isoflurane with 
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air, StO2 decreased to 87% (p = 0.028) compared to the control. StO2 continued to decrease 
within both O2 and air groups (p < 0.01) up to 3.0% isoflurane. Then, between 3.0% and 4.0% 
isoflurane, StO2 stabilized to ~8-15% compared to the control.  
For HbO2 (Figure 14c), despite there being no significant differences between using O2 or 
air for THC and StO2, there was a significant difference in HbO2 between using O2 and air at 
1.5% isoflurane (p = 0.04), suggesting that O2 is the preferred metabolic gas compared to air 
with regards to DRS-derived physiological parameters. Most notably, there were significant 
differences between using 1.5% isoflurane and the control for both O2 (88%, p = 0.043) and air 
(69%, p < 0.01) groups. This finding suggests that even at the lowest isoflurane concentration 
(1.5%) above the MAC value (1.4%) for mice, DRS-derived HbO2 values were affected.  
For μs’ (Figure 14d), there were no significant differences between using O2 or air. 
Additionally, μs’ was unaffected by changes in isoflurane concentration. These findings suggest 
that all anesthesia conditions affect at least one of the tested physiological parameters. However, 
1.5% isoflurane and 1 L/min O2 most closely mimicked ideal no-anesthesia conditions. 
258 
 
 
Figure 4. Physiological parameters of THC (a), StO2 (b), HbO2 (c), and μs’ (d) of 
the normal left flank of Balb/c mice (n=10) was compared for isoflurane 
concentration (1.5% to 4.0%) and either 100% O2 (dark gray) or 21% O2 (light 
gray). THC (a) and StO2 (b) were only affected by isoflurane concentration. HbO2 
(c) was affected by both isoflurane concentration and metabolic gas. Finally, μs’ 
(d) was unaffected by increases in isoflurane concentration and metabolic gas.  
Even at low isoflurane concentrations (1.5%), physiological parameters were 
affected. Based on these results, O2 is the preferred metabolic gas over air, and 
1.5% isoflurane is most appropriate when applicable. Control indicates 
measurements from non-anesthetized mice. Values are means ± SD. Significance 
is indicated by *(p<0.05) and ** (p<0.01). 
 
5.3.2 Temporal effects of isoflurane anesthesia on physiological tissue parameters 
DRS measurements were taken on Balb/c mice (n=10) every minute for five minutes with 
no isoflurane anesthesia as a baseline. During these five minutes, all physiological parameters 
remained stable. After one or four minutes with 4.0% or 1.5% isoflurane, respectively, and 1 
L/min O2, mice were transferred to a nose cone with 1.5% isoflurane and 1 L/min O2.  
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For both 4.0% and 1.5% isoflurane induction condition, THC (Figure 5a) decreased from 
approximately 3.7 mg/mL to 2.8-3.2 mg/mL and remained relatively stable throughout the 15-
minute duration. During the 5-minute recovery period, THC showed a slight rise to 
approximately 3.4 mg/mL. For StO2, on the other hand (Figure 5b), the induction period resulted 
in a decrease from approximately 50% to 31% and 7% for the 1.5% and 4.0% isoflurane 
induction conditions, respectively. For the 4.0% isoflurane condition, StO2 increased over time 
during the maintenance period, but not dramatically, having reached a final value of just 11% at 
the end of 15 minutes. On the other hand, for the 1.5% isoflurane condition, StO2 continued to 
decrease to 51% for 6 months, then rose back to 22% at the end of 15 minutes, indicating that, as 
expected, physiological changes occur more slowly in mice anesthetized with 1.5% isoflurane. 
Similarly, HbO2 (Figure 5c), as anticipated, demonstrated similar trends to StO2. 
Finally, μs’ (Figure 4d) was unaffected by isoflurane anesthesia. Following maintenance 
with 1.5% isoflurane and 1 L/min O2, mice were removed from isoflurane for a “recovery” 
period and DRS data was collected for an additional five minutes. Mice generally regained 
consciousness within one minute and full movement within two minutes, after which mice were 
gently restrained in the palm of the hand with the tail held secure between index and middle 
finger no more than three inches above the work surface. THC, StO2, and HbO2 increased within 
the five minutes; however, none reached 100% of the baseline values within the five-minute 
recovery period. On the other hand, μs’ remained constant during the 5 minutes of recovery. 
From these experiments, physiological parameters were affected by anesthetic induction 
with both 1.5% and 4.0% isoflurane. It cannot be assumed, once 1.5% isoflurane maintenance 
begins, that physiological parameters are representative. THC, StO2, and HbO2 did not recover to 
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the baseline values by the end of 15 minutes, nor did these physiological parameters fully 
recover after the five-minute recovery period.  
 
Figure 5. Temporal effects of 1.5% and 4.0% isoflurane anesthesia induction on 
physiological parameters of THC (a), StO2 (b), HbO2 (c), and μs’ (d) of the 
normal left flank of Balb/c mice (n=10). The μs’ (d) was unaffected by induction, 
maintenance, and recovery periods. Other physiological parameters all showed an 
initial decrease after induction, with a slight increase by the end of the 15-minute 
maintenance period, but not back to baseline values. Based on these results, it is 
clear than any isoflurane induction concentration influences DRS-derived 
physiological parameters. Values are means ± SD. 
 
5.3.3 Physiological parameters of CT26 colon carcinoma allografts 
Colon carcinoma murine CT26 allografts in Balb/c mice at volumes of 100 mm3 and 500 
mm3 were compared with adjacent normal tissue with (1.5% isoflurane and 1 L/min O2) and 
without isoflurane anesthesia to quantify physiological parameters (Figure 6). All mice were 
induced with 1.5% isoflurane for four minutes to avoid the effects of 4.0% isoflurane seen in 
Figure 4. 
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For adjacent tissue locations (no tumor), there was significant reduction in physiological 
parameters for the anesthesia condition compared to the no anesthesia condition for THC (p < 
0.01), StO2 (p = 0.04), and HbO2 (p = 0.02). However, overall trends within the anesthesia and 
no anesthesia groups were similar, with insignificant reductions in physiological parameters 
when using 1.5% isoflurane and 1 L/min O2. Additionally, as tumor size increased, StO2 and 
HbO2 decreased while THC increased and μs’ remained constant. Further comparisons across 
and within groups were visually expressed in Figure 6.  
 
Figure 6. Comparison of the physiological parameters, THC, StO2, HbO2, and μs’ 
of subcutaneous CT26 tumor allografts and adjacent normal tissue both with 
(light gray) and without (dark gray) isoflurane anesthesia. Similar to previous 
findings, THC, StO2, and HbO2 were reduced when comparing the no-anesthesia 
and 1.5% isoflurane conditions in adjacent normal tissue. Results demonstrate that 
isoflurane anesthesia causes experimentally-reduced HbO2 values, and that StO2 
and HbO2 decreased with increasing allograft tumor volumes, whereas THC 
increased and μs’ remained constant. Values are means ± SD. Significance is 
indicated by *(p<0.05) and ** (p<0.01). 
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5.4 Discussion 
Isoflurane anesthesia is a known respiratory and myocardial depressant, causing 
increased serum carbon dioxide and bicarbonate levels, and decreased arterial pressure. Despite 
this, isoflurane is commonly applied as an anesthetic agent in studies investigating volumetric 
perfusion of murine tissue, which is the aim of many DRS-based studies. To better understand 
the effects of isoflurane anesthesia on DRS-derived physiological parameters, the present study 
monitored murine THC, StO2, HbO2, and μs’ using DRS under various anesthesia conditions. 
Understanding the effects of isoflurane anesthesia on these tissue physiological parameters will 
help guide investigators in DRS experimental design. 
In this study, increasing isoflurane concentration significantly decreased THC, StO2, and 
HbO2 while having no effect on µs’ (Figs. 4-6). Of all four DRS-derived physiological 
parameters, StO2 was most influenced by changes in isoflurane concentration. Furthermore, 
using 100% O2, rather than 21% O2, resulted in closer approximation to no-anesthesia controls 
(Figure 4), a trend echoed by Gerling et al. who showed that supplying 100% O2
 led to increased 
StO2 (Gerling et al., 2014). Because of this, 100% O2 was used throughout the remainder of the 
study.  
In Figure 4b, StO2 did not decrease (50% to 48%, p = 0.32) when comparing the no-
anesthesia control to the 1.5% isoflurane condition. However, StO2 drastically decreased from 
48% to 6% when increasing isoflurane from 1.5% to 4.0% in normal tissue. StO2 values of ~6% 
have been observed in similar spectroscopy studies of mice tissue during anesthesia (Spliethoff 
et al., 2014). StO2 linearly correlates with the average of SaO2 and SvO2; thus, StO2 values are 
significantly lower than SaO2 (Hueber et al., 2001), which can be measured via pulse oximetry 
(Al-Samir et al., 2016). Decreased StO2 is primarily caused by isoflurane-induced decreased 
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mean arterial blood pressure (MAP) (Oshita et al., 1989). Szczesny et al. measured MAP of mice 
under increasing isoflurane concentrations, and showed that MAP decreased from 80 mmHg to 
below 40 mmHg as isoflurane concentration was increased from 1.0% to 4.0% (Szczesny et al., 
2004). Constantinides et al. echoed this trend, showing that MAP decreased from 85 mmHg to 
73 mmHg when increasing isoflurane concentration from 1.0% to 2.0% with 100% O2. 
Additionally, this research showed that MAP decreased from 92 mmHg to 84 mmHg when 
decreasing O2 from 100% to 21% with 1.5% isoflurane (Constantinides et al., 2012).  
To our knowledge, no other studies report StO2 (as low as 6% in Figure 14b) at high 
(4.0%) concentrations of isoflurane, since many studies state they DRS acquisition during 
isoflurane maintenance of 1.5%. However, this statement paints an incomplete picture. This 
report is important because the most common anesthetic practice in DRS studies is placing mice 
in an induction chamber where anesthesia is induced at ~4.0% isoflurane (Gargiulo et al., 2012). 
This isoflurane concentration can have long-lasting effects on blood physiology, even when mice 
are transferred to a nose cone where isoflurane is maintained at 1.5% (Figure 5). Therefore, we 
show that isoflurane induction, not just maintenance, highly affects DRS-derived StO2 (Figure 
5). We recommend 1.5% isoflurane with 100% O2 for both induction and maintenance, despite 
increased time to loss of pedal reflex. 
Of note are conflicting results from a study by Farzam et al. In this study, mice were 
anesthetized and maintained on 3.5% and 2.0% isoflurane, respectively, and StO2 values were 
~75% in orthotopic renal cell carcinoma tumors (Farzam et al., 2017), a stark increase from our 
StO2 of 22% at 2.0% isoflurane (Figure 4b). However, this study analyzed an orthotopic, rather 
than subcutaneous, tumor model of a different cell line. In a more comparable study, Rajaram et 
al. reported StO2 values near 30% under similar isoflurane conditions (1.5%) and wavelength 
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ranges (350 to 850 nm) of murine skin at a comparable SDS (2.5 mm) (Rajaram et al., 2015). 
The wavelength range used to fit data and SDS are paramount when comparing between studies. 
Unlike hemodynamic physiological parameters, the µs’ was unaffected by changes in 
isoflurane concentration and O2 levels. Tissue scattering is primarily caused by local density of 
lipid membranes from cellular tissues, mitochondria, lysosomes, and collagenous tissue like the 
skin (Jacques, 2013), which was the primary tissue type interrogated in this experiment. These 
scattering structures are unaffected by isoflurane conditions, resulting in stable µs’. 
Based on these results, isoflurane anesthesia should be carefully considered when 
performing DRS studies to quantify THC, StO2, and HbO2; however, some invasive and 
minimally invasive studies cannot eliminate the anesthesia use. For example, Spliethoff et al. 
used a 21G optical needle probe to perform deep intratumoral DRS measurements to overcome 
sampling depth limitations with mice under anesthesia (Spliethoff et al., 2014). Westerkamp et 
al. performed postmortem DRS on liver tissue following hepatectomy (Westerkamp et al., 2015). 
Finally, Palmer et al. performed DRS on 4T1 mammary tumor allografts while concurrently 
measuring the partial pressure of O2 using an OxyLite sensor, which required anesthesia (Palmer 
et al., 2009). Thus, it is not always applicable to perform live DRS with no anesthesia; 100% O2 
with minimal isoflurane (1.5%) is recommended in these cases. Using a minimum of 1.5% 
isoflurane for induction over a four-minute period also drastically decreased StO2 and HbO2, 
although changes were slower to occur compared to 4.0% isoflurane induction (Figure 5). If 
anesthesia is needed when measuring in vivo physiological parameters via DRS, it may be more 
representative to slowly induce anesthesia with 1.5% isoflurane rather than rapidly inducing 
anesthesia with 4.0% isoflurane and lowering concentration for anesthesia maintenance.  
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Finally, THC, StO2, HbO2, and μs’ of Balb/c-CT26 colon tumor were measured via DRS. 
Figure 6a indicates that increased tumor volume correlates to increased THC. Across Figs. 4-6, 
we report THC of 2.8 to 4.0 mg/mL in normal tissue and 4.0 to 4.8 mg/mL in subcutaneous 
CT26 tumor allografts under 1.5% isoflurane anesthesia, comparable to a study by Spliethoff et 
al (Spliethoff et al., 2014) in similar conditions. Increased tumor THC is due to increased tumor 
microvasculature coupled with increased ratio of deoxyhemoglobin to oxyhemoglobin. This 
trend of increased tumor THC is well known (Quincy Brown et al., 2009; Wang et al., 2009). 
Figure 16b shows that StO2 of tumors with volumes of 500 mm
3 was ~14%, both with and 
without 1.5% isoflurane. This low StO2 value is similar to a study by Spliethoff et al., which 
reported slightly lower StO2 values of 2-6% in larger mammary xenograft tumors (up to 800 
mm3) using 1.5% isoflurane anesthesia (Spliethoff et al., 2014). Rich et al. reported similar StO2 
values of 5-15% in head and neck cancer xenograft tumors, measured using photoacoustic 
imaging (Rich et al., 2016). Finally, Rajaram et al. reported DRS-derived StO2 around 20% for 
mammary xenografts at 1.5% isoflurane anesthesia (Rajaram et al., 2015). The Rajaram study 
also reported a ~1.5x decrease in StO2 of 100 mm
3 mammary tumor xenografts compared to 
normal tissue, whereas this present study reports a ~1.6x decrease (Figure 6b) in StO2 of 100 
mm3 colon tumor allografts compared to normal tissue. The comparable StO2 values in these 
studies lend support to our results. HbO2 in Figure 6c demonstrates similar trends as StO2. In 
Figure 6d, µs’ was unaffected by tumor size and isoflurane, similar to Figs. 4 and 5.  
Additionally, in tumors, there were insignificant decreases in THC, StO2, and HbO2 when 
using 1.5% isoflurane compared to a no-anesthesia control, suggesting it may be appropriate to 
monitor percent changes in physiological parameters over time. In longitudinal treatment studies, 
accompanying non-endpoint procedures such as chemotherapy, radiation therapy, 
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immunotherapy, or other treatment or observation procedures requiring anesthesia should ideally 
be performed after DRS measurements have concluded. 
One limitation of this study is the focus on non-invasive DRS of readily accessible 
murine tissue, such as skin and subcutaneous tumor allografts, which only requires contact 
between the probe and skin directly overlying the tumor. Additionally, DRS was the only 
technique used to quantify THC, StO2, HbO2, and μs’ and cannot provide insights into tumor 
vascular heterogeneity (Kwong et al., 2016; Greening et al., 2016; Valdés et al., 2016; Mourant 
et al., 2014). Other optical techniques exist to quantify these parameters including diffuse optical 
imaging (DOI) (Kwong et al., 2016), hyperspectral imaging (Hendargo et al., 2015), and near 
infrared spectroscopy (NIRS), which extends the wavelength range of DRS into the near infrared 
to quantify additional endogenous chromophores such as fat and water (Kawaguchi et al., 2017; 
Chen et al., 2015; Kondepati et al., 2008; Spliethoff et al., 2014). For example, DOI combined 
with magnetic resonance imaging can differentiate tumors with low and high vascular 
heterogeneity, and hyperspectral imaging can quantify vascular O2 supply and blood flow in 
rodent models. These spectral and imaging techniques would benefit from an in-depth analysis at 
how anesthetic drugs affect results. Next, DRS-derived physiological parameters were only 
quantified in response to isoflurane anesthesia. Despite being the most common type of 
anesthetic used in DRS-based mouse studies, other anesthesia drugs exist including sevoflurane, 
Pentobarbital, and ketamine/xylazine (Gargiulo et al., 2012). Finally, further tests with additional 
cell lines for murine subcutaneous allografts or xenografts will generalize results. An allograft 
model of colon carcinoma (Balb/c-CT26) was chosen because they are well-established models 
in literature but are understudied regarding DRS. Results compare well with other 
allograft/xenograft tumors in terms of physiological parameters (THC, StO2, HbO2, and μs’). 
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The findings presented here suggest that DRS is a valid tool to dynamically monitor 
changes in physiological parameters. These findings indicate that DRS has the potential to help 
investigators understand if limitations exist for certain cancer therapies that directly depend on 
tumor O2 consumption and help guide investigators in managing anesthesia-induced 
physiological changes in DRS studies of murine subcutaneous tumor allografts. Future studies 
analyzing DRS-derived physiological parameters in response to these drugs will increase the 
generalization of our findings. 
5.5 Conclusion 
Diffuse reflectance spectroscopy can be effectively used to monitor dynamic fluctuations 
in tissue physiological parameters, such as total hemoglobin concentration, tissue oxygen 
saturation, oxyhemoglobin, and tissue scattering, and is an attractive tool for monitoring tumor 
response to therapy. Additionally, diffuse reflectance spectroscopy has the potential to help 
investigators understand if limitations exist for certain cancer therapies, such as chemotherapy or 
PDT, that directly depend on oxygen consumption and well-perfused tumors. Investigators using 
this tool should understand the dynamic effects of isoflurane concentration on resulting 
physiologic values. We show that isoflurane induction, not just maintenance, highly affect 
hemodynamic parameters. Alternative methods to diffuse reflectance spectroscopy, such as pulse 
oximetry, should be considered when monitoring arterial, rather than tissue, oxygen saturation, 
during anesthesia.  
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Chapter 6 (Specific Aim 3): Quantification of subcutaneous murine colon carcinoma 
tumors in response to chemotherapy and macrophage-targeted immunotherapy measured 
using diffuse reflectance spectroscopy 
 
6.1 Introduction 
Colorectal cancer (CRC) is the fourth most common cancer in the United States, 
accounting for 140,000 new cases and 50,000 deaths in 2018 (Siegel et al., 2018). Until recently, 
patients with locally advanced CRC (high-risk stage II and stage III tumors) were treated via 
surgery followed by postoperative (adjuvant) chemotherapy. Adjuvant chemotherapy was given 
to ensure remaining cancer cells at tumor margins were eliminated after surgery (Jeon et al., 
2011; Wolmark et al., 1999; de Gramont et al., 2000; Andre et al., 2003). Patients with stage IV 
CRC may also receive chemotherapy, but only for palliative, rather than curative, measures 
(Ronnekleiv-Kelly et al., 2011). For early stage CRC patients, treatment options include 
polypectomy or local excision without chemotherapy or radiotherapy. Polypectomy is the 
removal of polyps during diagnostic colonoscopy (Horiuchi et al., 2014), whereas local excision 
is the removal of small tumors and a portion of healthy surrounding tissue during colonoscopy 
(Althumairi et al., 2015). 
In recent years, the addition of preoperative (neoadjuvant) chemotherapy for locally 
advanced CRC has become clinically accepted in recent years after success in esophageal(2002) 
and gastric cancers (Cunningham et al., 2006), and a series of clinical studies by the 
Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy (FOxTROT) 
Collaborative Group (Group, 2012). The goals of neoadjuvant chemotherapy include achieving 
complete eradication of cancer cells or pathological complete response (pCR) prior to surgery, 
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reducing intraoperative tumor cell shedding during surgery, and decreasing local recurrence rates 
(Van Cutsem et al., 2013; Zhou et al., 2013; Ludmir et al., 2017). In a feasibility phase trial by 
the FOxTROT Collaborative Group, 150 patients with locally advanced CRC were given a 
combination of chemotherapy drugs either in the neoadjuvant or adjuvant setting. Patients 
receiving neoadjuvant chemotherapy experienced significant tumor downstaging and regression, 
and the FOxTROT Collaborative Group is currently conducting a further Phase III trial (Group, 
2012). 
At present, in locally advanced colon cancer, neoadjuvant chemotherapy is generally 
given to patients in 2-12 two-week cycles over 4-24 weeks (Cercek et al., 2014). After assessing 
tumor therapeutic response after 4-6 cycles of neoadjuvant chemotherapy using techniques such 
as endorectal ultrasound (Cercek et al., 2014), CT, PET-CT, or MRI (or a combination of these 
techniques), patients with locally advanced disease either receive additional neoadjuvant 
chemotherapy cycles or proceed to surgery. Surgery is followed by 9-12 two-week cycles of 
adjuvant chemotherapy over 18-24 weeks (Zhou et al., 2013; Cheeseman et al., 2008; Habr-
Gama et al., 2010). In both the neoadjuvant and adjuvant settings, the current chemotherapy 
regimen is FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin and 
oxaliplatin (Jeon et al., 2011; Carrato, 2008). Variations of this type of chemotherapy have been 
a fixture in colorectal cancer treatment since the 1960’s and have been optimized since (Sharp et 
al., 1962; Nadler et al., 1964). 
Although there has been a steady reduction in CRC incidence and mortality since the 
1970’s, primarily attributed to reduction in preventable risk factors, advances in early detection 
(Miles et al., 2015), nationwide screening initiatives (Siegel et al., 2018; Levin, 2016; Bénard et 
al., 2018; Issa et al., 2017), and continued optimization of neoadjuvant and adjuvant 
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chemotherapy regimens (Zhou et al., 2013), current treatment standards and management of 
CRC remains problematic (Van Cutsem et al., 2013). Problems with standard CRC treatment 
include low 5-year survival rate (~10%) for patients presenting with metastatic CRC (mCRC) 
(Lynch et al., 2016), non-specificity for the genetic and biological heterogeneity of CRC 
(Blanco-Calvo et al., 2015), potential for multi-year treatment (Van Cutsem et al., 2013), high 
recurrence rates (30-40%) of locally advanced disease even after successful therapy and curative 
surgery (A. S. Walker et al., 2014), and chemoresistance (He et al., 2017; Hammond et al., 2016; 
Zhang et al., 2017). Therefore, investigators are exploring new therapeutic techniques to 
overcome these barriers. One broad technique that has gained clinical traction is immunotherapy. 
Immunotherapy is an emerging technique to treat CRC by stimulating or enhancing a 
patient’s immune system to combat cancer cells without the cytotoxic drawbacks of 
chemotherapy (Boland et al., 2017). Current immunotherapy techniques for CRC treatment 
include monoclonal antibody therapy, adoptive cell transfer (ACT) therapy, cancer vaccines and 
cell therapy (Lynch et al., 2016). Among the many types of immunotherapy strategies, 
monoclonal antibody therapy has gained the most clinical traction for treating CRC in recent 
years (Noguchi et al., 2013). This systematic review discusses current monoclonal antibody 
immunotherapy, which is divided into antibodies targeting either immune checkpoints or 
cytokines. Treatments discussed are either approved by the U.S. Food and Drug Administration 
(FDA), in clinical trials in humans, or in pre-clinical trials in animals. Finally, this review 
discusses emerging methods (optical and non-optical) to monitor tumor response to 
immunotherapy treatments in CRC patients. 
6.2 Immune checkpoints in colorectal cancer 
Immune checkpoints are any set of ligand-mediated inhibitory pathways that keep the 
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immune system in check and maintain homeostasis by regulating the duration and amplitude of 
immune responses (Pardoll, 2012; Lee et al., 2016). Several immune checkpoints have been used 
as immunotherapeutic targets in CRC, including cytotoxic T-lymphocyte antigen-4 (CTLA4), 
programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), tumor 
necrosis factor receptor (TNRF) superfamily member 9 (TNFRSF9 or CD137), and TNFRSF7 
(or CD27) (Pardoll, 2012; Lynch et al., 2016). Table 1 lists these CRC immune checkpoints that 
have been targeted by immunotherapy drugs and whether they are immunosuppressive or illicit a 
positive immune response.  
Table 1. Immune checkpoints targeted for immunotherapy in colorectal cancer 
Immune response Immune checkpoint 
Positive (anti-tumor) 
CD28/B7 
CD137/CD137L 
CD27/CD70 
Suppressive (pro-tumor) 
CTLA4/B7 
PD-1/PD-L1 
 
6.2.1 CTLA4 
CTLA4, and its homolog, CD28, are cell surface receptors found on CD4+ cells (helper 
T-cells) and CD8+ cells (cytotoxic T-cells) (Lynch et al., 2016). The ligands for CTLA4 and 
CD28 are the B7 proteins, B7-1 (CD80) and B7-2 (CD86), which are produced by antigen 
presenting cells (APCs) (Lynch et al., 2016). B7 ligands are upregulated and presented on the 
cell surface by APCs when the APCs encounter and acquire non-self-antigens (Buchbinder et al., 
2016). When T-cells detect B7, along with major histocompatibility complex loaded with 
cognate peptide, competitive binding ensues between CD28/B7 and CTLA4/B7 to maintain T-
cell homeostasis. CD28/B7 binding initiates immune stimulation by increasing T-cell 
proliferation whereas CTLA4/B7 binding initiates immunosuppression by competitively 
reducing signaling of the CD28/B7 complex (Beyersdorf et al., 2015; Seidel et al., 2018). Then, 
CTLA4 reduces the probability of future CD28/B7 binding by removing B7 proteins from the 
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APC surface via trans-endocytosis (Qureshi et al., 2011). Thus, CTLA4/B7 interaction is 
involved in immune tolerance and immunosuppression, a hallmark of cancer (Passardi et al., 
2017). Monoclonal antibodies targeting and blocking the CTLA4 immune checkpoint pathway 
results in increased CD28/B7-dependent clonal expansion of T-cells and has shown promising 
clinical benefits (Sun et al., 2016). 
6.2.2 PD-1 
PD-1 is a well-studied immune checkpoint, with its primary function to suppress the 
immune response to regulate tolerance and autoimmunity (Riley, 2009; Valentini et al., 2018; 
Keir et al., 2006). PD-1 is a cell surface receptor found on CD4+ cells, CD8+ cells, B-cells, 
natural killer (NK) cells, myeloid-derived cells, and macrophages (Valentini et al., 2018; Sundar 
et al., 2015). The primary function of PD-1 is to suppress the immune response (Riley, 2009). 
The ligands for PD-1 are the B7 proteins, B7-H1 (PD-L1) and B7-DC (PD-L2). PD-L2 is 
produced by APCs. PD-L1 is expressed by T-cells, B-cells, dendritic cells (DCs), and 
macrophages and is upregulated by many pro-tumor cytokines such as IL-4, IL-10 VEGF, and 
TNF-α produced by infiltrating immune cells (Riley, 2009; Wang et al., 2017; Dong et al., 2017; 
Sundar et al., 2015). Additionally, PD-L1 is directly expressed by many types of cancer cell, 
including CRC and is associated with poor prognosis (O'Neil et al., 2017). PD-1/PD-L1 binding 
results in T-cell apoptosis and reduced IL-2 (an anti-tumor cytokine) production (Valentini et al., 
2018). Thus, PD-1 and PD-L1 are active targets in CRC immunotherapy research with the goal 
of introducing monoclonal antibodies to block PD-1/PD-L1 binding and improve the anti-tumor 
immune response (Lynch et al., 2016).  
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6.2.3 CD137 
CD137 is a cell surface receptor expressed on activated T-cells, NK cells, and DCs (Segal 
et al., 2017). Its primary ligand is CD137L which is expressed on APCs including DCs, activated 
B-cells, and macrophages. Binding of CD137L to CD137 promotes an immune response through 
T-cell activation and proliferation (Wang et al., 2008). Thus, CD137/CD137L binding promotes 
polarization towards an anti-tumor environment. A study by Dimberg et al. showed a 
significantly lower CD137L concentration in CRC tissue compared to normal tissue., but similar 
concentrations of CD137 (Dimberg et al., 2006). 
6.2.4 CD27 
CD27 is part of the TNFR family cell surface receptor expressed on NK cells, B-cells, 
and naïve CD4+ and CD8+ cells. After activation, T-cells upregulate CD27. Its ligand is CD70, 
which is expressed, after activation, by activated DCs, B-cells, T-cells, and NK cells.(van de Ven 
et al., 2015) CD27/CD70 binding results in proliferation of CD4+ and CD8+ cells, promoting an 
anti-tumor environment. Therefore, agonistic antibodies for CD27, antibodies that target and 
activate receptor, have been developed to enhance this response and are currently in clinical 
trials for CRC (van de Ven et al., 2015).  
6.3 Immune checkpoint inhibition immunotherapy  
6.3.1 FDA-approved drugs 
FDA-approved CRC immunotherapy drugs for immune checkpoint inhibition include 
Nivolumab and Pembrolizumab. 
Nivolumab is an immunoglobulin immune checkpoint inhibitor that binds to PD-1 
receptors, blocking PD-1 activation and resulting in T-cell activation and immune response 
(Sundar et al., 2015). Nivolumab was granted accelerated approval by the FDA in 2017 
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following an ongoing, multicenter Phase II trial (NCT02060188) (Overman et al., 2017), funded 
by Bristol-Myers Squibb, that indicated Nivolumab was effective for CRC patients with deficient 
DNA mismatch repair (dMMR)/microsatellite instability high (MSI-H) disease (Smith et al., 
2018). dMMR/MSI-H CRC makes up approximately 12-15% of cases and is phenotypically 
characterized by a high quantify of tumor infiltrating lymphocytes (TILs), prevalence in the right 
side of the colon (proximal colon), and poor differentiation (Kawakami et al., 2015). The 
approval of Nivolumab was particularly important since standard FOLFOX-based chemotherapy 
has limited benefit for dMMR/MSI-H CRC patients (Kawakami et al., 2015). There are currently 
39 ongoing clinical trials further exploring Nivolumab as either stand alone or combinatorial 
treatment for CRC. 
Pembrolizumab is an IgG4-k monoclonal antibody that inhibits PD-1 binding with PD-L1 
and PD-L2. This results in an upregulated immune response against CRC cells (O'Neil et al., 
2017).  Pembrolizumab was granted accelerated approval by the FDA in 2017 as a second-line 
treatment for either unresectable, dMMR, or MSI-H CRC following multiple Phase II and III 
clinical trials (Diaz et al., 2017; Le et al., 2016). There are currently 52 ongoing clinical trials 
further exploring Pembrolizumab as either stand alone or combinatorial treatment for CRC.  
6.3.2 Clinical studies 
Immune checkpoint immunotherapy drugs for CRC that are currently undergoing clinical 
trials include Urelumab, Varlilumab, and Ipilimumab.  
Urelumab is a monoclonal antibody that targets CD137 and activates CD137-expressing 
T-cells and NK cells, resulting in a positive immune response against cancer cells. Urelumab was 
developed by Bristol-Myers Squibb and is undergoing a Phase I/II clinical trial (NCT01471210) 
for melanoma, B-cell non-Hodgkin’s lymphoma, and solid tumors, including 10 patients with 
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CRC. The objectives for this ongoing study include safety, tolerability, pharmacokinetics, and 
immunogenicity (Segal et al., 2017).  
Varlilumab is an agonistic (activating) anti-CD27 monoclonal antibody that binds to 
CD27, mimicking the CD70 ligand, and eliciting proliferation of CD4+ and CD8+ cells. 
Following a Phase I study with 10 CRC tumors (Burris et al., 2017), Varlilumab is currently 
undergoing a Phase II clinical trial (NCT02335918) in combination with the FDA-approved 
Nivolumab for several types of solid tumors, including CRC. The primary outcome measure is 
the objective response rate (ORR). 
Ipilimumab is a receptor antagonistic for CTLA4 (Selby et al., 2016) and was FDA 
approved in 2011 for treating melanoma (Specenier, 2016). Ipilimumab is currently undergoing 
multiple Phase I and Phase II clinical trials (12 active trials) for CRC (Toh et al., 2016), 
including microsatellite-stable (MSS), mCRC (NCT03271047), and dMMR/MSI-H CRC 
(NCT03350126), with no published results yet at the time of this writing. 
Additionally, a major area of clinical research in CRC is combinatorial therapy using one 
or more FDA-approved drugs. For example, there are currently 37 active clinical trials using 
FDA-approved Pembrolizumab in combination with experimental drugs or other FDA-approved 
drugs to treat CRC. 
6.3.3 Pre-clinical studies 
In a subcutaneous allograft model of murine CRC, mice were treated with a combination 
of anti-mouse CTLA4, and the chemotherapy agents ixabepilone, paclitaxel, gemcitabine, or 
etoposide (Jure-Kunkel et al., 2013). CRC allografts showed reduced tumor growth rate in mice 
treated with anti-mouse CTLA4 alone, and further reduction in growth rate in combination 
treatment groups. 50% and 70% of mice displayed complete tumor regression after treatment 
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with anti-CTLA4 and either ixabepilone or paclitaxel, respectively. Additionally, activated T-
cells in the TME significantly increased in response to therapy (Jure-Kunkel et al., 2013). 
Although immune checkpoint inhibition was successful in this subcutaneous murine model of 
CRC, some groups prefer to implement orthotopic models since they better represent the tumor 
immune environment. 
Zhao et al. established an orthotopic mouse model for CRC using endoscopy-guided 
microinjection of CT26 cells into the colon wall, and compared this to standard subcutaneous 
allograft models of CRC (Zhao et al., 2017). Mice were treated with a combination of immune 
checkpoint inhibitors, anti-mouse PD1 and anti-mouse CLTA4, 1 day after tumor implantation. 
They found that orthotopic models were more sensitive to this checkpoint inhibition compared to 
subcutaneous tumor models; in fact, tumors failed to grow in treated orthotopic models, while 
tumor growth only slowed in subcutaneous models, confirming an earlier study by Leach et al 
(Leach et al., 1996). Although subcutaneous models are easier to establish and represent a 
“worst-case scenario” in that the TME is highly immunosuppressive, orthotopic CRC mouse 
models better represent the human TME based on infiltration of immune cells (Zhao et al., 
2017).  
6.3.4 Conclusion 
Immune checkpoint inhibition is a promising approach for CRC treatment (Jenkins et al., 
2018), with several FDA-approved drugs already on the market and many more in clinical trials. 
Although immune checkpoint inhibition has shown success in treating CRC, the biggest 
challenge for investigators is identifying which patients may or not respond before treatment 
initiation (Jenkins et al., 2018) and overcoming tumor cell resistance to this immunotherapy (Lee 
et al., 2016). Jenkins et al. provides a comprehensive review of tumor cell resistance to immune 
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checkpoint inhibition (Jenkins et al., 2018). This heterogeneous patient response to immune 
checkpoint inhibition is a strikingly similar problem to identifying responders vs. non-responders 
for standard first-line neoadjuvant chemotherapy in CRC (Tsuji et al., 2012). The current state-
of-the-art is to biopsy the tumor during colonoscopy and determine expression levels of markers 
such as a PD-L1 using immunohistochemistry (IHC). Patients overexpressing the target 
biomarker, such as PD-LI, are considered the best candidates for that immunotherapy (Patel et 
al., 2015). In the future, investigators are looking into identifying other biomarkers and 
personalized gene-expression signatures to identify candidates most likely to respond to immune 
checkpoint inhibition (B. Li et al., 2017; Tsuji et al., 2012; Dunne et al., 2017; Guinney et al., 
2015; Kather et al., 2018). 
6.4 Cytokines in colorectal cancer 
Cytokines are small cell-signaling proteins, produced by immune cells (Akdis et al., 
2016), that are involved in myriad pathways in CRC (West et al., 2015). Chemokines, members 
of a family of cytokines able to induce cellular chemotaxis, are also involved in CRC pathways 
(Itatani et al., 2016). Thus, cytokines and chemokines, and their receptors, make attractive 
targets for CRC therapy, although pre-clinical and clinical research currently lags other discussed 
CRC immunotherapy techniques (Lynch et al., 2016; Akram et al., 2016). Development of 
cytokine-targeted immunotherapy can potentially be used as stand-alone treatment or, more 
likely, combinatorial treatment with either chemotherapy, radiotherapy, or other immunotherapy 
techniques to normalize the CRC tumor microenvironment (TME) (Klampfer, 2011). 
Multiple immune cells in the TME release cytokines and chemokines including tumor-
associated macrophages (TAMs), monocytes, neutrophils, cancer-associated fibroblasts (CAFs), 
dendritic cells, T-cells, NK cells, myeloid-derived suppressor cells (MDSCs), and mast cells 
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(Lynch et al., 2016; Mager et al., 2016). Table 1 shows an up-to-date snapshot of cytokines and 
chemokines involved in CRC, many of whose roles are under active investigation. Included in 
this table are interleukins and growth factors, which are types of cytokines (Itatani et al., 2016; 
Mager et al., 2016; Landskron et al., 2014; Klampfer, 2011; Ohlsson et al., 2016; Setrerrahmane 
et al., 2017; Allen et al., 2018; Manzat Saplacan et al., 2017; Yuan et al., 2015; Mira et al., 
2017; Wang et al., 2016; Liu et al., 2016). Chemokines and cytokines not listed may represent a 
research gap with regards to CRC. Several of these cytokines and chemokines have gained 
traction as effective immunotherapy targets for the treatment of CRC. 
Table 2. Cytokines and chemokines involved in human CRC pathogenesis 
 Interleukins Growth Factors Chemokines 
Pro-Tumor 
IL-1β 
IL-4 
IL-6 
IL-8 
IL-11 
IL-17 
IL-17A 
IL-22 
IL-23 
IL-33 
VEGF 
TNF-α 
EGF 
HGF 
FGF 
PDGF 
CSF1 
CXCL1 
CXCL2 
CXCL5 
CXCL8 
CXCL12 
CCL2 
CCL15 
CCL20 
CX3CL1 
Dual Role/ 
Controversial 
IL-1 
IL-9 
IL-10 
IL-21 
TGF-β 
TGF-β1 
TNF 
CSF2 
CXLC9 
CXCL17 
CXCL10 
CCL5 
CCL21 
CCL24 
Anti-Tumor 
IL-2 
IL-12 
IL-15 
IL-17F 
IL-18 
IFN-γ  
CCL3 
CCL4 
CCL19 
 
6.5 Cytokine-targeted immunotherapy 
6.5.1 FDA-approved drugs 
All current FDA-approved cytokine-targeted immunotherapy drugs for CRC either target 
vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), or epidermal growth 
factor (EGF) receptors (EGFR). Cytokine-targeted immunotherapy drugs targeting either VEGF 
or VEGFR include bevacizumab, aflibercept, and regorafenib. Drugs targeting EGRF include 
cetuximab and panitumumab. All five FDA-approved drugs primarily benefit mCRC patients, 
although many clinical trials are ongoing for other CRC subtypes in both neoadjuvant and 
adjuvant settings.  
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6.5.2 Anti-vascular endothelial growth factors (anti-VEGFs) 
Bevacizumab is a monoclonal antibody VEGF-inhibitor, preventing tumor blood vessel 
growth. The FDA approved bevacizumab as first line treatment for mCRC in 2004 (Strickler et 
al., 2012) and in 2006 for second-line treatment of mCRC in combination with FOLFOX4 
(Cohen et al., 2007), making it the first anti-VEGF drug for CRC. A phase III clinical trial by 
Eastern Cooperative Oncology Group (ECOG) tested bevacizumab’s efficacy and safety in 
combination with FOLFOX4 (Giantonio et al., 2007). Patients treated with the combination 
therapy saw a longer median overall survival of 12.9 months with a 22.2% response rate 
compared to an overall survival of 10.8 months and an 8.6% response rate for patients receiving 
standalone FOLFOX4 chemotherapy (Giantonio et al., 2007). Additional studies have confirmed 
the benefits of bevacizumab in treating mCRC (Hurwitz et al., 2004; Saltz et al., 2008; Ilic et al., 
2016). 
Six years later in 2012, aflibercept, an antiangiogenic VEGF inhibitor, was approved by 
the FDA as a second-line treatment for mCRC in combination with the FOLFIRI chemotherapy 
regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) (Stewart et al., 2012). 
Aflibercept is meant to be used for mCRC patients who failed to respond to previous FOLFOX-
based chemotherapy (Van Cutsem et al., 2012). In a phase III clinical trial (NCT00561470), the 
addition of aflibercept to FOLFIRI improved overall median survival from 12.1 to 13.5 months 
and progression-free survival from 4.7 to 6.9 months for stage IV mCRC patients (Van Cutsem 
et al., 2012). In an update to this same phase III clinical trial, published in 2014, investigators 
found that overall survival increased by 0.8 months for mCRC patients with no prior 
bevacizumab treatment and 1.5 months for patients with no prior bevacizumab treatment 
(Tabernero et al., 2014).  
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Regorafenib is an oral kinase inhibitor that targets oncogenic and angiogenic kinases to 
inhibit VEGFR activation, resulting in inhibition of tumor cell proliferation and angiogenesis 
(Dhillon, 2018). In 2012, the FDA granted approval for regorafenib to treat mCRC patients 
based on the CORRECT phase III clinical trial (NCT01103323). The median overall survival 
was 6.4 months in patients who received regorafenib monotherapy and 5.0 months in patients 
who received placebo. This study did, however, note adverse events in 93% of regorafenib-
treated patients (Grothey et al., 2013). In 2015, the CONCUR phase III clinical (NCT01584830) 
became the second trial to demonstrate overall survival benefits of regorafenib (8.8 months) vs. 
placebo (6.3 months) for mCRC patients (Li et al., 2015).  
6.5.3 Anti-epidermal growth factor receptors (anti-EGFRs) 
In 2004, the FDA approved the monoclonal antibody, cetuximab, to treat advanced CRC 
patients who have failed standard chemotherapy (Saltz et al., 2007; Mesia et al., 2016; Hubbard 
et al., 2013; Cunningham et al., 2004). Cetuximab targets the ligand-binding domain of EGFR, 
resulting in reduced tumor growth and differentiation (Lenz, 2007). A clinical trial conducted by 
the North Central Cancer Treatment Group (NCCTG) N0147 compared the use of FOLFIRI with 
and without cetuximab in stage III CRC patients with both wild-type KRAS and mutant KRAS. 
Combination treatment with cetuximab plus FOLFIRI showed that 5-year disease-free survival, 
overall survival, and time to recurrence in patients with wild-type KRAS improved from 64% to 
83% (p=0.10), 76% to 87% (p=0.21), and 67% to 86% (p=0.09), respectively (Huang et al., 
2014). Based in part on this study, as well as the CEGOG trial,(Ocvirk et al., 2010) the FDA 
approved cetuximab in 2012 as a first-line treatment in KRAS-/EGFR+ mCRC in combination 
with FOLFIRI.  
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In 2017, panitumumab, another EGFR inhibitor, was granted FDA approval to treat 
mCRC patients with wild-type RAS as a first-line treatment in combination with FOLFOX 
(Douillard et al., 2014; Price et al., 2014). A study by Leone et al. used panitumumab in 
combination with capecitabine plus oxaliplatin (XELOX) to study its efficacy in patients with 
liver only mCRC. Out of the forty-six patients, the objective response rate was 54% with two 
patients with complete responses and 23 with a partial response. The medial overall survival rate 
was observed to be 21.9 months with a median progression-free survival of 8.5 months. Overall, 
the combination of panitumumab with XELOX (P-XELOX) yield a high response for patients 
with liver only mCRC (Leone et al., 2013). 
6.5.4 Clinical studies 
One pathway currently being studied is the IL-6/STAT3 pathway. IL-6 binds to the IL-6 
receptor (IL-6R), activating the signal transducer and activator of transcription 3 (STAT3) 
signaling pathway. This pathway induces transcription of various genes involved in 
differentiation and proliferation and reduces CD4+ immune responses (Kitamura et al., 2017). In 
a phase I/II clinical trial, CRC patients with advanced solid tumors, along with other cancer 
patients, received IL-6 neutralizing antibodies at increasing doses. Although investigators 
showed increased tumor hemoglobin in response to IL-6 neutralization, colorectal tumors had a 
low response rate measured via RECIST criteria. Although this study indicate that stand-alone 
IL-6 inhibition was inadequate for advanced CRC solid tumors, investigation of IL-6/STAT3 
modulation is worth further exploration (Angevin et al., 2014). 
IL-10 is also being explored as an immunotherapy target. A future spotlight will be on a 
collaborative industry-academic phase I clinical trial, which has enrolled 350 patients with 
various solid tumors including CRC. In this study, AM0010, a PEGylated human IL-10, will be 
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self-administered subcutaneously in four monthly cycles, either as a monotherapy or with 
chemotherapy, to test the safety, toxicity, maximum tolerated dose, anti-tumor activity, and 
pharmacokinetics of this cytokine-targeted immunotherapy (Bauer et al., 2014). In addition to IL 
pathways, nimotuzumab (NCT00972465), a monoclonal antibody targeting EGFR, and 
imalumab (NCT02448810), a monoclonal antibody targeting macrophage inhibitory factor 
(MIF), are undergoing clinical trials for CRC (Xu et al., 2016; Mahalingam et al., 2015). 
6.5.5 Pre-clinical studies 
The effect of modulating cytokines and chemokines in the human CRC TME is mostly 
hypothesized and has not yet been rigorously tested in clinical trials. Most CRC cytokine 
modulation research, besides the aforementioned interleukins, exists in the pre-clinical and basic 
biology realms.  
Two chemokine receptors, C-C chemokine receptor type 1 (CCR1) and chemokine C-C 
motif receptor-like 2 (CCRL2), have been recently implicated in aiding in liver metastasis 
(Akram et al., 2016), the primary cause of death for CRC patients (Valderrama-Trevino et al., 
2017). Ligands for CCR1 and CCRL2 are the chemokines CCL3, CCL5, CCL7, and CCL23, and 
are suggested as potential targets for cytokine-targeted immunotherapy (Akram et al., 2016). 
CCL2 and CCL24 were also found to be highly elevated (>100-fold) in CRC liver metastases 
compared to healthy adjacent liver tissue, implying that these chemokines could also be targets 
for cytokine-targeted immunotherapy (Cheadle et al., 2007). 
Chemokine neutralization, especially of CCL2, has gained traction in both CRC and 
non-CRC studies of mice (Chun et al., 2015). CRC, independent of subtype (Lim et al., 2016; 
Becht et al., 2016), recruits circulating monocytes via chemotaxis to the TME primarily through 
the release of CCL2, also known as monocyte chemoattractant protein-1 (MCP1), a highly 
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elevated chemokine in CRC (Marech et al., 2016; Lim et al., 2016; Becht et al., 2016; Chun et 
al., 2015). In the TME, monocytes differentiate into TAMs, partially as a result of CCL2. TAMs, 
the most abundant immune cell in the TME, also have the most substantial and pervasive effect 
of any immune cell in the TME (Erreni et al., 2011; Allavena et al., 2008; Chen et al., 2005; 
Marech et al., 2016). In CRC, TAMs have been shown to have both anti-tumor and pro-tumor 
functions, depending on whether they are polarized more towards an M1 (classical) or M2 
(alternative) phenotype and their physical location within the tumor (Marech et al., 2016). Pro-
tumor functions of alternatively activated M2-polarized TAMs include tumor growth, 
angiogenesis, immunosuppression, and matrix remodeling (Liu et al., 2015). Additionally, CCL2 
binding to its receptor, CCR2, on endothelial cells increases vascular permeability and metastatic 
risk (Lim et al., 2016). Thus, targeting CCL2 to reduce M2-polarized, pro-tumor TAMs is an 
attractive ongoing cytokine-targeted immunotherapy strategy in pre-clinical settings. In mouse 
models, CCL2 blockade has resulted in reduced neovascularization and tumor size of 
orthotopic colon tumors in Balb/c mice, suggesting that CCL2 may be a promising target for 
treating colitis-associated colon cancer (Popivanova et al., 2009). Additionally, anti-CCL2 
immunotherapy prolonged survival in C57BL/6 mice with GL261 glioma (Zhu et al., 2011), and 
reduced TAM infiltration in FVB/N mice with MCF-7 breast cancer (Svensson et al., 2015). 
However, few cytokine-targeted immunotherapy techniques have been tested for efficacy in 
human CRC, although oral N-acetyl-L-cysteine (NAC) co-administered with mesalamine, an 
anti-inflammatory, has benefitted ulcerative colitis patients, attributed in part to the down-
regulation of CCL2 and IL-8 (Guijarro et al., 2008). In summary, many investigators now 
believe that CCL2-neutralizing immunotherapy will play an important role in early-stage CRC 
treatment in future clinical studies (Chun et al., 2015).  
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Besides CCL2, other cytokines and chemokines have been explored. For example, 
blocking the pro-angiogenic and pro-tumor chemokine ligand 1 (CXCL1), whose gene is also 
known as growth-regulated oncogene-α, using an anti-CXCL1 neutralizing antibody inhibited 
tumor growth and angiogenesis in a mouse xenograft model of human CRC (Wang et al., 
2006). Blockade of IL-1β reduced tumor formation in a mouse model of colitis-associated CRC 
(Wang et al., 2014). TNF blockade reduced CRC carcinogenesis in an AOM/DSS (colitis-
induced) mouse model (Popivanova et al., 2008). On the other hand, the addition of IL-15, which 
has anti-tumor effects in CRC (Table 3), was shown to increase the therapeutic effects of anti-
PD-L1 and anti-CTLA4 treatment in a CT26 colon carcinoma mouse model (Yu et al., 2010). 
The overarching current hypothesis is that cytokine-targeted immunotherapy, especially the 
blockade of pro-tumor cytokines in CRC, may enhance tumor therapeutic response in CRC 
tumors treated with chemotherapy, radiation, or approved checkpoint inhibitors (Mager et al., 
2016).  
6.5.6 Conclusion 
Cytokine-targeted immunotherapy research lags other discussed CRC immunotherapy 
methods, although further investigation is justified. The biggest challenge facing this type of 
therapy is determining which pharmacokinetic and pharmacodynamic variables are important 
navigating cytokine pathways while decreasing systemic toxicity in CRC patients. Additionally, 
the FDA approved drugs, cetuximab and panitumumab are ineffective in patients with RAS 
mutations (~23% of stage IV CRC patients). (sirisena, the pattern of KRAS mutations in 
metastatic, bmc res notes) Overall, cytokine therapies will likely be most effective in 
combination with other immunotherapies or chemo- and/or radiotherapy (Lynch et al., 2016). 
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6.6 Assessing tumor therapeutic response 
In addition to new CRC therapies being investigated, an important branch of CRC 
research is development of clinically-translatable methods to rapidly assess whether a therapy 
regimen is effective on a per patient basis (Berger et al., 2017; Roblyer et al., 2011). Rapid 
assessment of therapy can prevent unnecessary chemotherapy in both responders and non-
responders (Granata et al., 2015). Currently, tumors are assessed based on the widely accepted 
Response Evaluation Criteria in Solid Tumors (RECIST) criteria, which grades tumors as, from 
most desirable to least desirable, complete responders, partial responders, stable disease, or 
progressive disease (Eisenhauer et al., 2009; Wahl et al., 2009; Chung et al., 2012). The overall 
goal of assessing tumor therapeutic response is adjusting treatment if necessary, avoiding surgery 
and reducing morbidity (A.S. Walker et al., 2014). The standards for monitoring tumor 
therapeutic response to neoadjuvant therapy (chemotherapy, radiation, and/or immunotherapy) 
using RECIST are digital rectal examination (DRE), rigid proctoscopy, biopsy, 
carcinoembryonic antigen (CEA) level, and a radiological technique such as CT (A.S. Walker et 
al., 2014), PET-CT (Petersen et al., 2014), MRI (Van Cutsem et al., 2016), or Diffusion-
Weighted (DW)-MRI (A.S. Walker et al., 2014). However, following neoadjuvant treatment 
initiation, assessing tumor response does not occur for approximately two months (Habr-Gama et 
al., 2010; Van Cutsem et al., 2016). Additionally, for patients showing evidence of partial or 
complete response after these two months of neoadjuvant treatment, they must wait an additional 
1-2 months for follow-up as part of the “Wait and Watch Protocol” (A.S. Walker et al., 2014). 
Finally, studies have shown that current radiological techniques are insufficient to identify 
responders with positive predictive values less than 50% (Kekelidze et al., 2013). However, 
several research groups are investigating optical and imaging methods to rapidly assess 
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therapeutic response on a scale of days or weeks, rather than months.  
Optical methods to monitor CRC tumor therapeutic response use light to acquire relevant 
clinical information. Since the CRC screening, diagnostic, and, in some cases, therapeutic 
standard (in early CRC stages only) is colonoscopy, investigators are aiming to create minimally-
invasive endoscopy-compatible techniques. Techniques currently being evaluated, mostly in pre-
clinical laboratory settings, for use in CRC include nonlinear optical imaging, fluorescence-
based endoscopy, and diffuse reflectance spectroscopy. 
6.6.1 Nonlinear optical imaging 
Nonlinear optical imaging has been used to image freshly resected advanced rectal 
adenocarcinoma sections of patients who had received neoadjuvant radiochemotherapy. This ex 
vivo, label-free imaging method combined second harmonic generation (SHG) and two-photon 
excited fluorescence (TPEF) and showed that SHG microscopy could determine degree of 
fibrosis post-neoadjuvant chemoradiotherapy (L. H. Li et al., 2017). Therefore, this method 
could potentially direct ideal operating time. Although this study was performed ex vivo, future 
miniaturization of nonlinear optical microscopy techniques as an endoscopic method has 
important applications in early preoperative tumor evaluation and clinical disease management. 
In fact, miniaturization of similar techniques have been performed in in vivo rat colon tissue.  
A flexible multiphoton microendoscope, with a 3 mm outer diameter and 4 cm rigid 
length, has recently been developed by investigators out of Cornell University. This multiphoton 
microendoscope, the first of its kind, uses a resonant-nonresonant raster scanner to acquire en 
face images of unstained rat colon tissue at a field-of-view of 115 μm x 115 μm (Brown et al., 
2012). Potential clinical advantages of this research include diagnostic optical biopsy and real-
time histopathological assessment of CRC tumor response to neoadjuvant chemotherapy and 
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antibody immunotherapy.  
6.6.2 Fluorescence-based endoscopy 
Fluorescence-based endoscopy is a new approach imaging modality that integrates a 
colonoscopy with optical imaging. This technique is a “robust method for early detection of CRC 
owing to its intrinsic coupling of detection with the underlying molecular-level pathology of the 
disease”. With the use of molecular imaging, this type of optical system can detect variations in 
tissues unlike other system that only detect changes in structure (Sakuma et al., 2015). 
In a study by Mitsunaga et al., they developed a “rapid fluorescent detection method” 
using a “topically applied enzymatically activatable probe (gGlu-HMRG)” to detect the γ-
glutamyltranspeptidase (GGT) enzyme during a colonoscopy. Expression of GGT was higher in 
mouse models with CRC than those without. Five minutes after topical administration, gGlu-
HMRG fluorescent lesions were detected using fluorescent microscopy. Based on these results, 
the use of gGlu-HMRG can improve detection of colitis-associated colon cancer (CAC) with a 
“higher target to background ratio” compared to conventional white light colonoscopy 
(Mitsunaga et al., 2013). 
In a human study by Watanabe et al., used the PINPOINT® Endoscopic Fluorescence 
Imaging System intraoperatively to identify tumor sites using indocyanine green during 
laparoscopic surgery. Using this system, surgeons saw a tumor visibility rate of 93.8%. No 
adverse effects were observed during these procedures. As a result, this study provided evidence 
that the PINPOINT® system was able to identify colorectal tumors without adverse effects 
(Watanabe et al., 2017). 
Fluorescence-based endoscopy techniques are not only used for tumor detection, but they 
can also monitor tumor response to various therapies. Sakuma et al., used fluorescence-based 
294 
 
endoscopic imaging to investigate TF-antigen detection in CRC tumors during chemotherapy. 
With the use of a nanobeacon and fluorescence labeled (FL) endoscopy signals, they found that 
the tumors were above the signal threshold indicating a cancerous abnormality. After 
chemotherapy treatment with 4-paclitaxel, no tumors were detected through FL endoscopy. 
Based on these results, this type of imaging modality can be used to observe tumor response 
during chemotherapy (Sakuma et al., 2015). 
6.6.3 Diffuse reflectance spectroscopy 
Diffuse reflectance spectroscopy (DRS) is a non-invasive or minimally-invasive 
technique that uses a small probe to deliver broadband light to tissue and collect the diffusely 
reflected light with a spectrometer (G.J. Greening et al., 2018; Greening et al., 2016; Dadgar et 
al., 2018). DRS can provide relevant clinical information such as total hemoglobin content, 
tissue oxygen saturation, oxy- and deoxyhemoglobin, lipid and water content, and tissue 
scattering properties, and can thus be applied to monitoring tumor response to therapy (G.J. 
Greening et al., 2018; Spliethoff et al., 2014). 
DRS has recently been used in an ex vivo study of resected human colon tissue to 
differentiate tissue type with an overall accuracy of 95%. The investigators hope to eventually 
apply this technology in an in vivo setting for real-time guidance during CRC surgery (Baltussen 
et al., 2017). DRS has also been integrated into a fiber-optic biopsy needle to assess functional 
tissue properties in an in vivo study of lung cancer patients (Spliethoff et al., 2016). This same 
research group also used their DRS system to monitor tumor response to chemotherapy in a 
murine subcutaneous mammary tumor model. The investigators found that tumors showed an 
increase in lipid content and tissue oxygen saturation after just 2 days of treatment, and believe 
this technology can someday help optimize personalized cancer treatments (Spliethoff et al., 
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2014). Next, Schols et al. used DRS in open colorectal surgery to detect mesenteric arteries in 
real-time to reduce interoperative risk of iatrogenic surgery (Schols et al., 2015). One of primary 
limitations with optical methods, such as DRS, is poor light sampling into highly scattering 
tissues. However, it’s been shown that, at the optical properties found in colorectal tissue 
(Carneiro et al., 2018), DRS sampling depth is greater than 0.5 mm at 630 nm at source-detector 
separations (< 1 mm) compatible with the biopsy port of standard colonoscopes (G.J. Greening et 
al., 2018).  
As of yet, DRS applied to CRC is in its infancy; it has only been applied to monitor 
tumor therapeutic response to chemotherapy in mouse models, although investigators believe 
DRS technology can be used to quantify volumetric tumor perfusion in response to 
immunotherapies, which can eventually help guide clinicians in identifying potential responders 
and non-responders during early therapy (G.J. Greening et al., 2018).  
6.7 Introduction to study 
Colorectal cancer (CRC) is estimated to account for 140,050 new cancer cases annually 
in the United States, making it the 4th most common cancer type overall (behind breast, lung, and 
prostate), and resulting in 50,630 annual deaths (Siegel et al., 2016). Tumor stage is determined 
using the MRI-based tumor, node, and metastasis (TNM) Staging System, which guides CRC 
treatment (Ferrari et al., 2015; Dienstmann et al., 2017). Locally-advanced CRC (stages II-III), 
which account for approximately 20% of cases, describes cancer that has spread from the site of 
the primary tumor to surrounding tissue or lymph nodes, but has not metastasized (Landmann et 
al., 2005; Ferrari et al., 2015; Dienstmann et al., 2017). The standard of treatment for locally-
advanced CRC is neoadjuvant chemoradiotherapy (CRT) using 5-fluorouracil (5-FU), followed 
by total mesorectal excision (TME) surgery (Boland et al., 2014). Following neoadjuvant CRT, 
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biopsies are examined to determine pathologic response. Ideally, patients will exhibit pathologic 
complete response (pCR), defined as the absence of residual cancer cells in histological 
examination, since achieving pCR reduces distal recurrence risk (Ferrari et al., 2015). For 
example, the 5-year distal-metastases-free survival is significantly greater (89%) for patients 
achieving pCR compared to those who don’t (75%). However, pCR is achieved in less than 30% 
of cases, resulting in distal recurrence rates of 25%, which is the primary cause of CRC-related 
death (Ferrari et al., 2015). An emerging strategy known as immunotherapy, or 
immunomodulation therapy, has gained clinical momentum in recent years to aid neoadjuvant 
CRT in reducing pre-operative tumor burden and recurrence risk (Lynch et al., 2016; Yuan et al., 
2015; Sanchez-Castanon et al., 2016). 
Immunotherapy in CRC is a broad neoadjuvant therapy approach, with most strategies 
aimed at modulating the host immune system to inhibit checkpoints of pro-tumor pathways to 
increase the tumor’s sensitivity to chemotherapy (Lynch et al., 2016). One specific 
immunotherapy strategy is the blockade of CCL2/MCP-1 (monocyte chemoattractant protein-1), 
an elevated cytokine during CRC progression which recruits monocytes to the tumor 
microenvironment (Chun et al., 2015). Monocytes differentiate into tumor-associated 
macrophages (TAMs), which have pro-tumor functions in CRC (Erreni et al., 2011; Li et al., 
2016; Guo et al., 2016; Zhang et al., 2016; Kaler et al., 2009; Popovic et al., 2007; Herbeuval et 
al., 2004; Guo et al., 2013; Zou et al., 2017; Barbera-Guillem et al., 2002), although some 
conflicting studies have reported anti-tumor functions of TAMs at tumor margins (Funada et al., 
2003; Sugita et al., 2002; Forssell et al., 2007; Zhou et al., 2010). Pro-tumor functions of TAMs 
include direct secretion of angiogenic growth factors (GFs) leading to an increase in vascular 
endothelial growth factor (VEGF) (Burmeister et al., 2017; Erreni et al., 2011; Barbera-Guillem 
297 
 
et al., 2002), as well as ECM-degrading matrix metalloproteases (MMPs) which allow for tumor 
expansion and release of ECM-sequestered angiogenic GFs (Erreni et al., 2011; Guo et al., 
2013). Thus, CCL2-mediated TAM infiltration is linked to increased inflammation, angiogenesis 
and tumorigenesis (Guo et al., 2016; McClellan et al., 2012). Additionally, CCL2 has been 
linked to other pro-tumor/immunosuppressive functions such as inducing myeloid-derived 
suppressor cell (MDSC) accumulation and promoting STAT-mediated T-cell suppression of 
polymorphonuclear (PMN)-MDSCs (Chun et al., 2015). Therefore, anti-CCL2 immunotherapy 
has the potential to reduce tumor burden and recurrence risk. 
Recent research has explored CCL2 blockade as an immunotherapy strategy in mouse 
models of various cancers. Popivanova et al. showed that CCL2 blockade reduced 
neovascularization and colon tumor size in Balb/c mice (Popivanova et al., 2009). Zhu et al. 
showed that administration of anti-CCL2 in combination with temozolomide chemotherapy to 
C57BL/6 mice with GL261 glioma significantly prolonged survival (Zhu et al., 2011). Svensson 
et al. demonstrated that CCL2 blockade in FVB/N mice with MCF-7 breast cancer decreased 
TAM infiltration and reduced estrogen-stimulated cancer growth (Svensson et al., 2015). Kirk et 
al. showed that delivering anti-CCL2 in combination with docetaxel chemotherapy to SCID mice 
with C4-2B prostate adenocarcinoma inhibited tumor progression (Kirk et al., 2013). Finally, 
Zhang et al. demonstrated that TAMs directly contribute to 5-FU chemoresistance in CRC, and 
concluded that TAM pathways (such as CCL2) were potential immunotherapy targets to increase 
efficacy of 5-FU chemotherapy (Zhang et al., 2016). However, no studies have combined 
chemotherapy with CCL2 blockade in a mouse model of CRC.  
The present study uses anti-CCL2 as a neoadjuvant immunotherapy strategy (Singh et al., 
2014), combined with standard 5-FU chemotherapy, in Balb/c mice with subcutaneous CT26 
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colon carcinoma allografts. Female Balb/c mice were injected with CT26 tumor cells in the left 
flank, and then given the control vehicle, isotype control antibody, anti-CCL2 immunotherapy, 
5-FU chemotherapy, or combination therapy (five groups). Combination therapy was expected to 
alter CRC tumor perfusion due to effects of chemotherapy and CCL2-mediated effects on TAMs. 
Therefore, during the study, tumor perfusion was longitudinally measured via non-invasive 
diffuse reflectance spectroscopy (DRS), a non-invasive, probe-based technique which can 
quantify perfusion metrics such as tissue hemoglobin content (THC), tissue oxygen saturation 
(StO2), and oxyhemoglobin (HbO2), as well as the reduced scattering coefficient (μs’). DRS 
measurements were then correlated to end-point immunohistochemistry (IHC) analysis of 
hypoxia (pimonidazole), angiogenesis (CD105), tumor-associated macrophage (TAM) 
polarization (CD80, CD68, and CD206), proliferation (Ki67), and apoptosis (CC3). This study 
forms two major hypotheses: 1) CCL2 blockade in the tumor microenvironment as an 
immunotherapy strategy will increase sensitivity of CT26 tumors to 5-FU chemotherapy, 
quantified by tumor size, DRS perfusion metrics, IHC analysis, and CCL2 ELISA and 2) 
changes in tumor perfusion will precede measurable changes in tumor size. Confirmation of 
these hypotheses may indicate that DRS could potentially be used to monitor early tumor 
response to combinatorial immunotherapy and chemotherapy. 
6.8 Materials and methods 
6.9.1 Cell line 
CT26 (ATCC®, CRL-2638TM), a murine colon carcinoma cell line derived from the 
Balb/c mouse strain, was maintained in Roswell Park Memorial Institute (RPMI)-1640 medium 
(ATCC®, 30-2001TM) supplemented with 10% fetal bovine serum (ATCC®, 30-2020), 1% 
antibiotic antimycotic solution (Sigma-Alrich, A5955-100ML), and 0.2% amphotericin 
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B/gentamicin (Thermo Fisher Scientific, R015010). CT26 cells were brought to the third passage 
(P3). 
6.8.2 Animal model 
The study was approved by the University of Arkansas Institutional Animal Care and Use 
Committee (IACUC #17072). Eight-week-old female Balb/c mice (n=125) were obtained from 
The Jackson Laboratory (Bar Harbor, ME, USA). Upon arrival to the Small Animal Facility at 
the University of Arkansas, mice were housed in groups of three at 23°C ± 1°C and 50% ± 10% 
humidity with a 12:12-hour light-dark cycle and had access to water and standard rodent food ad 
libitum. Mice were weighed daily upon arrival. Mice underwent 2 weeks of environmental 
acclimation, including daily handling (2 minutes per mouse) for stress adaptation to future 
handling during measurements. After 2 weeks, the hair on the injection site (left flank) of the 
now 10-week old Balb/c mice was removed via shaving and NairTM, and then cleaned, prior to 
injection with CT26 cells. Then, the mice underwent subcutaneous (SQ) injection of 1x105 CT26 
cells into the shaved and depilated left flank (Figure 1). Tumors were allowed to grow until they 
reached 75 ± 5 mm3 (day 0), as measured via 𝑉 = (𝐿 ∙ 𝑊2)/2, which took an average of 14 ± 4 
days. 
 
Figure 1. Balb/c mice were the model organization for the studies presented here. 
CT26 cells were injected subcutaneously into the left flank to form colon tumor 
allografts. Image of mouse and syringe sourced from the Library of Science 
Medical Figures, which are free to share, copy, and redistribute under Create 
Commons License BY-NC-SA 4.0. 
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6.8.3 Anesthesia protocol 
Mice were anesthetized with isoflurane (ISO) and 1 L/min oxygen (O2) for various 
procedures throughout the study. Procedures included shaving and nairing of left flank, SQ CT26 
cell injection, intraperitoneal (IP) injection of therapy/control, IP injection of pimonidazole, and 
tumor vivisection and euthanasia. Mice undergoing DRS measurements were not anesthetized 
since isoflurane can depress StO2 and HbO2 (Gage J. Greening et al., 2018). All mice were 
physically maintained on a water-based warming pad (Stryker, #TP700) controlled by a warming 
pump (Stryker, Kalamazoo, MI, #TP12E) set to 42°C. Table 3 lists the isoflurane concentration 
for induction and maintenance for each procedure as well as approximate anesthesia time for 
each. 
Table 3. Isoflurane anesthesia specifications per procedure with 1 L/min O2 
Procedure 
[ISO] 
(Induction) 
Time 
(min) 
[ISO] 
(Maintenance) 
Time 
(min) 
SQ Injection of CT26 Cells 3.0% 2 2.0% 2 
IP Injection of Therapy/Control 3.0% 2 2.0% 1 
IP Injection of Pimonidazole 2.0% 2 2.0% 1 
Tumor Vivisection and Euthanasia 4.0% 1 4.0% 5 
 
6.8.4 Control and experimental groups 
For analysis of early tumor therapeutic response, 62 female Balb/c mice were randomly 
divided into five groups of up to 15 mice once the CT26-tumors reached 75 mm3 (Figure 2). The 
first group (control, n=15) received saline injections for vehicle control. The second group 
(n=13) received isotype antibody control. The third group (n=10) received immunotherapy but 
no chemotherapy. The fourth group (n=12) received chemotherapy but no immunotherapy. The 
fifth group (n=12) received a combination of both chemotherapy and immunotherapy. For each 
group of mice, mice were euthanized on either day 1 (n=5), day 3 (n=5), or day 7 (n=5) for end-
point immunohistochemical and ELISA analysis. Table 4 and Figure 2 shows the breakdown of 
control and experimental groups.  
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Table 4. Breakdown of control and experimental groups 
Group Sample Size Saline Control Isotype Control 
Anti-CCL2 
Immunotherapy 
5-FU 
Chemotherapy 
1 15 X    
2 13  X   
3 10   X  
4 11    X 
5 12   X X 
Total 61     
 
 
 
Figure 2. For analysis of early tumor therapeutic response, 62 female Balb/c mice 
were randomly divided into five groups of up to 15 mice once the CT26-tumors 
reached 75 mm3. Then, mice were subject to either one of five therapies: saline 
control, isotype (antibody) control, anti-CCL2 antibody immunotherapy, 5-FU 
chemotherapy, or a combination of immunotherapy and chemotherapy. Tumors 
then underwent daily DRS measurements. Image of mouse, syringe and 
antibodies sourced from the Library of Science Medical Figures, which are free 
to share, copy, and redistribute under Create Commons License BY-NC-SA 4.0. 
 
6.8.5 Chemotherapy 
5-Fluorouracil (5-FU), purchased from Sigma-Aldrich (St. Louis, MO, USA), is an 
antitumor chemotherapy agent that induces p53-dependent apoptosis and decreases proliferation 
(Balmer et al., 2014). 5-FU powder (Sigma Aldrich, #F6627-10G) was diluted in DMSO at 40 
mg/mL and stored at -20°C for a maximum of two months before injection. A second dilution of 
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5-FU/DMSO was then created in sterile saline (VWR, Radnor, PA, #89167-774) to bring the 5-
FU concentration to 20 mg/mL. On the day of 5-FU injection, aliquots of 20 mg/mL 5-
FU+DMSO in sterile saline were further diluted to 3 mg/mL 5-FU/saline in sterile 
microcentrifuge tubes (VWR, #20170-038), and brought to 37.3°C. Using a 28G insulin syringe 
(VWR, #BD329410), mice in groups 4 and 5 received daily intraperitoneal (IP) administration of 
5-FU at a concentration of 15 mg/kg/dose (Wu et al., 2016) starting at day 0 (tumor = 75 mm3) 
until day 6 (140 mg/kg/week). This resulted in an average injection of 300 µg 5-FU in 100 µL 
vehicle, based on average mouse weight of approximately 20 g at time of injection. 
A daily 5-FU dosage of 15 mg/kg was chosen to approximate average 5-FU dosage in 
humans. In the standard FOLFOX6 CRC chemotherapy treatment, 5-FU is given every 2 weeks 
at 2.4 g/m2, and repeated in 4-6 courses in the neoadjuvant settings (Fang et al., 2016). The 
average body surface area (BSA) in cancer patients is approximately 1.8 m2 (Sacco et al., 2010) 
and the average body weight of adult humans in North America is approximately 80 kg (Walpole 
et al., 2012). Based on FDA guidelines, to convert human dose (mg/m2) to mouse dose (mg/kg), 
the human dose is multiplied by 12.3 and divided by 3 (Nair et al., 2016). Based on this 
information, 5-FU dose in mice can be solved as shown in Equation 1. 
[
2,400 𝑚𝑔 5𝐹𝑈
𝑚2 ∙ 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
] ∙ [
1.8 𝑚2 
80 𝑘𝑔
] ∙ [
12.3
3
] ∙ [
𝑂𝑛𝑒 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
14 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒𝑠
] = 15.8 
𝑚𝑔 5𝐹𝑈
𝑘𝑔
 
(1) 
6.8.6 Immunotherapy 
Anti-CCL2 (2H5), purchased from Bio X Cell (West Lebanon, NH, USA), is a 
monoclonal antibody that neutralizes murine CCL2 (monocyte chemoattractant protein-1), and 
has been demonstrated as an in vivo immunotherapy agent (Singh et al., 2014; Palframan et al., 
2001). Anti-CCL2 (Bio X Cell, 2H5, #BE0185) was shipped at 7.4 mg/mL in PBS and stored at 
4°C for a maximum of two months before injection. On the day of anti-CCL2 injection, aliquots 
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of 7.4 mg/mL anti-CCL2/PBS solution were diluted with sterile saline (VWR, #89167-774) to 1 
mg/mL anti-CCL2/saline in sterile microcentrifuge tubes (VWR, #20170-038), and brought to 
37.3°C. Using a 28G insulin syringe (VWR, #BD329410), mice in groups 3 and 5 received IP 
administration of anti-CCL2 at a concentration of 4.0 mg/kg/dose (Zhu et al., 2011; Singh et al., 
2014) given every other day on days 0 (tumor = 75 mm3), 2, 4, and 6 (16 mg/kg/week). This 
resulted in an average injection of 80 µg anti-CCL2 (2H5) in 100 µL vehicle, based on average 
mouse weight of 20 g at time of injection. The isotype control antibody, polyclonal Armenian 
hamster IgG (Bio X Cell, #BE0091), was made in an identical manner to anti-CCL2 and mice 
were dosed at the same concentration, schedule, and method.  
6.8.7 Diffuse reflectance spectroscopy 
The purpose of DRS was to non-invasively quantify in vivo THC, StO2, and HbO2, and 
μs’ of subcutaneous CT26 tumors (Figure 3).  
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Figure 3. DRS can quantify StO2, THC, and μs’. The HbO2 can be calculated by 
the product of StO2 and THC. Thus, DRS can be used as a metric to determine 
low (blue) vs. high (red) oxygenation and low (less vessels) vs. high (more 
vessels) hemoglobin content. Image of cell sourced from the Library of Science 
Medical Figures by somersault1824, which are free to share, copy, and redistribute 
under Create Commons License BY-NC-SA 4.0. 
 
6.8.7.1 Diffuse reflectance spectroscopy probe 
This probe was described in Chapter 4. The DRS probe (FiberTech Optica, Kitchener, 
ON, Canada) was 1.0 m in total length, with the split position located 0.67 m from the common 
(distal) end. Five individual optical fibers (one source and four detectors) were integrated within 
the distal brass ferrule (6.35 mm diameter x 50 mm long). All fibers were arranged linearly in a 
slit line, resulting in source-detector separations (SDS) of 0.75, 2.00, 3.00, and 4.00 mm. Each 
optical fiber consisted of a high-OH silica core, a silica cladding, and polyimide jacket optimized 
for a wavelength range of 190-1200 nm, which exceeded the desired wavelength range of 450-
750 nm used in this study. The source fiber, as well as the 2.00, 3.00, and 4.00 SDS fibers 
(FiberTech Optica, SUV400/440PI) consisted of a 400/440 ± μm ± 2% silica core/cladding with 
a 470 μm ± 5% polyimide jacket. The 0.75 mm SDS fiber (FiberTech Optica, SUV200/220PI) 
consisted of a 200/220 μm ± 2% silica core/cladding with a 245 μm ± 5% polyimide jacket. 
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These optical fibers were included to sample into the subcutaneous murine CT26 tumor at 
multiple sampling depths to quantify THC, StO2, and HbO2, and μs’. 
Probe sheathing consisted of black PVC coated monocoil (4.8 mm OD, 0.67 length) at 
the common end and black PVC furcation tubing (3.0 mm OD, 0.33 length) for the individual 
legs originating at the breakout joint. The five individual optical fibers within the furcation 
tubing terminated at standard SMA connectors, reinforced with strain relief.  
6.8.7.2 Diffuse reflectance spectroscopy instrumentation 
A 20W tungsten-halogen lamp (Ocean Optics, HL-2000-HP) provided broadband light 
(360-2400 nm) to the 400 μm core source fiber. A spectrometer (Ocean Optics, FLAME-S) with 
a Sony ILX511B linear silicon CCD array (2,048 pixel elements) collected diffusely reflected 
light from the 2 and 3 mm SDSs. The spectrometer had a grating of 600 lines/mm and grating 
spectral range of 667 nm. Next, the spectrometer was fit with a 50 μm diameter laser cut slit 
within the round SMA connector (Ocean Optics, INTSMA-KIT), yielding a pixel resolution of 
6.5 pixels. This resulted in an optical resolution of 2.1 nm, as calculated from Equation 2. 
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝑅𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 (𝑛𝑚) = [
𝑆𝑝𝑒𝑐𝑡𝑟𝑎𝑙 𝑅𝑎𝑛𝑔𝑒 (𝑛𝑚)
𝑃𝑖𝑥𝑒𝑙 𝐸𝑙𝑒𝑚𝑒𝑛𝑡𝑠 (𝑝𝑖𝑥𝑒𝑙𝑠)
] ∙ [𝑃𝑖𝑥𝑒𝑙 𝑅𝑒𝑠. (𝑝𝑖𝑥𝑒𝑙𝑠)] 
(2) 
6.8.7.3 Diffuse reflectance spectroscopy measurements 
All mice (n=62) underwent DRS measurements starting at day 0 (tumor = 75 mm3) prior 
to therapy or control. The hair on the skin at the tumor site was removed via shaving and NairTM, 
and then cleaned, 24 hours prior to the first DRS measurement. In this study, only the 3.00 mm 
SDS was used. The 3.00 mm SDS provided an optimal balance of signal-to-noise (> 15 dB), 
appropriate in vivo integration time (75 ms), and wavelength-dependent sampling depth (~1.3 to 
2.1 mm). 
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In the early response groups (Table 2, n=75), DRS measurements were taken daily on 
days 0-7, whereas in the survival groups (Table 2, n=50), DRS measurements were taken on days 
0-7, 10, 15, 20, and then in increments of 10 days thereafter until humane end-point euthanasia 
criteria. Additionally, a final DRS measurement was taken immediately prior to euthanasia in the 
survival groups.  
In all cases, the DRS probe was placed on the tumor site such that the linear arrangement 
of optical fibers were collinear with the long axis of the tumor (cranial to caudal direction). 
Tumor sites for DRS measurements were kept consistent throughout the study by marking the 
skin with histopathology ink off the collinear axis. Data was acquired using custom LabVIEW 
software. The user placed the probe on the tumor site of non-anesthetized mice while spectra 
were collected via a foot pedal control. For each tumor, at least 10 DRS measurements were 
acquired at an integration time of 75 ms. Day-to-day fluctuations in light source intensity were 
controlled for by calibration with a Spectralon® 20% diffuse reflectance standard. Daily 
spectrometer dark noise was subtracted from each spectra. 
Each DRS measurement resulted in a value for THC, StO2, HbO2, μs’(630 nm) and a chi-
square (Χ2) value. THC, StO2, HbO2, μs’(630 nm) were quantified by inputting raw DRS spectra 
into custom lookup-table (LUT)-based MATLAB software with a priori values for oxygenated 
and deoxygenated hemoglobin extinction coefficients (Prahl, 2015; Greening et al., 2016; 
Greening et al., 2015). The software performed an iterative model fit (1x104 iterations) to the 
raw DRS data to quantify THC, StO2, HbO2, μs’(630 nm). The Χ2 value indicated goodness-of-
fit between the model fit and raw DRS data; high Χ2 values usually implied specular reflection 
due to user movement. Therefore, if Χ2 of a spectra exceeded 10, data was discarded. THC, StO2, 
HbO2, and μs’(630 nm) values (≥10) were averaged to yield a daily result. At the conclusion of 
307 
 
study (either after day 7 or at humane end-point euthanasia criteria), histopathology ink was used 
to indicate probe location and orientation for spatial correlation with IHC.  
6.8.8 Diffuse reflectance spectroscopy and tumor volume statistics 
The primary data set consisted of five metrics: tumor size, StO2, THC, HbO2, and μs’ 
(630 nm), henceforth just referred to as μs’, which are presented as raw scores and as normalized 
scores. Comparing raw scores allows seeing the range of values that should be expected for each 
metric. Comparing normalized scores allows us to see how metrics increase or decrease from 
each tumor’s baseline measurement. The data set consisted of observations on 61 subjects 
divided between 5 treatments, as shown in Table 4. Each subject was assessed at Day 0 and 
subsequently for one, three, or seven successive days according to the third (approximately) of 
the sample to which the mouse had been assigned, respectively. On each of the days on which 
each subject was assessed, the assessments were expressed in 5 raw score metrics and in 5 
normalized metrics. This resulted in a data set consisting of 16 subjects who were assessed only 
on the first day after the baseline, 23 who were assessed on each of the three days following the 
baseline, and 22 who were assessed on each of the seven days following the baseline. Three sets 
of analyses were conducted on these data. Each will be described below along with statistical 
procedures used to conduct the analyses. 
6.8.8.1 Comparisons of days 1, 3, and 7 to Day 0 within treatment by metric 
These analyses compared subjects’ scores at Days 1, 3, and 7 to their scores at Day 0, 
within each of the 5 treatments. Since the scores at Day 0 and at each of the other 3 days 
referenced the identical subjects, a repeated measures ANOVA analysis was required. The 
normality of the residual error scores for the raw and normalized metrics was tested using the 
Shapiro-Wilk test. Due to the large sample size, the rule of thumb of .90 or higher for the 
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Shapiro-Wilk test statistic (W) was used as the indicator of adequate normality in the error 
distribution. The W for the error residuals exceeded .90 for both the raw and normalized scores in 
8 of the 10 cases, as shown in Table 5. The W statistic for the residual for the normalized HbO2 
score was within .006 of .90, which is close enough to .90 to avert any concern about any 
problematic effect of its slight departure from normality.  
Table 5. Breakdown of control and experimental groups 
Error Measure 
Shapiro-Wilk 
Statistic df p 
Residual for Tumor Size (Raw) .925 296 <.001 
Residual for StO2 (Raw) .992 296 .111 
Residual for THC (Raw) .992 296 .113 
Residual for HbO2 (Raw) .988 296 .017 
Residual for μs’ (Raw) .956 296 <.001 
Residual for Tumor Size (Normalized) .906 297 <.001 
Residual for StO2 (Normalized) .934 297 <.001 
Residual for THC (Normalized) .913 297 <.001 
Residual for HbO2 (Normalized) .894 297 <.001 
Residual for μs’ (Normalized) .794 297 <.001 
 
The Šídák post-hoc test was used to adjust for multiple comparisons. The Šídák post-hoc 
test is a conservative test (Kim, 2015) assumes independence of all measurements, meaning that 
measurements have no connection to other measurements chances of happening. The Šídák post-
hoc test protects against type 1 errors but is sensitive to type 2 errors (Lee et al., 2018). A type 1 
error is the rejection of the null hypothesis (false positive) whereas a type 2 error is the failure to 
reject a false null hypothesis (false negative) (Banerjee et al., 2009). In these experiments, it was 
imperative to protect against type 1 errors. Additionally, the Šídák post-hoc test was appropriate 
since we operated under the universal null hypothesis assumption that all tests would not be 
significant (Armstrong, 2014). The normalized μs’ scores manifested a much larger departure 
from normality, necessitating the use of the nonparametric Wilcoxon Signed Rank test to assess 
the differences between Day 0 and Days 1, 3, and 7 within each of the 5 treatments. 
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6.8.8.2 Comparisons of treatments for days 1, 3, and 7, within metrics 
These analyses compared subjects’ scores between the 5 treatments at Days 1, 3, and 7, 
within each of the 5 metrics. Since the scores on each treatment and on each of the 3 days 
referenced the identical subjects, a repeated measures analysis methodology was required. Since 
the necessary pairwise comparisons were derived from the same repeated measures ANOVA as 
was used for the first set of comparisons described above, the residual error scores were 
identical, as were the results of the Shapiro-Wilk tests for departures from normality. Again, the 
Šídák post-hoc test was used to adjust for multiple comparisons. Additionally, the normalized μs’ 
scores were the only ones that manifested a serious departure from normality, necessitating the 
use of the nonparametric Wilcoxon Signed Rank test, this time for comparing all pairs of 
treatments on the normalized metric 5 scores within Days 1, 3, and 7. 
6.8.8.3 Correlations between normalized metrics within treatments 
These analyses computed the Pearson product-moment correlations between each pair of 
normalized metric scores within each of the five treatments. Shapiro-Wilk tests for normality 
were conducted for scores on all five normalized metrics within each treatment. Correlations 
between any pair of metrics within a treatment where one or both of the metrics had Shapiro-
Wilk values below .88 were recomputed using the nonparametric Spearman’s rho correlation. 
6.8.9 Immunohistochemistry 
Mice from each of the five groups (Table 4) were further divided into three cohorts (up to 
n=5) based on end-point IHC analysis. Tumors were vivisected immediately prior to euthanasia 
via cervical dislocation on day 1, 3, or 7 for IHC analysis. Tumors were resected following the 
final DRS measurement. 
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Tumors were oriented within the cryomolds (VWR, #25608-916) such that the cutting 
face would be coplanar to the light path from the DRS measurements. The cryomold was filled 
with optimal cutting temperature (OCT, VWR, #25608-930) and flash frozen in isopentane 
(VWR, #AA19387-AP) chilled in liquid nitrogen at -75°C for 15 seconds. Tissue was then 
stored at -80°C until sectioning. Tumors were longitudinally sectioned on Superfrost® Plus 
microslides (VWR, #48311-703) in 5 μm sections using a cryostat (Leica, #CM1860) at -25°C, 
which were then stored permanently at -80°C. Tumor tissue was stained for hypoxia, TAM-
polarization, proliferation, apoptosis, and hematoxylin and eosin (H&E). 
6.8.9.1 Tumor-associated macrophages 
Next, tumor sections were stained to quantify TAM count and M1-M2 polarization 
(Barros et al., 2013). Tumors were stained for CD68 (pan-macrophage), CD80 (M1 TAM 
marker), and CD206 (M2 TAM marker) (Peng et al., 2017). Cells were considered M1-polarized 
TAMs if they expressed both CD68 and CD80 and M2-polarized TAMs if they expressed both 
CD68 and CD206. Cells expressing all markers were considered non-polarized TAMs and cells 
stained with only CD80 or CD206 were not considered TAMs (Barros et al., 2013). For each 
tumor, two 5 μm tissue sections were stained for TAM analysis. 
Upon removal from -80°C, slides were fixed in 0°C acetone (VWR, #BDH1101-4LP) for 
10 minutes. Slides were blocked with sterile, 4% goat serum, 0.5% bovine serum albumin (BSA) 
(Sigma-Aldrich, #A9647-10G), 0.1% NaN3, 0.05% Triton-X, and 0.05% Tween-20 in PBS for 2 
hours at room temperature. Tumor sections were then stained with a cocktail of anti-CD80 
Brilliant Violet 421 (BioLegend, #104725), anti-CD68 Alexa Fluor 488 (BioLegend, #137012), 
and anti-CD206 Alexa Fluor 594 (BioLegend, #141726) at dilutions of 1:20, 1:100, and 1:125, 
respectively, and stored in a PBS-humidified incubator for 90 minutes at room temperature. 
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Slides were washed 3x with PBS-t between major steps. Slides were mounted with Fluoromount-
G (VWR, #100241-847) and permanently stored at 4°C in the dark. 
Slides were imaged with a upright microscope (Nikon, Eclipse Ni-U), 20X/0.50NA 
objective lens (Nikon, CFI Plan Fluor 20X), monochrome digital camera (Nikon, DS-Qi1Mc), 
and PC-based camera control unit (Nikon, DS-U3). The anti-CD80, anti-CD68, and anti-CD206 
stains were imaged with DAPI (Chroma Technology, 49000), FITC (Chroma Technology, 
SP101), and Texas Red (Chroma Technology, 41004) filter sets, respectively, at an integration 
time of 100 ms and gain of 1x. For each tumor, two 5 μm thick tissue sections were stained. Five 
high-powered fields-of-view (0.21 x 0.15 mm) were taken for each of the two sections for a total 
of 10 TAM FOVs per tumor. Cells per FOV were counted based on a previously published 
protocol. All counts were made blinded to DRS data. Total immune cells were counted over the 
10 FOVs to calculate TAM count and polarization. A more in-depth look at tumor-associated 
macrophages, including the precise staining procedure, is as follows: 
6.9 Tumor-associated macrophages 
Tumor-associated macrophages (TAMs) are the most abundant immune cells in the tumor 
microenvironment (TME) in most cancers (Noy and Pollard, 2014), and also have the most 
substantial and pervasive effect of any immune cell in the TME (Allavena et al., 2008; Erreni et 
al., 2011; Chen et al., 2005; Marech et al., 2016). TAMs have been shown to have both anti-
tumor and pro-tumor functions, depending on whether they are polarized more towards an M1 
(classical) or M2 (alternative) phenotype (Chen et al., 2005), respectively, and their physical 
location within a tumor (Marech et al., 2016). In reality, M1 and M2 TAMs are the extremes of a 
continuum of intermediate cells which may have both anti-tumor and pro-tumor functions. Broad 
anti-tumor functions of classically activated M1-polarized TAMs include inflammation and 
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immune response (Sugita et al., 2002; Funada et al., 2003; Zhou et al., 2010). On the other hand, 
pro-tumor functions of alternatively activated M2-polarized TAMs include tumor growth, 
angiogenesis, immunosuppression, and matrix remodeling (Liu and Cao, 2015). In most cancers, 
TAMs are skewed more towards the pro-tumor M2-phenotype (Yang and Zhang, 2017); 
therefore, TAMs have gained clinical momentum as immunotherapy targets for cancer. Currently, 
there are over 30 clinical trials targeting TAMs; strategies include reducing monocyte 
recruitment to the tumor and reprogramming M2-TAMs to M1-TAMs. Yang and Zhang provide a 
comprehensive review of TAM immunotherapy strategies (Yang and Zhang, 2017). Still many 
other groups are actively investigating TAMs in the basic science and pre-clinical realms 
(Cassetta et al., 2016; He et al., 2017; Jarosz-Biej et al., 2018; Suarez-Lopez et al., 2018). 
However, TAMs in some cancers, like colorectal cancer (CRC), simultaneously have both 
detrimental and beneficial effects on the patient (Zhong et al., 2018).  
The dual-role of TAMs in CRC has yet to be fully understood. It has recently been shown 
that macrophages induce resistance to fluorouracil-based chemotherapy, and that this TAM-
induced resistance may contribute to the poor chemotherapy response in some CRC patients 
(Zhang et al., 2008; Zhang et al., 2016). Currently, a gap in colon cancer research is how therapy 
affects TAMs in the colorectal TME, and, in turn, how altering TAM population and polarization 
affects tumor therapeutic response. Therefore, this immunohistochemistry staining protocol was 
developed to stain for TAMs in murine subcutaneous colon tumor allografts, although this 
protocol can be used for other murine tissue. In this article, Balb/c mice were subcutaneously 
injected in the left flank with CT26 murine colon carcinoma cells. Tumors grew until they 
reached 75 mm3. Following three days of additional tumor growth, untreated tumors were 
dissected, flash-frozen in isopentane and liquid nitrogen, and stored at -80 °C until 
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cryosectioning, and then sectioned at a thickness of 5 μm. The scope of this article is on 
macrophage immunohistochemistry of murine tumors, not on the tumor model itself. Therefore, 
this protocol can be readily modified to stain any murine tissue in allograft, xenograft, or 
orthotopic tumor models.  
This direct immunohistochemistry staining method uses three primary-conjugated 
macrophage antibodies: anti-CD68, anti-CD80, and anti-CD206. CD68 is a pan-macrophage 
surface marker (Gordon et al., 2014), CD80 is a cell surface marker for M1-type macrophages 
(Zhou et al., 2017), and CD206 is a cell surface marker for M2-type macrophages (Kigerl et al., 
2009). CD68, CD80, and CD206 are markers for other cell types as well but were chosen such 
that (CD68+/CD80+)-cells were considered M1-TAMs, (CD68+/CD206+)-cells were considered 
M2-TAMs, and (CD80+/CD206+)-cells were considered dendritic cells (DCs). Cells expressing 
all macrophage surface markers were considered to have a mixed M1-M2 phenotype (Figure 4). 
With this simple and reproducible method, we are able to accurately stain for M1 and M2 
macrophages. To ensure long-term relevancy and usability of this protocol, this work also 
provides an easy-to-follow mathematical analysis of antibody concentrations so that readers can 
easily modify and optimize this protocol for their specific test system. This work is relevant for 
investigators developing and/or testing TAM-targeting cancer immunotherapies in mice.   
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Figure 4. A double stain technique was used to distinguish M1- and M2- 
polarized macrophages. CD68+/CD80+ cells were considered M1 TAMs and 
CD68+/CD206+ cells were considered M2 TAMs. Additionally, 
CD68+/CD80+/CD206+ TAMs were considered to have a mixed phenotype. 
 
6.10.1 Materials and reagents 
A. Consumables 
1. Paper towel 
2. Aluminum foil 
3. Coverslip 
4. 10 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89140-160) 
5. 100 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89140-162) 
6. 1,000 μl sterile universal Fit S3 polymer pipette tips (VWR, catalog number: 89217-468) 
7. SuperSpinTM microcentrifuge tubes (VWR, catalog number: 20170-038) 
8. EasyDipTM slide staining rack (VWR, catalog number: CA87000-132) 
9. Superfrost® plus micro slide (VWR, catalog number: 48311-703) 
10. VistaVisionTM cover glasses, No. 1, 22 x 50 mm (VWR, catalog number: 16004-314) 
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B. Animal 
1. Balb/c mice (aged 10 weeks) 
C. Antibodies 
1. Brilliant Violet 421TM anti-mouse CD80 [stock solution concentration: 100 μg/ml, 
staining concentration: 5 μg/ml (1:20), storage temperature: 2-8 °C undiluted, shelf-life: 
~3 years (lot-specific)] (BioLegend, catalog number: 104725) 
2. Alexa Fluor® 488 anti-mouse CD68 [stock solution concentration: 500 μg/ml, staining 
concentration: 5 μg/ml (1:100), used at 5 μg/ml, storage temperature: 2-8 °C undiluted, 
shelf-life: ~3 years (lot-specific)]) (BioLegend, catalog number: 137012) 
3. Alexa Fluor® 594 anti-mouse CD206 [stock solution concentration: 500 μg/ml, staining 
concentration: 4 μg/ml (1:125), storage temperature: 2-8 °C undiluted, shelf-life: ~3 years 
(lot-specific)] (BioLegend, catalog number: 141726) 
D. Reagents 
1. Acetone (storage temperature: -20 °C, shelf-life: 4 years) (VWR, catalog number: 
BDH1101-4LP) 
2. Phosphate-buffered saline (PBS), 1x without Calcium and Magnesium (storage 
temperature: 2-8 °C, shelf-life: 3 years) (VWR, catalog number: 45000-446)  
3. TritonTM X-100 (storage temperature: room temperature, shelf-life: 2 years) (Sigma 
Aldrich, catalog number: X100-100ML) 
4. Tween® 20 (storage temperature: room temperature, shelf-life: 3 years) (Sigma-Aldrich, 
catalog number: P9416-100mL) 
5. Goat serum (storage temperature: -20 °C, shelf-life: 2 years) (Sigma-Aldrich, catalog 
number: G9023-10ML) 
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6. Sodium azide (NaN3) (storage temperature: room temperature) (Sigma-Aldrich, catalog 
number: S2002-25G)  
Note: This compound is toxic (GHS06), a health hazard (GHS08), and an environmental 
hazard (GHS09). It should be handled with protective clothing in a certified fume hood 
and disposed of at an approved waste disposal site per institutional regulations 
7. Bovine serum albumin (BSA) (storage temperature: 2-8 °C, shelf-life: 1 year) (Sigma-
Aldrich, catalog number: A8806-5G) 
8. Universal antibody dilution buffer (storage temperature: room temperature, shelf-life: 2 
years) (Sigma-Aldrich, catalog number: U3510-100ML) 
9. Isopentane (storage temperature: room temperature, shelf-life: 2 years) (VWR, catalog 
number: AA19387-AP) 
10. Liquid nitrogen (Airgas, catalog number: NI NF180LT22) 
11. Quick-dry nail polish 
12. Fluoromount-G® slide mounting medium (storage temperature: room temperature, shelf-
life: 15 months) (VWR, catalog number: 100241-874) 
13. Macrophage antibody cocktail (see Recipes) 
14. Blocking solution (see Recipes) 
15. PBS-T washing solution (see Recipes) 
6.9.2 Equipment 
1. Tweezer 
2. 0.5-10 μl ergonomic high performance single-channel mechanical pipettor (VWR, 
catalog number: 89079-962) 
3. 10-100 μl ergonomic high performance single-channel mechanical pipettor (VWR, 
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catalog number: 89079-968) 
4. 100-1,000 μl ergonomic high performance single-channel mechanical pipettor (VWR, 
catalog number 89079-974) 
5. Linear pipettor stand (VWR, catalog number: 40000-272) 
6. 80-Place storage system (VWR, catalog number: 30128-282) 
7. EasyDipTM slide staining jars, white (VWR, catalog number: CA87000-126) 
8. Low temperature organic liquid filled thermometer (VWR, catalog number: 89062-908) 
9. SlideTrayTM 20 slide humidity chamber with black lid (VWR, catalog number: 102097-
504) 
10. Laboratory bench and table protector with leakproof and moisture barrier (VWR, catalog 
number: 89126-790) 
11. -20 °C and -80 °C freezers 
12. Water bath (VWR, catalog number: 89501-464) 
13. Upright microscope (Nikon, model: Eclipse Ni-U) 
14. Monochrome digital camera (Nikon, model: DS-Qi1Mc) 
15. PC-based camera control unit (Nikon, model: DS-U3) 
16. SOLA Light Engine® fluorescent lamp (Lumencor, catalog number: SOLA SM 6-LCR-
SB) 
17. DAPI filter set (Chroma Technology, catalog number: 49000) 
18. FITC filter set (Chroma Technology, catalog number: SP101) 
19. Texas red filter set (Chroma Technology, catalog number: 41004) 
20. Objective lens, 20x/0.50NA (Nikon, catalog number: CFI Plan Fluor 20X) 
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6.9.3 Software 
1. NIS-Elements F Ver4.60.00 for 64bit edition (Nikon, 
https://www.nikoninstruments.com/Products/Software) 
2. ImageJ bundled with 64-bit Java 1.8.0_112 (National Institutes of Health and the 
Laboratory for Optical Computational Instrumentation, 
https://imagej.nih.gov/ij/download.html)  
6.9.4 Procedure 
The scope of this section is on macrophage immunohistochemistry of murine tumors, not 
on the tumor model itself; however, the tumor model is briefly described here. Five Balb/c mice 
(aged 10 weeks) were subcutaneously injected with 1 x 105 CT26 cells (passage 3) in sterile 
saline into the left flank until the tumors reached a volume of 75 mm3 (Greening et al., 2018a 
and 2018b). Three days after reaching this volume, the five untreated mice were euthanized, and 
the tumor was dissected for TAM analysis (Figure 5). This staining and imaging procedure 
works best with flash frozen tumors. Therefore, upon dissection, tumors were placed in a 
cryomold and covered completely in optimal cutting temperature (OCT). The cryomold with 
OCT and tumor was flash frozen in isopentane chilled in liquid nitrogen at -75 °C to -77 °C for 
at least 15 s and stored permanently in -80 °C until sectioning. The tumor was sectioned at 5 μm, 
although sections up to 10 μm are acceptable. Once sectioned, slides were stored for up to one 
month at -80 °C before staining. All antibody solutions and stained slides were handled in 
darkness. 
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Figure 5. Murine colon tumor allografts were (a) dissected and flash frozen. 
Tumors were (b) sectioned at 5 μm thickness (H&E shown for clarity, yellow box 
not to scale). Tumor sections were (c) stained for TAMs and imaged with a 20x 
objective at 10 regions of interest (ROI) along the section. Scale bar = 30 µm. 
Images enhanced for publication.   
 
A. Preparing slides for staining (20 min) 
Note: Keep at least 90 ml of acetone stored at -20 °C for at least 1 h prior to start of 
procedure. 
1. Remove 5 μm-thick slides from -80 °C. 
2. Place all slides in -20 °C. 
3. Keep the acetone for 20 min at -20 °C. 
4. Prepare macrophage antibody cocktail (see Recipes). 
5. Set out four EasyDipTM slide staining jars.  
6. Fill 3 staining jars with 90 ml of room temperature sterile PBS-T (see Recipes). 
7. Remove blocking solution aliquots (see Recipes) from 4 °C and set in 80-Place Storage 
System at room temperature. 
8. 20 min after Step A3, remove acetone from -20 °C. 
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9. Fill final staining jar with 90 ml of -20 °C acetone. 
10. Place low-temperature thermometer in 1st staining jar with acetone. 
B. Fixation with acetone (10 min) 
1. When the acetone reaches -3 °C, remove slides from -20 °C. 
2. Place slides (up to 12) in the EasyDipTM slide staining rack. 
3. Place the staining rack (with slides) in cold acetone for 10 min. 
4. Remove from acetone and air dry for 5 s. 
C. Wash with PBS-T (#1) (5 min) 
1. Place the staining rack in PBS-T (2nd staining jar) for 2 min. 
2. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips). 
3. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total 
swirls). 
4. Keep staining rack in PBS-T unmoving for an additional 1 min. 
D. Adding blocking solution (2 h) 
1. Remove staining rack from PBS-T (2nd staining jar). 
2. Remove 3 slides from the staining rack. 
3. Keep the other slides (if there are more than 3) in the staining rack and place back in 
PBS-T. 
4. Using a paper towel, dry the area around the tissue sections without touching the tissue 
sections. Note: A hydrophobic barrier PAP pen may be used to keep reagents localized 
on the tissue specimen but is not required. 
5. Add 50-100 μl (depending on size of tissue section) blocking solution to each tissue 
section. 
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6. Place slides (with blocking solution) in a dark humidified chamber at room temperature. 
7. Repeat Steps D1-D6 for additional slides. 
8. Incubate in the dark humidified chamber at room temperature for 60 min. 
9. Reapply 50-100 μl blocking solution to each tissue section. 
10. Incubate in the dark humidified chamber at room temperature for 60 min. 
E. Adding macrophage antibody cocktail (2 h) 
Note: The following steps must be performed in a dark room. 
1. Remove macrophage antibody cocktail from 4 °C and remove aluminum foil. 
2. Remove 1 slide from the dark humidified chamber. 
3. Using a paper towel, dry the area around the tissue sections without touching the tissue 
sections. 
4. Add 100 μl of macrophage antibody cocktail to each tissue section. 
5. Place slide with macrophage antibody cocktail in a dark humidified chamber. 
6. Repeat Steps E2-E5 for additional slides. 
7. Incubate in the dark humidified chamber at room temperature for 2 h. 
F. Wash with PBS-T (#2) (5 min) 
Note: The following steps must be performed in a dark room. 
1. Remove the dark humidified chamber from 4 °C. 
2. Place all slides back in staining rack. 
3. Place the staining rack in PBS-T (3rd staining jar) for 2 min. 
4. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips). 
5. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total 
swirls). 
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6. Keep staining rack in PBS-T unmoving for an additional 1 min. 
G. Wash with PBS-T (#3) (5 min) 
Note: The following steps must be performed in a dark room. 
1. Place the staining rack in PBS-T (4th staining jar) for 2 min. 
2. Dip the staining rack in PBS-T for 1 min such that each “dip” is 3 s (20 total dips). 
3. Swirl staining rack inside slide staining jar for 1 min such that each “swirl” is 1 s (60 total 
swirls). 
4. Keep staining rack in PBS-T unmoving for an additional 1 min. 
H. Mounting slides 
Note: The following steps must be performed in a dark room. 
1. Remove staining rack from PBS-T (4th staining jar). 
2. Set all slides face-up on paper towel. 
3. Using a paper towel, dry the area around the tissue sections without touching the tissue 
sections. 
4. Add 1-2 drops of Fluoromount-G® Slide Mounting Medium to each tissue section. 
5. Gently place 22 x 50 mm coverslip on each slide. 
6. Using tweezers, gently press out air bubbles.  
7. Wipe off any excess mounting medium.  
8. Let slides sit for 5 min. 
9. Apply quick-dry nail polish along the edges of the coverslip. Ensure edges are completely 
covered to prevent drying out of slides. 
10. Leave slides to dry for 1 h. 
11. Store slides permanently in the dark at 4 °C. 
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6.9.5 Data analysis 
A. Imaging 
1. Remove slides from 4 °C, but keep in the dark. 
2. Place slide under a microscope. 
3. Turn on fluorescent lamp, microscope, and camera. 
4. Open imaging software. 
5. Change the fast focus to 1,280 x 1,024 no binning. 
6. Change the quality capture to 1,280 x 1,024 no binning. 
7. Set the exposure to 100 ms. 
8. Set the gain to 1x. 
9. Switch to the 20x objective. 
10. Use the DAPI filter and bring the CD80+ cells into focus. 
11. Image the CD80-stained cells.  
Note: In the 5 μm thick slide, some cells may be in-focus while others are out-of-focus. 
Starting 1 μm beneath the tissue surface, adjust the z-axis travel 1 μm between each step 
and take at least 4 images of the same location in the x-y plane (Figure 6). 
12. Without moving tissue location, switch to the FITC filter and bring the CD68+ cells into 
focus. 
13. Image the CD68-stained cells.  
Note: See the note under step A11 (Image the CD80-stained cells). 
14. Without moving tissue location, use the Texas Red filter and bring the CD206+ cells into 
focus. 
15. Image the CD206-stained cells.  
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Note: See the note under step A11 (Image the CD80-stained cells). 
16. Switch to a new tissue location and repeat Steps A10-15. 
17. Acquire images from the desired amount of tissue locations.  
Note: In this study, 10 regions-of-interests (ROI) per tumor were imaged (image area = 
31,100 μm2). 
 
Figure 6. Multiple images in varying z-axis depths of the same x-y location may 
be needed for accurate TAM counting. Notice the red-circled cell starts in-focus 
at (A) and is out-of-focus at (D). Alternatively, notice the yellow-circled cells 
start off out-of-focus at (A) and are in-focus at (D). Each image (A-D) represents 
a 1 μm step along the z axis. Scale bars = 40 µm. 20x/0.50NA objective used for 
each image. Images enhanced for publication.  
 
Note: This part of the protocol may be modified depending on tissue section thickness 
and desired accuracy when quantifying image-based cell counts. 
B. TAM counting and polarization 
1. Count CD68+ cells in each ROI. 
2. Count CD80+ cells in each ROI. 
3. Count CD206+ cells in each ROI. 
4. Determine the number of CD68+/CD80+ cells in each ROI. These are M1-polarized 
TAMs. 
5. Determine the number of CD68+/CD206+ cells in each ROI. These are M2-polarized 
TAMs. 
6. Determine the number of CD68+/CD80+/CD206+ cells in each ROI. These are TAMs 
with a mixed M1/M2 phenotype (Figure 7). 
325 
 
 
Figure 7. Image of several TAMs imaged with DAPI (for CD80+), FITC (for 
CD68+), and Texas Red (for CD206+) filter sets. The composite image (ImageJ) 
shows a TAM with an M2 phenotype and a TAM with a mixed M1-M2 
phenotype. Scale bars = 30 µm. 20x/0.50NA objective used for each image. 
 
7. If desired, determine the number of CD80+/CD206+ cells in each ROI. There are dendritic 
cells. 
8. Calculate the average number of M1 TAMs (included TAMs with mixed phenotype) per 
image area. 
𝑇𝐴𝑀𝑀1 = (𝐶𝐷68
+/𝐶𝐷80+ 𝑐𝑒𝑙𝑙𝑠) + (𝐶𝐷68+/𝐶𝐷80+/𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠) 
9. Calculate the average number of M2 TAMs (including TAMs with mixed phenotype) per 
image area. 
𝑇𝐴𝑀𝑀2 = (𝐶𝐷68
+/𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠) + (𝐶𝐷68+/𝐶𝐷80+/𝐶𝐷206+ 𝑐𝑒𝑙𝑙𝑠) 
10. Calculate average M1/M2 ratio per mouse (Figure 8). 
𝑇𝐴𝑀𝑟𝑎𝑡𝑖𝑜 = (
𝑇𝐴𝑀𝑀1
𝑇𝐴𝑀𝑀2
) 
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Figure 8. TAMs in subcutaneous murine colon tumor allografts. In untreated 
Balb/c-CT26 tumors, 3 days after the tumor reaches a volume of 75 mm3, there is 
a significant difference (P < 0.01) between the number of M1 (58.8 ± 18.7 
cells/mm2) and M2 TAMs (127.5 ± 34.2 cells/mm2) in the tumor, resulting in an 
M1/M2 ratio of 46.1%.  
 
6.9.6 Notes on procedure 
This protocol can be modified to include nuclear staining. Figure 9 shows a Balb/c-CT26 
subcutaneous colon tumor allograft tissue section stained with DAPI and CD206 only.  
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Figure 9. This staining procedure can be modified to include nuclear stains. Here, 
an untreated Balb/c-CT26 subcutaneous colon tumor allograft tissue section was 
co-stained with DAPI and Alexa Fluor® 594 anti-mouse CD206. Scale bars = 100 
μm. 20x/0.50NA objective used for each image. 
 
A limitation of this staining protocol is the absence of a reliable stain for DCs. In addition 
to being a commonly used pan-macrophage marker (Gordon et al., 2014), CD68 can also stain 
for DCs at low levels in some tissues such as the lung (Yu et al., 2016, Figure 1). To control for 
the possibility of DCs, this protocol may be modified to include a panel of DC-specific markers 
for murine non-lymphoid tissues on adjacent tissue sections (Yu et al., 2016).   
The following calculations aid in reproducibility of results and modification of the 
protocol for specific test systems. Stock antibody concentrations and amount of antibodies per 
vial are accurate up to the publication of this article and are subject to change based on 
manufacturer lot specifications. The desired dilution from stock were experimentally-determined 
in lab for the Balb/c-CT26 murine subcutaneous allograft model and may be different per 
specific test system. The volume of macrophage antibody cocktail represents the total volume of 
diluted antibody mix placed on the tissue section via micropipette before incubation at room 
temperature for 2 h. The average area of our tissue sections was ~50 mm2. Thus, we recommend 
a macrophage antibody cocktail volume per tissue section area of ~2 μl/mm2 (100 μl total per 
328 
 
section).  
The following calculations determine the volume of concentrated stock antibody to add to 
the macrophage antibody cocktail, and how many trials can be performed with these settings.  
1. Brilliant Violet 421TM anti-mouse CD80 
Table 6. Constants for Brilliant Violet 421TM anti-mouse CD80 stain 
Stock Antibody Concentration* 100 μg/ml 
Desired Dilution from Stock* 1:20 
Amount of Antibodies per Vial* 100 μg 
Volume of Macrophage Antibody Cocktail per Tissue Section** 100 μl 
* Values subject to change based on manufacturer specifications and recommendations 
** Value depends on size of tissue section 
Table 7. Calculations for Brilliant Violet 421TM anti-mouse CD80 stain 
Desired Volume of Stock per Trial [
100 𝜇𝑙
1
] ∙ [
1
20
] = 5 𝜇𝑙 
Desired Antibody Amount per Trial [
100 𝜇𝑙
1
] ∙ [
1
20
] ∙ [
100 𝜇𝑔
𝑚𝑙
] ∙ [
1 𝑚𝑙
1000 𝜇𝑙
] = 0.5 𝜇𝑔 
Desired Antibody Concentration in 
Macrophage Antibody Cocktail 
[
1
20
] ∙ [
100 𝜇𝑔
1 𝑚𝑙
] = 5 𝜇𝑔/𝑚𝑙 
Trials per Vial of Antibodies [
100 𝜇𝑔 
1
] ∙ [
1
0.5 𝜇𝑔
] = 200 
 
2. Alexa Fluor® 488 anti-mouse CD68 
Table 8. Constants for Alexa Fluor® 488 anti-mouse CD68 stain 
Stock Antibody Concentration* 500 μg/ml 
Desired Dilution from Stock* 1:100 
Amount of Antibodies per Vial* 100 μg 
Volume of Macrophage Antibody Cocktail per Tissue Section** 100 μl 
* Values subject to change based on manufacturer specifications and recommendations 
** Value depends on size of tissue section 
Table 9. Calculations for Alexa Fluor® 488 anti-mouse CD68 stain 
Desired Volume of Stock per Trial [
100 𝜇𝑙
1
] ∙ [
1
100
] = 1 𝜇𝑙 
Desired Antibody Amount per Trial [
100 𝜇𝑙
1
] ∙ [
1
100
] ∙ [
500 𝜇𝑔
𝑚𝑙
] ∙ [
1 𝑚𝑙
1000 𝜇𝑙
] = 0.5 𝜇𝑔 
Desired Antibody Concentration in Macrophage 
Antibody Cocktail 
[
1
100
] ∙ [
500 𝜇𝑔
1 𝑚𝑙
] = 5 𝜇𝑔/𝑚𝑙 
Trials per Vial of Antibodies [
100 𝜇𝑔 
1
] ∙ [
1
0.5 𝜇𝑔
] = 200 
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3. Alexa Fluor® 594 anti-mouse CD206  
Table 10. Constants for Alexa Fluor® 594 anti-mouse CD206 stain 
Stock Antibody Concentration* 500 μg/ml 
Desired Dilution from Stock* 1:125 
Amount of Antibodies per Vial* 100 μg 
Volume of Macrophage Antibody Cocktail per Tissue Section** 100 μl 
* Values subject to change based on manufacturer specifications and recommendations 
** Value depends on size of tissue section 
Table 11. Calculations for Alexa Fluor® 594 anti-mouse CD206 stain 
Desired Volume of Stock per Trial [
100 𝜇𝑙
1
] ∙ [
1
125
] = 0.8 𝜇𝑙 
Desired Antibody Amount per Trial [
100 𝜇𝑙
1
] ∙ [
1
125
] ∙ [
500 𝜇𝑔
𝑚𝑙
] ∙ [
1 𝑚𝑙
1000 𝜇𝑙
] = 0.4 𝜇𝑔 
Desired Antibody Concentration in 
Macrophage Antibody Cocktail 
[
1
125
] ∙ [
500 𝜇𝑔
1 𝑚𝑙
] = 4 𝜇𝑔/𝑚𝑙 
Trials per Vial of Antibodies [
100 𝜇𝑔 
1
] ∙ [
1
0.4 𝜇𝑔
] = 250 
 
6.9.7 Recipes 
1. Macrophage antibody cocktail 
Note: The following steps must be prepared in the dark. 
a. Determine the number of tissue sections to be stained 
b. Add 100 μl of universal antibody dilution buffer, per number of tissue sections, to 
microcentrifuge tube 
Note: This volume of 100 μl/section can be changed based on the size of the specific 
tissue section. More than one microcentrifuge tube may be used if staining multiple 
tissue sections requiring > 1 ml. 
c. Add Brilliant Violet 421TM anti-mouse CD80 to universal antibody dilution buffer at 
5 μg/ml (i.e., 1:20 dilution from 100 μg/ml stock) 
d. Add Alexa Fluor® 488 anti-mouse CD68 to universal antibody dilution buffer at 5 
μg/ml (i.e., 1:100 dilution from 500 μg/ml stock) 
e. Add Alexa Fluor® 594 anti-mouse CD206 to universal antibody dilution buffer at 4 
μg/ml (i.e., 1:125 dilution from 500 μg/ml stock) 
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f. Gently and sufficiently pipette up and down to mix the macrophage antibody cocktail 
g. Wrap microcentrifuge tubes with macrophage antibody cocktail with aluminum foil 
and store at 4 °C until ready for use 
2. Blocking solution 
a. Bring sterile PBS to 37 °C in a water bath 
b. Bring goat serum to room temperature 
Note: The following steps must be prepared in a certified biological safety cabinet. 
c. Add 4% (v/v) of goat serum to PBS 
d. Add 0.5% (w/v) BSA to PBS 
e. Add 0.1% (w/v) NaN3 to PBS 
f. Perform sterile vacuum filtration of the blocking solution 
g. Add 0.1% (v/v) TritonTM X-100 to PBS 
h. Add 0.05% (v/v) Tween® 20 to PBS 
i. Shake solution vigorously until TritonTM X-100 and Tween® 20 have dispersed 
Note: If needed, solution can be placed in a 37 °C water bath for 5-10 min to aid 
dispersion. 
j. Aliquot blocking solution into sterile microcentrifuge tubes 
k. Store blocking solution at 4 °C (can be stored for up to 2 months) 
3. PBS-T washing solution 
a. Bring sterile PBS to 37 °C in a water bath 
Note: The following steps must be prepared in a certified biological safety cabinet. 
b. Add 0.2% (v/v) of Tween® 20 to PBS (1 ml) 
c. Shake solution vigorously until TritonTM X-100 and Tween® 20 have dispersed  
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Note: If needed, solution can be placed in a 37 °C water bath to aid dispersion. 
d. Store PBS-T washing solution at room temperature 
6.10 Results 
6.11.1  Repeated measures analysis of studied metrics 
Figure 10 shows representative images of Balb/c-CT26 tumor size over the 7-day time 
course as a function of treatment regimen. After the final DRS measurement, tumors were 
dissected, and mice were euthanized.  
 
Figure 10. Tumor size of Balb/c-CT26 colon tumor allografts over time in 
response to controls and therapies 
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Figure 11. Raw (non-normalized) tumor size per day per treatment group. For 
statistical analysis, see Table 12 
 
 
 
Figure 12. Raw (non-normalized) StO2 per day per treatment group. For 
statistical analysis, see Table 12 
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Figure 13. Raw (non-normalized) THC per day per treatment group. For 
statistical analysis, see Table 12 
 
 
 
Figure 14. Raw (non-normalized) HbO2 per day per treatment group. For 
statistical analysis, see Table 12 
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Figure 15. Raw (non-normalized) μs’ per day per treatment group. For statistical 
analysis, see Table 12 
 
Table 12. Comparisons to day 0 within treatment, within metric, raw values  
Treatment 
Raw 
Metric 
Pairwise 
Comparisons 
Mean 
Difference 
(I-J) 
Std. Error Sig.d 
95% Confidence Interval 
for Differenced 
(I) Day (J) Day 
Lower 
Bound 
Upper 
Bound 
Control: 
Saline 
Tumor size 0 
1 -27.465 17.707 .974 -83.285 28.356 
3 -108.425a,* 19.797 <.001 -170.834 -46.016 
7 -607.873a,* 25.041 <.001 -686.815 -528.931 
StO2 0 
1 .008 .031 1.000 -.089 .105 
3 -.005a .034 1.000 -.113 .103 
7 .035a .043 1.000 -.102 .172 
THC 0 
1 .020 .106 1.000 -.316 .355 
3 -.225a .119 .822 -.600 .150 
7 .009a .150 1.000 -.465 .483 
HbO2 0 
1 .017 .087 1.000 -.257 .291 
3 -.086a .097 1.000 -.392 .221 
7 .097a .123 1.000 -.290 .485 
μs’ 0 
1 .048 .118 1.000 -.325 .420 
3 .409a .132 .059 -.007 .826 
7 .286a .167 .924 -.240 .813 
Control: 
Isotype 
Tumor size 0 
1 -38.337a,c 19.020 .724 -98.298 21.624 
3 -147.328a,*,c 21.790 <.001 -216.022 -78.634 
7 -611.757a,*,c 36.832 <.001 -727.871 -495.643 
StO2 0 1 .042a,c .033 .998 -.062 .146 
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Table 12. Comparisons to day 0 within treatment, within metric, raw values (cont.) 
Treatment 
Raw 
Metric 
Pairwise 
Comparisons 
Mean 
Difference 
(I-J) 
Std. Error Sig.d 
95% Confidence Interval 
for Differenced 
(I) Day (J) Day 
Lower 
Bound 
Upper 
Bound 
Control: 
Isotype 
StO2 0 
3 .031a,c .038 1.000 -.088 .150 
7 -.041a,c .064 1.000 -.242 .160 
THC 0 
1 .128a,c .114 1.000 -.232 .488 
3 -.143a,c .131 1.000 -.555 .270 
7 -.053a,c .221 1.000 -.750 .644 
HbO2 0 
1 .145a,c .093 .974 -.150 .439 
3 .045a,c .107 1.000 -.292 .383 
7 -.064a,c .181 1.000 -.634 .506 
μs’ 0 
1 .126a,c .127 1.000 -.275 .526 
3 .066a,c .145 1.000 -.392 .525 
7 .663a,c .246 .191 -.112 1.437 
Immuno-
Therapy 
Tumor size 0 
1 -34.807a,c 21.686 .962 -103.173 33.559 
3 -84.687a,*,c 21.686 .003 -153.053 -16.321 
7 -463.176a,*,c 26.560 .000 -546.907 -379.445 
StO2 0 
1 .010a,c .038 1.000 -.108 .128 
3 .050a,c .038 .996 -.068 .169 
7 -.011a,c .046 1.000 -.156 .134 
THC 0 
1 .092a,c .130 1.000 -.319 .502 
3 .141a,c .130 1.000 -.270 .552 
7 -.521a,*,c .160 .035 -1.024 -.018 
HbO2 0 
1 .043a,c .107 1.000 -.293 .379 
3 .146a,c .107 .995 -.190 .482 
7 -.174a,c .130 .997 -.585 .237 
μs’ 0 
1 .193a,c .145 .997 -.263 .650 
3 .339a,c .145 .434 -.118 .795 
7 .604a,*,c .177 .021 .045 1.163 
Chemo-
Therapy 
Tumor size 0 
1 -20.716 22.280 1.000 -90.955 49.524 
3 -107.261a,* 22.644 <.001 -178.646 -35.876 
7 -186.511a,* 26.805 <.001 -271.013 -102.008 
StO2 0 
1 -.020 .039 1.000 -.141 .102 
3 .040a .039 1.000 -.084 .164 
7 -.031a .046 1.000 -.177 .115 
THC 0 
1 -.255 .134 .813 -.677 .167 
3 -.192a .136 .992 -.621 .237 
7 -.005a .161 1.000 -.512 .503 
HbO2 0 
1 -.088 .109 1.000 -.433 .257 
3 .059a .111 1.000 -.291 .410 
7 -.060a .132 1.000 -.476 .355 
μs’ 0 1 .183 .149 .999 -.285 .652 
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Table 12. Comparisons to day 0 within treatment, within metric, raw values (cont.) 
Treatment 
Raw 
Metric 
Pairwise 
Comparisons 
Mean 
Difference 
(I-J) 
Std. Error Sig.d 
95% Confidence Interval 
for Differenced 
(I) Day (J) Day 
Lower 
Bound 
Upper 
Bound 
Chemo-
Therapy 
μs’ 0 
3 .014a .151 1.000 -.463 .490 
7 -.049a .179 1.000 -.613 .515 
Combo-
Therapy 
Tumor size 0 
1 -14.134 19.797 1.000 -76.544 48.275 
3 -53.994a 23.214 .446 -127.175 19.188 
7 -99.300a,* 27.997 .013 -187.561 -11.040 
StO2 0 
1 -.032 .034 1.000 -.140 .076 
3 -.030a .040 1.000 -.156 .097 
7 -.026a .049 1.000 -.178 .127 
THC 0 
1 .130 .119 1.000 -.244 .505 
3 -.081a .139 1.000 -.520 .359 
7 -.256a .168 .979 -.786 .274 
HbO2 0 
1 -.050 .097 1.000 -.356 .257 
3 -.094a .114 1.000 -.454 .265 
7 -.121a .138 1.000 -.554 .313 
μs’ 0 
1 -.122 .132 1.000 -.538 .295 
3 .096a .155 1.000 -.392 .584 
7 .484a .187 .248 -.105 1.073 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. An estimate of the modified population marginal mean (J). 
c. An estimate of the modified population marginal mean (I). 
d. Adjustment for multiple comparisons: Sidak. 
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Figure 16. Normalized tumor size per day per treatment group. For statistical 
analysis, see Table 13 
 
 
Figure 17. Normalized StO2 per day per treatment group. For statistical analysis, 
see Table 13 
 
 
 
Figure 18. Normalized StO2 per day per treatment group. For statistical analysis, 
see Table 13 
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Figure 19. Normalized HbO2 per day per treatment group. For statistical analysis, 
see Table 13 
 
 
Figure 20. Normalized μs’ per day per treatment group. For statistical analysis, 
see Table 13 
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Table 13. Comparisons to day 0 within treatment, within metric, normalized values  
Treatment 
Normalized 
Metric 
Pairwise 
Comparisons 
Mean 
Difference 
(I-J) 
Std. Error Sig.d 
95% Confidence Interval 
for Differenced 
(I) Day (J) Day 
Lower 
Bound 
Upper 
Bound 
Control: 
Saline 
Tumor size 0 
1 -.375 .234 .962 -1.112 .363 
3 -1.448a,* .262 <.001 -2.272 -.623 
7 -8.020a,* .331 <.001 -9.063 -6.976 
StO2 0 
1 -.058 .109 1.000 -.403 .287 
3 .100a .122 1.000 -.286 .486 
7 .250a .155 .960 -.238 .738 
THC 0 
1 .003 .053 1.000 -.163 .168 
3 -.070a .059 .999 -.255 .115 
7 -.039a .074 1.000 -.273 .195 
HbO2 0 
1 -.049 .139 1.000 -.486 .388 
3 .039a .155 1.000 -.450 .527 
7 .221a .196 1.000 -.397 .839 
μs’ 0 
1 .003 .037 1.000 -.114 .120 
3 .111 .042 .208 -.020 .242 
7 .032 .053 1.000 -.134 .198 
Control: 
Isotype 
Tumor size 0 
1 -.486a,c .251 .790 -1.279 .306 
3 -1.863a,*,c .288 <.001 -2.771 -.955 
7 -7.735a,*,c .487 <.001 -9.270 -6.201 
StO2 0 
1 .078a,c .118 1.000 -.293 .448 
3 .220a,c .135 .953 -.205 .645 
7 .270a,c .228 .999 -.448 .988 
THC 0 
1 .052a,c .056 1.000 -.126 .230 
3 -.029a,c .065 1.000 -.233 .175 
7 -.001a,c .109 1.000 -.345 .343 
HbO2 0 
1 .114a,c .149 1.000 -.355 .583 
3 .208a,c .171 .999 -.329 .746 
7 .299a,c .288 1.000 -.609 1.208 
μs’ 0 
1 .029a,c .040 1.000 -.097 .155 
3 .055a,c .046 .999 -.089 .199 
7 .252a,*,c .077 .036 .008 .496 
Immuno-
Therapy 
Tumor size 0 
1 -.444a,c .287 .975 -1.347 .460 
3 -1.090a,*,c .287 .005 -1.993 -.186 
7 -5.741a,*,c .351 <.001 -6.848 -4.635 
StO2 0 
1 .021a,c .134 1.000 -.402 .443 
3 .185a,c .134 .994 -.237 .608 
7 -.020a,c .164 1.000 -.538 .497 
THC 0 
1 .031a,c .064 1.000 -.171 .234 
3 .048a,c .064 1.000 -.154 .251 
7 -.195a,c .079 .325 -.444 .053 
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Table 13. Comparisons to day 0 within treatment, within metric, normalized values (cont.) 
Treatment 
Normalized 
Metric 
Pairwise 
Comparisons 
Mean 
Difference 
(I-J) 
Std. Error Sig.d 
95% Confidence Interval 
for Differenced 
(I) Day (J) Day 
Lower 
Bound 
Upper 
Bound 
Immuno-
Therapy 
HbO2 0 
1 .031a,c .170 1.000 -.504 .566 
3 .205a,c .170 .999 -.330 .740 
7 -.282a,c .208 .996 -.938 .373 
μs’ 0 
1 .046a,c .046 1.000 -.098 .189 
3 .082a,c .046 .876 -.061 .226 
7 .139a,c .056 .320 -.037 .315 
Chemo-
Therapy 
Tumor size 0 
1 -.280 .294 1.000 -1.208 .648 
3 -1.467a,* .299 <.001 -2.411 -.524 
7 -2.453a,* .354 <.001 -3.570 -1.336 
StO2 0 
1 -.169 .138 .999 -.604 .265 
3 .041a .140 1.000 -.400 .482 
7 -.301a .166 .872 -.823 .222 
THC 0 
1 -.137 .066 .669 -.346 .071 
3 -.160a .067 .402 -.372 .052 
7 -.056a .080 1.000 -.307 .195 
HbO2 0 
1 -.371 .174 .626 -.920 .179 
3 -.118a .177 1.000 -.676 .441 
7 -.361a .210 .920 -1.023 .300 
μs’ 0 
1 .043 .047 1.000 -.104 .191 
3 -.029a .048 1.000 -.179 .121 
7 -.035a .056 1.000 -.212 .143 
Combo-
Therapy 
Tumor size 0 
1 -.183 .262 1.000 -1.007 .642 
3 -.447a .293 .978 -1.369 .475 
7 -1.225a,* .370 .030 -2.391 -.058 
StO2 0 
1 -.243 .122 .748 -.629 .143 
3 -.108a .137 1.000 -.539 .323 
7 -.253a .173 .988 -.799 .293 
THC 0 
1 .048 .059 1.000 -.137 .233 
3 .102a .066 .974 -.105 .309 
7 -.083a .083 1.000 -.345 .178 
HbO2 0 
1 -.179 .155 1.000 -.668 .309 
3 -.134a .173 1.000 -.680 .412 
7 -.371a .219 .932 -1.062 .320 
μs’ 0 
1 -.040 .042 1.000 -.171 .091 
3 .053a .047 1.000 -.094 .200 
7 .038a .059 1.000 -.147 .224 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. An estimate of the modified population marginal mean (J). 
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c. An estimate of the modified population marginal mean (I). 
d. Adjustment for multiple comparisons: Sidak. 
 
Figure 21. Comparison of treatments for days 1, 3, and 7 for raw (non-
normalized) tumor size. For statistical analysis, see Table 14 
 
 
Figure 22. Comparison of treatments for days 1, 3, and 7 for raw (non-
normalized) StO2. For statistical analysis, see Table 14 
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Figure 23. Comparison of treatments for days 1, 3, and 7 for raw (non-
normalized) THC. For statistical analysis, see Table 14 
 
 
Figure 24. Comparison of treatments for days 1, 3, and 7 for raw (non-
normalized) HbO2. For statistical analysis, see Table 14 
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Figure 25. Comparison of treatments for days 1, 3, and 7 for raw (non-
normalized) μs’. For statistical analysis, see Table 14 
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values 
Day 
Raw 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
1 
Tumor 
size 
Control: Saline 
Control: Isotype -15.152a 18.375 .995 -67.086 36.781 
Immunotherapy -9.930a 19.797 1.000 -65.881 46.021 
Chemotherapy 5.771 20.124 1.000 -51.105 62.647 
Combo-therapy 11.748 18.781 .999 -41.332 64.828 
Control: Isotype 
Immunotherapy 5.222a,b 20.397 1.000 -52.425 62.869 
Chemotherapy 20.924b 20.714 .977 -37.621 79.469 
Combo-therapy 26.901b 19.412 .839 -27.964 81.765 
Immunotherapy 
Chemotherapy 15.702b 21.985 .998 -46.435 77.838 
Combo-therapy 21.678b 20.763 .971 -37.003 80.360 
Chemotherapy Combo-therapy 5.977 21.075 1.000 -53.588 65.541 
StO2 
Control: Saline 
Control: Isotype .021 .032 .999 -.069 .111 
Immunotherapy .115 .034 .009 .018 .212 
Chemotherapy .120 .035 .007 .021 .219 
Combo-therapy .087 .033 .078 -.005 .179 
Control: Isotype 
Immunotherapy .094 .035 .077 -.005 .194 
Chemotherapy .099 .036 .060 -.002 .201 
Combo-therapy .066 .034 .406 -.029 .161 
Immunotherapy 
Chemotherapy .005 .038 1.000 -.103 .112 
Combo-therapy -.028 .036 .996 -.130 .073 
Chemotherapy Combo-therapy -.033 .037 .989 -.136 .070 
THC 
Control: Saline 
Control: Isotype .570a,* .110 <.001 .258 .882 
Immunotherapy .350a,* .119 .035 .014 .686 
Chemotherapy .384* .121 .017 .042 .725 
Combo-therapy .419* .113 .003 .100 .737 
Control: Isotype 
Immunotherapy -.220a,b .122 .533 -.567 .126 
Chemotherapy -.187b .124 .765 -.538 .165 
Combo-therapy -.151b .117 .886 -.481 .178 
Immunotherapy 
Chemotherapy .034b .132 1.000 -.339 .407 
Combo-therapy .069b .125 1.000 -.284 .421 
Chemotherapy Combo-therapy .035 .127 1.000 -.323 .393 
HbO2 
Control: Saline 
Control: Isotype .236a .090 .092 -.019 .491 
Immunotherapy .392a,* .097 .001 .117 .667 
Chemotherapy .408* .099 .001 .129 .687 
Combo-therapy .339* .092 .003 .078 .600 
Control: Isotype 
Immunotherapy .156a,b .100 .723 -.127 .439 
Chemotherapy .172b .102 .620 -.116 .460 
Combo-therapy .103b .095 .963 -.166 .373 
Immunotherapy 
Chemotherapy .016b .108 1.000 -.289 .321 
Combo-therapy -.053b .102 1.000 -.341 .235 
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.) 
Day 
Raw 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
1 
HbO2 Chemotherapy Combo-therapy -.069 .104 .999 -.361 .224 
μs’ 
Control: Saline 
Control: Isotype -.083a .123 .999 -.430 .264 
Immunotherapy .044a .132 1.000 -.330 .417 
Chemotherapy .271 .134 .365 -.108 .651 
Combo-therapy -.151 .125 .925 -.506 .203 
Control: Isotype 
Immunotherapy .127a,b .136 .987 -.258 .512 
Chemotherapy .355b .138 .104 -.036 .745 
Combo-therapy -.068b .130 1.000 -.435 .298 
Immunotherapy 
Chemotherapy .228b .147 .728 -.187 .642 
Combo-therapy -.195b .139 .825 -.587 .196 
Chemotherapy Combo-therapy -.423* .141 .029 -.820 -.025 
3 
Tumor 
size 
Control: Saline 
Control: Isotype -43.183a,b 23.002 .471 -108.192 21.826 
Immunotherapy 21.150a,b 21.686 .982 -40.141 82.441 
Chemotherapy .186a,b 22.354 1.000 -62.992 63.364 
Combo-therapy 52.849a,b 24.043 .254 -15.103 120.802 
Control: Isotype 
Immunotherapy 64.333a,b 23.002 .055 -.676 129.342 
Chemotherapy 43.369a,b 23.632 .504 -23.421 110.160 
Combo-therapy 96.033a,b,* 25.236 .002 24.709 167.356 
Immunotherapy 
Chemotherapy -20.964a,b 22.354 .986 -84.142 42.214 
Combo-therapy 31.699a,b 24.043 .876 -36.253 99.652 
Chemotherapy Combo-therapy 52.663a,b 24.647 .290 -16.995 122.322 
StO2 
Control: Saline 
Control: Isotype .024a,b .040 1.000 -.089 .136 
Immunotherapy .169a,b,* .038 <.001 .063 .275 
Chemotherapy .193a,b,* .039 <.001 .083 .302 
Combo-therapy .103a,b .042 .132 -.015 .221 
Control: Isotype 
Immunotherapy .146a,b,* .040 .003 .033 .258 
Chemotherapy .169a,b,* .041 <.001 .054 .285 
Combo-therapy .080a,b .044 .517 -.044 .203 
Immunotherapy 
Chemotherapy .024a,b .039 1.000 -.086 .133 
Combo-therapy -.066a,b .042 .701 -.184 .052 
Chemotherapy Combo-therapy -.090a,b .043 .312 -.210 .031 
THC 
Control: Saline 
Control: Isotype .544a,b,* .138 .001 .153 .934 
Immunotherapy .644a,b,* .130 <.001 .276 1.012 
Chemotherapy .691a,b,* .134 <.001 .312 1.070 
Combo-therapy .452a,b,* .144 .020 .044 .860 
Control: Isotype 
Immunotherapy .100a,b .138 .998 -.290 .490 
Chemotherapy .147a,b .142 .972 -.254 .548 
Combo-therapy -.092a,b .152 1.000 -.520 .336 
Immunotherapy Chemotherapy .047a,b .134 1.000 -.332 .426 
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.) 
Day 
Raw 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
3 
THC 
Immunotherapy Combo-therapy -.192a,b .144 .871 -.600 .216 
Chemotherapy Combo-therapy -.239a,b .148 .680 -.657 .179 
HbO2 
Control: Saline 
Control: Isotype .239a,b .113 .303 -.080 .558 
Immunotherapy .598a,b,* .107 <.001 .296 .899 
Chemotherapy .658a,b,* .110 <.001 .348 .968 
Combo-therapy .397a,b,* .118 .009 .063 .731 
Control: Isotype 
Immunotherapy .358a,b,* .113 .017 .039 .678 
Chemotherapy .419a,b,* .116 .004 .091 .747 
Combo-therapy .158a,b .124 .898 -.192 .508 
Immunotherapy 
Chemotherapy .060a,b .110 1.000 -.250 .371 
Combo-therapy -.201a,b .118 .614 -.534 .133 
Chemotherapy Combo-therapy -.261a,b .121 .279 -.603 .081 
μs’ 
Control: Saline 
Control: Isotype -.504a,b,* .153 .012 -.938 -.070 
Immunotherapy -.172a,b .145 .931 -.581 .237 
Chemotherapy -.259a,b .149 .582 -.681 .162 
Combo-therapy -.295a,b .160 .502 -.748 .158 
Control: Isotype 
Immunotherapy .332a,b .153 .276 -.102 .765 
Chemotherapy .245a,b .158 .729 -.201 .690 
Combo-therapy .209a,b .168 .912 -.267 .685 
Immunotherapy 
Chemotherapy -.087a,b .149 1.000 -.509 .335 
Combo-therapy -.123a,b .160 .997 -.576 .331 
Chemotherapy Combo-therapy -.036a,b .164 1.000 -.501 .429 
7 
Tumor 
size 
Control: Saline 
Control: Isotype -8.164a,b 40.571 1.000 -122.829 106.502 
Immunotherapy 142.108a,b,* 30.669 <.001 55.429 228.787 
Chemotherapy 420.385a,b,* 30.669 <.001 333.706 507.064 
Combo-therapy 506.990a,b,* 32.529 <.001 415.053 598.927 
Control: Isotype 
Immunotherapy 150.272a,b,* 40.571 .003 35.607 264.938 
Chemotherapy 428.548a,b,* 40.571 <.001 313.883 543.214 
Combo-therapy 515.154a,b,* 41.995 <.001 396.464 633.844 
Immunotherapy 
Chemotherapy 278.276a,b,* 30.669 <.001 191.597 364.955 
Combo-therapy 364.882a,b,* 32.529 <.001 272.945 456.819 
Chemotherapy Combo-therapy 86.606a,b 32.529 .080 -5.331 178.543 
StO2 
Control: Saline 
Control: Isotype -.089a,b .070 .899 -.288 .109 
Immunotherapy .067a,b .053 .902 -.083 .217 
Chemotherapy .082a,b .053 .740 -.069 .232 
Combo-therapy .067a,b .056 .934 -.093 .226 
Control: Isotype 
Immunotherapy .157a,b .070 .239 -.042 .355 
Chemotherapy .171a,b .070 .147 -.028 .369 
Combo-therapy .156a,b .073 .286 -.050 .362 
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Table 14. Comparisons of treatments for days 1, 3 and 7, within metrics, raw values (cont.) 
Day 
Raw 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
7 
StO2 
Immunotherapy 
Chemotherapy .014a,b .053 1.000 -.136 .164 
Combo-therapy -.001a,b .056 1.000 -.160 .159 
Chemotherapy Combo-therapy -.015a,b .056 1.000 -.174 .144 
THC 
Control: Saline 
Control: Isotype .400a,b .244 .659 -.289 1.089 
Immunotherapy -.252a,b .184 .851 -.772 .269 
Chemotherapy .644a,b,* .184 .006 .124 1.165 
Combo-therapy .043a,b .195 1.000 -.509 .595 
Control: Isotype 
Immunotherapy -.652a,b .244 .077 -1.340 .037 
Chemotherapy .244a,b .244 .978 -.444 .933 
Combo-therapy -.357a,b .252 .822 -1.070 .356 
Immunotherapy 
Chemotherapy .896a,b,* .184 <.001 .375 1.416 
Combo-therapy .295a,b .195 .759 -.257 .847 
Chemotherapy Combo-therapy -.601a,b,* .195 .023 -1.153 -.049 
HbO2 
Control: Saline 
Control: Isotype -.053a,b .199 1.000 -.617 .510 
Immunotherapy .095a,b .151 .999 -.331 .520 
Chemotherapy .355a,b .151 .177 -.071 .781 
Combo-therapy .188a,b .160 .937 -.264 .639 
Control: Isotype 
Immunotherapy .148a,b .199 .998 -.415 .711 
Chemotherapy .409a,b .199 .345 -.155 .972 
Combo-therapy .241a,b .206 .939 -.342 .824 
Immunotherapy 
Chemotherapy .260a,b .151 .590 -.165 .686 
Combo-therapy .093a,b .160 1.000 -.359 .545 
Chemotherapy Combo-therapy -.168a,b .160 .970 -.619 .284 
μs’ 
Control: Saline 
Control: Isotype .216a,b .271 .996 -.550 .981 
Immunotherapy .216a,b .205 .968 -.362 .795 
Chemotherapy -.199a,b .205 .982 -.778 .379 
Combo-therapy .216a,b .217 .979 -.397 .830 
Control: Isotype 
Immunotherapy .001a,b .271 1.000 -.765 .766 
Chemotherapy -.415a,b .271 .742 -1.180 .350 
Combo-therapy .001a,b .280 1.000 -.791 .793 
Immunotherapy 
Chemotherapy -.416a,b .205 .359 -.994 .163 
Combo-therapy 
-6.000E-
5a,b 
.217 1.000 -.614 .613 
Chemotherapy Combo-therapy .415a,b .217 .443 -.198 1.029 
*. The mean difference is significant at the .05 level. 
a. An estimate of the modified population marginal mean (J). 
c. An estimate of the modified population marginal mean (I). 
d. Adjustment for multiple comparisons: Sidak. 
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Figure 26. Comparison of treatments for days 1, 3, and 7 for normalized tumor 
size. For statistical analysis, see Table 15 
 
 
Figure 27. Comparison of treatments for days 1, 3, and 7 for normalized StO2. 
For statistical analysis, see Table 15 
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Figure 28. Comparison of treatments for days 1, 3, and 7 for normalized THC. 
For statistical analysis, see Table 15 
 
 
Figure 29. Comparison of treatments for days 1, 3, and 7 for normalized HbO2. 
For statistical analysis, see Table 15 
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Figure 30. Comparison of treatments for days 1, 3, and 7 for normalized μs’. For 
statistical analysis, see Table 15 
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values 
Day 
Norm. 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
1 
Tumor 
size 
Control: Saline 
Control: Isotype -.112a .243 1.000 -.798 .575 
Immunotherapy -.069a .262 1.000 -.808 .670 
Chemotherapy .095 .266 1.000 -.657 .847 
Combo-therapy .192 .248 .997 -.509 .894 
Control: Isotype 
Immunotherapy .042a,b .270 1.000 -.719 .804 
Chemotherapy .207b .274 .998 -.567 .980 
Combo-therapy .304b .257 .934 -.421 1.029 
Immunotherapy 
Chemotherapy .164b .291 1.000 -.657 .985 
Combo-therapy .261b .274 .985 -.514 1.037 
Chemotherapy Combo-therapy .097 .279 1.000 -.690 .884 
StO2 
Control: Saline 
Control: Isotype .135a .114 .931 -.186 .456 
Immunotherapy .078a .122 .999 -.268 .424 
Chemotherapy -.112 .124 .990 -.463 .240 
Combo-therapy -.186 .116 .693 -.514 .143 
Control: Isotype 
Immunotherapy -.057a,b .126 1.000 -.413 .299 
Chemotherapy -.247b .128 .432 -.609 .115 
Combo-therapy -.321b .120 .077 -.660 .018 
Immunotherapy 
Chemotherapy -.190b .136 .832 -.574 .194 
Combo-therapy -.264b .128 .341 -.627 .099 
Chemotherapy Combo-therapy -.074 .130 1.000 -.442 .294 
THC 
Control: Saline 
Control: Isotype .049a .055 .990 -.105 .203 
Immunotherapy .029a .059 1.000 -.137 .194 
Chemotherapy -.140 .060 .179 -.309 .028 
Combo-therapy .045 .056 .996 -.112 .203 
Control: Isotype 
Immunotherapy -.021a,b .061 1.000 -.192 .150 
Chemotherapy -.190b,* .061 .022 -.363 -.016 
Combo-therapy -.004b .058 1.000 -.167 .159 
Immunotherapy 
Chemotherapy -.169b .065 .098 -.353 .016 
Combo-therapy .017b .062 1.000 -.157 .191 
Chemotherapy Combo-therapy .185* .063 .033 .009 .362 
HbO2 
Control: Saline 
Control: Isotype .163a .144 .949 -.243 .570 
Immunotherapy .080a .155 1.000 -.358 .518 
Chemotherapy -.322 .157 .350 -.767 .123 
Combo-therapy -.130 .147 .991 -.546 .285 
Control: Isotype 
Immunotherapy -.083a,b .160 1.000 -.534 .368 
Chemotherapy -.485b,* .162 .030 -.943 -.027 
Combo-therapy -.294b .152 .429 -.723 .136 
Immunotherapy 
Chemotherapy -.402b .172 .186 -.888 .084 
Combo-therapy -.211b .162 .887 -.670 .249 
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values 
(cont.) 
Day 
Norm. 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
1 
HbO2 Chemotherapy Combo-therapy .191 .165 .941 -.275 .657 
μs’ 
Control: Saline 
Control: Isotype .026a .039 .999 -.083 .135 
Immunotherapy .043a .042 .974 -.075 .160 
Chemotherapy .040 .042 .985 -.079 .160 
Combo-therapy -.043 .040 .961 -.155 .069 
Control: Isotype 
Immunotherapy .017a,b .043 1.000 -.104 .138 
Chemotherapy .014b .044 1.000 -.109 .138 
Combo-therapy -.069b .041 .620 -.184 .046 
Immunotherapy 
Chemotherapy -.002b .046 1.000 -.133 .128 
Combo-therapy -.086b .044 .405 -.209 .038 
Chemotherapy Combo-therapy -.083 .044 .467 -.209 .042 
3 
Tumor 
size 
Control: Saline 
Control: Isotype -.415a,b .304 .851 -1.274 .444 
Immunotherapy .358a,b .287 .909 -.452 1.168 
Chemotherapy -.020a,b .295 1.000 -.855 .815 
Combo-therapy 1.001a,b,* .304 .011 .141 1.860 
Control: Isotype 
Immunotherapy .773a,b .304 .110 -.086 1.632 
Chemotherapy .396a,b .312 .901 -.487 1.278 
Combo-therapy 1.416a,b,* .320 <.001 .510 2.321 
Immunotherapy 
Chemotherapy -.378a,b .295 .896 -1.213 .457 
Combo-therapy .642a,b .304 .304 -.217 1.502 
Chemotherapy Combo-therapy 1.020a,b,* .312 .012 .138 1.903 
StO2 
Control: Saline 
Control: Isotype .120a,b .142 .994 -.282 .522 
Immunotherapy .085a,b .134 .999 -.294 .464 
Chemotherapy -.059a,b .138 1.000 -.450 .331 
Combo-therapy -.208a,b .142 .791 -.610 .194 
Control: Isotype 
Immunotherapy -.035a,b .142 1.000 -.436 .367 
Chemotherapy -.179a,b .146 .918 -.592 .234 
Combo-therapy -.328a,b .150 .260 -.752 .096 
Immunotherapy 
Chemotherapy -.145a,b .138 .970 -.535 .246 
Combo-therapy -.293a,b .142 .336 -.695 .108 
Chemotherapy Combo-therapy -.149a,b .146 .975 -.562 .264 
THC 
Control: Saline 
Control: Isotype .040a,b .068 1.000 -.152 .233 
Immunotherapy .118a,b .064 .505 -.064 .300 
Chemotherapy -.090a,b .066 .855 -.277 .097 
Combo-therapy .172a,b .068 .118 -.021 .365 
Control: Isotype 
Immunotherapy .078a,b .068 .948 -.115 .270 
Chemotherapy -.130a,b .070 .484 -.329 .068 
Combo-therapy .131a,b .072 .512 -.072 .335 
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values 
(cont.) 
Day 
Norm. 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
3 
THC 
Immunotherapy 
Chemotherapy -.208a,b,* .066 .019 -.396 -.021 
Combo-therapy .054a,b .068 .997 -.139 .247 
Chemotherapy Combo-therapy .262a,b,* .070 .002 .064 .460 
HbO2 
Control: Saline 
Control: Isotype .170a,b .180 .986 -.339 .678 
Immunotherapy .166a,b .170 .981 -.314 .646 
Chemotherapy -.157a,b .175 .990 -.651 .338 
Combo-therapy -.173a,b .180 .984 -.681 .336 
Control: Isotype 
Immunotherapy -.003a,b .180 1.000 -.512 .505 
Chemotherapy -.326a,b .185 .562 -.849 .197 
Combo-therapy -.342a,b .190 .529 -.878 .194 
Immunotherapy 
Chemotherapy -.323a,b .175 .497 -.817 .172 
Combo-therapy -.339a,b .180 .467 -.848 .170 
Chemotherapy Combo-therapy -.016a,b .185 1.000 -.539 .506 
μs’ 
Control: Saline 
Control: Isotype -.056a,b .048 .943 -.193 .081 
Immunotherapy -.028a,b .046 1.000 -.157 .101 
Chemotherapy -.140a,b,* .047 .032 -.273 -.007 
Combo-therapy -.058a,b .048 .929 -.195 .079 
Control: Isotype 
Immunotherapy .027a,b .048 1.000 -.109 .164 
Chemotherapy -.084a,b .050 .619 -.225 .056 
Combo-therapy -.002a,b .051 1.000 -.146 .142 
Immunotherapy 
Chemotherapy -.112a,b .047 .170 -.244 .021 
Combo-therapy -.030a,b .048 1.000 -.166 .107 
Chemotherapy Combo-therapy .082a,b .050 .652 -.058 .223 
7 
Tumor 
size 
Control: Saline 
Control: Isotype .284a,b .536 1.000 -1.231 1.800 
Immunotherapy 2.278a,b,* .405 <.001 1.133 3.424 
Chemotherapy 5.566a,b,* .405 <.001 4.421 6.712 
Combo-therapy 6.795a,b,* .430 <.001 5.580 8.010 
Control: Isotype 
Immunotherapy 1.994a,b,* .536 .002 .479 3.509 
Chemotherapy 5.282a,b,* .536 <.001 3.767 6.797 
Combo-therapy 6.511a,b,* .555 <.001 4.942 8.079 
Immunotherapy 
Chemotherapy 3.288a,b,* .405 <.001 2.143 4.434 
Combo-therapy 4.517a,b,* .430 <.001 3.302 5.731 
Chemotherapy Combo-therapy 1.228a,b,* .430 .046 .013 2.443 
StO2 
Control: Saline 
Control: Isotype .020a,b .251 1.000 -.689 .729 
Immunotherapy -.270a,b .190 .816 -.806 .266 
Chemotherapy -.550a,b,* .190 .040 -1.086 -.014 
Combo-therapy -.503a,b .201 .124 -1.071 .066 
Control: Isotype Immunotherapy -.290a,b .251 .942 -.999 .419 
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Table 15. Comparisons of treatments for days 1, 3 and 7, within metrics, normalized values 
(cont.) 
Day 
Norm. 
Metric 
Pairwise Comparisons Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.d 
95% Confidence 
Interval for Differenced 
(I) Treatment (J) Treatment 
Lower 
Bound 
Upper 
Bound 
7 
StO2 
Control: Isotype 
Chemotherapy -.570a,b .251 .214 -1.279 .138 
Combo-therapy -.523a,b .260 .370 -1.257 .211 
Immunotherapy 
Chemotherapy -.280a,b .190 .780 -.816 .256 
Combo-therapy -.233a,b .201 .943 -.801 .336 
Chemotherapy Combo-therapy .048a,b .201 1.000 -.521 .616 
THC 
Control: Saline 
Control: Isotype .038a,b .120 1.000 -.302 .378 
Immunotherapy -.156a,b .091 .602 -.413 .101 
Chemotherapy -.017a,b .091 1.000 -.274 .240 
Combo-therapy -.044a,b .097 1.000 -.317 .229 
Control: Isotype 
Immunotherapy -.194a,b .120 .681 -.534 .146 
Chemotherapy -.055a,b .120 1.000 -.395 .285 
Combo-therapy -.082a,b .125 .999 -.434 .270 
Immunotherapy 
Chemotherapy .139a,b .091 .744 -.118 .396 
Combo-therapy .112a,b .097 .942 -.161 .385 
Chemotherapy Combo-therapy -.027a,b .097 1.000 -.300 .245 
HbO2 
Control: Saline 
Control: Isotype .078a,b .318 1.000 -.819 .976 
Immunotherapy -.503a,b .240 .315 -1.182 .175 
Chemotherapy -.582a,b .240 .149 -1.261 .096 
Combo-therapy -.592a,b .255 .190 -1.311 .127 
Control: Isotype 
Immunotherapy -.582a,b .318 .507 -1.479 .316 
Chemotherapy -.661a,b .318 .324 -1.558 .236 
Combo-therapy -.670a,b .329 .352 -1.599 .258 
Immunotherapy 
Chemotherapy -.079a,b .240 1.000 -.758 .599 
Combo-therapy -.089a,b .255 1.000 -.808 .631 
Chemotherapy Combo-therapy -.010a,b .255 1.000 -.729 .710 
μs’ 
Control: Saline 
Control: Isotype .220a,b .085 .101 -.021 .461 
Immunotherapy .107a,b .065 .649 -.076 .289 
Chemotherapy -.067a,b .065 .973 -.249 .116 
Combo-therapy .006a,b .068 1.000 -.187 .200 
Control: Isotype 
Immunotherapy -.113a,b .085 .873 -.354 .128 
Chemotherapy -.287a,b,* .085 .009 -.528 -.045 
Combo-therapy -.214a,b .088 .152 -.463 .036 
Immunotherapy 
Chemotherapy -.173a,b .065 .074 -.356 .009 
Combo-therapy -.100a,b .068 .787 -.294 .093 
Chemotherapy Combo-therapy .073a,b .068 .966 -.120 .266 
*. The mean difference is significant at the .05 level. 
a. An estimate of the modified population marginal mean (J). 
c. An estimate of the modified population marginal mean (I). 
d. Adjustment for multiple comparisons: Sidak. 
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6.11.2 Correlation of spectroscopy-derived data 
 
Figure 31. Correlations of normalized spectroscopy-dervied data. For statistical 
analysis on Pearson (parametric) and Spearman (non-parametric) correlations and 
significance, see Tables 16-30 
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Table 16. Test of normality for saline control group 
 Shapiro-Wilk 
Statistic Statistic Statistic 
Tumor size .771 70 .000 
StO2 .890 70 .000 
THC .925 70 .000 
HbO2 .880 70 .000 
μs’ .968 70 .066 
 
Table 17. Pearson correlation (parametric) of normalized metrics for saline control group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.344** .116 -.298* -.074 
Sig. (2-tailed) .003 .340 .012 .545 
N 70 70 70 70 
StO2 
Pearson Correlation  -.280* .894** .232 
Sig. (2-tailed)  .019 .000 .053 
N  70 70 70 
THC 
Pearson Correlation   .168 -.162 
Sig. (2-tailed)   .164 .180 
N   70 70 
HbO2 
Pearson Correlation    .172 
Sig. (2-tailed)    .155 
N    70 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
Red shading = excluded significant correlation due to normality violation 
Table 18. Spearman correlation (non-parametric) of normalized metrics for saline control group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.363** .195 -.312** -.287* 
Sig. (2-tailed) .002 .106 .009 .016 
N 70 70 70 70 
StO2 
Pearson Correlation  -.451** .840** .311** 
Sig. (2-tailed)  .000 .000 .009 
N  70 70 70 
THC 
Pearson Correlation   .002 -.241* 
Sig. (2-tailed)   .987 .044 
N   70 70 
HbO2 
Pearson Correlation    .153 
Sig. (2-tailed)    .205 
N    70 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
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Table 19. Test of normality for isotype control group 
 Shapiro-Wilk 
Statistic Statistic Statistic 
Tumor size .728 51 .000 
StO2 .948 51 .026 
THC .916 51 .002 
HbO2 .905 51 .001 
μs’ .902 51 .001 
 
Table 20. Pearson correlation (parametric) of normalized metrics for isotype control group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.302* .128 -.280* -.657** 
Sig. (2-tailed) .031 .370 .047 .000 
N 51 51 51 51 
StO2 
Pearson Correlation  -.092 .936** .141 
Sig. (2-tailed)  .521 <.001 .322 
N  51 51 51 
THC 
Pearson Correlation   .252 -.059 
Sig. (2-tailed)   .074 .683 
N   51 51 
HbO2 
Pearson Correlation    .141 
Sig. (2-tailed)    .323 
N    51 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
Red shading = excluded significant correlation due to normality violation 
Table 21. Spearman correlation (non-parametric) of normalized metrics for isotype control group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.484** -.184 -.516** -.624** 
Sig. (2-tailed) <.001 .196 <.001 <.001 
N 51 51 51 51 
StO2 
Pearson Correlation  -.009 .923** .211 
Sig. (2-tailed)  .950 .000 .137 
N  51 51 51 
THC 
Pearson Correlation   .304* .099 
Sig. (2-tailed)   .030 .489 
N   51 51 
HbO2 
Pearson Correlation    .249 
Sig. (2-tailed)    .078 
N    51 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
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Table 22. Test of normality for immunotherapy-treated group 
 Shapiro-Wilk 
Statistic Statistic Statistic 
Tumor size .789 60 .000 
StO2 .974 60 .240 
THC .890 60 .000 
HbO2 .887 60 .000 
μs’ .974 60 .226 
 
Table 23. Pearson correlation (parametric) of normalized metrics for immunotherapy-treated 
group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation .076 .542** .327* -.390** 
Sig. (2-tailed) .565 .000 .011 .002 
N 60 60 60 60 
StO2 
Pearson Correlation  .552** .915** -.078 
Sig. (2-tailed)  <.001 <.001 .554 
N  60 60 60 
THC 
Pearson Correlation   .825** -.315* 
Sig. (2-tailed)   <.001 .014 
N   60 60 
HbO2 
Pearson Correlation    -.247 
Sig. (2-tailed)    .057 
N    60 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
Red shading = excluded significant correlation due to normality violation 
Table 24. Spearman correlation (non-parametric) of normalized metrics for immunotherapy-
treated group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.058 .282* .014 -.502** 
Sig. (2-tailed) .660 .029 .916 <.001 
N 60 60 60 60 
StO2 
Pearson Correlation  .502** .929** .039 
Sig. (2-tailed)  .000 .000 .767 
N  60 60 60 
THC 
Pearson Correlation   .717** -.027 
Sig. (2-tailed)   .000 .841 
N   60 60 
HbO2 
Pearson Correlation    -.016 
Sig. (2-tailed)    .905 
N    60 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
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Table 25. Test of normality for chemotherapy-treated group 
 Shapiro-Wilk 
Statistic Statistic Statistic 
Tumor size .799 60 .000 
StO2 .934 60 .003 
THC .929 60 .002 
HbO2 .837 60 .000 
μs’ .967 60 .100 
 
Table 26. Pearson correlation (parametric) of normalized metrics for chemotherapy-treated 
group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation .294* .192 .275* .261* 
Sig. (2-tailed) .023 .141 .033 .044 
N 60 60 60 60 
StO2 
Pearson Correlation  .400** .926** -.207 
Sig. (2-tailed)  .002 .000 .112 
N  60 60 60 
THC 
Pearson Correlation   .693** .006 
Sig. (2-tailed)   .000 .964 
N   60 60 
HbO2 
Pearson Correlation    -.150 
Sig. (2-tailed)    .254 
N    60 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
Red shading = excluded significant correlation due to normality violation 
Table 27. Spearman correlation (non-parametric) of normalized metrics for chemotherapy-
treated group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation .203 .267* .215 .302* 
Sig. (2-tailed) .120 .040 .100 .019 
N 60 60 60 60 
StO2 
Pearson Correlation  .297* .912** -.214 
Sig. (2-tailed)  .021 <.001 .100 
N  60 60 60 
THC 
Pearson Correlation   .601** .048 
Sig. (2-tailed)   <.001 .714 
N   60 60 
HbO2 
Pearson Correlation    -.165 
Sig. (2-tailed)    .208 
N    60 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
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Table 28. Test of normality for combination therapy-treated group 
 Shapiro-Wilk 
Statistic Statistic Statistic 
Tumor size .930 56 .003 
StO2 .906 56 .000 
THC .609 56 .000 
HbO2 .909 56 .000 
μs’ .601 56 .000 
 
Table 29. Pearson correlation (parametric) of normalized metrics for combination therapy-
treated group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.012 .219 -.036 .377** 
Sig. (2-tailed) .927 .105 .793 .004 
N 56 56 56 56 
StO2 
Pearson Correlation  .364** .970** .404** 
Sig. (2-tailed)  .006 .000 .002 
N  56 56 56 
THC 
Pearson Correlation   .470** .622** 
Sig. (2-tailed)   .000 .000 
N   56 56 
HbO2 
Pearson Correlation    .345** 
Sig. (2-tailed)    .009 
N    56 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
Red shading = excluded significant correlation due to normality violation 
Table 30. Spearman correlation (non-parametric) of normalized metrics for combination therapy-
treated group 
 StO2 THC HbO2 μs’ 
Tumor size 
Pearson Correlation -.100 -.137 -.125 .319* 
Sig. (2-tailed) .464 .315 .357 .017 
N 56 56 56 56 
StO2 
Pearson Correlation  .199 .936** .189 
Sig. (2-tailed)  .142 .000 .163 
N  56 56 56 
THC 
Pearson Correlation   .425** -.311* 
Sig. (2-tailed)   .001 .020 
N   56 56 
HbO2 
Pearson Correlation    .059 
Sig. (2-tailed)    .663 
N    56 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Green shading = significance 
 
 
 
361 
 
6.11.3 Tumor associated macrophages 
In our macrophage staining, we were able to stain for two different cell types: M1 and 
M2 macrophages using a triple staining procedure, which reduces the possibly of the common 
problem of including dendritic cells when counting macrophages. In general, M1 macrophages 
are considered anti-tumor and M2 macrophages are considered pro-tumor, although this is an 
oversimplification. M1 macrophages are counted if stained with both CD68 and CD80, whereas 
M2 macrophages are counted if stained with both CD68 and CD206. In a comparison between 
the isotype control and immunotherapy groups (Fig. 32), on both day 3 and day 7, the M1/M2 
ratio in the isotype control group is elevated, as expected based on a reduction in the number of 
M2-polarized pro-tumor macrophages. The literature shows that an increase in the M1/M2 ratio 
is a positive prognostic indicator of cancer-specific survival (Edin et al., 2012).    
Specifically, on day 3, the M1/M2 ratio for the isotype control and immunotherapy 
groups are 45.1% ± 18.4% and 52.2% ± 14.2% (p = 0.28). On day 7, the M1/M2 ratio for the 
isotype control and immunotherapy groups are 29.5% ± 6.5% and 43.6% ± 16.1% (p = 0.13). 
These results, although insignificant, seem to indicate an increase in the M1/M2 ratio in tumors 
treated with anti-CCL2 immunotherapy. However, both groups show a decrease in the M1/M2 
ratio over time. For example, in the isotype control group, M1/M2 ratio decreases from 45.1% ± 
18.4% to 29.5% ± 6.5% (p = 0.14). In the anti-CCL2 immunotherapy group, M1/M2 ratio 
decreases from 52.2% ± 14.2% to 43.6% ± 16.1% (p = 0.28). Note that the decrease is more 
significant for the control group. 
 In the isotype control treatment group (i.e. mice treated with isotype antibodies as a 
control for anti-CCL2 immunotherapy), more and more M2 macrophages infiltrate the tumor 
over time, lowering the M1/M2 ratio significantly. In the immunotherapy group, there is a slight 
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but insignificant decrease in the M1/M2 ratio, potentially indicating that our anti-CCL2 
immunotherapy is working to reduce monocyte infiltration as expected. Work in this area is 
ongoing and research will be needed in correlating M1/M2 ratios to HbO2 values among 
treatment groups. We expect that a decrease in M2 macrophages, coupled with chemotherapy, 
will increase survival in mice compared to chemotherapy alone, although the precise interplay 
between TAMs and DRS-derived HbO2 remains to be determined.  
 
Figure 32. In both the isotype control (dark gray) and anti-CCL2 immunotherapy 
treated groups (light gray), the M1/M2 ratio decreased over time, although the 
M1/M2 ratio decreased more in the isotype control group. On both days 3 and 7, 
the M1/M2 is elevated in the immunotherapy-treated group, albeit insignificantly. 
An increase in the M1/M2 ratio has been shown to be a positive prognostic 
indicator of cancer-specific survival (Edin et al., 2012). 
 
6.11 Discussion 
In this study, Balb/c mice were subcutaneously injected with murine CT26 colon 
carcinoma cells in the left flank. Tumors were allowed to grow until they reached 75 mm3. Once 
the tumor reached 75 mm3, mice underwent intraperitoneal treatment with either saline control, 
isotype control, anti-CCL2 neutralizing antibody immunotherapy, 5-FU chemotherapy, or a 
combination of anti-CCL2 immunotherapy and 5-FU chemotherapy for up to 7 days.  
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A two-way ANOVA with repeated measures was used to assess both the comparisons of 
treatments for days 1, 3, and 7 within metrics and comparisons to day 0 within treatment and within 
metrics. The normality of the residual error scores for the raw and normalized metrics was tested using 
the Shapiro-Wilk test. The Wilcoxon Signed Rank test was used to assess the differences between Day 0 
and Days 1, 3, and 7 within each of the 5 treatments and for comparing all pairs of treatments on Days 1, 
3, and 7 for any metrics in which normality failed (W < 0.9). These analyses computed the Pearson 
product-moment correlations between each pair of normalized metric scores within each of the 
five treatments. Shapiro-Wilk tests for normality were conducted for scores on all five 
normalized metrics within each treatment. Correlations between any pair of metrics within a 
treatment where one or both of the metrics had Shapiro-Wilk values below .88 were recomputed 
using the nonparametric Spearman’s rho correlation. 
The first topic of discussion is the effect of treatment on tumor size. Tumor size is the 
most common metric to assess response to anticancer therapy. Tumors were measured daily with 
external calipers. By the end of 7 days, tumors grew to 682 ± 85 mm3 (128% growth per day), 
690 ± 119 mm3 (125% growth per day), 540 ± 82 mm3 (96% growth per day), 262 ± 131 mm3 
(49% growth per day), and 175 ± 26 mm3 (32% growth per day) for the saline control, isotype 
control, immunotherapy, chemotherapy, and combination groups, respectively (Figure 10, 11 and 
16). Tables 12 and 14 shows the statistics for raw tumor size; however; tables 13 and 15, which 
shows statistics for normalized tumor size, is perhaps more important since growth is normalized 
to the tumor size at day 0. This allows for comparisons between mice that may have had different 
initial tumor sizes of 74 or 77 mm3, for example. In all groups except for the combination 
therapy group, tumor size had significantly increased by day 3 (Table 13). In the combination 
therapy group, tumor size had significantly increased by day 7 (Table 13). So, it is noteworthy 
that tumors from all treatment groups experienced tumor growth. At day 3, tumors treated with 
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combination therapy (anti-CCL2 + 5-FU) showed significantly reduced tumor growth compared 
to saline control (p=0.011), isotype control (<0.001), and chemotherapy (p=0.012) groups. By 
day 7, all groups showed significantly different tumor growth rates, expect for the saline and 
isotype control groups (p=1.000), as expected. By day 7, combination therapy proved just 
slightly better than chemotherapy alone (p=0.046) with regards to tumor growth. Based on this 
data alone, it would appear that both immunotherapy and chemotherapy slowed tumor growth, 
albeit chemotherapy being more successful. A combination of the two treatments slowed tumor 
growth even further. One surprising result indicated that, according to Pearson correlations, 
tumor size significantly, albeit weakly, correlated with μs’ (Figure 31(a), Tables 18, 21, 24, 27, 
and 30) in all treatment groups. There was a negative correlation of μs’ vs. tumor size for the 
saline control (R=-0.287, p=0.016), isotype control (R=-0.624, p<0.001), and immunotherapy 
groups (R=-0.502, p<0.001), and a positive correlation of μs’ vs. tumor size for the chemotherapy 
(R=-0.302, p=0.019) and combination treatment groups (R=0.319, p=0.017). However, the small 
R values give reason to question the importance of these results. Additionally, Wang et al. found 
that chemotherapy-treated breast cancer xenografts had reduced tumor cell density and 
proliferating cell density (Wang et al., 2013), which would theoretically lead to a negative 
correlation of μs’ vs. tumor size (Su et al., 2015) in chemotherapy-treated mice, rather than the 
small positive correlation seen in our study. A potential confounding variable in this situation 
could be the skin layer overlying the tumor in this subcutaneous tumor model. It is reasonable to 
assume that, in larger tumors, the skin is stretched. Since chemotherapy and combination therapy 
treated mice had reduced tumor growth, it may be reasonable to assume that the skin was less 
stretched, although this was not explicitly tested. If this was the case, light from the DRS probe 
could potentially interact with the skin layer less in (Rajaram, Gopal, et al., 2010) the control 
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groups compared to treatment groups. Skin has a higher scattering coefficient due to its collagen 
content (Lister et al., 2012; Zonios et al., 2008) compared to a tumor (Cerussi et al., 2006; 
Spliethoff et al., 2014; Su et al., 2015), so “stretching” of the skin in a subcutaneous model could 
certain affect measured μs’. Some groups have solved this issue by creating a fiber-optic needle 
that penetrates the skin layer to sample μs’ at the center of allograft or xenograft tumors 
(Spliethoff et al., 2014). Interestingly, tumor size negatively and significantly correlated with 
StO2 and HbO2 (Figure 31(c, d), Tables 18, 21, 24, 27, and 30) in only the saline control (R=-
0.363 and -0.312, p=0.002 and p=0.009) and isotype control groups (R=-0.484 and -0.516, 
p<0.001 and p<0.001), but not the treatment groups. This indicates that in control groups, as 
tumor size increases, StO2 and HbO2 decreases, indicating a more hypoxic tumor 
microenvironment with tumor growth. Furthermore, tumor hypoxia, as seen in the control tumors 
here, have been linked to tumor progression (Vaupel et al., 2006), which is what these results 
indicate. Spectroscopically-derived StO2 and HbO2 (StO2 * THC) have been shown to be 
correlated with tumor hypoxic fraction, validated with pimonidazole, an established hypoxia 
biomarker (Dadgar et al., 2018). These studies by Dadgar et al. showed that DRS-based 
measurements of StO2 and HbO2 can indirectly and non-invasively quantify tumor hypoxia 
(Dadgar et al., 2018). Although there was a correlation between tumor size and HbO2 in control 
tumors in this study, other groups have shown that hypoxia cannot be predicted by tumor size 
alone (Walsh et al., 2014), which perhaps partially explains why there was no correlation 
between tumor size and HbO2 in experimental treatment groups. There were no correlations 
between tumor size and THC, except in the immunotherapy group (R=0.282, p=0.029). Although 
tumor size did correlate with many DRS-based metrics, it should be noted that volumetric 
measurements of allograft or xenograft tumors via external calipers is highly affected by error. 
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More accurate ways of measuring tumor size include micro-computed tomography (microCT) 
(Jensen et al., 2008).  
The next topic of discussion is the effect of treatment on the DRS-derived perfusion 
metrics, StO2, THC, and HbO2. StO2 is the tissue oxygen saturation, which is a metric of 
assessing oxygen saturation, and is defined as the oxygen saturation averaged over the arterio-
venous network (Christen et al., 2014). Optical methods quantifying StO2, including DRS and 
near-infrared spectroscopy (NIRS), has already made its way to the clinic, where it is currently 
being used to noninvasively alert clinicians of peripheral hypoperfusion and tissue hypoxia at the 
patient bedside (Epstein et al., 2014). THC is the volume-averaged total hemoglobin, given as a 
concentration, of the tissue sampled by spectroscopic methods (G.J. Greening et al., 2018; 
Rajaram, Gopal, et al., 2010). HbO2 is simply the amount of oxygenated hemoglobin from the 
total hemoglobin content and is mathematically a simple product of StO2 and THC (Quincy 
Brown et al., 2009; G.J. Greening et al., 2018). Raw values for volume-averaged StO2 ranged 
from 3% to 63% (Figure 12). These StO2 values are comparable to other spectroscopy-based 
cancer studies (G.J. Greening et al., 2018; G. J. Greening et al., 2018; Palmer et al., 2009; 
Spliethoff et al., 2014). It is important to note that these raw values are lower than what is 
expected of arterial oxygen saturation (SaO2), which is typically between 96% to 98% measured 
via pulse oximetry (Collins et al., 2015). Raw values for volume-averaged THC ranged between 
1.54 mg/mL to 3.42 mg/mL (Figure 13), corresponding to blood volume fractions of 0.95% to 
2.28%, based on the well-established assumption that the concentration of hemoglobin in whole 
blood is 150 mg/mL (Prahl, 1999). These THC/blood volume fraction values are comparable to 
other spectroscopy-based cancer studies (Rajaram, Gopal, et al., 2010; Spliethoff et al., 2014). 
Based on these comparisons to literature, it was reasonable to assume that HbO2 values were as 
367 
 
expected, although studies explicitly reporting spectroscopy-derived HbO2 are uncommon. Raw 
values for volume-averaged HbO2 ranged between 0.05 mg/mL to 1.79 mg/mL (Figure 14).    
Tables 12 and 14 shows the statistics for raw StO2, THC, and HbO2; however; tables 13 
and 15, which shows statistics for normalized StO2, THC, and HbO2, is perhaps more important 
since these metrics are normalized to the value at day 0. This allows for comparisons between 
mice that may have had different initial StO2, THC, and HbO2 values. Within each treatment, 
neither StO2, THC, and HbO2 significantly changed from baseline (Figures 17-19). However, 
there were several noteworthy trends that may show significance with increased sample power.  
By day 7, StO2 and HbO2 in the saline control group decreased to 75% ± 5% and 78% ± 
6% of baseline values, respectively, whereas THC barely increased to 104% ± 6% of baseline 
values, although all changes were insignificant (Figure 27-29). Similarly, by day 7, StO2 and 
HbO2 in the isotype control group decreased to 73% ± 21% and 70% ± 10% of baseline values, 
respectively, whereas THC remained at exactly that of baseline values (100% ± 15%), although 
all changes were insignificant (Figure 27-29). In the immunotherapy group, by day 7, StO2 and 
HbO2 increased to 102% ± 28% and 128% ± 56% of baseline values, respectively, whereas THC 
increased to 120% ± 26% of baseline values, although all changes were insignificant (Figure 27-
29). It is worth noting that there was a large increase in standard deviation of the 
immunotherapy-treatment group compared to the isotype control group, indicating variability in 
treatment effect within subjects. In the chemotherapy group, by day 7, StO2 and HbO2 increased 
to 130% ± 37% and 136% ± 44% of baseline values, respectively, whereas THC increased to 
106% ± 15% of baseline values, although all changes were insignificant (Figure 27-29). Again, 
standard deviations were much greater compared to the saline control group. Finally, in the 
combination-treatment group, by day 7, StO2 and HbO2 increased to 125% ± 22% and 137% ± 
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31% of baseline values, respectively, whereas THC barely increased to 108% ± 7% of baseline 
values, although again all changes were insignificant (Figure 27-29). Another noteworthy find 
was the oxyhemoglobin flare on day 1 in the chemotherapy-treatment group (144% ± 62% 
compared to day 0 baseline) (Figure 29). Although there was a high standard deviation with no 
significance, three mice had tumors had HbO2 flares that doubled compared to baseline (213%, 
230%, and 257%) and 6 of 11 mice experience HbO2 flares in the chemotherapy-treatment 
group. However, subject-to-subject variability was high. In the future, the DRS-derived HbO2 
metric will be correlated to survival. For example, the question can be asked: do these mice with 
tumors that experience an increase in HbO2 one day post-chemotherapy have increased survival 
compared to those that experience no HbO2 flare or a decreased HbO2 flare? In 2011, Roblyer et 
al. found that an HbO2 flare one day post-treatment correlated with increased neoadjuvant 
chemotherapy response in human breast cancer patients (Roblyer et al., 2011). This is important 
because many patients receiving neoadjuvant chemotherapy do not achieve any measurable 
response while undergoing toxic chemotherapy. Thus, optical spectroscopy techniques such as 
DRS may be beneficial in evaluating a patient’s (or mouse) early response to therapy, and, if it 
has been shown to correlate with survival, can guide clinicians in deciding whether to continue 
with treatment, switch treatments, or proceed more quickly to surgery to reduce unnecessary 
toxic side effects (Roblyer et al., 2011; A.S. Walker et al., 2014). This indicates that DRS may 
be useful as a future complimentary tool to monitor early tumor therapeutic response in colon 
cancer. Next, at 7 days post-treatment, HbO2, a marker currently being explored as a functional 
prognostic cancer marker, trended to increase in immunotherapy, chemotherapy, and 
combination therapy groups compared to their appropriate controls (p=0.315, 0.149, and 0.190).  
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StO2 correlated with THC in the saline control, immunotherapy-treatment group, and 
chemotherapy-treatment groups, while not correlating with THC in the isotype control and 
combination-treatment groups (Figure 31). However, the author cautions to not look too deeply 
into these significant results. Since the change in THC over the 7-day treatment period was 
insignificant for all treatment groups and lacked any relevant or interesting trends, it can be 
concluded that, in this study, THC did not change in response to treatment. Therefore, any 
significance in the correlation between StO2 and THC is likely a false positive due to low-
powered data (Figure 31). There was always a necessary significant correlation between StO2 
and HbO2 since these metrics are mathematically related.   
While StO2, and HbO2 are often used as an indicator of tissue/tumor health, it has been 
suggested that these metrics can fail as reliable indicators in certain circumstances (Boas et al., 
2011). For example, StO2 alone cannot detect differences in oxygen delivery or utilization 
between tumors of different treatment groups or even within a single treatment group. 
Furthermore, in breast cancer, StO2 alone values measured via optical techniques can fail to 
distinguish malignant from non-malignant lesions (Boas et al., 2011). However, by combining 
several metrics such as StO2, THC, HbO2, and μs’, along with anatomical tumor size measured 
via external calipers, DRS may be able to overcome this limitation. Although not explicitly 
studied in these experiments, DRS can also provide data on scattering exponent, average blood 
vessel radius, fat content and water content (Rajaram et al., 2016; Rajaram et al., 2015; Rajaram, 
Reichenberg, et al., 2010; Spliethoff et al., 2016; Spliethoff et al., 2014). However, since these 
studies indicated no changes in THC or μs’ in response to therapy, or in response to simple tumor 
growth in control animals, and since HbO2 values are determined in part by StO2, it’s possible 
DRS may be limited in providing reliable information to clinicians making vital decisions in 
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managing their patients’ therapy regimens. DRS combined with other imaging techniques such 
as high-resolution microendoscopy (Parikh et al., 2014), or spectroscopic techniques such as 
Raman spectroscopy (Jenkins et al., 2016) or hyperspectral imaging (Awan et al., 2018) may be 
more valuable than single-modality DRS. 
6.12 Conclusion  
Colorectal cancer is still one of the most prominent cancer types within the United States. 
Although current treatment standards (neoadjuvant therapy, surgery, and adjuvant therapy) treat 
a wide spectrum of cancer patients, recurrence, patient heterogeneity, toxicity, and poor survival 
rate remain problematic. Therefore, research into antibody-based immunotherapies in both 
clinical and pre-clinical settings is highly active. Clinical research into immune checkpoint 
inhibitors is more mature than cytokine-targeted immunotherapy. At present, cytokine-targeted 
immunotherapy is limited to anti-VEGF, anti-VEGFR, and anti-EGFR therapies for mCRC 
patients, although there is a growing interest in interleukin and chemokine therapies in both pre-
clinical and early clinical trials. Additionally, monitoring CRC tumor response is a major 
problem, and investigators are continuing to engineer optical methods to improve the state-of-
the-art. One of the biggest emerging challenges for immunotherapy in CRC is elucidating the 
genomic biomarkers for identifying patients likely to be responders or non-responders for certain 
immunotherapy regimens and monitoring response in real-time (Kather et al., 2018). In this 
study, DRS probe was applied to subcutaneous murine colon tumors undergoing either antibody 
immunotherapy or standard 5-fluorouracil chemotherapy. Mice treated with a combination of 
these therapies showed reduced tumor growth compared to saline control, isotype control, 
immunotherapy, and chemotherapy groups 7 days post-treatment. Additionally, at 7 days post-
treatment, oxyhemoglobin, a marker currently being explored as a functional prognostic cancer 
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marker, trended to increase in immunotherapy, chemotherapy, and combination therapy groups 
compared to controls. Also of interest, an oxyhemoglobin flare was shown in tumors treated with 
chemotherapy, indicating that DRS may be useful as a complimentary tool to monitor early 
tumor therapeutic response in colon cancer. However, subject-to-subject variability was high and 
studies correlating survival to early oxyhemoglobin flares are suggested. Additionally, single-
modality DRS may be limited in providing clinicians reliable clinical information, and it is 
suggested to combine DRS with other endoscopically-compatible imaging or spectroscopic 
methods. Finally, ongoing research in the Muldoon laboratory at the University of Arkansas is 
analyzing the correlation of DRS-derived metrics with TAMs in the tumor microenvironment, 
which will provide valuable microscopic information about how immunotherapy and 
chemotherapy affect immune cell populations.   
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Chapter 7: Conclusion 
 
Colorectal cancer is the 4th most common and 2nd deadliest cancer. Problems exist with 
predicting which patients will respond best to certain therapy regimens. Diffuse reflectance 
spectroscopy has been suggested as a candidate to optically monitor a patient’s early response to 
therapy and has been received favorably in experimentally managing other cancers such as breast 
and skin. In this dissertation, two diffuse reflectance spectroscopy probes were designed: one with 
a combined high-resolution microendoscopy modality, and one that was optimized for acquiring 
data from subcutaneous murine tumors. 
For Specific Aim 1, our objective was to Develop and validate a quantitative hybrid 
imaging and spectroscopy microendoscope to monitor dysplastic progression within epithelial 
tissues. Co-registration of both techniques is important because this technique can be potentially 
used to not only detect dysplasia using two different modalities, but also to monitor personalized 
response of sub-surface dysplastic lesions to anti-tumor therapy at multiple source-detector 
separations. Our central hypothesis was that High-resolution microendoscopy and DRS can be 
combined within a single optical probe to co-register image and spectral data of in vivo epithelia. 
With this multimodal system, epithelial morphological data can be correlated with quantitative 
spectroscopy data of the subsurface microenvironment, including associated optical properties. 
This multimodal microendoscopy approach encompasses both structural and spectroscopic 
reporters of perfusion within the tissue microenvironment and can potentially be used to monitor 
tumor response to therapy. This hybrid imaging and spectroscopy platform may be capable of 
collecting a wealth of information about the structural and functional properties of tissue at various 
imaging sites in ex vivo and in vivo models. The potential of this technique to be coupled to the 
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biopsy port of a conventional endoscope makes further clinical translation and complimentary 
optical biopsy in the oral cavity and other epithelial tissues feasible. For both probes, percent errors 
for estimating tissue optical properties (reduced scattering coefficient and absorption coefficient) 
were less than 5% and 10%, respectively. 
 For Specific Aim 2, our objective was to demonstrate a method for producing thin phantom 
layers with tunable optical properties using poly(dimethylsiloxane) (PDMS) as a substrate material 
at six discrete wavelengths (591, 631, 659, 691, 731, and 851 nm) at varying concentrations of 
titanium dioxide and nigrosin. Our central hypothesis was that thin, PDMS-based optical phantoms 
can accurately simulate the geometry and optical properties of target epithelia and can be used to 
tst the sensitivity of various imaging and spectroscopy equipment to heterogeneities. From the 
presented data, we provide lookup tables to determine appropriate concentrations of scattering and 
absorbing agents to be used in the design of PDMS-based phantoms with specific optical 
coefficients. In addition, heterogeneous phantoms, mimicking the layered features of certain tissue 
types, may be fabricated from multiple stacked layers, each with custom optical properties. These 
thin, tunable PDMS optical phantoms can simulate many tissue types and have broad imaging 
calibration applications in endoscopy, diffuse optical spectroscopic imaging (DOSI), or optical 
coherence tomography (OCT), among others.  
 For Specific Aim 3, our objectives were to (1) Design a DRS probe with four SDSs (0.75, 
2.00, 3.00, and 4.00 mm) to interrogate increasing tissue volumes between 450-900 nm. The goal 
was to quantify percent errors in extracting μa and μs’, and to quantify sampling depth into 
subcutaneous Balb/c-CT26 colon tumor allografts. Using an optical phantom-based experimental 
method, lookup-tables were constructed relating μa, μs’, diffuse reflectance, and sampling depth. 
(2) Examine whether blockade of monocyte recruitment via anti-CCL2 (macrophage 
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chemoattractant protein-1) leads to enhanced sensitivity of 5-FU (5-fluorouracil) therapy in a 
CT26-Balb/c mouse model of CRC, and whether this effect can be quantified via DRS. The 
oxyhemoglobin flare has not been quantified after combinatorial chemotherapy and 
immunotherapy, and furthermore, has not been quantified in colon cancer tumors. Can DRS be 
used to quantify the therapy-induced oxyhemoglobin flare in a mouse model of colon cancer? 
The central hypothesis is that tumors treated with immunotherapy will have increased tumor 
therapeutic response to chemotherapy, as measured via tumor size and DRS-derived metrics. 
This work shows that the DRS probe can accurately extract optical properties, and the resultant 
physiological parameters such as total hemoglobin concentration and tissue oxygen saturation, 
from sufficient depth within subcutaneous Balb/c-CT26 colon tumor allografts. Methods 
described here can be generalized for other murine tumor models. The diffuse reflectance 
spectroscopy probe was applied to subcutaneous murine colon tumors (n=61) undergoing either 
antibody immunotherapy or standard 5-fluorouracil chemotherapy. Mice treated with a 
combination of these therapies showed reduced tumor growth compared to saline control, isotype 
control, immunotherapy, and chemotherapy groups (p<0.001, <0.001, <0.001, and 0.046, 
respectively) 7 days post-treatment. Additionally, at 7 days post-treatment, oxyhemoglobin, a 
marker currently being explored as a functional prognostic cancer marker, trended to increase in 
immunotherapy, chemotherapy, and combination therapy groups compared to controls (p=0.315, 
0.149, and 0.190). Also of interest, an oxyhemoglobin flare (average increase of 1.44x from 
baseline, p=0.03 compared to controls) was shown in tumors treated with chemotherapy, 
indicating that diffuse reflectance spectroscopy may be useful as a complimentary tool to 
monitor early tumor therapeutic response in colon cancer. There were no differences observed 
for total hemoglobin content, reduced scattering coefficient, scattering exponent, or blood vessel 
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radius. However, subject-to-subject variability was high and studies correlating survival to early 
oxyhemoglobin flares are suggested. In this study, 5-fluorouracil (5-FU) was chosen as the 
chemotherapy agent. Fluorouracil-based chemotherapy, especially 5-FU, has been a staple in 
CRC treatment for nearly 60 years. For example, the FOLFOX chemotherapy regimen for colon 
and colorectal cancer (CRC) consists of 5-FU, leucovorin, and oxaliplatin. Besides FOLFOX, 
there are three other first-line treatments for CRC including FOLFIRI, FOLFOXIRI, and 
XELOX. FOLFIRI consists of 5-FU, leucovorin, and irinotecan hydrochloride. FOLFOXIRI 
consists of 5-FU, leucovorin, oxaliplatin, and hydrochloride. XELOX is slightly different in that 
it consists of oxaliplatin and capecitabine. Thus, in three of four common first-line treatments, 5-
FU is the common drug. To simplify study design, 5-FU was chosen as the only chemotherapy 
agent. It would also be interesting to perform this same study using oxaliplatin as the primary 
chemotherapy agent, since it is also used in three of four first-line treatments. In the body, 5-FU 
is converted to fluorodeoxyuridine monophosphate (FdUMP). FdUMP forms a complex with 
thymidylate synthase (TS), an enzyme that catalyzes deoxyuridine monophosphate (dUMP) 
to deoxythymidine monophosphate (dTMP), which is a DNA monomer and key for DNA 
replication. Thus, 5-FU-mediated depletion of dTMP results in cytotoxicity and apoptosis in the 
rapidly growing cells in CRC (Zhang et al., 2008). However, there are several remaining 
questions.  
The Tromberg group recently found that neoadjuvant chemotherapy causes an early (1-
day post treatment initiation) flare in tumor oxyhemoglobin (HbO2) in breast cancer patients that 
eventually show increased survival. Alternatively, breast cancer patients with tumors that did not 
have an early HbO2 had decreased survival. Why is this? What are the biological mechanisms 
contributing to this early chemotherapy-derived HbO2 flare? Can this HbO2 be observed in other 
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tumors, including in murine xenograft and allograft models? The HbO2 flare hasn’t widely been 
discussed in animal models. Can optical methods such as diffuse reflectance spectroscopy be 
used to accurately monitor the HbO2? Is the correlation of early HbO2 flares with positive 
neoadjuvant chemotherapy response universal to other cancers besides breast cancer? How will 
early knowledge of tumor HbO2 lead to improved therapy management? Many of these questions 
are currently open-ended and hot topics of research. These questions could be future avenues of 
research that the present dissertation work will help lead to. Thus, it is important to discuss what 
is currently known about these questions, what doors this dissertation research has closed, and 
what doors this dissertation research has opened.  
First, discussion will focus on the biological origin of the HbO2 flare. There are two 
current hypotheses in the field. First, it is possible that chemotherapy induction decreases cancer 
cellular metabolism leading to a decrease in the conversion of oxyhemoglobin to 
deoxyhemoglobin. Second, it is possible that chemotherapy induction increases perfusion to 
tissue. For the first hypothesis, HbO2 is formed when oxygen (O2) binds to heme, the iron-
containing compound of hemoglobin in red blood cells. During gas exchange, HbO2 forms in 
pulmonary capillaries and is transported to the rest of the body, where O2 serves as the final 
electron acceptor during oxidative phosphorylation. As a brief review, oxidative phosphorylation 
is the primary cellular metabolism pathway in which O2 is the final electron acceptor to produce 
adenosine triphosphate (ATP), the organic chemical that provides energy to most cellular 
processes. Thus, how does chemotherapy induction decrease cancer cellular metabolism and the 
conversion of oxyhemoglobin to deoxyhemoglobin? From the perspective of 5-FU, it is possible 
that the FdUMP-TS complex causes a decrease in cellular metabolism since TS is a known 
regulator of several critical cellular metabolic pathways (Chu et al., 1996). However, since the 
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Tromberg group reported the HbO2 in patients treated with a variety of different 
chemotherapy/immunotherapy drugs instead of 5-FU, including doxorubicin, cyclophosphamide, 
paclitaxel, carboplatin, trastuzumab, and bevacizumab, other mechanisms may be responsible 
(Tromberg et al., 2017; Roblyer et al., 2011). A 2016 study shows that chemotherapy increases 
the risk of metabolic syndrome in patients with breast cancer (Bicakli et al., 2016). However, 
exact biological mechanisms are unknown. A 2018 study by Gorini et al. stated that, “Many 
cancer therapies produce toxic side effects whose molecular mechanisms await full elucidation.” 
On interesting hypothesis is that because chemotherapy and radiation (including 5-FU) are 
known to increase intracellular reactive oxygen species (ROS) (Focaccetti et al., 2015), the ROS 
can lead to a mitochondrial imbalance of the normally tightly-regulated ROS production and 
detoxification, leading to a shift towards glycolysis (Warburg effect) and impaired oxidative 
phosphorylation (Liemburg-Apers et al., 2015), even in the presence of oxyhemoglobin (Liberti 
et al., 2016). In brief review, the Warburg effect is the phenomenon of tumor cells favoring 
glycolysis for their energy demands, even when there is enough oxygen for oxidative 
phosphorylation. If indeed the assumption is true that chemotherapy can lead to further shifts 
away from oxidative phosphorylation, this would support the hypothesis that cancer therapy can 
lead to a decrease in the conversion of oxyhemoglobin to deoxyhemoglobin, resulting in an 
HbO2 flare (Tromberg et al., 2017; Roblyer et al., 2011), although it is unclear how this would 
correlate with increased survival. The Tromberg group also notes that a drop in 
deoxyhemoglobin, as well as oxyhemoglobin, should accompany a decrease in metabolism 
(Roblyer et al., 2011), although no changes in total hemoglobin (THC) were observed in our 
study. For the second hypothesis that chemotherapy induction increases perfusion to tumor 
tissue, it is suggested that ROS triggers downstream activation of HIF-1 transcription factor, 
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which progresses both angiogenesis and the metabolic switch to glycolysis (Constans et al., 
2011). Additionally, chemotherapy induction can cause an acute inflammatory response (Feng et 
al., 2017; Lian et al., 2017). Acute inflammatory response is marked by increased vascular 
permeability and vessel dilation over the course of hours to several days, potentially contributing 
to the increased HbO2 observed in our group and the Tromberg group. However, based on this 
hypothesis, it would have been expected to observe an increase in tumor THC as well, something 
that was observed in the Tromberg group but not in the present study. However, it is entirely 
possibly that tumor THC changes were masked by the overlying skin layer or inability to sample 
the entire tumor or intra-tumoral heterogeneities. Many previous studies have shown that clinical 
outcome has a positive correlation with serum inflammatory biomarkers such as IL-1, IL-6, and 
TNF-α (Roblyer et al., 2011). Forward studies can take several directions. First, switching from a 
subcutaneous model of colon cancer to a chemically-induced orthotopic model of colon cancer 
with a smaller probe compatible with the biopsy port of small animal colonoscopes may 
elucidate possible differences in both THC and HbO2 in treated vs. control tumors. Furthermore, 
further thin-film phantom studies are needed to elucidate DRS sensitivity to THC-based 
heterogeneities.  
This leads back into Specific Aim 2 in which there is a critical need to simulate 
epithelium-like structures in the field of biomedical optics (Greening et al., 2014). The phantoms 
created in Specific Aim 2 can mimic simple squamous epithelium in terms of the geometry and 
optical properties. Therefore, it would be of interest to combine study design from Specific Aims 
2 and 3 to test various DRS probes in monitoring a THC-based, rather than StO2-based, HbO2 
flare. Small (~100 μm) geometrical heterogeneities could be created, both at the surface and sub-
surface levels, with varying concentrations of hemoglobin-simulating absorbing agent to 
396 
 
elucidate DRS sensitivity to THC changes. Coupling this with measuring in vivo changes in 
tissues with known inflammation may provide more evidence for DRS in the clinical 
management of inflammatory-based diseases such as CRC. 
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Chapter 8: Appendix 
Protocols and Methodology 
Creating PDMS Phantoms 
1. Place a THINKY cup on the scale and zero out the weight of the THINKY cup. 
 
2. Dispense desired weight of Sylgard® 184 Silicone Elastomer Base into a THINKY cup. 
 
a. For making thin phantoms, dispense between 6.5-7.0 grams of elastomer base. 
 
3. Record, to the nearest hundredth, the amount of Sylgard® 184 Silicone Elastomer Base 
dispensed. 
 
4. Open the MATLAB program called PDMSphantom.m. 
 
5. Run the program. 
 
6. Type a reference wavelength. For most purposes, type “621”. 
 
7. Type the desired reduced scattering coefficient (cm-1) at this reference wavelength. 
 
8. Type the desired layer thickness (μm). If you are making a thick phantom, just type in any 
number. 
 
9. Type in the measured weight of the PDMS elastomer base from step 3. 
 
10. The output parameters will be displayed in the Command Window. 
 
11. Weigh out an appropriate amount of titanium dioxide in a weigh boat and dispense into the 
THINKY cup containing the PDMS elastomer base. 
 
12. Place the mixture inside the tan plastic THINKY cup holder. 
 
13. Weigh the tan plastic THINKY cup holder.  
 
14. Put the cup holder containing the THINKY cup in the THINKY machine. 
 
15. Manually adjust the wheel so that the indicator is the same weight as measured in step 14. 
 
16. Run the mixture through two cycles (8 total minutes) of the THINKY machine. 
 
17. Using a micropipette, dispense the appropriate amount of curing agent inside the mixture. 
 
18. Repeat steps 14-17. 
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19. For creation of thin phantoms, follow the following steps: 
 
a. Begin a timer upon removal of the final mixture from the THINKY machine. 
 
b. After exactly 1 minute from removal, place the THINKY cup onto plastic petri dish 
and place in the oven at 70ºC for exactly 3 minutes.  
 
c. Remove from the oven. Exactly 1 minute after removal, dispense the PDMS mixture 
onto a silicone wafer in the Spin Coater.  
 
d. Run the Spin Coater on the desired settings. 
 
e. After completion, remove the silicone wafer from the Spin Coater and immediately 
place in the oven at 70ºC for 2 hours. 
 
f. Remove the silicon wafer from the over after 2 hours of curing at 70°C. 
 
20. For creation of thick phantoms or phantoms in a mold, follow the following steps: 
 
a. Remove the mixture from the THINKY machine. 
 
b. Poor mixture into desired mold. 
 
c. Place mold into vacuum chamber. 
 
d. Ensure that the downstream vacuum tubes in the fume hood are clamped off with 
surgical clamps such that the only path is from the vacuum to the vacuum chamber. 
 
e. Plug in the vacuum. 
 
f. Turn the knob on the vacuum so that air is getting sucked out. If you are unsure, you 
should start seeing bubbles appear at the top of the PDMS mixture between 1-5 
minutes. 
 
g. Leave the phantom in the vacuum chamber for 1 hour. 
 
h. Slowly let air back into the vacuum chamber.  
 
i. Remove mold from vacuum chamber.  
 
j. Place mold in the oven for 2 hours at 70°C to complete the curing process.  
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SCS Spincoat G3P-8 
1. Turn on the power in the back of the machine. 
 
2. Turn on the vacuum pump. 
 
3. Turn on the air valve. This will activate the main menu screen.  
 
4. Change to channel 10 on the Spincoat G3P-8. 
 
5. Click Mode on the control panel to get to the settings menu. 
 
6. Scroll through the steps until you reach Step 0. Set the Ramp to 0, the RPM to 0, and the Dwell 
to 0. 
 
7. Scroll through the steps until you reach Step 1. Set the Ramp to 0, the RPM to 0, and the Dwell 
to 1. 
 
8. Scroll through the steps until you reach Step 2. Set the Ramp to 4, the RPM to any desired 
value, and the Dwell to 20. 
 
9. Scroll through the steps until you reach Step 3. Set the Ramp to 4, the RPM to 0, and the Dwell 
to 1. 
 
10. Scroll through the steps until you reach Step 5. Set the Ramp to 0, the RPM to 0, and the Dwell 
to 0. 
 
11. Click Enter to save the settings. 
 
12. Click Mode on the control panel to get back to the home screen. 
 
13. Place the large circular white chuck onto the Spincoat G3P-8. 
 
14. Test run the spin coater to make sure everything is working. 
 
15. If everything is working, turn off the vacuum and air pump for now until the spin coater is 
ready to be used. 
 
16. Place a silicone wafer on the chuck.  
 
17. Close the lid. 
 
18. Run  
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Creating Multi-Layered Phantoms 
1. Remove the silicon wafer from the over after 2 hours of curing at 70°C. 
 
2. Put on latex or nitrile gloves. 
 
3. Without scratching the silicon wafer, peel off the PDMS layer. If all steps were followed 
completely, the layer should peel off fairly easily. 
 
Note: If you make a phantom layer that is 200 microns or thinner, peeling the layer off the 
silicon wafer will be difficult, but possible. Some tearing, especially at first, is expected. 
 
4. Lay the layer as flat as possible on a clean surface, such as in the petri dish.  
 
5. With a disposable scalpel or razor blade, cut a square approximately 1.5 x 1.5 centimeters.  
 
6. Place this square layer over another layer using tweezers. Be careful not to squeeze the layer 
too hard.  
 
7. After the application of one layer on top of another layer, you must place the entire system in 
a vacuum chamber. 
 
8. Use the vacuum chamber to vacuum the system so that the single layer can adhere to the base 
layer underneath. Vacuum for at least 40 minutes or until there are no air bubbles between 
phantom layers 
 
9. Once there are no air bubbles between layer interfaces, continue adding more layers and 
vacuuming until the multi-layered phantom is complete. 
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Software Implementation for the DRSME 
Downloading Software for Dual-Camera System in LabVIEW 
Note that software and firmware versions listed in this protocol will likely have been updated 
since the time of this publication. 
1. Obtain 2 Point Grey monochrome Flea3 USB cameras (model number FL3-U3-13S2M-CS) 
 
2. Go to the following URL: https://www.ptgrey.com/support/downloads  
 
3. Login 
 
4. Product Families: Flea3 
 
5. Camera Models: FL3-U3-32S2M-CS 
 
6. Operating System: Windows 7 64bit 
 
7. Search 
 
8. Click “Software” 
 
9. Download FlyCapture 2.9.3.11 SDK - Windows (64-bit) — 02/15/2016 - 251.1416MB under 
the heading of Latest FlyCapture2 Full SDK 
 
10. Click “Install” → Next → Check “I accept the terms in the License Agreement” → Next → 
Next 
 
11. Enter the appropriate full name, organization, and email. 
 
12. Check “Anyone who uses this computer” 
 
13. Check “Automatically register with PGR via the internet” → Next → Next 
 
14. Click “Complete” 
 
15. Check “I will use USB Cameras” and then check “Install PGRUSBCam – Point Grey USB 
Camera Driver” and then uncheck “Install USBPro – Point Grey USB Interface Driver” → 
Next 
 
16. Check “Click to Confirm” 
 
17. Check “FlyCapture 2 will manage processor idle states” 
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18. Check “The installer will register the DirectShow dlls” → Next → Install → Finish 
 
19. Go to the following URL: https://www.ptgrey.com/support/downloads 
 
20. Login 
 
21. Camera Family: Flea3 
 
22. Model Number: FL3-U3-13S2M-CS 
 
23. Operating System: Windows 7 x64 
 
24. Search 
 
25. Click “Firmware” 
 
26. Download “Flea3 USB3 2.7.3.0 Firmware” 
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Creating Dual-Camera System in LabVIEW 
1. Connect both Flea3 cameras to the computer 
 
2. Open FlyCapture: Start menu → type “Point Grey FlyCap2” → Click “Point Grey FlyCap2”  
 
3. Open the UpdatorGUI utility: Start menu → type “UpdatorGUI3” → Click “UpdatorGUI3” 
 
4. Select one of the cameras 
 
5. Click “Open” to select the firmware file (C:\Program Files (x86)\Point Grey Research\Flea3 
USB3 2.7.3.0 Firmware\fl3-u3-2.07.3-00.ez2) 
 
6. Click “Update” 
 
7. Repeat steps 36-38 for the second camera (make sure you wait for the update to finish on the 
first camera before proceeding to the second camera) 
 
8. Download National Instruments’ Vision Acquisition Software 
 
9. Extract all the files to C:\Program Files (x86)\National Instruments 
 
10. Once installation of “NI Vision Acquisition Software February 2014” has finished, open the 
Driver Control GUI: Start menu → type “DriverContolGUI” → Click “DriverControlGUI”  
 
11. Click the “USB” tab (loading may take a few moments) 
 
12. Select “Point Grey USB3 Vision Camera” 
 
13. Select “Third-Party Drivers” → then select the driver that is listed under the menu  
(“NI: niu3vk.inf 1.1.0.49152”) 
 
14. Click “Install Driver” 
 
15. Repeat steps 42-46 for the second camera 
 
16. Both cameras will now be listed as “NI-IMAQdx USB3 Vision Device” 
 
17. Start → Type “MAX” → Click “NI MAX” (Make a shortcut for this on the desktop) 
 
18. On the Configuration Tree, click “My System” → “Devices and Interfaces”  
 
19. Both cameras will be listed as “Point Grey Research Flea3 FL3-U3-32S2M 
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Using Cameras in FlyCapture 
1. Open the “DriverControl GUI.” 
 
2. Navigate to the USB tab. 
 
3. Locate one of the “NI-IMAQdx USB3 Vision Device” devices and highlight it. 
 
4. On the right, select “Point Grey Drivers.” 
 
5. In the drop down menu, click “USB Camera (Signed) 2.6.3.0” 
 
6. Click “Install Driver” 
 
7. The device will now be listed as “Point Grey USB3 Vision Camera” 
 
8. Exit the DriverControlGUI. 
 
9. Open FlyCapture. 
 
10. Highlight the camera. 
 
11. Click “Configure Selected” in the lower right corner. 
 
12. Click “Advanced Camera Settings” in the menu on the left. 
 
13. Under “Memory Channel,” select “Default” 
 
14. Click “Restore” and then save. 
 
15. Do this for the other camera and both will revert back to their original settings. 
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Running Spectrometer in LabVIEW 
1. Go to http://www.oceanoptics.com/Technical/softwaredownloads.asp 
 
2. Navigate to the OmniDriver+SPAM Windows Version (32-bit) – The current version is 2.37. 
 
3. Click the “Windows Version (32-bit)” link to run the installer.  
 
4. Run the Installer.  
 
5. Select English as the language. 
 
6. Select the “Redistributable version (for end-users)” 
 
7. Select the Installation Directory (you shouldn’t have to change this), but if you do it should be 
C:\Program Files (x86)\Ocean Optics\OmniDriverSPAM. 
 
8. Check Yes for “Install VCREDIST silently” → Next 
 
9. Finish the installation. 
 
10. Visit the following link to set up an introductory LabVIEW GUI to run the USB2000+VIS-
NIR-ES spectrometer with LabVIEW: https://www.youtube.com/watch?v=tT5C43D3rRA  
 
11. Note: The spectrometer will not run with LabVIEW and SpectraSuite at the same time. 
 
12. Note: To access the Wrapper library that contains all the LabVIEW sub-vi’s for the 
spectrometer, navigate to C:\Program Files (x86)\Ocean 
Optics\OmniDriverSPAM\labview\win32\Version8.5 and then click “Wrapper.llb” 
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Arduino IDE and Libraries 
1. Go to http://arduino.cc/en/main/software 
 
2. Download Arduino 1.0.5 by clicking the link titled “Windows Installer” 
 
3. Open the Installer. 
 
4. Install the Arduino software. 
 
5. Go to https://learn.adafruit.com/adafruit-motor-shield-v2-for-arduino/install-software 
 
6. Click the green box that is titled “Download latest Adafruit Motor Shield V2 Library” 
 
7. Navigate to C:\Program Files (x86)\Arduino\libraries 
 
8. Create a new folder titled “Adafruit_Motorshield” 
 
9. Open the contents of the downloaded .zip file 
 
10. Copy all the material in the downloaded .zip file 
 
11. Paste all the material from the .zip file to the “Adafruit_Motorshield” folder created in step 8. 
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LabVIEW Interface for Arduino (LIFA) 
1. Go to http://www.ni.com/download/ni-visa-5.4.1/4626/en/ 
 
2. Click the link for NI Downloader: NIVISA541full_downloader.exe (634.78 MB)  
 
3. Open the downloaded folder → Run 
 
4. Save the application (.exe) file to C:\Program Files (x86)\National Instruments\LabVIEW 
2012 
 
5. The National Instruments Downloader will begin the N-VISA download (this may take several 
minutes). 
 
6. When the download is complete, click “Open” 
 
7. Click OK to the prompt. 
 
8. In the “Unzip to folder:” box, copy “C:\National Instruments Downloads\NI-VISA\5.4.1” 
 
9. Check “Override files without prompting” 
 
10. Check “When done unzipping open: . \setup.exe” 
 
11. Click “Unzip.” A blue progress bar will appear. 
 
12. Once complete, click “Yes,” allowing the program to make changes on the computer. 
 
13. Next → when prompted for a Destination Directory, copy “C:\Program Files (x86)\National 
Instruments\” into the box (without the quotation marks) → Next → Next → Next 
 
14. Check “I accept the above 2 License Agreement(s)” → Next → Next 
 
15. NI-VISA 5.4.1 will now be installing. This will take several minutes.  
 
16. Once the installation is complete, restart the computer. 
 
17. Go to http://jki.net/vipm 
 
18. Download the free version of VI Package Manager. 
 
19. Open the Installer. 
 
20. Install VI Package Manager. 
 
21. Open VI Package Manager. 
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22. Browse to “LabVIEW Interface for Arduino” – Version 2.2.0.79 
 
23. Highlight the “LabVIEW Interface for Arduino” section. 
 
24. Click the “Install Package(s)” button. 
 
25. Accept the terms and conditions. 
 
26. After a few moments, a confirmation window will appear. Click “Finish.” 
 
27. Plug in the Arduino Uno R3 to the computer. 
 
28. Navigate to C:\Program Files (x86)\Arduino and click “arduino.exe” 
 
29. The Arduino IDE will open. 
 
30. Click File → Open, and browse to LIFA_Base.ino found in C:\Program Files (x86)\National 
Instruments\LabVIEW 2012\vi.lib\LabVIEW Interface for Arduino\Firmware\LIFA_Base 
 
31. Click LIFA_Base.ino 
 
32. Click Tools → Board → Arduino Uno 
 
33. Determine the COM port that corresponds to the Arduino by opening Device Manager and 
expanding “Ports (COM and LPT)” 
 
34. Go back to the Arduino IDE 
 
35. Click Tools → Serial Port → COMx (x is to be determined from step 17) 
 
36. Click the “Upload” button. 
 
37. If uploaded successfully, the firmware necessary to use the LabVIEW Interface for Arduino 
(LIFA) will be successfully installed. 
 
38. Close the Arduino IDE. 
 
39. Open LabVIEW 2012. 
 
40. Go to the Block Diagram 
 
41. Right-click → Search → Type “Arduino” → Place an “Init” and “Close” function onto the 
block diagram. Place the “Init” function somewhere on the left and the “Close” function 
somewhere on the right. 
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42. Right-click → Executive control → While Loop → Place the while loop in between (not 
surrounding) the “Init” and “Close” function. 
 
43. On the “Init” function, right-click “VISA-resource” → Create → Constant → change to COMx 
(Determine the COM correct port that corresponds to the Arduino by opening Device Manager 
and expanding “Ports (COM and LPT)”) 
 
44. On the “Init” function, right-click “Baud Rate (115200)” → Create → Constant → change the 
constant to 115200. 
 
45. On the “Init” function, right-click “Board Type (Uno)” → Create → Constant → change to 
Uno 
 
46. On the “Init” function, right-click “Connection Type (USB/Serial)” → Create → Constant → 
change to USB/Serial 
 
47. Right-click → Search → Type “Arduino” → Digital Write Pin (place inside while loop). 
 
48. Right-click → Search → Type “Arduino” → Set Digital Pin Mode (place inside while loop to 
the left of the icon you placed in step 8). 
 
49. From “Init,” connect “Arduino Resource” to “Arduino Research” on “Set Digital Pin Mode” 
 
50. From “Init,” connect “error out” to “error in” on “Set Digital Pin Mode” 
 
51. From “Set Digital Pin Mode,” connect “Arduino Resource” to “Arduino Research” on “Digital 
Write Pin” 
 
52. From “Set Digital Pin Mode,” connect “error out” to “error in” on “Digital Write Pin” 
 
53. From “Digital Write Pin,” connect “Arduino Resource” to “Arduino Research” on “Close” 
 
54. From “Digital Write Pin,” connect “error out” to “error in” on “Close” 
55. Create a control on the Digital I/O Pin on “Set Digital Pin Mode” and change to 13 in the front 
panel. 
 
56. Create a constant on the Pin Mode on “Set Digital Pin Mode” and change to Output 
 
57. From the Digital I/O Pin on “Digital Write Pin,” run a wire to the wire that is connected to the 
Digital I/O Pin control created in step 17. 
 
58. Go to the Front Panel. 
 
59. Right-click → LED → Round LED → place in Front Panel 
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60. Once this is place, move to the block diagram and place the LED icon (Boolean) inside the 
while loop. 
 
61. Right-click the LED icon in the block diagram → Change to Control 
 
62. Right-click → Search → Type “Boolean to” → click “Boolean To (0,1) <<Conversion>> → 
click “Boolean To (0,1)” 
 
63. Connect the output of the LED to the input of the Boolean converter and the output of the 
Boolean converter to the input of the “Digital Write Pin” input called “Value” 
 
64. In the block diagram, click the icon that says “Clean Up Diagram” 
 
65. Save the VI as “LIFA_Verification_Test.vi” 
 
Reference Page 1 (Installing LIFA from VI Package Manager – Steps 17-26): 
http://digital.ni.com/public.nsf/allkb/A20FBBD36820669086257886004D5F4D 
 
Reference Page 2 (Installing LIFA Firmware onto Arduino Uno – Steps 27 – 37): 
http://digital.ni.com/public.nsf/allkb/8C07747189606D148625789C005C2DD6? 
 
 
 
66. Load the correct firmware onto the Arduino by completing steps 27-36 of Section 8. 
 
67. Exit the Arduino IDE then go back to the front panel on LabVIEW. 
 
68. Click the “run” arrow on the front panel. 
 
69. Turn the LED on and off. If the on-board LED on the Arduino blinks, then LabVIEW is 
successfully communicating with the Arduino. 
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Stepper Motor Control with LabVIEW 
1. Purchase the EasyDriver Stepper Motor Driver from Sparkfun: 
https://www.sparkfun.com/products/10267 
 
2. Solder connector pins on all the pins. 
 
3. Plug the EasyDriver into a breadboard (across the middle ridge). 
 
4. Run a jumper wire from “STEP” to the Arduino pin 2. 
 
5. Run a jumper wire from “DIR” to the Arduino pin 3. 
 
6. Run a jumper wire from “GND” (next to “STEP”) to the Arduino GND pin. 
 
7. In the top left of the EasyDriver PCB, you will see 4 pins in a row (2 “A” pins and 2 “B” pins). 
Going from A to B, connect the wires of the stepper motor in the following order: Grey, Green, 
Yellow, Red. 
 
8. Plug in the 9.6V, 300mA wall wart to the top right of the EasyDriver PCB (GND and M+). 
 
9. Flash the Arduino with the LIFA_Base firmware (steps 27-37 of section 8). 
 
10. Open LabVIEW → Help → Find Examples → Search → Type “Arduino” → Open “Arduino 
Stepper Motor.vi” 
 
11. Open the Block Diagram. 
 
12. On the “Init” terminal, create constants for the following parameters: VISA resource, Baud 
Rate, Board Type, and Connection Type. 
 
13. Keep the Baud Rate at 115200. 
 
14. Change the VISA resource to whatever COM port your Arduino is using.  
 
15. Open the Front Panel. 
 
16. Set the “Set Speed” to around 400, “# of Steps to Move” to 1600 (one full rotation), “Set 
Acceleration” to 0, the “Stepper #” to 1.  
 
17. Click Run. 
 
18. Finally, click “Start Stepping.” If everything worked properly, the stepper motor should make 
one counter clockwise rotation in 4 seconds (1600/400). 
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Cell Culture 
Equipment and Materials 
Item Distributor Item Number 
CT26.WT Colon Carcinoma Cells ATCC CRL-2638 
Gloves VWR 89038-270 
Laboratory Bench and Table Protector VWR 89126-790 
KimWipes VWR 470224-038 
95% Reagent Ethanol VWR BDH1156-4LP 
100% Isopropyl Alcohol VWR MK303206 
10% Bleach VWR 89501-620 
RPMI-1640 Medium VWR 71002-878 
Fetal Bovine Serum (FBS) ATCC 30-2020 
Antibiotic Antimycotic Solution (Pen/Strep) Sigma-Aldrich A5955-100ML 
Amphotericin B (AmpB)/Gentamicin (GM) Thermo Fisher R01510 
Dulbecco’s Phosphate Buffered Saline VWR 45000-434 
Trypsin-EDTA Solution, 1X VWR  VWRL0154-0100 
Dimethyl Sulfoxide (DMSO) VWR 97063-136 
Sterile Saline (0.9% NaCl) VWR S5825 
T75 Vented Cell culture Flask (Sterile) VWR 10861-650 
Nalgene Rapid-Flow Filter Units, 500 mL VWR  16211-054 
5 mL Serological Pipet Tip VWR 89130-896 
10 mL Serological Pipet Tip VWR 89130-898 
25 mL Serological Pipet Tip VWR 89130-900 
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Pipetting Device VWR 53498-001 
Variable Volume Pipettors VWR 75788-458 
Universal Shelf Clip for 3 Pipettors VWR 40000-272 
10 µL Pipette Tips (Sterile-Aerosol) VWR 89174-520 
100 µL Pipette Tips (Sterile-Aerosol) VWR 10126-388 
1000 µL Pipette Tip (Sterile-Aerosol) VWR 89174-530 
1000 µL Pipette Tip (Non-Sterile) VWR 83007-384 
15 mL Conical-Bottom Centrifuge Tubes VWR 89039-666 
50 mL Conical-Bottom Centrifuge Tubes VWR 89039-658 
Water Bath VWR 89501-464 
Parafilm M, Bemis VWR 52858-076 
Nalgene Cryo 1°C “Mr. Frosty” Container VWR 55710-200 
Cryogenic Vials, 2 mL, externally threaded VWR 66021-978 
Microcentrifuge Tube VWR 20170-038 
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Making RPMI-FBS Complete Growth Media 
 
Step 1: Preparation and Storage of Solutions 
1. Aliquot 100 mL of Pen/Strep into twenty 15 mL centrifuge tubes (5 mL each) 
2. Store 20 aliquots of 5 mL Pen/Strep at -20°C 
3. Store AmpB/GM (10 x 1 mL) at -20°C 
4. Aliquot 500 mL of FBS into ten 50 mL centrifuge tubes (50 mL each) 
5. Store 10 aliquots of 50 mL FBS at -20°C 
6. Store base RPMI media at 4°C. Label 
 
Step 2: Preparation 
1. Obtain the following supplies and spray into the hood 
a. 50 mL Fetal bovine serum (FBS) 
b. 5 mL Antibiotic Antimycotic Solution (Pen/Strep) 
c. 1 mL Amphotericin B (AmpB)/Gentamicin (GM) 
d. One (1) Base Media 
e. Twelve (12) 50 mL centrifuge tubes (2 for waste and 10 for media) 
f. Three (3) 25 mL serological pipette tips 
g. Two (2) 5 mL serological pipette tip 
h. One (1) Rapid-Flow Filter Unit (“hourglass bottles”) 
 
Step 3: Making and Filtering Media 
1. Dispense 56 mL of base media into the two (2) 50 mL conical vials 
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2. Put 50 mL of FBS directly into the base media bottle 
3. Put 5 mL of Antibiotic Antimycotic (Pen/Strep) into base media bottle 
4. Put 1 mL of AmpB/GM directly into the base media bottle  
5. Attach the aspiration tube to the filter bottle 
6. Dispense approximately 20 mL of media into the filter bottle 
7. Push down the foot pedal 
8. Wait for 20 mL of media to dispense to the bottom of the filter bottle 
9. Slowly pour in the rest of the media while continuing to push down foot pedal 
10. Wait for all media to dispense to the bottom 
11. Release the foot pedal 
12. Detach the aspiration tube 
 
Step 4: Aliquoting and Storing Media 
1. Unscrew the top of the filter bottle and throw away in Biohazard trash. 
2. Aliquot the 500 mL media into ten (10) 50 mL centrifuge tubes  
3. Remove complete media solutions from the hood 
4. Clean hood thoroughly with 70% EtOH 
5. Wrap Parafilm around the caps of the 50 mL centrifuge tubes 
6. Place 50 mL centrifuge tubes with media at 4°C 
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Feeding CT26 Cells 
 
Step 1: Preparation 
1. Place cell culture media in the 37.3°C water bath and wait 30 minutes 
2. Clean hood with 70% EtOH 
 
Step 2: Checking Cell Health 
1. Spray gloves with 70% EtOH and rub hands together thoroughly 
2. Remove tissue culture flask from incubator 
3. Visually inspect the flask for mold or cloudiness 
4. Set the flask on the microscope platform and turn lamp on 
5. Focus the cells 
6. Move the flask around above the objective to spot check for contamination 
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away 
8. Set flask it in the middle of the hood 
9. Place all necessary serological pipettes in the left side of the hood 
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media 
11. Spray in the 50 mL centrifuge tube with culture media into the hood 
12. Obtain one (1) 50 mL centrifuge tube for waste 
13. Loosen all caps slightly 
14. Fully open the cap of the 50 mL waste tube 
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Step 3: Media Dispensing 
1. Unscrew lid on tissue culture flask 
2. Put the pipette tip in the corner of the flask and remove old media 
3. Dispense old media into the 50 mL waste tube 
4. Screw the lid back onto the tissue culture flask 
5. Set the flask down in the hood 
 
Step 4: Media Addition 
1. Obtain 15 mL of media 
2. Unscrew the cap of the tissue culture flask 
3. Dispense 15 mL of media into the flask without introducing bubbles 
4. Gently swirl liquid around in the bottom of the flask 
5. Place flask in incubator until next feeding or passaging 
6. Clean everything appropriately 
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Passaging CT26 Cells 
 
Step 1: Preparation 
1. Place cell culture media in the 37.3°C water bath. 
2. Place PBS in the 37.3°C water bath 
3. Place 0.25% Trypsin-EDTA in the 37.3°C water bath 
4. Wait 30 minutes 
5. Clean hood with 70% EtOH 
 
Step 2: Checking Cell Health 
1. Spray gloves with 70% EtOH and rub hands together 
2. Remove tissue culture flask from incubator 
3. Visually inspect the flask for mold or cloudiness 
4. Set the flask on the microscope platform and turn lamp on 
5. Focus the cells 
6. Move the flask around above the objective to spot check for contamination 
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away 
8. Set flask it in the middle of the hood 
9. Place all necessary serological pipettes in the left side of the hood  
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media 
11. Spray in the 50 mL centrifuge tube with culture media into the hood 
12. Obtain two (2) 50 mL centrifuge tube for waste 
13. Obtain one (1) 15 mL centrifuge tube for centrifuging 
420 
 
14. Loosen all caps slightly 
 
Step 3: Media Dispensing 
1. Unscrew lid on tissue culture flask 
2. Put the pipette tip in the corner of the flask and remove old media 
3. Dispense old media into the 50 mL waste tube 
4. Screw the lid back onto the tissue culture flask 
5. Set the flask down in the hood 
 
Step 4: PBS Rinse 
1. Obtain 10 mL of PBS 
2. Unscrew lid on tissue culture flask 
3. Dispense the PBS in the tissue culture flask 
4. Screw lid back on tissue culture flask 
5. Gently swirl flask with a rocking motion for 20 seconds 
6. Unscrew lid on tissue culture flask 
7. Remove PBS 
8. Screw lid back on tissue culture flask 
9. Dispense PBS in 50 mL waste tube 
 
Step 5: Trypsin Re-Suspension 
1. Unscrew lid on tissue culture flask 
2. Obtain 5 mL of Trypsin-EDTA 
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3. Dispense the trypsin in the tissue culture flask 
4. Screw lid back on tissue culture flask 
5. Gently swirl flask with a rocking motion for 30 seconds 
6. Put the flask in the incubator for 3 minutes 
7. Remove flask from incubator 
8. Tap flask to break up cells from the bottom 
9. Place flask underneath the inverted microscope to ensure that cells are detaching 
10. Put tissue culture flask back in hood 
 
Step 6: Media Addition #1 
1. Obtain 4 mL of media 
2. Unscrew lid on tissue culture flask 
3. Dispense 4 mL of media into the flask (with the trypsin – total 9 mL) 
4. Gently swirl flask with a rocking motion for 20 seconds 
 
Step 7: Transfer to Centrifuge Tube  
1. Obtain a 15 mL centrifuge tube 
2. Remove all liquid from the tissue culture flask 
3. Dispense the liquid (9 mL) into the 15 mL centrifuge tube 
4. Set 15 mL centrifuge tube aside 
 
Step 8: Media Rinse 
1. Obtain 4 mL of media 
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2. Dispense 4 mL of media into the “empty” tissue culture flask 
3. Gently swirl flask with a rocking motion for 10 seconds 
4. Remove 4 mL of media 
5. Dispense the 4 mL of media into the centrifuge tube (total volume of 13 mL) 
 
Step 9: Centrifuging Cells #1 
1. Obtain the 15 mL centrifuge tube with 13 mL liquid 
2. Place the 15 mL centrifuge tube in the centrifuge 
3. Place the appropriate counter balance 
4. Spin the tubes at 200 RCF for 5 minutes at 4°C 
5. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood 
 
Step 10: Dispensing of Supernatant #1 
1. Unscrew the cap of the centrifuge tube 
2. Remove supernatant (media/Trypsin-EDTA), leaving the pellet intact 
3. Screw the cap gently back on the tube 
 
Step 11: Media Addition #2 
1. Obtain 10 mL of media 
2. Unscrew the cap of the centrifuge tube 
3. Dispense 10 mL of media into the tube (10 mL total)  
4. Pipette up and down to mix cells 
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Step 12: Counting Cells 
1. Dispense 80 μL of media into a microcentrifuge tube 
2. Dispense 20 μL of cells in media to the microcentrifuge tube 
3. Mix the tube well 
4. Obtain the hemacytometer 
5. Load both chambers by pipetting the suspension under the cover slip 
6. Place the hemacytometer on the microscope platform 
7. View the first chamber 
8. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes. 
9. Total the cell count from the first 5 boxes 
10. View the second chamber 
11. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes 
12. Total the cell count from the second 5 boxes 
 
Step 13: Plating New Cells 
1. Obtain one (1) new T75 tissue culture flask. 
2. Fill the tissue culture flask with 15 mL of media 
3. Place the required cell/media volume into the tissue culture flask  
4. Screw lid back on tissue culture flask 
5. Gently swirl flask with a rocking motion for 10 seconds 
6. Place tissue culture flask quickly in the incubator 
7. Clean everything appropriately 
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Freezing CT26 Cells 
 
Step 1: Preparing Freezing Container 
1. Obtain an empty (no cryovials) Mr. Frosty Freezing Container from the -80°C freezer 
2. Set on a paper towel 
3. Unscrew the cap 
 
Step 2: Complete Passaging Steps 
1. Complete either a P1, P2, or a P3 passage (see the appropriate protocol) 
2. Place DMSO in 37.3° water bath 
 
Step 3: Preparation for Freezing 
1. Obtain DMSO (50 µL required aliquot per freeze vial) 
2. Obtain the desired number of cryo-vials for storage 
3. Label the cryo-vials with date, initials, cell type, number of cells, and passage number 
4. Slightly unscrew the caps of the cryo-vials so they are loose 
 
Step 4: Creating Freeze Media 
1. Dispense the appropriate amount of media into each cryo-vial 
2. Obtain the centrifuge tube (with media and cells) 
3. Dispense the appropriate amount of cells/media into each cryo-vial 
4. Dispense the 50 µL DMSO into each cryo-vial 
5. Cap the cryo-vials 
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6. Gently mix 
7. Place cryo-vials into Mr. Frosty container 
8. Ensure Mr. Frosty has at least 1 inch of 100% isopropyl alcohol and refill as necessary 
9. Place Mr. Frosty container in -80°C freezer for 12 hours 
10. After 12 hours, remove Mr. Frosty container 
11. Transfer cryo-vials to liquid nitrogen dewar 
12. Clean everything appropriately 
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Thawing CT26 Cells 
 
Step 1: Preparation 
1. Place cell culture media in the 37.3°C water bath. 
2. Place PBS in the 37.3°C water bath 
3. Place 0.25% Trypsin-EDTA in the 37.3°C water bath 
4. Wait 30 minutes 
5. Clean hood with 70% EtOH 
6. Obtain a 50 mL centrifuge tube for liquid waste storage 
7. Obtain one T75 tissue culture flask and spray it into the hood. 
 
Step 2: Preparing T75 Flask 
1. Label T75 flask with initials, date, CT26, P#, and 5x105 
2. Loosen cap on the empty T75 flask 
3. Dispense 14 mL of cell culture media into the T75 flask 
 
Step 3: Preparing Cells 
1. Remove the cryovial with cells from liquid nitrogen Dewar 
2. Bring cryovial with cells to the 37.3°C warm water bath 
3. Thaw the cells in the water bath without submerging the cryovial lid 
4. When a small chunk of ice remains inside, remove from the water bath 
5. Wipe the vial with 70% EtOH on a Kimwipe. Do not directly spray the vial 
6. Place the cryovial vial into the hood 
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7. Loosen cap on cell vial 
 
Step 4: Plating Cells in T75 Flask 
1. Fill the tissue culture flask with contents of the thawed cryovial 
2. Screw caps gently back on tissue culture flask 
3. Gently swirl flask with a rocking motion for 30 seconds 
4. Place tissue culture flask quickly in the incubator  
5. Clean everything appropriately 
 
Step 5: Feeding Cells 
1. Feed cells within 24 hours (see the appropriate protocol) 
 
 
 
 
 
 
 
 
 
 
 
 
428 
 
Aliquoting CT26 Cells in Sterile Saline for Injection 
 
Step 1: Preparation 
1. Place cell culture media in the 37.3°C water bath. 
2. Place dPBS in the 37.3°C water bath 
3. Place saline in the 37.3°C water bath 
4. Place 0.25% Trypsin-EDTA in the 37.3°C water bath 
5. Wait 30 minutes 
6. Clean hood with 70% EtOH 
7. Obtain a small bucket of ice and set aside in freezer 
 
Step 2: Checking Cell Health 
1. Spray gloves with 70% EtOH and rub hands together 
2. Remove tissue culture flask from incubator 
3. Visually inspect the flask for mold or cloudiness 
4. Set the flask on the microscope platform and turn lamp on 
5. Focus the cells 
6. Move the flask around above the objective to spot check for contamination 
7. Spray the flask (but not the cap) with 70% EtOH, holding the bottle 12 inches away 
8. Set flask it in the middle of the hood 
9. Place all necessary serological pipettes in the left side of the hood  
10. Obtain the 50 mL centrifuge tube with 37.3°C culture media 
11. Spray in the 50 mL centrifuge tube with culture media into the hood 
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12. Obtain two (2) 50 mL centrifuge tube for waste 
13. Obtain one (1) 15 mL centrifuge tube for centrifuging 
14. Loosen all caps slightly 
 
Step 3: Media Dispensing 
1. Unscrew lid on tissue culture flask 
2. Put the pipette tip in the corner of the flask and remove old media 
3. Dispense old media into the 50 mL waste tube 
4. Screw the lid back onto the tissue culture flask 
5. Set the flask down in the hood 
 
Step 4: PBS Rinse 
1. Obtain 10 mL of PBS 
2. Unscrew lid on tissue culture flask 
3. Dispense the PBS in the tissue culture flask 
4. Screw lid back on tissue culture flask 
5. Gently swirl flask with a rocking motion for 20 seconds 
6. Unscrew lid on tissue culture flask 
7. Remove PBS 
8. Screw lid back on tissue culture flask 
9. Dispense PBS in 50 mL waste tube 
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Step 5: Trypsin Re-Suspension 
1. Unscrew lid on tissue culture flask 
2. Obtain 5 mL of Trypsin-EDTA 
3. Dispense the trypsin in the tissue culture flask 
4. Screw lid back on tissue culture flask 
5. Gently swirl flask with a rocking motion for 30 seconds 
6. Put the flask in the incubator for 3 minutes 
7. Remove flask from incubator 
8. Tap flask to break up cells from the bottom 
9. Place flask underneath the inverted microscope to ensure that cells are detaching 
10. Put tissue culture flask back in hood 
 
Step 6: Media Addition #1 
1. Obtain 4 mL of media 
2. Unscrew lid on tissue culture flask 
3. Dispense 4 mL of media into the flask (with the trypsin – total 9 mL) 
4. Gently swirl flask with a rocking motion for 20 seconds 
 
Step 7: Transfer to Centrifuge Tube  
1. Obtain a 15 mL centrifuge tube 
2. Remove all liquid from the tissue culture flask 
3. Dispense the liquid (9 mL) into the 15 mL centrifuge tube 
4. Set 15 mL centrifuge tube aside 
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Step 8: Media Rinse 
1. Obtain 4 mL of media 
2. Dispense 4 mL of media into the “empty” tissue culture flask 
3. Gently swirl flask with a rocking motion for 10 seconds 
4. Remove 4 mL of media 
5. Dispense the 4 mL of media into the centrifuge tube (total volume of 13 mL) 
 
Step 9: Centrifuging Cells #1 
1. Obtain the 15 mL centrifuge tube with 13 mL liquid 
2. Place the 15 mL centrifuge tube in the centrifuge 
3. Place the appropriate counter balance 
4. Spin the tubes at 200 RCF for 5 minutes at 4°C 
5. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood 
 
Step 10: Dispensing of Supernatant #1 
1. Unscrew the cap of the centrifuge tube 
2. Remove supernatant (media/Trypsin-EDTA), leaving the pellet intact 
3. Screw the cap gently back on the tube 
 
Step 11: Saline Addition #1 
1. Obtain 10 mL of saline 
2. Unscrew the cap of the centrifuge tube 
3. Dispense 10 mL of saline into the tube (10 mL total)  
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4. Pipette up and down to mix cells 
 
Step 12: Counting Cells 
1. Dispense 80 μL of media into a microcentrifuge tube 
2. Dispense 20 μL of cells in saline to the microcentrifuge tube 
3. Mix the tube well 
4. Obtain the hemacytometer 
5. Load both chambers by pipetting the suspension under the cover slip 
6. Place the hemacytometer on the microscope platform 
7. View the first chamber 
8. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes. 
9. Total the cell count from the first 5 boxes 
10. View the second chamber 
11. Count the cells in the top left, top right, bottom right, bottom left, and middle 4x4 boxes 
12. Total the cell count from the second 5 boxes 
 
Step 13: Centrifuging Cells #2 
1. Put the 15 mL centrifuge tube with cells into the centrifuge 
2. Place the appropriate counter balance 
3. Spin the tubes at 200 RCF for 5 minutes at 4°C 
4. Without disturbing the pellet, place the 15 mL centrifuge tube back in the hood 
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Step 14: Dispensing of Supernatant #2 
4. Unscrew the cap of the centrifuge tube 
5. Remove supernatant (sterile saline), leaving the pellet intact 
Screw the cap gently back on the tube 
 
Step 15: Saline Addition #2 
1. Obtain appropriate volume of warm sterile saline 
2. Dispense appropriate volume of saline into the tube 
3. Slowly pipette up and down to mix cells 
 
Step 16: Aliquot Cells into Microcentrifuge Tubes 
1. Obtain desired number of sterile microcentrifuge tubes 
2. Pipette 1x105 CT26 cells/sterile saline into each microcentrifuge tube 
3. Cap tubes 
4. Label tubes with CT26 
5. Place tubes on ice (pre-prepared from earlier step) 
6. Clean everything appropriately 
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Subcutaneous Injection of CT26 Cells into Balb/c Mice 
Equipment and Materials 
Item Distributor Item Number 
Gloves VWR 89038-270 
KimWipes VWR 470224-038 
Distilled Water Walmart 009594226 
Sterile Saline (0.9% NaCl) VWR S5825 
95% Reagent Ethanol VWR BDH1156-4LP 
10% Bleach VWR 89501-620 
28G U-100 BD Micro-Fine IV Syringe VWR BD329410 
Microcentrifuge Tubes VWR 20170-038 
Alcohol Swab VWR BD326859 
Water Bath VWR 89501-464 
Ear Punch, Scissor Style VWR  10806-292 
Aluminum Dissecting Pan Carolina 629210 
Lab Coat (Men’s) VWR 10141-300 
Lab Coat (Women’s) VWR 10141-316 
Analytical Balance VWR 10159-998 
Eye Gel CVS 332692 
Warm Water Pump Global Medical TP700 
Warm Water Pump Pad Kent Scientific TPZ-0510EA 
Valved In-Line Hose Barb Coupling Body Fresh Water Systems 42100 
Non-Valved In-Line Hose Barb Coupling Fresh Water Systems 40900 
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Rodent Trimmer Set Braintree Scientific CLP-9990 1201 
Nair Hair Remover Lotion Walmart 000287746 
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Subcutaneous Injection of CT26 Cells into Balb/c Mice 
 
Step 1: Preparation 
1. Clean all surfaces with 70% EtOH 
2. Set out the metal dissection pan 
3. Set up the anesthesia cart (see appropriate instructions) 
4. Turn on the hot water pump pad at least 30 minutes before the first injection 
5. Obtain necessary amount of 28G needles 
6. Obtain microcentrifuge tubes with aliquot of 1x105 CT26 cells in sterile saline in ice 
7. Draw up entire aliquot (150 μL) of 1x105 CT26 cells in sterile saline 
8. Get rid of any air bubbles in the needle 
 
Step 2: Anesthetizing Mouse 
1. Let mice become aware of presence for 30 seconds 
2. Remove mouse from cage 
3. Place the mouse in the mouse-isoflurane chamber 
4. Secure the lid on the mouse-isoflurane chamber 
5. Anesthetize mouse 
6. Remove mouse without grabbing the tail 
7. Place the mouse on the nosecone 
8. Put eye drop gel in the mouse’s eyes 
9. Ensure the mouse is on the nose cone for 30 seconds before proceeding 
10. Ear punch the mouse appropriately 
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11. Shave the tumor cell injection site 
 
Step 3: Subcutaneous Injection into Flank 
1. Hold the 28G needle at a 5-10° angle  
2. Place the needle 5 mm away from the spine at the level of the thigh 
3. Stretch the skin taught with the left hand 
4. Insert the needle so that it goes just underneath the skin at the upper thigh 
5. Lift the needle up to test that you have good skin penetration 
6. Inject slowly 
7. Withdraw needle 
8. Remove mouse from anesthesia 
9. Warm mouse up with your hand 
10. Place the mouse back in its cage once it’s awake 
11. Clean everything appropriately 
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Treatment Preparation 
Equipment and Materials 
Item Distributor Item Number 
5-Fluorouracil Sigma-Aldrich F6627-1G 
CCL2 (MCP-1) Monoclonal Antibody (2H5) Bio X Cell BE0185-A005MG 
CCL2 (MCP-1) Isotype Control Bio X Cell BE0091-A005MG 
15 mL Conical-Bottom Centrifuge Tubes VWR 89039-666 
Dimethyl Sulfoxide (DMSO) VWR 97063-136 
Microcentrifuge Tubes VWR 20170-038 
80-Place Storage System VWR 30128-276 
Sterile Saline (0.9% NaCl) VWR 101320-574 
Gloves VWR 89038-270 
KimWipes VWR 470224-038 
Variable Volume Pipettors VWR 75788-458 
Universal Shelf Clip for 3 Pipettors VWR 40000-272 
10 µL Pipette Tips (Sterile-Aerosol) VWR 89174-520 
10 µL Pipette Tips (Sterile) VWR 89368-970 
100 µL Pipette Tips (Sterile-Aerosol) VWR 10126-388 
100 µL Pipette Tips (Sterile) VWR 89140-162 
1000 µL Pipette Tip (Sterile-Aerosol) VWR 89174-530 
1000 µL Pipette Tip (Sterile) VWR 83007-380 
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Preparation of 5-Fluorouracil Chemotherapy 
 
Quantity per Container 1 g 
Dose Schedule Daily 
Dose per Day 15 mg/kg/day 
5-FU per Injection (15 g to 30 g mouse) 0.225 – 0.450 mg 
5-FU per Injection in Microcentrifuge Tube 1 mg 
Injections (cohort 1) 2 
Injections (cohort 2) 4 
Injections (cohort 3) 7 
Injection Method Intraperitoneal 
 
Step 1: Making 5-FU 
1. Determine the number of injections you want to make 
2. Prepare the biosafety cabinet 
3. Obtain container of 5-FU and spray into hood 
4. Obtain a 50 mL centrifuge tube 
5. Label the 50 mL centrifuge tube with 40 mg/mL 5-FU/DMSO, initials, and date 
6. Dispense 25 mL DMSO into 50 mL centrifuge tube 
7. Dispense entire bottle (1 g) of 5-FU into 50 mL centrifuge tube 
8. Remove solution from the hood 
9. Vortex for 30 minutes at room temperature or until completely dissolved 
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Step 2: Pre-Preparation of 5-FU 
1. Obtain a 15 mL centrifuge tube 
2. Dispense 5 mL of 40 mg/mL 5-FU/DMSO into 15 mL centrifuge tube 
3. Dispense 5 mL of sterile saline into 15 mL centrifuge tube 
4. Label the 15 mL centrifuge tube with 20 mg/mL 5-FU/Saline 
5. Remove solution from the hood 
6. Vortex for 1 minute or until completely dissolved 
7. Store both solutions permanently at -20°C 
 
Step 3: Preparing 5-FU for Injection 
1. Obtain normal sterile saline 
2. Remove 20 mg/mL 5-FU/Saline from -20°C 
3. Obtain desired amount of 1.5 mL microcentrifuge tubes 
4. Sterilize microcentrifuge tubes in autoclave 
5. Place 23 μL of 20 mg/mL 5-FU/Saline in microcentrifuge tubes  
6. Place 130 μL of saline in each tube to get a 3 mg/mL concentration of 5-FU/saline 
7. Place 20 mg/mL 5-FU/Saline solution back in -20°C 
8. Store aliquots at -20°C 
 
Calculations: 
1. Minimum Daily Dose of 5-FU per Mouse (15 g mouse)  
[
15 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [15 𝑔] = 0.225 𝑚𝑔 
2. Maximum Daily Dose of 5-FU per Mouse (30 g mouse) 
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[
15 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [30 𝑔] = 0.450 𝑚𝑔 
3. Total Number of 5-FU Injections 
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [
5 𝑚𝑖𝑐𝑒
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
] ∙ [(
2 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 1
) + (
4 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 2
) + (
7 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 3
)]
= 130 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 
4. Total 5-FU used: 
[130 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [
0.450 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛
] = 58.5 𝑚𝑔 
5. DMSO Measurement for 40 mg/mL 5-FU/DMSO Storage Solution 
𝑉𝐷𝑀𝑆𝑂 = [
1 𝑚𝐿
40 𝑚𝑔
] ∙ [𝑥 𝑚𝑔] = 25 𝑚𝐿 
6. Recovering 0.450 mg of 5-FU (for a 30 g mouse) per Microcentrifuge Tube 
[
1 𝑚𝐿
20 𝑚𝑔 5𝐹𝑈
] ∙ [0.450 𝑚𝑔 5𝐹𝑈] ∙ [
1000 𝜇𝐿
1 𝑚𝐿
] = 22.5 𝜇𝐿 
7. Required Saline per 5-FU Aliquot 
𝑉𝑇𝑜𝑡𝑎𝑙(𝜇𝐿) = [
20 𝑚𝑔 5𝐹𝑈
1 𝑚𝐿
] ∙ [
23 𝜇𝐿 
1
] ∙ [
1 𝑚𝐿
3 𝑚𝑔 5𝐹𝑈
] = 153 𝜇𝐿 
𝑉𝑎𝑙𝑖𝑞𝑢𝑜𝑡(𝜇𝐿) = 23 𝜇𝐿 
𝑉𝑆𝑎𝑙𝑖𝑛𝑒(𝜇𝐿) = 𝑉𝑇𝑜𝑡𝑎𝑙(𝜇𝐿) − 𝑉𝑎𝑙𝑖𝑞𝑢𝑜𝑡(𝜇𝐿) = 130 𝜇𝐿 
8. Required Volume of 3 mg/mL 5-FU/saline Per Mouse 
[
1 𝑚𝐿 𝑠𝑎𝑙𝑖𝑛𝑒
3 𝑚𝑔 5𝐹𝑈
] ∙ [
1000 𝜇𝐿
1 𝑚𝐿
] ∙ [
15 𝑚𝑔 5𝐹𝑈
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑀𝑜𝑢𝑠𝑒 (𝑔)
= 𝑥 𝜇𝐿 5𝐹𝑈/𝑠𝑎𝑙𝑖𝑛𝑒 
Justification for 5-FU Dosage in Mice  
5-FU Chemotherapy in Humans 
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▪ 2,400 mg/m2 given during treatment – repeated every 2 weeks 
▪ Body surface area (BSA) is the unit in humans 
5FU Dose (based on Body Surface Area) in Humans: [
2,400 𝑚𝑔 5𝐹𝑈
𝑚2∙2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
] 
Average Ratio of Body Surface Area to Weight in Humans: [
1.6 𝑚2 
60 𝑘𝑔
] 
Standard Human-to-Mouse FDA Conversion Factor: [
12.3
3
] 
Conversion of Human BSA-based Dosage to Mouse Weight-based Dosage: 
[
2,400 𝑚𝑔 5𝐹𝑈
𝑚2 ∙ 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
] ∙ [
1.6 𝑚2 
60 𝑘𝑔
] ∙ [
12.3
3
] ∙ [
1 2 𝑤𝑒𝑒𝑘 𝑑𝑜𝑠𝑒
14 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒𝑠
] = 𝟏𝟖. 𝟕 
𝒎𝒈 𝟓𝑭𝑼
𝒌𝒈
≈ 𝟏𝟓
𝒎𝒈 𝟓𝑭𝑼
𝒌𝒈
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Preparation of anti-CCL2 Immunotherapy 
 
Quantity per Container 5 mg 
Dose Schedule Every Other Day (0, 2, 4, 6) 
Dose per Day 4 mg/kg/day 
Anti-CCL2 per Injection (15 g to 30 g mouse) 60 – 120 μg 
Injections (cohort 1) 1 
Injections (cohort 2) 2 
Injections (cohort 3) 4 
Injection Method Intraperitoneal (I.P.) 
 
Step 1: Making Anti-CCL2 (or Isotype Control) 
1. Determine number of injections you want to make 
2. Obtain desired amount of 1.5 mL microcentrifuge tubes  
3. Sterilize microcentrifuge tubes in autoclave  
4. Prepare the biosafety cabinet 
5. Obtain stock anti-CCL2 solution 
6. Obtain normal sterile saline 
7. Spray everything into biosafety hood 
8. Label tubes with initials, date, and 150 μg anti-CCL2/Saline 
9. Aliquot 20 μL (150 μg anti-CCL2 protein) of stock anti-CCL2 into each tube 
10. Aliquot 106 µL sterile saline into each tube to create a 1.2 mg/mL anti-CCL2/saline solution 
11. Place anti-CCL2 stock solution back in 4°C fridge 
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12. Place 1.2 mg/mL anti-CCL2 solutions back in 4°C fridge 
13. Store aliquots at 4°C for no more than 2 months 
 
Calculations: 
1. Minimum Dose of Anti-CCL2 per Injection per Mouse (15 g mouse)  
[
4 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [15 𝑔] = 0.06 𝑚𝑔 = 60 𝜇𝑔 
2. Maximum Dose of Anti-CCL2 per Injection per Mouse (30 g mouse) 
[
4 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [30 𝑔] = 0.12 𝑚𝑔 = 120 𝜇𝑔 
3. Total Number of Anti-CCL2 Injections (per group) 
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [
5 𝑚𝑖𝑐𝑒
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
] ∙ [(
1 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 1
) + (
2 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 2
) + (
4 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 3
)]
= 70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 
4. Total Anti-CCL2 used: 
[70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [
0.12 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛
] = 8.4 𝑚𝑔 
5. Required Volume of anti-CCL2/Saline (not diluted) Per Mouse: 
𝑉𝑎𝑛𝑡𝑖−𝐶𝐶𝐿2(𝜇𝐿)
= [
0.7 𝑚𝐿 𝑠𝑜𝑙𝑣.
5.3 𝑚𝑔 𝑎𝑛𝑡𝑖𝐶𝐶𝐿2
] ∙ [
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
]
∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔) 
6. Required Volume of Saline for 1.2 mg/mL Aliquot of anti-CCL2 
𝑉𝑠𝑎𝑙𝑖𝑛𝑒(𝜇𝐿) = ([
5.3 𝑚𝑔
0.7 𝑚𝐿
] ∙ [0.020 𝑚𝐿 (𝑓𝑟𝑜𝑚 𝑒𝑞. 5, 25𝑔 𝑚𝑜𝑢𝑠𝑒)] ∙ [
1 𝑚𝐿
1.2 𝑚𝑔
]) − 0.020 𝑚𝐿
= 106 𝜇𝐿 
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7. Required Volume of anti-CCL2/Saline (diluted) Per Mouse 
𝑉𝑎𝑛𝑡𝑖−𝐶𝐶𝐿2 𝑑𝑖𝑙. = [
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
1.2 𝑚𝑔 𝑎𝑛𝑡𝑖𝐶𝐶𝐿2
] ∙ [
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
]
∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔) 
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Preparation of Isotype Control Antibodies 
 
Quantity per Container 5 mg 
Dose Schedule Every Other Day (0, 2, 4, 6) 
Dose per Day 4 mg/kg/day 
Anti-CCL2 per Injection (15 g to 30 g mouse) 60 – 120 μg 
Injections (cohort 1) 1 
Injections (cohort 2) 2 
Injections (cohort 3) 4 
Injection Method Intraperitoneal (I.P.) 
 
Step 1: Making Isotype Control 
1. Determine number of injections you want to make 
2. Obtain desired amount of 1.5 mL microcentrifuge tubes  
3. Sterilize microcentrifuge tubes in autoclave  
4. Prepare the biosafety cabinet 
5. Obtain stock isotype control solution 
6. Obtain normal sterile saline 
7. Spray everything into biosafety hood 
8. Label tubes with initials, date, and 150 μg isotype control/Saline 
9. Aliquot 20 μL (150 μg Isotype Control) of stock isotype control into each tube 
10. Aliquot 106 µL saline into each tube to create a 1.2 mg/mL isotype control/saline solution 
11. Place isotype control stock solution back in 4°C fridge 
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12. Place 1.2 mg/mL anti-CCL2 solutions back in 4°C fridge 
13. Store aliquots at 4°C for no more than 2 months 
 
Calculations: 
1. Minimum Dose of Isotype Control per Injection per Mouse (15 g mouse)  
[
4 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [15 𝑔] = 0.06 𝑚𝑔 = 60 𝜇𝑔 
2. Maximum Dose of Isotype Control per Injection per Mouse (30 g mouse) 
[
4 𝑚𝑔
𝑘𝑔
] ∙ [
1 𝑘𝑔
1000 𝑔
] ∙ [30 𝑔] = 0.12 𝑚𝑔 = 120 𝜇𝑔 
3. Total Number of Isotype Control Injections (per group) 
[2 𝑔𝑟𝑜𝑢𝑝𝑠] ∙ [
5 𝑚𝑖𝑐𝑒
𝑐𝑜ℎ𝑜𝑟𝑡 ∙ 𝑔𝑟𝑜𝑢𝑝
] ∙ [(
1 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 1
) + (
2 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 2
) + (
4 𝑖𝑛𝑗𝑒𝑐𝑡.
𝑐𝑜ℎ𝑜𝑟𝑡 3
)]
= 70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠 
4. Total Isotype Control used: 
[70 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠] ∙ [
0.12 𝑚𝑔
𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛
] = 8.4 𝑚𝑔 
5. Required Volume of Isotype Control/Saline (not diluted) Per Mouse: 
𝑉𝑖𝑠𝑜𝑡𝑦𝑝𝑒(𝜇𝐿) = [
0.7 𝑚𝐿 𝑠𝑜𝑙𝑣.
5.3 𝑚𝑔 𝑖𝑠𝑜𝑡𝑦𝑝𝑒
] ∙ [
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
]
∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔) 
6. Required Volume of Saline for 1.2 mg/mL Aliquot of Isotype Control 
𝑉𝑠𝑎𝑙𝑖𝑛𝑒(𝜇𝐿) = ([
5.3 𝑚𝑔
0.7 𝑚𝐿
] ∙ [0.020 𝑚𝐿 (𝑓𝑟𝑜𝑚 𝑒𝑞. 5, 25𝑔 𝑚𝑜𝑢𝑠𝑒)] ∙ [
1 𝑚𝐿
1.2 𝑚𝑔
]) − 0.020 𝑚𝐿
= 106 𝜇𝐿 
7. Required Volume of Isotype Control/Saline (diluted) Per Mouse 
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𝑉𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑑𝑖𝑙. = [
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
1.2 𝑚𝑔 𝑖𝑠𝑜𝑡𝑦𝑝𝑒
] ∙ [
4 𝑚𝑔
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
𝑘𝑔 𝑚𝑜𝑢𝑠𝑒
1000 𝑔 𝑚𝑜𝑢𝑠𝑒
] ∙ [
1000 𝜇𝐿 𝑠𝑜𝑙𝑣.
1 𝑚𝐿 𝑠𝑜𝑙𝑣.
]
∙ 𝑚𝑜𝑢𝑠𝑒 𝑤𝑒𝑖𝑔ℎ𝑡(𝑔) 
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Tissue Preparation 
Equipment and Materials 
Item Distributor Item Number 
Gloves VWR 89038-270 
KimWipes VWR 470224-038 
Leica CM1860 Cryostat Leica CM1860 
Low-Profile 819 Disposable Blades VWR 10015-014 
SuperFrost Plus Microscope Slides VWR 48311-703 
Coverslips (22 x 50) VWR 16004-314 
Microscope Slide Storage Box (Red) VWR 89510-824 
Tissue-Tek Cryomold (25x20x5) VWR 25608-916 
Razor Blades VWR 55411-050 
Artificial Tears Ointment Walmart 305366550917 
Plastic Divider Box (x2) DigiKey 510-1030-ND 
Plastic Divider Tabs (x6) DigiKey 510-1035-ND 
Steel Cooker Amazon B00H3377W6 
Nalgene Dewar Flask (1 L) VWR 633880-052 
Dissecting Forceps (12”) VWR 470018-958 
Tissue-Tek O.C.T. Compound VWR 25608-930 
Low Temperature Organic Thermometer VWR 89062-908 
Lab Markers, Black VWR 52877-310 
Parafilm M Roll VWR 52858-076 
Nair Hair Removal Lotion Amazon B009ZCFSO2 
450 
 
Small Animal Surgical Cordless Trimmer Braintree Scientific CLP-9868 14 
Aluminum Foil VWR 89107-726 
Isopentane (2-Methylbutane) VWR AA19387-AP 
Liquid Nitrogen Tank Airgas NI NF180LT22 
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Tissue Dissection and Freezing 
 
Step 1: Preparation of Supplies 
1. Pre-cut the necessary amount of 5” x 5” aluminum foil squares (1 per tumor) 
2. Label aluminum foil with the mouse identification number 
3. Pre-prep 25 x 20 cryomolds (1 per tumor) with 2 mm of OCT in the base 
4. Label cyromolds with initials, date, mouse number¸ either IHC and the T shape 
5. Obtain plastic bag 
6. Label plastic bag with initials, date, mouse number, and IACUC protocol number 
7. Obtain steel cooker and Styrofoam container 
8. Obtain white cutting board and ruler 
 
Step 2: Anesthetize Mouse 
1. Prep anesthesia machine 
2. Place mouse in induction chamber 
3. Anesthetize mouse with 1.5% isoflurane and 1 L/min O2 
 
Step 3: Preparation of Liquid Nitrogen 
1. In the chemical fume hood, dispense ~250 mL of isopentane into the steel cooker 
2. Fill Styrofoam container with liquid nitrogen 
3. In the chemical fume hood, place steel cooker (with isopentane) in liquid nitrogen 
4. Place thermometer in steel cooker so that the tip is submerged in liquid nitrogen 
5. Begin swirling around the isopentane to distribute heat 
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6. Turn up mouse anesthesia to 4.0% isoflurane and 1 L/min O2 
7. Continually monitor temperature of isopentane 
 
Step 4: Preparation of Mouse 
1. Once mouse is fully anesthetized, transfer to nosecone 
2. Maintain mouse on 4.0% isoflurane with 1 L/min O2 
3. Obtain a black lab marker 
4. Draw a 5 mm line through the DRS measurement axis of each measurement location. 
5. Dissect tumor with scissors 
6. Set tumor on white cutting board with ruler in background and photograph  
7. Continually monitor temperature of isopentane 
 
Step 5: Flash Freezing Tumor in Liquid Nitrogen 
1. Place tumor in the OCT filled cryomold 
2. Fill the cyromold with more OCT to cover the tumor 
3. Remove isopentane from liquid nitrogen 
4. Grab the edge of cryomold with 12” dissecting forceps 
5. When the temperature of isopentane is 73-78°C, dip cryomold in isopentane for 15 seconds 
6. Remove cryomold from isopentane 
7. Place more OCT on any exposed parts of the tumor and cryomold  
8. Dip cryomold in isopentane for 15 seconds 
9. Set the frozen cryomold on the aluminum foil square 
10. Wrap the frozen cryomold in aluminum foil 
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11. Transport the foil-wrapped tissue sample to the -80°C freezer 
 
Step 6: Euthanizing Mouse 
1. Euthanize the mouse via cervical dislocation 
2. Keep euthanized mouse on 4.0% isoflurane for 60 seconds following cervical dislocation 
3. Place the euthanized mouse in plastic bag 
4. Place the plastic bag with the mouse in the freezer in the small animal facility for disposal 
 
Tips for Monitoring Isopentane Temperature 
1. Continually use the thermometer to stir the isopentane 
2. When the isopentane reaches 65-70°C, remove from liquid nitrogen – the temperature will 
continue to drop 
3. Place the isopentane back in the liquid nitrogen when the temperature rises to 65°C 
4. Do not let the temperature get below 90°C – this can ruin the thermometer 
5. Only place the tumor/cryomold/OCT in the isopentane when the temperature is 73-78°C 
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Cryotome Sectioning 
 
Step 1: Preparing the Cryotome and Materials 
1. Obtain microscope slides (x8)  
2. Transfer cryotome blades from -20°C freezer to the cryotome 
3. Place the frozen tissue sample(s) into the cryotome 
4. Leave the frozen tissue sample(s) and blades in the cryotome (at -20°C) for 20 minutes 
5. Using the pencil, label the microscope slides (on the rough side) (x8) with the following (i.e. 
example shown in picture): 1) mouse identification number, 2) Balb/c, 3) CT26, 4) initials, 
and 5) slide number (out of 8) 
 
 
Step 2: Preparing and Mounting the Blade 
1. Check to see if there is a blade in the blade holder. If there is a blade in the blade holder, look 
for a small black handle on the right side of the main carrier that is located in the center of 
the cryotome and pull the black handle towards you. (This releases the blade) 
2. Remove the old blade 
3. Obtain a new blade 
4. Using the magnet on the bottom of the white brush, place the blade into the blade holder, 
making sure that the sharp portion of the blade is facing up 
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5. Once the blade is in place, push the small black handle back 
 
Step 3: Adjusting Angles 
1. Obtain calipers 
2. Ensure that the distance between the 2 cylinders is 6mm, measured with at least 3 points 
 
3. Ensure the angle of the blade is at ~7° 
 
4. Ensure the glass blade cover is directly aligned over the top of the blade (i.e. cover and blade 
edge are parallel) 
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Step 4: Cutting Away Excess OCT 
1. Obtain OCT/tumor sample 
2. Obtain a razorblade 
3. Cut away excess OCT surrounding the tumor so there is just 2-4 mm of OCT surrounding the 
tumor. Note: this doesn’t have to be perfect; we’ve noticed cutting away some excess OCT 
helps with getting good tissue sections 
 
Step 5: Preparation of Sample on Chuck 
1. Obtain the chuck 
2. Place a dime-sized amount of OCT onto the chuck 
3. Take the sample out of the cryomold 
4. Place the non-cutting edge of sample onto the chuck making sure that the correct corner is 
point up. (The cutting edge is the flat square face. Note: the tissue sample should be in a 
diamond shape) 
5. Place the chuck with the sample onto the blue freezing panel 
6. Close the lid of the cryotome and let the chuck/sample freeze for 5 minutes 
7. Set the cutting thickness to 100 µm 
 
Step 6: Preparation of Sample for Sectioning 
1. Turn the wheel until the sample is close to the blade 
2. Move the sample forward using the fast and slow track buttons on the left side of the 
cryotome. (The blade should not be hitting the plastic guard or the carrier) 
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3. Start turning the rotating arm on the right side of the cryotome to start slicing away excess 
OCT 
4. Once the blade has sliced through approximately 1/3 way through the tumor, set the cutting 
thickness to 10 µm 
 
Step 7: Sample Sectioning (10 μm) 
1. Turn the wheel at ~1 turn per second. 
2. Lift the cover and place the rough side of the slide onto the sample 
3. The OCT will melt onto the slide and the actual tissue will remain intact 
4. Leave the microscope slide in the cryotome to maintain temperature 
5. Use the same microscope slide for the 2nd tissue slice 
6. Repeat until you have four (4) good microscope slides (8 good tissue slices) 
 
Step 8: Sample Sectioning (5 μm) 
1. Set the cutting thickness to 5 μm 
2. Lift the cover and place the rough side of the slide onto the sample 
3. The OCT will melt onto the slide and the actual tissue will remain intact 
4. Leave the microscope slide in the cryotome to maintain temperature 
5. Use the same microscope slide for the 2nd tissue slice 
6. Repeat until you have four (4) good microscope slides (8 good tissue slices) 
 
Step 10: Storing Slides 
1. Once complete, place all slides into a microscope storage box 
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2. Immediately places the microscope slide storage box in the -80°C freezer 
3. Save the excess tumor, wrap it in foil, and place it back in the -80°C freezer  
4. Clean the cryotome appropriately 
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Tissue Analysis 
Equipment and Materials 
Item Distributor Item Number 
Anti-CD68 (anti-mouse) Alexa Fluor 488 BioLegend 137012 
Anti-CD80 (anti-mouse) Brilliant Violet 421 BioLegend 104725 
Anti-CD206 (anti-mouse) Alexa Fluor 594 BioLegend 141726 
NucBlueTM Fixed Cell ReadyProbe (DAPI) Thermo Fisher R37606 
Universal Antibody Dilution Buffer Sigma-Aldrich U3510-100ML 
Hematoxylin Solution, Mayer’s VWR 100504-404 
Eosin Y VWR 10143-130 
Bluing Reagent Solution VWR 95057-852 
Xylene VWR EM-XX0060-4 
Cytoseal XYL VWR 48212-196 
100% Reagent Ethanol VWR EM-EX0276-4S 
95% Reagent Ethanol VWR BDH1156-4LP 
Microcentrifuge Tubes VWR 20170-038 
80-Place Storage System VWR 30128-276 
15 mL Conical-Bottom Centrifuge Tubes VWR 89039-666 
50 mL Conical-Bottom Centrifuge Tubes VWR 89039-658 
Gloves VWR 89038-270 
KimWipes VWR 470224-038 
Acetone VWR BDH1101-4LP 
SuperFrost Plus Microscope Slides VWR 48311-703 
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Coverslips (22 x 50) VWR 16004-314 
EasyDipTM Kit with Rack VWR CA10154-052 
EasyDipTM Slide Staining Jars – White VWR 87000-126 
Whatman Grade 1 Qualitative Filter Paper VWR 10035-812 
Laboratory Bench and Table Protector VWR 89126-790 
Powder Funnel (Wide Stem) VWR 16126-912 
Phosphate Buffered Saline (PBS), 1X VWR 45000-446 
Phosphate Buffered Saline (PBS) Tablet Sigma-Aldrich P4417-100TAB 
Tween 20 Sigma-Aldrich P9416-50ML 
Triton-X100 Sigma-Aldrich X100-100ML 
Goat serum Sigma-Aldrich G9023-10ML 
Sodium Azide Sigma-Aldrich S2002-5G 
Bovine Serum Albumin Sigma-Aldrich A8806-5G 
Fluoromount-G Slide Mounting Medium VWR 100241-874 
Sterile Saline (0.9% NaCl) VWR S5815 
Pipetting Device VWR 53498-001 
5 mL Serological Pipet Tip VWR 89130-896 
Rapid-Flow Sterilization Filter Unit VWR 28199-098 
Analytical Balance VWR 10159-998 
Variable Volume Pipettors VWR 75788-458 
Universal Shelf Clip for 3 Pipettors VWR 40000-272 
Universal Shelf Clip for 3 Pipettors VWR 40000-272 
10 µL Pipette Tips (Sterile-Aerosol) VWR 89174-520 
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10 µL Pipette Tips (Sterile) VWR 89368-970 
100 µL Pipette Tips (Sterile-Aerosol) VWR 10126-388 
100 µL Pipette Tips (Sterile) VWR 89140-162 
1000 µL Pipette Tip (Sterile-Aerosol) VWR 89174-530 
1000 µL Pipette Tip (Sterile) VWR 83007-380 
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Immunohistochemistry Reagent Preparation 
 
Step 1: Cold Acetone 
1. Obtain 250 mL of acetone 
2. Label with initials, date, and Acetone and store at -20° C 
 
Step 2: Dilution Buffer for IHC: Universal Antibody Dilution Buffer 
1. Purchase pre-made Universal Antibody Dilution Buffer 
2. Store at room temperature 
Universal Antibody Dilution Buffer Percentages 
▪ 1.0% BSA 
▪ 0.3% Tris HCl 
▪ 0.025% Triton-X 
 
Step 3: Making PBS-t Washing Solution 
1. Obtain a bottle that can hold at least 600 mL 
2. Fill with 600 mL of MilliPore filtered water 
3. Add three PBS tablets to the canister 
4. Obtain Tween-20 
5. Obtain 1.2 mL of Tween-20 
6. Dispense 1.2 mL of Tween-20 into the canister of 600 mL PBS 
7. Cap canister 
8. Place magnetic stirrer in PBS-t 
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9. Place PBS-t on magnetic plate at RT and 300 RPM until everything is dissolved 
10. Label canister as PBS-t, mm/dd/yyyy, and initials 
 
Step 4: Blocking Buffer for IHC (Goat Serum-Based) 
1. Prepare biosafety hood 
2. Obtain 50 mL centrifuge tube of sterile 1X PBS from 4°C 
3. Obtain Goat Serum from -20°C 
4. Place the Goat Serum in the 37.3°C water bath until liquid. Do not submerge the lid 
5. Place the 1X PBS tube in the 37.3°C water bath for 15 minutes. Do not submerge the lid 
6. Obtain Bovine Serum Albumin (BSA) from 4°C 
7. Obtain Triton-X100 from 23°C 
8. Obtain Tween-20 from 23°C 
9. Obtain Sodium Azide from 23°C 
10. Obtain one (1) empty 50 mL centrifuge tube 
11. Label the 50 mL tube with date, initials, and Blocking Buffer: 4% Goat Serum, 0.5% BSA 
12. Dispense 38.4 mL of 1X PBS into the empty 50 mL centrifuge tube 
13. Obtain the analytical balance 
14. Weigh 0.04 g (40 mg) of Sodium Azide (NaN3) and dispense Sodium Azide (NaN3) into 50 
mL centrifuge tube 
15. Weigh 0.2 g (200 mg) of BSA and dispense BSA into 50 mL centrifuge tube 
16. Dispense 40 µL of Triton-X100 into the 50 mL centrifuge tube 
17. Dispense 20 µL of Tween-20 into the 50 mL centrifuge tube 
18. Vortex the solution for 2 minutes 
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19. Prepare biosafety hood 
Complete all of the following steps in the Biosafety hood in ENRC 2545 
20. Spray the 50 mL centrifuge tube (with the blocking buffer) into the hood 
21. Spray the Goat Serum into the hood 
22. Obtain Rapid-Flow Sterilization Filter Unit and spray into the hood 
23. Using a sterile 1000 µL pipette, dispense 1,600 µL of goat serum into the 50 mL centrifuge 
tube 
24. Mix well 
25. Perform sterile vacuum filtration 
26. Label the beaker with initials, date, and Blocking Buffer: 4% Goat Serum, 0.5% BSA 
27. Aliquot into microcentrifuge tubes (1.6 mL) and label with B 
28. Store at 4°C  
29. Clean the hood 
Blocking Solution Percentages (B) 
▪ 4% Goat Serum 
▪ 0.5% BSA 
▪ 0.1% NaN3 
▪ 0.1% Triton-X 
▪ 0.05% Tween-20 
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CD68-CD80-CD206 Stain 
 
Step 1: Preparing Blocking Solution 
1. Obtain empty microcentrifuge tubes 
2. Remove goat-based blocking solution from 4°C 
3. Dispense 800 µL of goat-based blocking solution into microcentrifuge tubes (each tube ≈ 10 
sections) 
4. Label microcentrifuge tubes with B 
5. Obtain necessary quantity of full microcentrifuge tubes per number of tissue sections (each 
tube ≈ 10 sections) 
 
Step 2: Preparing Slides for Staining 
1. Remove slides from the -80°C freezer 
2. Remove the slides you want to stain with anti-CD68/80/206 
3. Label the slides appropriately with a pencil 
4. Place the slides in a -20°C freezer. Start a timer 
5. Bring the rest of the slides not being stained back to the -80°C freezer for permanent storage 
 
Step 3: Preparation of Solution Boxes 
1. Fill 2nd staining jar with ~90 mL of new room temperature PBS-t 
2. Fill 3rd staining jar with ~90 mL of new room temperature PBS-t 
3. Fill 4th staining jar with ~90 mL of new room temperature PBS-t. 
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Step 4: Preparing Macrophage Antibody Cocktail (MAC) 
1. Store the undiluted 0.5 mg/mL anti-CD68 solution (100 μg/200 μL total) in the 4° C fridge 
2. Store the undiluted 0.5 mg/mL (lot-specific) anti-CD80 in the 4° C fridge 
3. Store the undiluted 0.5 mg/mL anti-CD206 solution (100 μg/200 μL total) in the 4° C fridge 
4. Determine number of tissue sections to be stained. One microcentrifuge tube can hold 10 trials 
5. Multiply the number of tissue sections by 100 μL (x) 
6. Multiply the number of tissue sections by 1.0 μL (a – M). (1:100) 
7. Multiply the number of tissue sections by 5.0 μL (b – M1). (1:100) 
8. Multiply the number of tissue sections by 0.8 μL (c – M2). (1:125) 
9. Obtain microcentrifuge tubes (≤10 tissue sections = 1 tube, 11-20 tissue sections = 2 tubes, 
etc.) 
10. Label microcentrifuge tubes appropriately 
11. Dispense x μL of the Universal Antibody Dilution Buffer into each microcentrifuge tube 
12. Dispense a μL of undiluted anti-CD68 antibody into the microcentrifuge tube 
13. Dispense b μL of undiluted anti-CD80 antibody into the microcentrifuge tube 
14. Dispense c μL of undiluted anti-CD206 antibody into the microcentrifuge tube 
15. Gently and sufficiently pipette up and down within the microcentrifuge tube to mix using 1000 
µL pipette 
16. Wrap microcentrifuge tubes with aluminum foil and store at 4°C for 4 hr. maximum 
 
Step 5: Preparing Acetone 
1. 17 minutes after step 2.4, remove acetone from the -20°C freezer 
2. Fill 1st staining jar with ~90 mL of -20°C acetone 
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3. Place Celsius thermometer in 1st staining jar with acetone 
 
Step 6: Fixation with Acetone 
1. When the acetone reaches -5°C to -3°C, remove slides from the -20°C freezer 
2. Place the slides (up to 10) in the black slide holder 
3. Place the slide holder in acetone (Jar 1) for 10 minutes 
4. Remove from acetone (Jar 1) 
5. Air dry and let drip for 5 seconds 
 
Step 7: Wash with PBS-t (#1) 
1. Place the slide holder in PBS-t (Jar 2) for 3 minutes 
2. Remove slides from PBS-t (Jar 2) 
3. Air dry and let drip for 5 seconds 
 
Step 8: Adding Blocking Solution 
1. Obtain one paper towel and split in half 
2. Lay out one-half of the paper towel. Set the other half aside for now 
3. Obtain the Eppendorf tube labeled B 
4. Obtain the 10-100 μL micropipette and place an appropriate pipette tip on the end 
5. Remove the slide holder from the PBS-t (Jar 2) 
6. Air-dry and let drip for 5 seconds 
7. Remove 3 slides from the slide holder and place on the paper towel half 
8. Keep the other slides (if more than 3) in the slide holder and place back in the PBS-t 
468 
 
9. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue 
10. Slowly drip ~80 μL (depends on tissue size) blocking solution onto each tissue section 
11. Place the slides in the dark humidified chamber at room temperature 
12. Repeat steps 5-11 for more than 3 slides. Do no more than 3 slides at a time 
13. Leave slides in dark humidified chamber for 50 minutes 
14. After 50 minutes, reapply ~80 µL blocking solution 
15. Leave slides in dark humidified chamber for additional 40 minutes (90 minutes total) 
 
Step 9: Adding Macrophage Antibody Cocktail 
1. Obtain one paper towel and split in half 
2. Lay out one of the paper towel halves. Set the other paper towel half aside for now 
3. Obtain the microcentrifuge tube with the macrophage antibody cocktail 
4. Remove 1 slide from the humidified chamber. Keep the others in the chamber for now 
5. Drain off blocking solution onto the 1st paper towel half 
6. Set slide down on the 1st paper towel half 
7. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue 
8. Slowly drip ~90 μL of the macrophage antibody cocktail onto each tissue section 
9. Place the slides in the dark humidified chamber at room temperature for 90 minutes 
10. Immediately after step 10, finish the remaining slides. Do no more than 3 slides at a time to 
avoid tissue drying 
 
Step 10: Wash with PBS-t (#2) 
1. Obtain one paper towel 
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2. Remove one slide from the dark humidified chamber 
3. Drain off the excess macrophage antibody cocktail onto the paper towel 
4. Place the slide in the slide holder 
5. Repeat steps 1-4 for up to 10 slides 
6. Place the slide holder in PBS-t (Jar 3) for 3 minutes 
7. Remove slides from PBS-t (Jar 3) 
8. Air dry and let drip for 5 seconds 
9. Dip the slide holder slowly in the PBS-t (Jar 3) 20 times. Let each “dip cycle” be 3 seconds 
(60s total) 
10. Gently “swirl” the black slide holder in the staining jar for 1 minute 
11. Set the black slide holder stable in PBS-t (Jar 3) for 1 more minute 
 
Step 11: Wash with PBS-t (#3) 
1. Obtain one paper towel and set on the IHC table 
2. Remove one slide from the dark humidified chamber 
3. Drain off the excess macrophage antibody cocktail onto the paper towel. 
4. Place the slide in the slide holder 
5. Repeat steps 1-4 for up to 10 slides 
6. Place the slide holder in PBS-t (Jar 4) for 3 minutes 
7. Remove slides from PBS-t (Jar 4) 
8. Air dry and let drip for 5 seconds 
9. Dip the slide holder slowly in the PBS-t (Jar 4) 20 times. Let each “dip cycle” be 3 seconds 
(60s total) 
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10. Gently “swirl” the black slide holder in the staining jar for 1 minute 
11. Set the black slide holder stable in PBS-t (Jar 4) for 1 more minute 
 
Step 12: Mounting with Fluoromount G 
1. Obtain two paper towels and split in half and split one of them in half 
2. Obtain a 22x50 coverslip. 
3. Obtain Fluoromount G 
4. Obtain a 5 mL serological pipette and open 
5. Lay out one of the paper towel halves. Set the other paper towel half aside for now 
6. Remove the slide holder from the PBS-t (Jar 5) 
7. Air-dry and let drip for 5 seconds 
8. Remove 3 slides from the slide holder and place on the 1st paper towel half 
9. Keep the other slides (if more than 3) in the slide holder and place back in the PBS-t 
10. Use the 2nd paper towel half and dry off the top of the slides at the areas around the tissue 
11. Place the 5 mL serological pipette tip barely in the Fluoromount G and then remove 
12. Drip the Fluoromount G onto the tissue sections – only enough to cover the tissue, don’t use 
too much 
13. Gently place a coverslip on the slide 
14. Use tweezers to gently press the coverslip onto the slide 
15. Use tweezers to gently press out all air bubbles on the samples 
16. Place the slides with coverslips on paper towel 
17. Wipe off any excess mounting solution. Although if there is excess, you used too much 
18. Repeat steps for additional slides. Do no more than 3 slides at a time 
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Step 13: Attaching Coverslip to Slide with Nail Polish 
1. Apply nail polish along the edges of the coverslip 
2. Ensure the edges are completely covered 
3. Set all completed slides in drying chamber to finish drying 
4. After 1 hour, store completed slides permanently in slide rack 
5. Store in the dark at room temperature 
6. Clean everything appropriately 
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Hematoxylin and Eosin (H&E) Staining 
 
Step 1: Preparing Hematoxylin 
1. Aliquot Hematoxylin into two (2) 50 mL centrifuge tubes (45 mL each) 
2. Label 50 mL centrifuge tube lids with Hematoxylin, initials, and date 
3. Cover the tubes with aluminum foil 
4. Store at 23°C in the dark 
5. Dispense 90 mL of hematoxylin into hematoxylin jar 
 
Step 2: Preparing Eosin 
1. Aliquot eosin into two (2) 50 mL centrifuge tubes (45 mL each) 
2. Label 50 mL centrifuge tube lids with Eosin, initials, and date 
3. Cover the tubes with aluminum foil 
4. Store at 23°C in the dark 
5. Dispense 90 mL of eosin into eosin jar 
 
Step 3: Preparing Slides for Staining 
1. Remove slides from the -80°C freezer 
2. Remove the slides you want to stain with hematoxylin and eosin 
3. Label the slides appropriately with a pencil 
4. Place the petri dish in the -20°C freezer for 12 minutes. Start a timer 
5. Bring the rest of the slides not being stained back to the -80°C freezer for permanent storage 
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Step 4: Preparing Work Station 
Fill all jars. All jars receive 80 mL of liquid 
1. Obtain 600 mL beaker 
2. Obtain 250 mL beaker 
3. Jar #2: Hematoxylin  
4. Jar #3: Bluing Solution 
5. Jar #4: Distilled H2O  
6. Jar #5: Eosin  
7. Jar #6: EtOH (70%)  
8. Jar #7: EtOH (95%)  
9. Jar #8: EtOH (100%)  
10. Jar #9: Xylene (must remain in the chemical fume hood at all times) 
11. 12 minutes after step 3.4, remove acetone from the -20°C freezer 
12. Fill 1st staining jar with ~90 mL of -20°C acetone 
13. Place thermometer in acetone 
14. Proceed to Step 6 once the acetone reaches 0°C (may need to stir to disperse heat) 
 
Step 5: H&E Staining 
Each “dip” cycle lasts one (4) seconds, such that the slides are submerged and then taken out of 
solution 
1. Obtain 6 µm sliced sections. There should be two sections per slide 
2. Set slides in cold acetone (Jar #1) for 6 minutes 
3. Gently shake off and air dry sections in your gloved hands for 5 seconds 
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4. Set slides in hematoxylin (Jar #2) for 5 minutes. Drain well (i.e. let excess liquid drip off) 
5. While waiting for step 5 to finish, fill a 600 mL beaker with cool tap water 
6. After step 6 is complete, set slides in full 600 mL beaker 
7. Run cool tap water in beaker for 7 minutes 
8. Remove slides from bucket. Drain well 
9. Dip slides in bluing solution (Jar #3) 15 times. Drain well 
10. Dip slides in distilled H2O (Jar #4) 2 times. Drain well 
11. Set slides in eosin (Jar #5) for 30 seconds. Drain well 
 
Step 6: Ethanol Dehydration 
Each “dip” cycle lasts one (4) seconds, such that the slides are submerged and then taken out of 
solution 
1. Dip slides in 70% EtOH (Jar #6) 15 times (slow 4-second dips). Drain well 
2. Dip slides in 95% EtOH (Jar #7) 15 times (slow 4-second dips). Drain well 
3. Dip slides in 100% EtOH (Jar #8) 15 times (slow 4-second dips). Drain well 
4. Dip slides in 95% EtOH (Jar #7) 15 times (slow 4-second dips). Drain well 
5. Dip slides in 100% EtOH (Jar #8) 15 times (slow 4-second dips). Drain well 
 
Step 7: Xylene Clearing 
1. Place black slide holder (with slides) in a 250 mL beaker 
2. Transfer 250 mL beaker to the chemical fume hood near the xylene (Jar #9) 
3. Set slides in xylene (Jar #9) for 4 minutes. Drain well 
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Step 8: Coverslip Mounting 
All steps must be completed in an approved chemical fume hood 
1. Lay out paper towel in hood (avoid xylene/Cytoseal dripping on the fume hood surface) 
2. Lay out three 22x50 mm coverslips on the Kimwipes 
3. Remove slides from xylene. Drain well 
4. Remove three slides from the black slide holder 
5. Set the 3 slides on the Kimwipes near the coverslips so the rough/labeled side is facing up 
6. Set slides back in xylene (Jar #9) temporarily (avoid slides drying out) 
7. Place Cytoseal XYL drops (5-7 mm diameter) on the tissue sections 
8. Set the 22x40 coverslips on the slides at a slow, controlled, 45° angle 
9. Cytoseal XYL should spread without leaving air bubbles. Use tweezers to facilitate spread 
10. Set the cover-slipped slides to the side to dry 
11. Repeat steps 2-10 until all slides are finished 
12. Wipe off Cytoseal container well so it doesn’t harden on the tip 
13. Obtain nail polish 
14. Apply nail polish along the edges of the coverslip 
15. Ensure the edges are completely covered 
16. Clean everything appropriately 
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Tissue Analysis 
Equipment and Materials 
Item Distributor Item Number 
Upright microscope Nikon 89501-464 
Monochrome digital camera Nikon Ds-Qi1Mc 
PC-based camera control unit Nikon DS-U3 
SOLA Light Engine® fluorescent lamp Lumencor SOLA SM 6-LCR-SB 
DAPI filter set Chroma 49000 
FITC filter set Chroma SP101 
Texas red filter set Chroma 41004 
Objective lens, 20X/0.50NA Nikon CFI Plan Fluor 20X 
NIS-Elements F Ver4.60.00 for 64bit edition Nikon N/A 
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Imaging Macrophage-Stained Slides 
 
Step 1: Preparing Microscope 
1. Close the shutter for the fluorescence lamp 
2. Switch to the 20X objective 
3. Turn on the Nikon camera, microscope, and Lumencor fluorescent lamp 
4. Open up NIS Elements F 4.00.00 
5. Select “Camera Ds-Qi iMc-U3….” 
6. For the Ds-Qi1Mc Settings:  
o Change the mode to normal 
o Fast focus at “1280x1024 no binning” 
o Change the quality capture to “1280x1024 no binning” 
o Set the exposure to 100 ms (can be changed later) 
o Set the analog gain to 1.0x 
o Click commands: ROI, then select to use Current ROI 
 
Step 2: Preparing Slide Position 
1. Obtain the desired slide.  
2. Set the slide on the microscope slide stage 
3. Turn the filter wheel to the DAPI filter 
4. Open the shutter for the fluorescence lamp 
5. Adjust the translation stage so the light is hitting some part of the desired tissue section 
6. Apply course focus 
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7. Locate the top of the tissue either by the hair or a marking on the slide. 
8. Apply fine focus to bring the M1 macrophages in-focus  
9. Manually adjust the exposure (between 50-250 ms) to reduce background noise. 
 
Step 3: Saving M1 Macrophage Images with DAPI Filter 
1. Bring the M1 macrophages (DAPI filter) in-focus 
2. Click “Capture” then “Save as” 
3. Save as a TIFF file 
4. Click “LIVE” 
 
Step 4: Saving Non-Polarized Macrophage Images with FITC Filter 
1. Do not move the slide or translation stage 
2. Bring the non-polarized macrophages (FITC filter) in-focus 
3. Click “Capture” then “Save as” 
4. Save as a TIFF file 
5. Click “LIVE” 
    
Step 5: Saving M2 Macrophage Images with Texas Red 
1. Do not move the slide or translation stage 
2. Bring the M2 macrophages (Texas Red filter) in-focus 
3. Click “Capture” then “Save as” 
4. Save as a TIFF file 
5. Click “LIVE” 
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Counting Tumor-Associated Macrophages (TAMs) 
 
Step 2: Run Code 
1. Ensure there are at least three TIFF files in the appropriate folder: M1 (DAPI), non-polarized 
(FITC), and M2 (Texas Red) images 
Note: Ideally, there will be 12 images for each region-of-interest: 4 from each filter to account 
for cells slightly out of the plane-of-focus in the 5 μm thick slide. This is how the code, 
tamcount.m, is set up to run 
2. Open and run tamcount.m 
3. A black-and-white image will appear full screen 
4. With the mouse, click the center of each mostly-in-focus TAM you see. It is very important to 
click the center 
a. TAMs will often appear as elongated “rings” or “C shapes” with a dark center and 
white ring/C 
5. Once you are done clicking the center of each TAM, hit the enter button 
6. A new black-and-white image will appear full screen 
7. Repeat these steps until you are finished with all 12 images 
Notes: 
1. Be sure the click the center of each TAM. Use your best judgement 
2. There may be instances in which the same TAM appears in-focus across multiple images – it 
is okay to select the same TAM twice (or more) in back-to-back images. The code will 
automatically identify duplicates and only include one in the count 
3. Something being in-focus or out-of-focus is slightly subjective. Use your best judgement 
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Other General Procedures 
Equipment and Materials 
Item Distributor Item Number 
Tabletop Animal Anesthesia System VWR 89012-492 
Mobile Cart for Anesthesia System Amazon OF-STC111-B 
Gloves VWR 89038-270 
KimWipes VWR 470224-038 
Microcentrifuge Tubes VWR 20170-038 
Alcohol Swab VWR BD326859 
80-Place Storage System VWR 30128-276 
Water Bath VWR 89501-464 
Warm Water Pump Global Medical TP700 
Warm Water Pump Pad Kent Scientific TPZ-0510EA 
Valved In-Line Hose Barb Coupling Body Fresh Water Systems 42100 
Non-Valved In-Line Hose Barb Coupling Fresh Water Systems 40900 
Analytical Balance VWR 10159-998 
Alcohol Swab VWR BD326859 
28G U-100 BD Micro-Fine IV Syringe VWR BD329410 
Compressed Air Cylinder, Size 200L Airgas AI USP200 
Compressed O2 Cylinder, Size 200L Airgas OX USP200 
Isothesia (Isoflurane) Solution Henry Schein 1169567762 
Regulator for Air Cylinder Airgas HCL3000762 
Regulator for O2 Cylinder Airgas HCL3000714 
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O2 DISS Femaile Hex Nut – ¼” Hose Barb Med. Support Products 0115 
Activated Charcoal Filter VaporGuard VWR 89012-608 
Cylinder Bench Clamp VWR 60142-003 
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Anesthetizing Mice with Isoflurane 
 
Step 1: Preparing Warm Water Pad. 
1. Place the heated water pump in the hood 
2. Place the heated water pad in the hood 
3. Connect the water pad to the pump using the in-line hose barb coupling 
4. Turn on the heated water pump 
5. Place a large Kimwipe over the heated water pad (so the mouse won’t lay directly on the pad) 
6. Wait 20 minutes until the water is warm 
 
Step 2: Preparing the Anesthesia Machine 
1. Place the carbon filter in the back of the hood, such that it is 2 inches from the back wall 
2. Place the mouse-isoflurane chamber in the hood, such that it is 6 inches from the front of the 
hood 
3. Place the analytical scale in the hood 
4. Place a large folded paper towel in the mouse-isoflurane chamber 
5. Open both valves (tank valve and nosecone valve)  
6. Tape the nosecone down on the edge of the warm water pump pad such that it is parallel to the 
surface 
7. Slightly loosen the top gray knob of the oxygen tank to start gas flow 
8. Adjust the silver isoflurane tank knob between 1.5 and 4 (% isoflurane) 
a. 1.5%: Immobility (no analgesia, use for giving shots) 
b. 2%: Shallow Anesthesia 
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c. 3%: Medium Anesthesia 
d. 4%: Deep Anesthesia (used for euthanasia)  
e. 5%: Very Deep Anesthesia (not used in any of our studies) 
9. Set the green isoflurane tank knob to 1.0 (1.0 L/min oxygen) 
 
Step 3: Anesthetizing Mice 
1. Obtain a mouse 
2. Pick the mouse up by the tail 
3. Place the mouse in the mouse-isoflurane chamber 
4. Secure the lid by locking the black hinge 
5. When mouse passes out, remove the mouse by the tail 
6. Place the mouse on the nosecone such that its eyes are at the level of the cone bottom 
7. Put eye drop gel in the mouse’s eyes 
8. Ensure the mouse is on the nose cone for 30 seconds 
9. Remove mouse from nosecone and quickly weigh the mouse 
10. Put mouse back on nosecone for 20 seconds 
11. Perform desired task 
12. Remove mouse from nosecone 
13. Place mouse in hands and wait until it wakes up (time depends on anesthesia level) 
14. Place mouse back in cage 
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Intraperitoneal Injection (I.P.) of Mice 
 
Step 1: Preparation for Injection 
1. Set up the isoflurane tank and chamber  
2. With 28G syringe, draw up required volume to nearest 10 μL 
3. Get rid of all air bubbles 
4. Set the 28G needle aside  
5. Remove mouse from cage 
6. Put mouse in isoflurane chamber until sedated 
7. Remove mouse from isoflurane chamber and weigh mouse 
8. Remove mouse from scale and place under nosecone in biosafety cabinet 
 
Step 2: Intraperitoneal (IP) Injection  
1. Obtain 28G needle from the Kimwipe 
2. Turn the needle so that the bevel points up and the numbers on the syringe barrel can be read 
3. Bring the needle to a 35° ± 5° angle from the abdomen 
4. Place the needle 2 mm off the abdominal midline (you can see where the hair parts) 
5. Place the needle on the same line as the visible knee bones 
6. Push needle in until ~1/2 of the needle length is inserted 
7. Depress the plunger until the solution has been fully administered (2-second plunge) 
8. Do not allow the needle to move around inside the abdomen 
9. Pull the needle straight out and place the syringe/needle into a Sharps container without 
recapping 
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10. Leave mouse in hand or on warm water pad until awake 
11. Place the mouse back in the cage 
 
Potential Complications 
Note: These complications were not experienced throughout the study. IACUC should be 
contacted immediately if these complications are experienced 
1. Aspiration of green material: bowel has been punctured 
2. Aspiration of yellow liquid: bladder has been punctured 
3. Aspiration of blood: abdominal blood vessel has been punctured 
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Humane Endpoint Criteria 
 
Mice will be euthanized based their appropriate endpoint per study, or on humane endpoint criteria, 
whichever comes first: 
 
Humane endpoint criteria are as follows. 
1. Tumor Volume = 1500 mm3 
2. Maximum Tumor Diameter = 20 mm (or 2 cm) 
3. Body Condition Score < 2 
4. Weight Loss ≥ 20% (~3-4 g) 
5. Chronic Pain or Distress 
a. Changes in Health and Well-Being (monitored by IACUC and Investigator) 
b. Impaired mobility (the inability to reach food and water) 
c. Inability to remain upright 
d. Interference with a vital physiological function: 
i. Respiration, mastication, swallowing, urination, defecation, or locomotion 
e. Location of the tumor causing interference with movement 
f. Hunched abnormal posture for more than 48 hours 
g. Labored breathing and cyanosis [bluish pinnae (ears) or feet or mucous 
membranes] 
h. Clinical dehydration and/or prolonged decreased food intake 
i. Muscle atrophy and signs of lethargy and lack of physical activity 
j. Chronic diarrhea or constipation for more than 48 hours 
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k. Hematological or biochemical values that indicate organ failure 
l. Severe anemia [pale pinnae (ears) or feet or mucous membranes] 
m. Bloodstained or mucopurulent discharge from any orifice 
n. Lack of grooming behavior; rough/unkempt hair coat for more than 48 hours 
o. Enlarged lymph nodes or spleen 
p. Significant abdominal distension 
q. Cranial deformity/neurological signs 
r. Exophthalmos (bulging eye) 
s. Ulceration or necrosis of tumor  
t. Restlessness/inability to get comfortable 
u. Unconsciousness with no response to external stimuli 
 
 
 
 
 
 
 
 
 
 
 
 
488 
 
Institutional Review Board (IRB) Approval 
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Institutional Animal Care and Use Committee (IACUC) Approval
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MATLAB Code 
SiliconePhantom.m 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% Translational Biophotonics and Imaging Laboratory 
% February 9, 2017 
  
clear all; close all; clc; 
  
  
% This MATLAB script will determine the following user-specified variables 
% in order to construct a PDMS-based optical tissue phantom using  
% titanium dioxide as the scattering agent. 
  
    % 1. Application wavelength                     [nm] 
    % 2. Desired Reduced Scattering Coefficient     [1/cm] 
    % 3. Desired thickness of thin layer            [um] 
    % 4. Weight of PDMS elastomer base measured     [g] 
  
% Then, this MATLAB script will output the following parameters 
  
    % 1. Volume of PDMS elastomer base              [uL] 
    % 2. Volume of Curing Agent                     [uL] 
    % 3. Concentration of TiO2                      [g/g PDMS elastomer 
base]   
    % 4. Amount of TiO2                             [g] 
    % 5. Spin Speed in Spincoater                   [rpm] 
     
     
%% Determine the 5 user-specified variables     
fprintf('\nSilicone Phantom Design Module\n'); 
fprintf('by Gage J. Greening\n') 
fprintf('Department of Biomedical Engineering, University of Arkansas\n'); 
fprintf('From the Journal of Biomedical Optics, Manuscript #115002-2, Nov. 
2014\n\n'); 
fprintf('Substrate Material: Poly(dimethylsiloxane) (PDMS)\n'); 
fprintf('Scattering Agent: Titanium Dioxide\n'); 
fprintf('Absorbing Agent: Red Food Dye\n'); 
fprintf('Acceptable Wavelengths: 591, 621, 659, 691, 731, and 851 nm\n\n'); 
  
fprintf('Input Parameters\n'); 
wl_s   = input('Reference Wavelength for Scattering [nm]?:        ');   % 1. 
Scattering wavelength 
wl_a   = input('Reference Wavelength for Absorption [nm]?:        ');   % 2. 
Absorption wavelength 
us     = input('Desired Reduced Scattering Coefficient [1/cm]?:   ');   % 3. 
Desired Reduced Scattering Coefficient 
ua     = input('Desired Absorption Coefficient [1/cm]?:           ');   % 4. 
Desired Absorption Coefficient 
thick  = input('Desired Layer Thickness [um]?:                    ');   % 5. 
Desired thickness of thin layer 
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base   = input('Weight of PDMS Elastomer Base [g]?:               ');   % 6. 
Weight of PDMS elastomer base measured 
  
  
%% 1. Concentration of Scattering Agent 
  
if wl_s == 591 
    scat_conc = (0.0003797*us) + (-0.0001878); 
  
elseif wl_s == 621 
    scat_conc = (0.0004367*us) + (-0.000174); 
    
elseif wl_s == 659 
    scat_conc = (0.0004904*us) + (-0.0001579);   
       
elseif wl_s == 691 
    scat_conc = (0.0005377*us) + (-0.00009323);    
  
elseif wl_s == 731 
    scat_conc = (0.0005852*us) + (-0.00007569);    
  
elseif wl_s == 851 
    scat_conc = (0.0007266*us) + (-0.00007963); 
   
else  
    disp('Tested wavelength not specified: choose from 591, 631, 659, 691, 
731, or 851 nm'); 
end 
  
scat_conc_new = scat_conc*1000; 
  
%% Volume of PDMS elastomer base 
vol_base = (base) * (1/1030) * (1/1000) * (100^3) * (1/1000) * (1000000/1); 
  
%% Amount of Curing Agent 
mass_ca = (base/10); 
% The average experimental density of curing agent is 889 kg/m^3 
vol_ca = (mass_ca)*(1/889)*(1/1000)*(1000/1)*(1000000/1);  
  
%% Amount of Scattering Agent 
scat_amt = scat_conc*(base); 
  
%% Amount of Absorpting Agent 
  
% Read in the Excel file of the absorption coefficient of the stock solution     
mua = xlsread('abs.csv'); 
row = wl_a - 449; 
  
if ua < mua(row,2) 
    abs_conc = (ua/(mua(row,2))) * 0.417; 
else 
    abs_conc = (ua/(mua(row,3))) * 0.782; 
end 
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abs_amt = abs_conc * (base);    
     
%% Spin Speed in Spincoater 
speed = ((115900)*(thick^-0.9985))-15.09; 
  
%% Display all the values necessary to complete construction of the PDMS-
based tissue phantom 
  
fprintf('\nOutput Parameters\n'); 
fprintf('Volume of PDMS Elastomer Base:\t\t\t\t\t  %.1f uL\n',vol_base); 
fprintf('Volume of Curing Agent:\t\t\t\t\t\t\t  %.1f uL\n',vol_ca); 
fprintf('Concentration of Scattering Agent:\t\t\t\t  %.4f 
mg/g\n',scat_conc_new); 
fprintf('Amount of Scattering Agent:\t\t\t\t\t\t  %.4f g\n',scat_amt); 
fprintf('Concentration of Absorbing Agent:\t\t\t\t  %.4f uL/g\n',abs_conc); 
fprintf('Amount of Absorbing Agent:\t\t\t\t\t\t  %.2f uL\n',abs_amt); 
fprintf('Spin Speed:\t\t\t\t\t\t\t\t\t\t  %.0f rpm\n\n',speed); 
 
lutfunc1.m 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% March 19, 2016 
% lutfunc1.m 
  
function [lambda, Qsca, Qback, g] = lutfunc1(l_min, l_max, dl, r, 
sphere_type) 
  
%%%%%%%%%%%%%%%%%%%%%%%%%  mie_lambda  %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% This function calculates scattering crosssections, Qsca, and anisotropy 
% parameter, g, vs. wavelength. 
% 
% Inputs: 
%       - l_min:        minimum wavelength [um] 
%       - l_max:        maximum wavelength [um] 
%       - dl:           wavelength step [um] 
%       - r:            radius of particle [um] 
%       - bead_type:    type of sphere (bead (1) or tissue (2)) 
% 
% Outputs: 
%       - lambda:   wavelength [nm] 
%       - Qsca:     Total scattering efficiency [1/um^3] 
%       - Qback:    Backscattering efficiency [1/um^3] 
%       - g:        Anisotropy parameter 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
  
  
for lambda = l_min:dl:l_max, 
     
    switch lower(sphere_type) 
        case {'tissue'} 
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            n_sph = 1.424; 
            n_med = 1.36; 
            m = n_sph/n_med; 
        case  {'beads'} 
            n_sph = 1.5663; 
            %A=1.31279; 
            %B=0.015763; 
            %C=0.004382; 
            %D=0.0011455; 
            %n_med=(A+B./lambda-C./lambda.^2+D./lambda.^3); 
            n_med = 1.33; 
            %m=1.59/n_med; 
            m=(n_sph + .00785/(lambda.^2) + .000334/(lambda.^4))/n_med; 
            %m=(n_sph + .010002/(lambda^2))/n_med; 
            %m=(1.5663 + (0.00785/lambda^2) - (0.000334/lambda^4))/n_med; 
    end 
    k=2*pi*n_med/lambda; 
    x=r*k; 
    F = lutfunc2(m,x);   % returns [Re(m) Im(m) x Qext Qsca Qabs Qback g 
Qratio] 
    Qsca(round((lambda-l_min)/dl+1))   = F(5); 
    g(round((lambda-l_min)/dl+1))      = F(8); 
    Qback(round((lambda-l_min)/dl+1))  = F(7); 
      
end 
lambda = l_min:dl:l_max; 
 
lutfunc2.m 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% March 19, 2016 
% lutfunc2.m 
  
function result = lutfunc2(m, x) 
% Computation of Mie Efficiencies for given  
% complex refractive-index ratio m=m'+im"  
% and size parameter x=k0*a, where k0= wave number in ambient  
% medium, a=sphere radius, using complex Mie Coefficients 
% an and bn for n=1 to nmax, 
% s. Bohren and Huffman (1983) BEWI:TDD122, p. 103,119-122,477. 
% Result: m', m", x, efficiencies for extinction (qext),  
% scattering (qsca), absorption (qabs), backscattering (qb),  
% asymmetry parameter (asy=<costeta>) and (qratio=qb/qsca). 
% Uses the function "Mie_abcd" for an and bn, for n=1 to nmax. 
% C. Mätzler, May 2002. 
  
if x==0                 % To avoid a singularity at x=0 
    result=[real(m) imag(m) 0 0 0 0 0 0 1.5]; 
elseif x>0              % This is the normal situation 
    nmax=round(2+x+4*x^(1/3)); 
    n1=nmax-1; 
    n=(1:nmax);cn=2*n+1; c1n=n.*(n+2)./(n+1); c2n=cn./n./(n+1); 
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    x2=x*x; 
    f=lutfunc3(m,x); 
    anp=(real(f(1,:))); anpp=(imag(f(1,:))); 
    bnp=(real(f(2,:))); bnpp=(imag(f(2,:))); 
    g1(1:4,nmax)=[0; 0; 0; 0]; % displaced numbers used for 
    g1(1,1:n1)=anp(2:nmax);    % asymmetry parameter, p. 120 
    g1(2,1:n1)=anpp(2:nmax); 
    g1(3,1:n1)=bnp(2:nmax); 
    g1(4,1:n1)=bnpp(2:nmax);    
    dn=cn.*(anp+bnp); 
    q=sum(dn); 
    qext=2*q/x2; 
    en=cn.*(anp.*anp+anpp.*anpp+bnp.*bnp+bnpp.*bnpp); 
    q=sum(en); 
    qsca=2*q/x2; 
    qabs=qext-qsca; 
    fn=(f(1,:)-f(2,:)).*cn; 
    gn=(-1).^n; 
    f(3,:)=fn.*gn; 
    q=sum(f(3,:)); 
    qb=q*q'/x2; 
    asy1=c1n.*(anp.*g1(1,:)+anpp.*g1(2,:)+bnp.*g1(3,:)+bnpp.*g1(4,:)); 
    asy2=c2n.*(anp.*bnp+anpp.*bnpp); 
    asy=4/x2*sum(asy1+asy2)/qsca; 
    qratio=qb/qsca; 
    result=[real(m) imag(m) x qext qsca qabs qb asy qratio]; 
end; 
 
lutfunc3.m 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% March 19, 2016 
% lutfunc3.m 
  
function result = lutfunc3(m, x) 
  
% Computes a matrix of Mie coefficients, a_n, b_n, c_n, d_n,  
% of orders n=1 to nmax, complex refractive index m=m'+im",  
% and size parameter x=k0*a, where k0= wave number  
% in the ambient medium, a=sphere radius;  
% p. 100, 477 in Bohren and Huffman (1983) BEWI:TDD122 
% C. Mätzler, June 2002 
  
nmax=round(2+x+4*x^(1/3)); 
n=(1:nmax); nu = (n+0.5); z=m.*x; m2=m.*m;  
sqx= sqrt(0.5*pi./x); sqz= sqrt(0.5*pi./z); 
bx = besselj(nu, x).*sqx; 
bz = besselj(nu, z).*sqz; 
yx = bessely(nu, x).*sqx; 
hx = bx+i*yx; 
b1x=[sin(x)/x, bx(1:nmax-1)]; 
b1z=[sin(z)/z, bz(1:nmax-1)]; 
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y1x=[-cos(x)/x, yx(1:nmax-1)]; 
h1x= b1x+i*y1x; 
ax = x.*b1x-n.*bx; 
az = z.*b1z-n.*bz; 
ahx= x.*h1x-n.*hx; 
  
an = (m2.*bz.*ax-bx.*az)./(m2.*bz.*ahx-hx.*az); 
bn = (bz.*ax-bx.*az)./(bz.*ahx-hx.*az); 
cn = (bx.*ahx-hx.*ax)./(bz.*ahx-hx.*az); 
dn = m.*(bx.*ahx-hx.*ax)./(m2.*bz.*ahx-hx.*az); 
result=[an; bn; cn; dn]; 
 
step1_createPhantoms 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% May 3, 2016 
% step1_createPhantoms.m 
  
% This program provides the amount of beads to generate each phantom and 
% the amount of ink needed at each step. Although this program generates 
% exact numbers for the volume to be added, it might not be always possible 
% to pipet out the exact numbers. In such cases, correct x1 and volumeDist 
% to represent actual volumes added.  
  
clear all; close all; clc; 
  
% The total volume of solution 
tot_vol = input('Phantom Volume (mL): '); 
  
% The reduced scattering coefficients (us') of the phantoms at 630 nm 
redscatCoef = [3.43, 4.94, 7.14, 10.31, 14.88, 21.48] / 10; 
  
% Diameter of the beads (um) 
actBeadSize = 0.99; 
  
% Standard deviation of the bead size (um) 
stdev = 0.03; 
  
% Percent solid of beads 
perSol = 2.6; 
  
%% Use the function 'lutfunc1.m' to determine scattering efficiency 
  
% Input parameters for the mie2 function (also described in mie2.m) 
minwave = 0.30;         % Minimum wavelength (um) 
maxwave = 0.80;         % Maximum wavelength (um) 
wavestep = 0.001;       % Wavelength step (um) 
radius = actBeadSize/2; % Radius of beads (um) 
  
% Output parameters for the mie2 function (also described in mie2.m) 
    % lambda:   Wavelength 
    % Qsca:     Total scattering efficiency [1/um^3] 
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    % Qback:    Backscattering efficiency [1/um^3] 
    % g:        Anisotropy coefficient 
     
[lambda, Qsca, Qback, g] = 
lutfunc1(minwave,maxwave,wavestep,radius,'beads'); 
  
% Convert lambda (um) to lambda_nm (nm) for plotting purposes 
lambda_nm = lambda.*1000; 
  
% Calculation of the scattering cross section (Tsca = scattering cross 
section) 
Tsca = Qsca.*pi*(radius)^2;     % [1/um^3] * [um^2] = [um^-1] ???? 
  
% Calculation of the reduced scattering cross section 
redScat = Tsca.*(1-g); 
  
%% Absorption Coefficient 
  
% The stock solution is made with the following: 
    % 2,000 uL yellow food dye  
    % 800 uL red food dye 
    % 400 uL blue food dye 
    % 16,800 uL deionized water 
    % 20,000 uL total volume 
     
% Read in the Excel file of the absorption coefficient of the stock solution     
mua_init = xlsread('Dye Combination Stock - Dilution of 10x - 
05192017.csv'); 
  
% Absorption coefficient of the stock solution (without 1st column of 
% wavelength) 
mua_init_c1 = mua_init(:,1); 
mua_init_c2 = mua_init(:,2)*10;     % 10x stock solution 
for i = 1:501                       % absorbance data btw 300-800 nm 
    if mua_init_c2(i) < 0 
        mua_init_c2(i) = 0.001; 
    end 
end 
  
% Desired maxiumum absorption coefficient of calibration phantoms 
max_mua = input('Maximum Absorption Coefficient (1/cm): '); 
wavelength_min = input('Minimum Wavelength (nm): '); 
wavelength_min_index = (wavelength_min - (mua_init_c1(1) - 1)); 
wavelength_max = input('Maximum Wavelength (nm): '); 
wavelength_max_index = (wavelength_max - (mua_init_c1(1) - 1)); 
  
% The scale of the desired max ua and the ua of the stock solution 
scale = max_mua / 
max(mua_init_c2(wavelength_min_index:wavelength_max_index)); 
  
% The absorption coefficient of the calibration phantoms 
mua = scale * mua_init_c2; 
  
% The volume of the stock solution needed to yield the desired ua 
540 
 
mLAbsorber = zeros(1,2*length(redscatCoef)); 
mLAbsorber(length(redscatCoef)+1:2*length(redscatCoef)) = (tot_vol)*scale;  
  
%% Create the phantoms  
  
% Density [1/um^3] 
density = redscatCoef(1,:)./redScat(331)/1000; 
% #part per ml of bead solution 
partBeads = tot_vol.*density.*10^12; 
%Total number of beads in Solution 
totBeads = (6.*(perSol./100).*10^12)./(1.05*pi.*actBeadSize.^3); 
%mL of beads to use to create phantom 
mLBeads = partBeads./totBeads; 
mLBeads = horzcat(mLBeads,mLBeads); 
%mL of water used to create phantom 
mLWater(1:length(redscatCoef)) = tot_vol - (mLBeads(1:length(redscatCoef)) + 
mLAbsorber(1:length(redscatCoef))); 
mLWater(length(redscatCoef)+1:2*length(redscatCoef)) = tot_vol - 
(mLBeads(length(redscatCoef)+1:2*length(redscatCoef)) + 
mLAbsorber(length(redscatCoef)+1:2*length(redscatCoef))); 
%volumeDist is a table with mLs beads in the first column and the 
%corresponding mLs of water in the second. 
volumeDist = [mLBeads' mLAbsorber' mLWater' mLBeads'+mLWater'+mLAbsorber']; 
  
% Volume distribution in uL (microliters) 
volumeDist = round(volumeDist*1000); 
  
%% Reduced Scattering Coefficient 
  
% If less than 6 phantoms are needed to span the desired range of reduced 
% scattering coefficients, comment out the extra phantoms. 
  
redScatCS = redScat;        % Reduced scattering cross section [cm^2] 
  
% Reduced scattering coefficients for all phantoms put in terms of cm 
musp1 = redScatCS.*(density(1,1))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 1 [cm^-1] 
musp2 = redScatCS.*(density(1,2))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 2 [cm^-1] 
musp3 = redScatCS.*(density(1,3))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 3 [cm^-1] 
musp4 = redScatCS.*(density(1,4))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 4 [cm^-1] 
musp5 = redScatCS.*(density(1,5))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 5 [cm^-1] 
musp6 = redScatCS.*(density(1,6))*10000;    % Reduced scattering cross 
section * volume density = musp for phantom 6 [cm^-1] 
  
% Currently, the resolution of the reduced scattering coefficients is 1. 
% Interpolate these values such that they correlate with the resoultion of 
% the spectrometer (~0.35). 
load('Wavelength.mat'); 
musp1 = interp1(lambda_nm,musp1,wavelength_501); 
musp1 = musp1(wavelength_min_index:wavelength_max_index); 
musp2 = interp1(lambda_nm,musp2,wavelength_501); 
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musp2 = musp2(wavelength_min_index:wavelength_max_index); 
musp3 = interp1(lambda_nm,musp3,wavelength_501); 
musp3 = musp3(wavelength_min_index:wavelength_max_index); 
musp4 = interp1(lambda_nm,musp4,wavelength_501); 
musp4 = musp4(wavelength_min_index:wavelength_max_index); 
musp5 = interp1(lambda_nm,musp5,wavelength_501); 
musp5 = musp5(wavelength_min_index:wavelength_max_index); 
musp6 = interp1(lambda_nm,musp6,wavelength_501); 
musp6 = musp6(wavelength_min_index:wavelength_max_index); 
  
muspmin = 
[min(musp1);min(musp2);min(musp3);min(musp4);min(musp5);min(musp6)]; 
muspmax = 
[max(musp1);max(musp2);max(musp3);max(musp4);max(musp5);max(musp6)]; 
  
% Plot the reduced scattering and absorption coefficients 
figure(1) 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp1,'Linewi
dth',2); 
hold on; 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp2,'Linewi
dth',2); 
hold on; 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp3,'Linewi
dth',2); 
hold on; 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp4,'Linewi
dth',2); 
hold on; 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp5,'Linewi
dth',2); 
hold on; 
subplot(1,2,1); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),musp6,'Linewi
dth',2); 
[yaxis]=get(get(gca,'children'),'ydata'); 
legend('Phantom 1,7','Phantom 2,8','Phantom 3,9','Phantom 4,10','Phantom 
5,11','Phantom 6,12'); 
title('\mu_s^'' vs. wavelength for LUT calibration phantoms'); 
xlabel('Wavelength (nm)'); 
ylabel('\mu_s^'' (cm^-^1)'); 
axis square; axis([wavelength_min wavelength_max 0 max(musp6)*1.1]); 
  
mua_zeros = zeros(length(wavelength_501),1); 
mua_zeros(:) = 0.001; 
subplot(1,2,2); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),mua_zeros(wav
elength_min_index:wavelength_max_index),'Linewidth',2); 
hold on; 
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subplot(1,2,2); 
plot(wavelength_501(wavelength_min_index:wavelength_max_index),mua(wavelengt
h_min_index:wavelength_max_index),'Linewidth',2); 
legend('Phantom 1-6','Phantom 7-12'); 
title('\mu_a vs. wavelength for LUT calibration phantoms'); 
xlabel('Wavelength (nm)'); 
ylabel('\mu_a (cm^-^1)'); 
axis square; axis([wavelength_min wavelength_max 0 max(mua)*1.1]); 
  
% Write data to table 
  
table = {'Phantom', 'Polystyrene Beads (uL)', 'Absorber (uL)', 'Deionized 
Water (uL)', 'Total Volume (mL)', 'Min. us'' (cm-1)', 'Max. us'' (cm-1)', 
'Min. ua (cm-1)', 'Max. ua (cm-1)'}; 
  
for i = 2:13 
    table{i,1} = i-1; 
    table{i,2} = volumeDist(i-1,1); 
    table{i,3} = volumeDist(i-1,2); 
    table{i,4} = volumeDist(i-1,3); 
    table{i,5} = volumeDist(i-1,1)+volumeDist(i-1,2)+volumeDist(i-1,3); 
end 
  
for i = 2:7 
    table{i,6} = muspmin(i-1,1); 
    table{i,7} = muspmax(i-1,1); 
    table{i,8} = 0; 
    table{i,9} = 0; 
end 
  
for i = 8:13 
    table{i,6} = muspmin(i-7,1); 
    table{i,7} = muspmax(i-7,1); 
    table{i,8} = 0; 
    table{i,9} = max_mua; 
end 
  
table_double = cell2mat(table(2:13,:)); 
  
total_beads = sum(table_double(:,2)); 
total_dye  =sum(table_double(:,3)); 
total_water = sum(table_double(:,4)); 
total_volume = sum(table_double(:,5)); 
  
table{16,1} = 'Total (mL)'; 
table{16,2} = total_beads/1000; 
table{16,3} = total_dye/1000; 
table{16,4} = total_water/1000; 
table{16,5} = total_volume/1000; 
  
filename = 'PhantomSpecifications.xlsx'; 
xlswrite(filename,table,'PhantomSpecifications','A1'); 
  
% Save an Excel file with absorption coefficients 
table2(:,1) = wavelength_501(wavelength_min_index:wavelength_max_index); 
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table2(:,2) = mua_zeros(wavelength_min_index:wavelength_max_index); 
filename = 'PhantomAbsCoeffZeros.xlsx'; 
xlswrite(filename,table2,'PhantomAbsCoeffZeros','A1') 
  
table3(:,1) = wavelength_501(wavelength_min_index:wavelength_max_index); 
table3(:,2) = mua(wavelength_min_index:wavelength_max_index); 
filename = 'PhantomAbsCoeff.xlsx'; 
xlswrite(filename,table3,'PhantomAbsCoeff','A1') 
  
% Save variables 
  
mua_P01toP06 = mua_zeros'; 
mua_P07toP12 = mua'; 
  
save('temp.mat','volumeDist','musp1','musp2','musp3','musp4','musp5','musp6'
,'mua_P01toP06','mua_P07toP12','table','wavelength_min','wavelength_max'); 
  
clear all; 
  
load('Wavelength.mat'); 
load('temp.mat'); 
  
% 
save('temp.mat','musp1','musp2','musp3','musp4','musp5','musp6','mua_P08toP1
4','mua_P01toP07','sample','wavelength_301','wavelength_857'); 
 
step2_createLUT.m 
%% Gage J. Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% March 6, 2017 
% step2_createLUT.m 
  
clc; close all; 
  
%% Load in the calibration curve taken with the reflectance standard 
fprintf('Load Calibration Curve:\n\n'); 
filename = uigetfile; 
C = csvread(filename); 
wavelength_long = C(1:2228,1);      % cut off at 800 nm 
calibration_curve = C(1:2228,2);    % cut off at 800 nm     
  
%% Load in the dark noise curve taken when all lights are off 
fprintf('Load Darknoise Curve:\n\n'); 
filename = uigetfile; 
D = csvread(filename); 
darknoise_curve = D(1:2228,2);      % cut off at 800 nm    
  
%% Interpolate phantom generation data to match wavelengths of spectrometer 
  
% Set the standard 1 nm resolution wavelength range 
wavelength_range = wavelength_min:1:wavelength_max; 
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% Create interpolated musp values based on spectrometer resolution 
musp_interp(:,1) = interp1(wavelength_range,musp1,wavelength_long); 
musp_interp(:,2) = interp1(wavelength_range,musp2,wavelength_long); 
musp_interp(:,3) = interp1(wavelength_range,musp3,wavelength_long); 
musp_interp(:,4) = interp1(wavelength_range,musp4,wavelength_long); 
musp_interp(:,5) = interp1(wavelength_range,musp5,wavelength_long); 
musp_interp(:,6) = interp1(wavelength_range,musp6,wavelength_long); 
musp_interp(:,7) = interp1(wavelength_range,musp7,wavelength_long); 
  
% Create interpolated mua values based on spectrometer resolution 
mua_ranges = input('Ranges of Absorption Coefficients: '); 
fprintf('Load Phantoms Absorption Curves, starting with zeros:\n\n'); 
fprintf('\n'); 
for i = 1:mua_ranges 
    filename = uigetfile; 
    A = csvread(filename); 
    abs_coeff(:,i) = A(:,2); 
end 
mua_interp(:,1) = interp1(wavelength_range,abs_coeff(:,1),wavelength_long); 
mua_interp(:,2) = interp1(wavelength_range,abs_coeff(:,2),wavelength_long); 
mua_interp(:,3) = interp1(wavelength_range,abs_coeff(:,3),wavelength_long); 
  
phantom_number = input('Number of Phantoms: '); 
fprintf('Load Phantom Raw Reflectance Data:\n\n'); 
for i = 1:phantom_number 
    filename = uigetfile; 
    P = csvread(filename); 
    phantom(:,i) = P(1:2228,2);  
end 
  
phantom_calibrated = zeros(length(calibration_curve),phantom_number); 
for i = 1:phantom_number 
    phantom_calibrated(:,i) = (phantom(:,i) - darknoise_curve(:,1)) ./ 
((calibration_curve(:,1) - darknoise_curve(:,1)) * 5); 
end 
  
%% Create mesh 
  
% Reduced Scattering Coefficient 
musp(:,1:7) = musp_interp; 
musp(:,8:14) = musp_interp; 
musp(:,15:21) = musp_interp; 
musp(isnan(musp)) = 0;  
  
% Absorption Coefficient 
for i = 1:7 
mua(:,i) = mua_interp(:,1); 
mua(:,i+7) = mua_interp(:,3); 
mua(:,i+14) = mua_interp(:,2); 
end 
mua(isnan(mua)) = 0;  
  
% Calibrated Reflectance 
ref(:,:) = phantom_calibrated(:,:); 
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% Convert matrices to vectors 
vector_musp = musp(:); 
vector_mua = mua(:); 
vector_ref = ref(:); 
  
% Create LResolution for Lookup Table 
  
musp_min = min(vector_musp(vector_musp>0)); 
musp_max = max(vector_musp); 
mua_min = min(vector_mua(vector_mua>0)); 
mua_max = max(vector_mua); 
ref_min = min(vector_ref(vector_ref>0)); 
ref_max = max(vector_ref(vector_ref<1)); 
  
res_musp = linspace(musp_min,musp_max,200); 
res_mua = linspace(mua_min,mua_max,200); 
  
% Create Lookup Table 
lut = griddata(vector_musp,vector_mua,vector_ref,res_musp',res_mua); 
surf(res_musp',res_mua,lut); hold on; 
scatter3(vector_musp,vector_mua,vector_ref,'k'); 
axis([5, 40, -1, 10, 0, 0.3]); 
xlabel('\mu_s^'' (cm^-^1)'); 
ylabel('\mu_a (cm^-^1)'); 
zlabel('Reflectance (A.U.)'); 
title('Lookup Table'); 
box on; grid on; axis square; colormap(jet); colorbar; 
  
% Save necessary variables 
save('specLookupTable.mat','res_musp','res_mua','lut'); 
 
calcOP_hb_3000_hb.m 
function R = calcOP_hb_3000_hb(InitialValues,lambda,Hb,HbO2,mel) 
  
% The goal of this function is to determine R 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% lambda in um 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
A                   = InitialValues(1); 
B                   = InitialValues(2); 
C                   = InitialValues(3); 
cHb                 = InitialValues(4); 
alpha               = InitialValues(5); 
S                   = InitialValues(6); 
  
if cHb<0 
    cHb = 0; 
end 
  
% Reduced Scattering Coefficient 
mu_sp = (A*10).*(lambda./0.730).^(-B); 
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% Absorption Coefficient 
mu_a1 = (2.303*(150).*(alpha.*HbO2(:,2) + (1-alpha).*Hb(:,2))); 
mu_a = 0.01*cHb.*mu_a1.*(1 - exp(-S.*mu_a1))./(S.*mu_a1); 
% mu_a = mu_a + (2.303*0.1.*C*mel(:,2));      
  
% Loading the appropriate LUT 
load('calcOP.mat'); 
R = interp2(musp3000',mua3000,lut3000,mu_sp,mu_a); 
  
end 
 
calcOP_hb_3000_oxy.m 
function R = calcOP_hb_3000_oxy(InitialValues,lambda,Hb,HbO2,mel) 
  
% The goal of this function is to determine R 
  
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
% lambda in um 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
  
A                   = InitialValues(1); 
B                   = InitialValues(2); 
C                   = InitialValues(3); 
cHb                 = InitialValues(4); 
alpha               = InitialValues(5); 
S                   = InitialValues(6); 
  
if cHb<0 
    cHb = 0; 
end 
  
% Reduced Scattering Coefficient 
mu_sp = (A*10).*(lambda./0.590).^(-B); 
  
% Absorption Coefficient 
mu_a1 = (2.303*(150).*(alpha.*HbO2(:,2) + (1-alpha).*Hb(:,2))); 
mu_a = 0.01*cHb.*mu_a1.*(1 - exp(-S.*mu_a1))./(S.*mu_a1); 
% mu_a = mu_a + (2.303*0.1.*C*mel(:,2));      
  
% Loading the appropriate LUT 
load('calcOP.mat'); 
R = interp2(musp3000',mua3000,lut3000,mu_sp,mu_a); 
  
end 
 
chisqOP_hb_3000_hb.m 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%This function calculates the chi-squared error between the 
%OP model and measured data (Rmeas) 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function chisq = chisqOP_hb_3000_hb(InitialValues,Rmeas,lambda,Hb,HbO2,mel) 
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R = calcOP_hb_3000_hb(InitialValues,lambda,Hb,HbO2,mel); 
chisq = sum(((R - Rmeas)./R).^2); 
 
chisqOP_hb_3000_oxy.m 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%This function calculates the chi-squared error between the 
%OP model and measured data (Rmeas) 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
function chisq = chisqOP_hb_3000_oxy(InitialValues,Rmeas,lambda,Hb,HbO2,mel) 
  
R = calcOP_hb_3000_oxy(InitialValues,lambda,Hb,HbO2,mel); 
chisq = sum(((R - Rmeas)./R).^2); 
 
PostProcess3mm.m 
%% Gage Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% June 30, 2016 
  
  
%% Loading in Calibration and Dark Noise Data 
  
clear all; close all; clc; 
  
% Load in the calibration curve 
[filename, ~] = uigetfile('*.csv', 'Select the calibration dataset'); 
cal = load(filename); 
cal = cal; 
  
% Load in the dark noise curve 
dn = csvread('3mm_75ms_DARKNOISE.csv'); 
data(:,1) = dn(:,1); 
  
  
%% Initialize variables 
  
samples = input('Number of Spectra: ' ); 
% samples = input('Number of Spectroscopy Measurements: '); 
name = ['3-1';'3-2';'3-3';'3-4';'3-5';'3-6';'3-7';'3-8';'3-9']; 
name2 = ['3-10';'3-11';'3-12';'3-13';'3-14';'3-15';'3-16';'3-17';'3-18';'3-
19';'3-20';'3-21';'3-22';'3-23';'3-24';'3-25';'3-26';'3-27';'3-28';'3-
29';'3-30';'3-31';'3-32';'3-33';'3-34';'3-35']; 
temp = zeros(2048,2); 
temp2 = zeros(2048,2); 
specraw = zeros(2048,samples); 
  
  
%% Create Matrix with Raw Spectra 
  
% Raw spectra 
for i = 1:9 
    temp = csvread([name(i,:),'.csv']); 
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    specraw(:,i) = temp(:,2); 
end 
for i = 10:samples 
    temp2 = csvread([name2(i-9,:),'.csv']); 
    specraw(:,i) = temp2(:,2); 
end 
  
% (Raw spectra - darknoise) / (5(calibration - darknoise)) 
for i = 1:samples 
    data(:,i+1) = (specraw(:,i)-dn(:,2))./((cal(:,2)-dn(:,2))*5); 
end 
  
  
%% Boundary Conditions: Wavelength 
  
% Set the minimum and maximum wavelengths: Oxygenation 
wmin_oxy = 515; 
wmax_oxy = 595; 
  
% Set the minimum and maximum wavelengths: [Hb] and scattering 
wmin_hb = 475; 
wmax_hb = 750; 
           
% Load in the absorbance values for hemoglobin and melanin 
load('HbO2.txt'); 
load('Hb.txt'); 
load('mel.txt'); 
  
  
%% Boundary Conditions: Optical Properties 
  
% Set the initial values: Oxygenation [A B cMel cHb SaO2 S wmin wmax] 
InitParams1 =    [0.400   -1.00   0.000   2.000    0.20    0.001   wmin_oxy   
wmax_oxy]; 
InitVal1 = InitParams1(1:6); 
lb1 =            [0.000   -4.00   0.000   0.0000   0.000   0.000]; 
ub1 =            [1.000   0.000   0.000   12.000   1.000   0.010]; 
  
% Set the initial values: Hemoglobin [A B cMel cHb SaO2 S wmin wmax] 
InitParams2 =    [0.400   0.500   0.000   2.000    0.20    0.001   wmin_hb   
wmax_hb]; 
InitVal2 = InitParams2(1:6); 
lb2 =            [0.000   -1.00   0.000   0.0000   0.000   0.000]; 
ub2 =            [1.000   1.500   0.000   12.000   1.000   0.010]; 
  
  
%% Model Fit 
  
for i = 1:samples 
    % Choose wavelength range by index: Oxygenation 
    [~, lambdaMinIndex1] = min((data(:,1) - InitParams1(7)).^2); 
    [~, lambdaMaxIndex1] = min((data(:,1) - InitParams1(8)).^2); 
    lambda1 = data(lambdaMinIndex1:lambdaMaxIndex1,1)/1000; 
    % Choose wavelength range by index: Hemoglobin 
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    [~, lambdaMinIndex2] = min((data(:,1) - InitParams2(7)).^2); 
    [~, lambdaMaxIndex2] = min((data(:,1) - InitParams2(8)).^2); 
    lambda2 = data(lambdaMinIndex2:lambdaMaxIndex2,1)/1000; 
  
    % Scale = initParams(6): Oxygenation 
    eHbO21   = [lambda1 interp1q(HbO2(:,1)/1000,HbO2(:,2),lambda1)]; 
    eHb1    = [lambda1 interp1q(Hb(:,1)/1000,Hb(:,2),lambda1)]; 
    emel1    = [lambda1 interp1q(mel(:,1)/1000,mel(:,2),lambda1)]; 
    % Scale = initParams(6): Hemoglobin 
    eHbO22   = [lambda2 interp1q(HbO2(:,1)/1000,HbO2(:,2),lambda2)]; 
    eHb2    = [lambda2 interp1q(Hb(:,1)/1000,Hb(:,2),lambda2)]; 
    emel2    = [lambda2 interp1q(mel(:,1)/1000,mel(:,2),lambda2)]; 
  
    % Generate first guess at reflectance based on initial parameters: 
Oxygenation 
    RFirstGuess1 = calcOP_hb_3000_oxy(InitVal1,lambda1,eHb1,eHbO21,emel1); 
    % Generate first guess at reflectance based on initial parameters: 
Hemoglobin 
    RFirstGuess2 = calcOP_hb_3000_hb(InitVal2,lambda2,eHb2,eHbO22,emel2); 
  
    % Get measured reflectance data: Oxygenation 
    Rmeas1(:,i) = data(lambdaMinIndex1:lambdaMaxIndex1,i+1); 
    % Get measured reflectance data: Hemoglobin 
    Rmeas2(:,i) = data(lambdaMinIndex2:lambdaMaxIndex2,i+1); 
  
    % Adjust fit parameters 
    % FitOptimize =optimset('MaxFunEvals',6000,'MaxIter',6000,'TolX',5E-
5,'TOlFun',5E-5,'LevenbergMarquardt','on'); 
    fitOptimize = 
optimset('LargeScale','off','MaxFunEvals',6000,'MaxIter',6000,'TolX',5E-
5,'TOlFun',5E-5); 
     
    %[FitVals chisq] = 
fminsearch('chisqOP',InitVal,fitOptimize,Rmeas,lambda,eHbO2): Oxygenation 
    [FitVals1(i,:), chisq1(i,:)] = 
fmincon('chisqOP_hb_3000_oxy',InitVal1,[],[],[],[],lb1,ub1,[],fitOptimize,Rm
eas1(:,i),lambda1,eHb1,eHbO21,emel1); 
    %[FitVals chisq] = 
fminsearch('chisqOP',InitVal,fitOptimize,Rmeas,lambda,eHbO2): Hemoglobin 
    [FitVals2(i,:), chisq2(i,:)] = 
fmincon('chisqOP_hb_3000_hb',InitVal2,[],[],[],[],lb2,ub2,[],fitOptimize,Rme
as2(:,i),lambda2,eHb2,eHbO22,emel2); 
  
     
    Fit1(:,i) = calcOP_hb_3000_oxy(FitVals1(i,:),lambda1,eHb1,eHbO21,emel1); 
    Fit2(:,i) = calcOP_hb_3000_hb(FitVals2(i,:),lambda2,eHb2,eHbO22,emel2); 
     
    if exist('chisq1')==0 
        chisq1(i) = sum(((Fit1(:,i) - Rmeas1(:,i))./Fit1(:,i)).^2); 
    end 
    if exist('chisq2')==0 
        chisq2(i) = sum(((Fit2(:,i) - Rmeas2(:,i))./Fit2(:,i)).^2); 
    end 
  
end 
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% Multiply lambda by 1000 to get values in nm 
lambda1 = lambda1 * 1000; 
lambda2 = lambda2 * 1000; 
  
clc; 
  
% Creating optical property tables (for both wavelength ranges) 
Quantify1 = zeros(samples,7); % Initializing the 1st table per number of 
samples 
Quantify2 = zeros(samples,7); % Initializing the 2nd table per number of 
samples 
for i = 1:samples 
    % Table for fit values: Accurate Oxygenation (515-595 nm) 
    Quantify1(i,1:6) = FitVals1(i,:); Quantify1(i,7) = chisq1(i); 
    % Table for fit values: Accurate Hemoglobin (475-750 nm) 
    Quantify2(i,1:6) = FitVals2(i,:); Quantify2(i,7) = chisq2(i); 
end 
  
% Creating table of relevant optical properties 
% 1st column: Oxygenation 
% 2nd column: Oxygenation Chi-Squared Value 
% 3rd column: Hemoglobin Content 
% 4th column: Hemoglobin Content Chi-Squared Value 
% 5th column: Reduced Scattering Coefficient 
table1 = zeros(samples,4); 
table1(:,1) = Quantify1(:,5); 
table1(:,2) = Quantify1(:,7); 
table1(:,3) = Quantify2(:,4); 
table1(:,4) = Quantify2(:,7); 
table1(:,5) = Quantify2(:,1); 
  
% Exclude samples that don't meet Chi-Squared criteria 
table2 = zeros(size(table1)); 
for i = 1:samples 
    if table1(i,2) > 2 | table1(i,4) > 6 | table1(i,1) < 0.01 | table1(i,3) 
< 1.2   
        table2(i,:) = NaN; 
    else 
        table2(i,:) = table1(i,:); 
    end 
end 
table2(isnan(table2(:,1)),:) = []; 
  
% Create a 3rd table with the average oxygenation and hemoglobin 
table3(1,1) = mean(table2(:,1)); 
table3(2,1) = mean(table2(:,3)); 
table3(3,1) = mean(table2(:,5)*10); 
  
disp(table3); 
 
tamcount.m 
%% Gage Greening 
% University of Arkansas 
% College of Engineering 
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% Department of Biomedical Engineering 
% May 24, 2018 
% tamcount.m 
  
clear all; close all; clc; 
  
%% Load in 12 image files 
Files = dir('*.tif');  
numfiles = length(Files); 
mydata = cell(1, numfiles); 
  
for k = 1:numfiles  
  mydata{k} = imread(Files(k).name);  
end 
  
x = mydata{1}; 
[height width] = size(x); 
  
error = round(height * 0.06); 
  
%% Mark the macrophages you see in the images; click ENTER when done for 
each image 
figure 
a=imshow(mydata{1}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(a); 
[x01,y01] = getpts; 
  
figure 
b=imshow(mydata{2}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(b); 
[x02,y02] = getpts; 
  
figure 
c=imshow(mydata{3}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(c); 
[x03,y03] = getpts; 
  
figure 
d=imshow(mydata{4}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(d); 
[x04,y04] = getpts; 
  
figure 
e=imshow(mydata{5}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(e); 
[x05,y05] = getpts; 
  
figure 
552 
 
f=imshow(mydata{6}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(f); 
[x06,y06] = getpts; 
  
figure 
g=imshow(mydata{7}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(g); 
[x07,y07] = getpts; 
  
figure 
h=imshow(mydata{8}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(h); 
[x08,y08] = getpts; 
  
figure 
i=imshow(mydata{9}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(i); 
[x09,y09] = getpts; 
  
figure 
j=imshow(mydata{10}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(j); 
[x10,y10] = getpts; 
  
figure 
k=imshow(mydata{11}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(k); 
[x11,y11] = getpts; 
  
figure 
l=imshow(mydata{12}); set(gcf, 'Units', 'Normalized', 'OuterPosition', [0.5 
0.5 0.5 0.5]); 
imcontrast(l); 
[x12,y12] = getpts; 
  
close all; 
  
%% Exclude duplicate M1 TAMs 
  
plot(x01,y01,'k*'); hold on; 
plot(x02,y02,'k*'); hold on; 
plot(x03,y03,'k*'); hold on; 
plot(x04,y04,'k*'); hold on; 
  
max_length_M1tams(1) = length(x01); 
max_length_M1tams(2) = length(x02); 
max_length_M1tams(3) = length(x03); 
max_length_M1tams(4) = length(x04); 
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M1tams_x = 
zeros(max_length_M1tams(1)+max_length_M1tams(2)+max_length_M1tams(3)+max_len
gth_M1tams(4),1); 
M1tams_y = 
zeros(max_length_M1tams(1)+max_length_M1tams(2)+max_length_M1tams(3)+max_len
gth_M1tams(4),1); 
  
M1tams_x(1:length(x01),1) = x01; 
M1tams_x(1+length(x01):length(x01)+length(x02),1) = x02;  
M1tams_x(1+length(x01)+length(x02):length(x01)+length(x02)+length(x03),1) = 
x03;  
M1tams_x(1+length(x01)+length(x02)+length(x03):length(x01)+length(x02)+lengt
h(x03)+length(x04),1) = x04; 
  
M1tams_y(1:length(x01),1) = y01;  
M1tams_y(1+length(x01):length(x01)+length(x02),1) = y02;  
M1tams_y(1+length(x01)+length(x02):length(x01)+length(x02)+length(x03),1) = 
y03;  
M1tams_y(1+length(x01)+length(x02)+length(x03):length(x01)+length(x02)+lengt
h(x03)+length(x04),1) = y04;  
  
M1tams = zeros(length(M1tams_x),2); 
M1tams(:,1) = round(M1tams_x); M1tams(:,2) = round(M1tams_y); 
M1tams(:,3) = M1tams(:,1).*M1tams(:,2); 
M1tams_update = M1tams; 
  
distance = zeros(length(M1tams(:,1)),length(M1tams(:,1))); 
for i = 1:length(M1tams(:,1)) 
    for j = 1:length(M1tams(:,1)) 
        if i > j 
            distance(i,j) = sqrt(((M1tams(i,1) - M1tams(j,1))^2) + 
((M1tams(i,2) - M1tams(j,2))^2)); 
        else 
            distance(i,j) = 0; 
        end 
    end 
end 
distance(distance==0) = NaN; 
  
distance_logic = zeros(length(M1tams(:,1)),length(M1tams(:,1))); 
for i = 1:length(M1tams(:,1)) 
    for j = 1:length(M1tams(:,1)) 
        if distance(i,j) < error 
            distance_logic(i,j) = 1; 
        else 
            distance_logic(i,j) = 0; 
        end 
    end 
end 
  
for i = 1:length(M1tams(:,1)) 
    for j = 1:length(M1tams(:,1)) 
        if distance_logic(i,j) == 1 
            M1tams_update(i,1) = 0; M1tams_update(i,2) = 0; 
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        end 
    end 
end 
  
temp = find(M1tams_update(:,1) > 0); 
count_M1 = length(temp); 
M1tams_update = M1tams_update(temp,:); 
  
%% Exclude duplicate TAMs 
  
plot(x05,y05,'k*'); hold on; 
plot(x06,y06,'k*'); hold on; 
plot(x07,y07,'k*'); hold on; 
plot(x08,y08,'k*'); hold on; 
  
max_length_Mtams(1) = length(x05); 
max_length_Mtams(2) = length(x06); 
max_length_Mtams(3) = length(x07); 
max_length_Mtams(4) = length(x08); 
  
Mtams_x = 
zeros(max_length_Mtams(1)+max_length_Mtams(2)+max_length_Mtams(3)+max_length
_Mtams(4),1); 
Mtams_y = 
zeros(max_length_Mtams(1)+max_length_Mtams(2)+max_length_Mtams(3)+max_length
_Mtams(4),1); 
  
Mtams_x(1:length(x05),1) = x05; 
Mtams_x(1+length(x05):length(x05)+length(x06),1) = x06;  
Mtams_x(1+length(x05)+length(x06):length(x05)+length(x06)+length(x07),1) = 
x07;  
Mtams_x(1+length(x05)+length(x06)+length(x07):length(x05)+length(x06)+length
(x07)+length(x08),1) = x08; 
  
Mtams_y(1:length(x05),1) = y05;  
Mtams_y(1+length(x05):length(x05)+length(x06),1) = y06;  
Mtams_y(1+length(x05)+length(x06):length(x05)+length(x06)+length(x07),1) = 
y07;  
Mtams_y(1+length(x05)+length(x06)+length(x07):length(x05)+length(x06)+length
(x07)+length(x08),1) = y08;  
  
Mtams = zeros(length(Mtams_x),2); 
Mtams(:,1) = round(Mtams_x); Mtams(:,2) = round(Mtams_y); 
Mtams(:,3) = Mtams(:,1).*Mtams(:,2); 
Mtams_update = Mtams; 
  
distance = zeros(length(Mtams(:,1)),length(Mtams(:,1))); 
for i = 1:length(Mtams(:,1)) 
    for j = 1:length(Mtams(:,1)) 
        if i > j 
            distance(i,j) = sqrt(((Mtams(i,1) - Mtams(j,1))^2) + 
((Mtams(i,2) - Mtams(j,2))^2)); 
        else 
            distance(i,j) = 0; 
        end 
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    end 
end 
distance(distance==0) = NaN; 
  
distance_logic = zeros(length(Mtams(:,1)),length(Mtams(:,1))); 
for i = 1:length(Mtams(:,1)) 
    for j = 1:length(Mtams(:,1)) 
        if distance(i,j) < error 
            distance_logic(i,j) = 1; 
        else 
            distance_logic(i,j) = 0; 
        end 
    end 
end 
  
for i = 1:length(Mtams(:,1)) 
    for j = 1:length(Mtams(:,1)) 
        if distance_logic(i,j) == 1 
            Mtams_update(i,1) = 0; Mtams_update(i,2) = 0; 
        end 
    end 
end 
  
temp = find(Mtams_update(:,1) > 0); 
count_total = length(temp); 
Mtams_update = Mtams_update(temp,:); 
  
%% Exclude duplicate M2 TAMs 
  
plot(x09,y09,'k*'); hold on; 
plot(x10,y10,'k*'); hold on; 
plot(x11,y11,'k*'); hold on; 
plot(x12,y12,'k*'); hold on; 
  
max_length_M2tams(1) = length(x09); 
max_length_M2tams(2) = length(x10); 
max_length_M2tams(3) = length(x11); 
max_length_M2tams(4) = length(x12); 
  
M2tams_x = 
zeros(max_length_M2tams(1)+max_length_M2tams(2)+max_length_M2tams(3)+max_len
gth_M2tams(4),1); 
M2tams_y = 
zeros(max_length_M2tams(1)+max_length_M2tams(2)+max_length_M2tams(3)+max_len
gth_M2tams(4),1); 
  
M2tams_x(1:length(x09),1) = x09; 
M2tams_x(1+length(x09):length(x09)+length(x10),1) = x10;  
M2tams_x(1+length(x09)+length(x10):length(x09)+length(x10)+length(x11),1) = 
x11;  
M2tams_x(1+length(x09)+length(x10)+length(x11):length(x09)+length(x10)+lengt
h(x11)+length(x12),1) = x12; 
  
M2tams_y(1:length(x09),1) = y09;  
M2tams_y(1+length(x09):length(x09)+length(x10),1) = y10;  
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M2tams_y(1+length(x09)+length(x10):length(x09)+length(x10)+length(x11),1) = 
y11;  
M2tams_y(1+length(x09)+length(x10)+length(x11):length(x09)+length(x10)+lengt
h(x11)+length(x12),1) = y12;  
  
M2tams = zeros(length(M2tams_x),2); 
M2tams(:,1) = round(M2tams_x); M2tams(:,2) = round(M2tams_y); 
M2tams(:,3) = M2tams(:,1).*M2tams(:,2); 
M2tams_update = M2tams; 
  
distance = zeros(length(M2tams(:,1)),length(M2tams(:,1))); 
for i = 1:length(M2tams(:,1)) 
    for j = 1:length(M2tams(:,1)) 
        if i > j 
            distance(i,j) = sqrt(((M2tams(i,1) - M2tams(j,1))^2) + 
((M2tams(i,2) - M2tams(j,2))^2)); 
        else 
            distance(i,j) = 0; 
        end 
    end 
end 
distance(distance==0) = NaN; 
  
distance_logic = zeros(length(M2tams(:,1)),length(M2tams(:,1))); 
for i = 1:length(M2tams(:,1)) 
    for j = 1:length(M2tams(:,1)) 
        if distance(i,j) < error 
            distance_logic(i,j) = 1; 
        else 
            distance_logic(i,j) = 0; 
        end 
    end 
end 
  
for i = 1:length(M2tams(:,1)) 
    for j = 1:length(M2tams(:,1)) 
        if distance_logic(i,j) == 1 
            M2tams_update(i,1) = 0; M2tams_update(i,2) = 0; 
        end 
    end 
end 
  
temp = find(M2tams_update(:,1) > 0); 
count_M2 = length(temp); 
M2tams_update = M2tams_update(temp,:); 
  
%% Reorder matrices from left to right 
  
TAM_M0 = sortrows(Mtams_update); 
TAM_M1 = sortrows(M1tams_update); 
TAM_M2 = sortrows(M2tams_update); 
  
figure(1) 
subplot(1,3,1) 
imagesc(mydata{3}); colormap gray; axis image; hold on; 
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plot(M1tams_update(:,1),M1tams_update(:,2),'b*'); hold off; 
title('M1 Macrophages (CD80)'); 
figure(1) 
subplot(1,3,2) 
imagesc(mydata{7}); colormap gray; axis image; hold on; 
plot(Mtams_update(:,1),Mtams_update(:,2),'g*'); hold off; 
title('All Macrophages (CD68)'); 
figure(1) 
subplot(1,3,3) 
imagesc(mydata{11}); colormap gray; axis image; hold on; 
plot(M2tams_update(:,1),M2tams_update(:,2),'r*'); hold off; 
title('M2 Macrophages (CD206)'); 
  
%% Exclude M1 TAMs without associated M0 (CD68) stain 
  
r = cell(length(TAM_M1),1); 
c = cell(length(TAM_M1),1); 
s = cell(length(TAM_M1),1); 
check = zeros(length(TAM_M1),1); 
TAM_M1_new = TAM_M1; 
newerror = 0.05; 
for i = 1:length(TAM_M1) 
    r{i} = find(TAM_M0(:,1)>TAM_M1(i,1)-(width*newerror) & 
TAM_M0(:,1)<TAM_M1(i,1)+(width*newerror)); 
    c{i} = find(TAM_M0(:,2)>TAM_M1(i,2)-(width*newerror) & 
TAM_M0(:,2)<TAM_M1(i,2)+(width*newerror)); 
    s{i} = intersect(r{i},c{i}); 
    check(i) = any(s{i}); 
    if check(i) == 1 
        TAM_M1_new(i,1) = TAM_M1(i,1); 
        TAM_M1_new(i,2) = TAM_M1(i,2); 
        TAM_M1_new(i,3) = TAM_M1(i,3); 
    else 
        TAM_M1_new(i,1) = 0; 
        TAM_M1_new(i,2) = 0; 
        TAM_M1_new(i,3) = 0; 
    end 
end 
temp = find(TAM_M1_new(:,1) > 0); 
TAM_M1_new = TAM_M1_new(temp,:); 
  
%% Exclude M2 TAMs without associated M0 (CD68) stain 
  
r = cell(length(TAM_M2),1); 
c = cell(length(TAM_M2),1); 
s = cell(length(TAM_M2),1); 
check = zeros(length(TAM_M2),1); 
TAM_M2_new = TAM_M2; 
newerror = 0.05; 
for i = 1:length(TAM_M2) 
    r{i} = find(TAM_M0(:,1)>TAM_M2(i,1)-(width*newerror) & 
TAM_M0(:,1)<TAM_M2(i,1)+(width*newerror)); 
    c{i} = find(TAM_M0(:,2)>TAM_M2(i,2)-(width*newerror) & 
TAM_M0(:,2)<TAM_M2(i,2)+(width*newerror)); 
    s{i} = intersect(r{i},c{i}); 
    check(i) = any(s{i}); 
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    if check(i) == 1 
        TAM_M2_new(i,1) = TAM_M2(i,1); 
        TAM_M2_new(i,2) = TAM_M2(i,2); 
        TAM_M2_new(i,3) = TAM_M2(i,3); 
    else 
        TAM_M2_new(i,1) = 0; 
        TAM_M2_new(i,2) = 0; 
        TAM_M2_new(i,3) = 0; 
    end 
end 
temp = find(TAM_M2_new(:,1) > 0); 
TAM_M2_new = TAM_M2_new(temp,:); 
  
%% M1/M2 Ratio 
  
ratio = length(TAM_M1_new) / length(TAM_M2_new); 
fprintf('\nM1/M2 Ratio: %.2f\n\n',ratio); 
  
%% Final Data 
  
close all; 
  
figure(2) 
subplot(1,3,1) 
imagesc(mydata{3}); colormap gray; axis image; hold on; 
plot(M1tams_update(:,1),M1tams_update(:,2),'b*'); hold off; 
title('M1 Macrophages (CD80)'); 
figure(2) 
subplot(1,3,2) 
imagesc(mydata{7}); colormap gray; axis image; hold on; 
plot(Mtams_update(:,1),Mtams_update(:,2),'g*'); hold off; 
title('All Macrophages (CD68)'); 
figure(2) 
subplot(1,3,3) 
imagesc(mydata{11}); colormap gray; axis image; hold on; 
plot(M2tams_update(:,1),M2tams_update(:,2),'r*'); hold off; 
title('M2 Macrophages (CD206)'); 
  
a = 'M1/M2 Ratio = '; 
b = num2str(ratio*100); 
c = '%'; 
d = strcat(a,b,c); 
  
fig = gcf; 
saveas(fig,'tamcount.jpg'); 
  
  
format compact; 
M0_totalcount = length(Mtams_update(:,1)); 
M1_totalcount = length(TAM_M1_new(:,1)); 
M2_totalcount = length(TAM_M2_new(:,1)); 
  
fprintf('M1:\t\t %.1d\n',M1_totalcount); 
fprintf('Total:\t %.1d\n',M0_totalcount); 
fprintf('M2:\t\t %.1d\n',M2_totalcount); 
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samplingdepth.m 
%% Gage Greening 
% University of Arkansas 
% College of Engineering 
% Department of Biomedical Engineering 
% samplingdepth_3mm.m 
  
% Initialize Variables 
close all; clear all; clc; 
n = input('Number of Phantoms: '); 
name = ['s (01)';'s (02)';'s (03)';'s (04)';'s (05)';'s (06)';'s (07)';'s 
(08)';'s (09)';'s (10)';'s (11)';'s (12)';'s (13)';'s (14)';'s (15)';'s 
(16)';'s (17)';'s (18)';'s (19)';'s (20)';'s (21)';'s (22)';'s (23)';'s 
(24)';'s (25)';'s (26)';'s (27)';'s (28)';'s (29)';'s (30)';'s (31)';'s 
(32)';'s (33)';'s (34)';'s (35)';'s (36)';'s (37)';'s (38)';'s (39)';'s 
(40)';'s (41)';'s (42)';'s (43)';'s (44)';'s (45)';'s (46)';'s (47)';'s 
(48)';'s (49)';'s (50)';'s (51)';'s (52)';'s (53)';'s (54)';'s (55)';'s 
(56)';'s (57)';'s (58)';'s (59)';'s (60)';'s (61)';'s (62)';'s (63)';'s 
(64)';'s (65)';'s (66)';'s (67)';'s (68)';'s (69)';'s (70)';'s (71)';'s 
(72)';'s (73)';'s (74)';'s (75)';'s (76)';'s (77)';'s (78)';'s (79)';'s 
(80)';'s (81)';'s (82)';'s (83)';'s (84)';'s (85)';'s (86)';'s (87)';'s 
(88)';'s (89)';'s (90)';'s (91)';'s (92)';'s (93)';'s (94)';'s (95)';'s 
(96)';'s (97)';'s (98)';'s (99)']; 
wavelength = csvread('s (01).csv'); wavelength = wavelength(:,1); 
temp = zeros(2048,2); 
specori = zeros(2048,n); 
  
% Determine matrix index for getting 1 nm resolution in spectra 
x = linspace(1,1050,1050); 
wavelength_550to890 = round(wavelength(575:1624)); 
p = polyfit(wavelength_550to890,x',2); 
x1 = linspace(550,890,341); 
y1 = round(polyval(p,x1))'; 
  
% Create matrix with all spectra of increasing distance from abs. layer 
for i = 1:n 
    temp = csvread([name(i,:),'.csv']); 
    specori(:,i) = temp(:,2); 
    for i = 1:2048 
        for j = 1:n 
            specori(i,j) = round(specori(i,j)); 
        end 
    end 
end 
specori = specori - 300; 
  
spectra_550to890 = specori(575:1624,:); 
spectra = spectra_550to890([y1(1:341)],:); 
wavelength = linspace(550,890,341)'; 
  
maxspec = spectra(:,n); 
halfspec = round(maxspec./2); 
  
x1 = zeros(341,1); 
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x2 = zeros(341,1); 
sampdepth = zeros(341,1); 
for i = 1:341 
    x1 = find(spectra(i,:)<halfspec(i)); 
    x2(i) = max(x1); 
    sampdepth = (((x2*50)/1000)-0.05); 
end 
  
scatter(wavelength,sampdepth); axis square; box on; 
xlabel('Wavelength (nm)') 
ylabel('Sampling depth (mm)'); 
title('Sampling depth of probe into optical phantom'); 
  
save('sd.mat','wavelength','sampdepth'); 
clc; 
 
Input Text Files for PostProcess3mm.m 
Wavelength Hb.txt HbO2.txt mel.txt 
250 
251 
252 
253 
254 
255 
256 
257 
258 
259 
260 
261 
262 
263 
264 
265 
266 
267 
268 
269 
270 
271 
272 
273 
274 
275 
276 
277 
278 
279 
280 
281 
282 
1.747845 
1.747845 
1.747845 
1.747845 
1.747845 
1.756279 
1.764713 
1.77414 
1.783566 
1.793302 
1.803039 
1.812868 
1.822698 
1.832868 
1.843039 
1.853364 
1.86369 
1.874047 
1.884403 
1.89476 
1.905116 
1.906791 
1.908465 
1.899597 
1.890729 
1.88186 
1.872992 
1.865488 
1.857985 
1.850481 
1.842977 
1.833333 
1.82369 
1.645147 
1.640806 
1.636465 
1.652806 
1.669147 
1.685643 
1.70214 
1.726605 
1.75107 
1.777674 
1.804279 
1.833829 
1.86338 
1.896124 
1.928868 
1.962078 
1.995287 
2.029147 
2.063008 
2.086295 
2.109581 
2.118605 
2.127628 
2.136744 
2.14586 
2.138233 
2.130605 
2.118171 
2.105736 
2.075628 
2.045519 
2.012837 
1.980155 
30.92699 
30.92699 
30.65722 
30.52234 
30.38745 
30.25257 
30.11768 
29.9828 
29.84791 
29.71303 
29.57814 
29.44326 
29.31882 
29.2008 
29.08278 
28.96475 
28.84673 
28.7287 
28.61068 
28.49265 
28.37463 
28.2566 
28.13858 
28.02055 
27.90253 
27.78451 
27.66648 
27.54846 
27.43043 
27.31241 
27.19049 
27.06691 
26.94333 
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283 
284 
285 
286 
287 
288 
289 
290 
291 
292 
293 
294 
295 
296 
297 
298 
299 
300 
301 
302 
303 
304 
305 
306 
307 
308 
309 
310 
311 
312 
313 
314 
315 
316 
317 
318 
319 
320 
321 
322 
323 
324 
325 
326 
327 
328 
329 
330 
331 
332 
1.801922 
1.780155 
1.758357 
1.736558 
1.698822 
1.661085 
1.593054 
1.525023 
1.472868 
1.420713 
1.375628 
1.330543 
1.262946 
1.195349 
1.136 
1.076651 
1.03786 
0.99907 
0.974729 
0.950388 
0.931225 
0.912062 
0.897178 
0.882295 
0.887814 
0.893333 
0.90524 
0.917147 
0.941116 
0.965085 
0.989085 
1.013085 
1.036093 
1.059101 
1.08155 
1.104 
1.129581 
1.155163 
1.184434 
1.213705 
1.242977 
1.272248 
1.299628 
1.327008 
1.349674 
1.372341 
1.390481 
1.40862 
1.426729 
1.444837 
1.937985 
1.895814 
1.85107 
1.806326 
1.744124 
1.681922 
1.652992 
1.624062 
1.578977 
1.533891 
1.450171 
1.36645 
1.298078 
1.229705 
1.164341 
1.098977 
1.060899 
1.022822 
1.001395 
0.979969 
0.970233 
0.960496 
0.963597 
0.966698 
0.970605 
0.974512 
0.978357 
0.982202 
1.002512 
1.022822 
1.046419 
1.070016 
1.096279 
1.122543 
1.146822 
1.171101 
1.196031 
1.220961 
1.248124 
1.275287 
1.304093 
1.332899 
1.362543 
1.392186 
1.422977 
1.453767 
1.482791 
1.511814 
1.538574 
1.565333 
26.81975 
26.69617 
26.57258 
26.449 
26.32542 
26.20184 
26.07826 
25.95467 
25.83109 
25.70751 
25.58393 
25.46035 
25.33702 
25.23869 
25.14036 
25.04204 
24.94371 
24.84538 
24.74706 
24.64873 
24.5504 
24.45208 
24.35375 
24.25542 
24.15709 
24.05877 
23.96044 
23.86211 
23.76379 
23.66546 
23.56745 
23.47307 
23.37869 
23.28431 
23.18993 
23.09555 
23.00117 
22.90679 
22.81241 
22.71803 
22.62365 
22.52927 
22.42292 
22.31477 
22.20663 
22.09849 
21.99034 
21.8822 
21.77406 
21.66592 
562 
 
333 
334 
335 
336 
337 
338 
339 
340 
341 
342 
343 
344 
345 
346 
347 
348 
349 
350 
351 
352 
353 
354 
355 
356 
357 
358 
359 
360 
361 
362 
363 
364 
365 
366 
367 
368 
369 
370 
371 
372 
373 
374 
375 
376 
377 
378 
379 
380 
381 
382 
1.462977 
1.481116 
1.51414 
1.547163 
1.583473 
1.619783 
1.65076 
1.681736 
1.701302 
1.720868 
1.740465 
1.760062 
1.779659 
1.799256 
1.820186 
1.841116 
1.867008 
1.892899 
1.918822 
1.944744 
1.970636 
1.996527 
2.02245 
2.048372 
2.060093 
2.071814 
2.081953 
2.092093 
2.100651 
2.109209 
2.116403 
2.123597 
2.130791 
2.137985 
2.145395 
2.152806 
2.161426 
2.170047 
2.178698 
2.187349 
2.195969 
2.204589 
2.21324 
2.221891 
2.230512 
2.239132 
2.245395 
2.251659 
2.251659 
2.251659 
1.585023 
1.604713 
1.616062 
1.627411 
1.638915 
1.650419 
1.661519 
1.67262 
1.681736 
1.690853 
1.698853 
1.706853 
1.698636 
1.690419 
1.682295 
1.674171 
1.663256 
1.652341 
1.640434 
1.628527 
1.618109 
1.60769 
1.591194 
1.574698 
1.545705 
1.516713 
1.492806 
1.468899 
1.44955 
1.430202 
1.411504 
1.392806 
1.382326 
1.371845 
1.36431 
1.356775 
1.361922 
1.36707 
1.39355 
1.420031 
1.447535 
1.475039 
1.504465 
1.533891 
1.568744 
1.603597 
1.651132 
1.698667 
1.756062 
1.813457 
21.55777 
21.44963 
21.34149 
21.23335 
21.1252 
21.01706 
20.90892 
20.80077 
20.69263 
20.58449 
20.46183 
20.33825 
20.21467 
20.09109 
19.96751 
19.84392 
19.72034 
19.59676 
19.47318 
19.3496 
19.22601 
19.10243 
18.97885 
18.85527 
18.73169 
18.61756 
18.53178 
18.44601 
18.36024 
18.27447 
18.1887 
18.10292 
18.01715 
17.93138 
17.84561 
17.75984 
17.67406 
17.58829 
17.50252 
17.41675 
17.33097 
17.2452 
17.15943 
17.07366 
16.98789 
16.90211 
16.81634 
16.73057 
16.6448 
16.55902 
563 
 
383 
384 
385 
386 
387 
388 
389 
390 
391 
392 
393 
394 
395 
396 
397 
398 
399 
400 
401 
402 
403 
404 
405 
406 
407 
408 
409 
410 
411 
412 
413 
414 
415 
416 
417 
418 
419 
420 
421 
422 
423 
424 
425 
426 
427 
428 
429 
430 
431 
432 
2.278295 
2.30493 
2.34555 
2.386171 
2.42986 
2.47355 
2.537395 
2.60124 
2.696 
2.79076 
2.880186 
2.969612 
3.051659 
3.133705 
3.215783 
3.29786 
3.379907 
3.461953 
3.561891 
3.661829 
3.795008 
3.928186 
4.061364 
4.194543 
4.324837 
4.455132 
4.583814 
4.712496 
4.847287 
4.982078 
5.146822 
5.311566 
5.47631 
5.641054 
5.810295 
5.979535 
6.149147 
6.31876 
6.491783 
6.664806 
6.907597 
7.150388 
7.310388 
7.470388 
7.617674 
7.764961 
7.980155 
8.195349 
8.377985 
8.56062 
1.878977 
1.944496 
2.019783 
2.09507 
2.195597 
2.296124 
2.448434 
2.600744 
2.771225 
2.941705 
3.114729 
3.287752 
3.439318 
3.590884 
3.721054 
3.851225 
3.989426 
4.127628 
4.267101 
4.406574 
4.596434 
4.786295 
5.138946 
5.491597 
6.019597 
6.547597 
6.892713 
7.237829 
7.496434 
7.755039 
7.941705 
8.128372 
8.109767 
8.091163 
8.04186 
7.992558 
7.72 
7.447442 
7.071628 
6.695814 
6.264465 
5.833116 
5.443938 
5.05476 
4.722047 
4.389333 
4.102202 
3.81507 
3.56738 
3.31969 
16.46076 
16.35346 
16.24616 
16.13886 
16.03156 
15.92425 
15.81695 
15.70965 
15.60235 
15.49504 
15.38774 
15.28044 
15.17314 
15.06584 
14.95853 
14.85123 
14.74393 
14.63663 
14.52932 
14.42202 
14.31472 
14.20742 
14.10012 
13.99281 
13.88551 
13.80487 
13.72623 
13.64759 
13.56895 
13.49031 
13.41168 
13.33304 
13.2544 
13.17576 
13.09712 
13.01849 
12.93985 
12.86121 
12.78257 
12.70393 
12.6253 
12.54666 
12.46802 
12.38938 
12.31074 
12.23211 
12.15347 
12.07483 
11.99619 
11.92096 
564 
 
433 
434 
435 
436 
437 
438 
439 
440 
441 
442 
443 
444 
445 
446 
447 
448 
449 
450 
451 
452 
453 
454 
455 
456 
457 
458 
459 
460 
461 
462 
463 
464 
465 
466 
467 
468 
469 
470 
471 
472 
473 
474 
475 
476 
477 
478 
479 
480 
481 
482 
8.56062 
8.56062 
8.52093 
8.48124 
8.128682 
7.776124 
7.091783 
6.407442 
6.019535 
5.631628 
5.007473 
4.383318 
4.030605 
3.677891 
3.182512 
2.687132 
2.144279 
1.601426 
1.286295 
0.971163 
0.765969 
0.560775 
0.518363 
0.47595 
0.438645 
0.40134 
0.381978 
0.362617 
0.343256 
0.323895 
0.311256 
0.298617 
0.289947 
0.281278 
0.27262 
0.263963 
0.257225 
0.250487 
0.243926 
0.237364 
0.235336 
0.233309 
0.231327 
0.229346 
0.228295 
0.227243 
0.226412 
0.225581 
0.228149 
0.230716 
2.941488 
2.563287 
2.311256 
2.059225 
1.953178 
1.847132 
1.71876 
1.590388 
1.514419 
1.43845 
1.350574 
1.262698 
1.223008 
1.183318 
1.11138 
1.039442 
1.006667 
0.973891 
0.943256 
0.91262 
0.871442 
0.830264 
0.798822 
0.76738 
0.751876 
0.736372 
0.712992 
0.689612 
0.665116 
0.64062 
0.628893 
0.617166 
0.595972 
0.574778 
0.557705 
0.540633 
0.527752 
0.514871 
0.502552 
0.490233 
0.478555 
0.466878 
0.457088 
0.447299 
0.438518 
0.429736 
0.421296 
0.412856 
0.405665 
0.398474 
11.85542 
11.78988 
11.72434 
11.6588 
11.59326 
11.52772 
11.46218 
11.39664 
11.3311 
11.26556 
11.20002 
11.13448 
11.06894 
11.0034 
10.93786 
10.87231 
10.80677 
10.74123 
10.67569 
10.61015 
10.54461 
10.47907 
10.41353 
10.34799 
10.28245 
10.21691 
10.15648 
10.10642 
10.05636 
10.0063 
9.956237 
9.906176 
9.856115 
9.806055 
9.755994 
9.705933 
9.655872 
9.605812 
9.555751 
9.50569 
9.455629 
9.405569 
9.355508 
9.305447 
9.255386 
9.205326 
9.155265 
9.105204 
9.055143 
9.005083 
565 
 
483 
484 
485 
486 
487 
488 
489 
490 
491 
492 
493 
494 
495 
496 
497 
498 
499 
500 
501 
502 
503 
504 
505 
506 
507 
508 
509 
510 
511 
512 
513 
514 
515 
516 
517 
518 
519 
520 
521 
522 
523 
524 
525 
526 
527 
528 
529 
530 
531 
532 
0.233284 
0.235851 
0.238419 
0.240986 
0.243733 
0.246481 
0.252574 
0.258667 
0.264757 
0.270847 
0.27694 
0.283033 
0.289122 
0.295212 
0.301802 
0.308391 
0.315916 
0.323442 
0.330967 
0.338493 
0.346019 
0.353544 
0.36107 
0.368595 
0.376121 
0.383647 
0.391619 
0.399591 
0.408608 
0.417625 
0.426642 
0.435659 
0.444676 
0.453693 
0.46271 
0.471727 
0.480744 
0.489761 
0.499541 
0.509321 
0.521309 
0.533296 
0.545284 
0.557271 
0.569256 
0.58124 
0.593228 
0.605216 
0.617212 
0.629209 
0.394434 
0.390394 
0.386434 
0.382474 
0.378639 
0.374803 
0.371002 
0.3672 
0.362567 
0.357935 
0.353057 
0.34818 
0.343473 
0.338766 
0.334189 
0.329612 
0.327076 
0.32454 
0.321932 
0.319324 
0.317941 
0.316558 
0.312899 
0.30924 
0.309628 
0.310016 
0.310319 
0.310623 
0.311516 
0.312409 
0.314571 
0.316732 
0.321169 
0.325606 
0.337296 
0.348986 
0.362109 
0.375231 
0.392657 
0.410084 
0.431935 
0.453786 
0.478803 
0.50382 
0.530902 
0.557985 
0.588735 
0.619485 
0.649867 
0.680248 
8.955022 
8.906236 
8.858166 
8.810097 
8.762028 
8.713958 
8.665889 
8.61782 
8.569751 
8.521681 
8.473612 
8.425543 
8.377473 
8.329404 
8.281335 
8.233265 
8.185196 
8.137127 
8.089057 
8.040988 
7.992919 
7.94485 
7.89678 
7.848711 
7.800642 
7.752572 
7.704503 
7.656434 
7.608364 
7.560295 
7.512226 
7.464156 
7.416087 
7.368018 
7.319949 
7.271879 
7.22381 
7.175741 
7.127671 
7.079602 
7.031533 
6.98398 
6.938063 
6.892146 
6.846229 
6.800313 
6.754396 
6.708479 
6.662562 
6.616645 
566 
 
533 
534 
535 
536 
537 
538 
539 
540 
541 
542 
543 
544 
545 
546 
547 
548 
549 
550 
551 
552 
553 
554 
555 
556 
557 
558 
559 
560 
561 
562 
563 
564 
565 
566 
567 
568 
569 
570 
571 
572 
573 
574 
575 
576 
577 
578 
579 
580 
581 
582 
0.640868 
0.652527 
0.664186 
0.675845 
0.687473 
0.699101 
0.710729 
0.722357 
0.734419 
0.746481 
0.758574 
0.770667 
0.78276 
0.794853 
0.804372 
0.813891 
0.820992 
0.828093 
0.833271 
0.83845 
0.84186 
0.845271 
0.845426 
0.845581 
0.842667 
0.839752 
0.836837 
0.833922 
0.822202 
0.810481 
0.797271 
0.784062 
0.770543 
0.757023 
0.74245 
0.727876 
0.713333 
0.698791 
0.685364 
0.671938 
0.659349 
0.64676 
0.634171 
0.621581 
0.608989 
0.596397 
0.585175 
0.573953 
0.563538 
0.553122 
0.703876 
0.727504 
0.749426 
0.771349 
0.786543 
0.801736 
0.81355 
0.825364 
0.825798 
0.826233 
0.816961 
0.80769 
0.790419 
0.773147 
0.748279 
0.723411 
0.695163 
0.666915 
0.641017 
0.615119 
0.592949 
0.570778 
0.552651 
0.534524 
0.526611 
0.518698 
0.512164 
0.505631 
0.505684 
0.505736 
0.51578 
0.525823 
0.54582 
0.565817 
0.594319 
0.622822 
0.656341 
0.68986 
0.726109 
0.762357 
0.794419 
0.826481 
0.843783 
0.861085 
0.854791 
0.848496 
0.812651 
0.776806 
0.724093 
0.67138 
6.570728 
6.524811 
6.478895 
6.432978 
6.387061 
6.341144 
6.295227 
6.24931 
6.203393 
6.157477 
6.11156 
6.065643 
6.019726 
5.973809 
5.927892 
5.881976 
5.836059 
5.790142 
5.74827 
5.715836 
5.683402 
5.650968 
5.618534 
5.586101 
5.553667 
5.521233 
5.488799 
5.456365 
5.423931 
5.391498 
5.359064 
5.32663 
5.294196 
5.261762 
5.229328 
5.196894 
5.164461 
5.132027 
5.099593 
5.067159 
5.034725 
5.002291 
4.969857 
4.937424 
4.90499 
4.872556 
4.840122 
4.807688 
4.775254 
4.742821 
567 
 
583 
584 
585 
586 
587 
588 
589 
590 
591 
592 
593 
594 
595 
596 
597 
598 
599 
600 
601 
602 
603 
604 
605 
606 
607 
608 
609 
610 
611 
612 
613 
614 
615 
616 
617 
618 
619 
620 
621 
622 
623 
624 
625 
626 
627 
628 
629 
630 
631 
632 
0.542707 
0.532291 
0.520809 
0.509327 
0.495557 
0.481786 
0.460462 
0.439138 
0.417011 
0.394884 
0.37244 
0.349997 
0.328487 
0.306977 
0.285724 
0.264471 
0.246012 
0.227553 
0.219377 
0.2112 
0.203023 
0.194847 
0.186673 
0.178499 
0.170471 
0.162443 
0.154428 
0.146412 
0.139805 
0.133197 
0.126769 
0.120341 
0.117107 
0.113873 
0.110636 
0.107398 
0.104161 
0.100924 
0.098471 
0.096019 
0.093798 
0.091578 
0.089355 
0.087132 
0.085169 
0.083206 
0.081516 
0.079826 
0.078136 
0.076447 
0.604214 
0.537048 
0.474729 
0.412409 
0.359408 
0.306406 
0.264837 
0.223268 
0.192785 
0.162301 
0.140676 
0.119051 
0.103585 
0.088118 
0.078977 
0.069836 
0.059724 
0.049612 
0.045457 
0.041302 
0.037147 
0.032992 
0.030366 
0.02774 
0.026642 
0.025544 
0.024447 
0.023349 
0.022251 
0.021153 
0.020056 
0.018958 
0.018084 
0.017209 
0.016558 
0.015907 
0.015256 
0.014605 
0.013953 
0.013302 
0.012651 
0.012 
0.011485 
0.010971 
0.010592 
0.010214 
0.009836 
0.009457 
0.009079 
0.008701 
4.710387 
4.677953 
4.645519 
4.613085 
4.580651 
4.548217 
4.517434 
4.497694 
4.477953 
4.458213 
4.438473 
4.418732 
4.398992 
4.379252 
4.359512 
4.339771 
4.320031 
4.300291 
4.280551 
4.26081 
4.24107 
4.22133 
4.20159 
4.181849 
4.162109 
4.142369 
4.122629 
4.102888 
4.083148 
4.063408 
4.043668 
4.023927 
4.004187 
3.983271 
3.957 
3.93073 
3.904459 
3.878188 
3.851917 
3.825646 
3.799375 
3.773104 
3.746833 
3.720563 
3.694292 
3.668021 
3.64175 
3.615479 
3.589208 
3.562937 
568 
 
633 
634 
635 
636 
637 
638 
639 
640 
641 
642 
643 
644 
645 
646 
647 
648 
649 
650 
651 
652 
653 
654 
655 
656 
657 
658 
659 
660 
661 
662 
663 
664 
665 
666 
667 
668 
669 
670 
671 
672 
673 
674 
675 
676 
677 
678 
679 
680 
681 
682 
0.074896 
0.073346 
0.07235 
0.071355 
0.070357 
0.069358 
0.068363 
0.067367 
0.066372 
0.065377 
0.064381 
0.063386 
0.06243 
0.061474 
0.060641 
0.059808 
0.058975 
0.058141 
0.057308 
0.056475 
0.055642 
0.054809 
0.053976 
0.053142 
0.052309 
0.051476 
0.05075 
0.050024 
0.049355 
0.048687 
0.048017 
0.047348 
0.046679 
0.046011 
0.045342 
0.044673 
0.044004 
0.043335 
0.042666 
0.041998 
0.041368 
0.040739 
0.040171 
0.039603 
0.039035 
0.038468 
0.0379 
0.037332 
0.036764 
0.036197 
0.008322 
0.007944 
0.007684 
0.007423 
0.007281 
0.007138 
0.006995 
0.006853 
0.00671 
0.006567 
0.006425 
0.006282 
0.006167 
0.006053 
0.005966 
0.005879 
0.005792 
0.005705 
0.005619 
0.005532 
0.005445 
0.005358 
0.005278 
0.005197 
0.005122 
0.005048 
0.005002 
0.004955 
0.004912 
0.004868 
0.004825 
0.004781 
0.004738 
0.004695 
0.004657 
0.00462 
0.004589 
0.004558 
0.004527 
0.004496 
0.004462 
0.004428 
0.0044 
0.004372 
0.00435 
0.004329 
0.004316 
0.004304 
0.004291 
0.004279 
3.536666 
3.510396 
3.484125 
3.457854 
3.431583 
3.405312 
3.379041 
3.35277 
3.326499 
3.300229 
3.276784 
3.262801 
3.248819 
3.234836 
3.220853 
3.20687 
3.192888 
3.178905 
3.164922 
3.15094 
3.136957 
3.122974 
3.108991 
3.095009 
3.081026 
3.067043 
3.05306 
3.039078 
3.025095 
3.011112 
2.99713 
2.983147 
2.969164 
2.955181 
2.941199 
2.927216 
2.913233 
2.899251 
2.885268 
2.871285 
2.857302 
2.84332 
2.829337 
2.815354 
2.801372 
2.787389 
2.773406 
2.759423 
2.745323 
2.728408 
569 
 
683 
684 
685 
686 
687 
688 
689 
690 
691 
692 
693 
694 
695 
696 
697 
698 
699 
700 
701 
702 
703 
704 
705 
706 
707 
708 
709 
710 
711 
712 
713 
714 
715 
716 
717 
718 
719 
720 
721 
722 
723 
724 
725 
726 
727 
728 
729 
730 
731 
732 
0.035629 
0.035062 
0.034494 
0.033926 
0.033358 
0.032791 
0.032302 
0.031813 
0.031414 
0.031015 
0.030616 
0.030218 
0.029819 
0.02942 
0.02902 
0.028621 
0.02822 
0.027818 
0.027405 
0.026992 
0.02658 
0.026167 
0.025754 
0.025341 
0.024946 
0.024551 
0.024217 
0.023883 
0.023549 
0.023216 
0.022882 
0.022548 
0.022215 
0.021881 
0.021547 
0.021214 
0.020885 
0.020556 
0.020241 
0.019925 
0.019609 
0.019294 
0.018978 
0.018662 
0.018267 
0.017873 
0.017481 
0.017088 
0.017088 
0.017088 
0.004267 
0.004254 
0.004242 
0.004229 
0.004242 
0.004254 
0.004267 
0.004279 
0.004291 
0.004304 
0.004316 
0.004329 
0.00435 
0.004372 
0.004403 
0.004434 
0.004465 
0.004496 
0.004527 
0.004558 
0.004589 
0.00462 
0.004657 
0.004695 
0.004738 
0.004781 
0.004825 
0.004868 
0.004912 
0.004955 
0.004998 
0.005042 
0.005095 
0.005147 
0.005209 
0.005271 
0.005333 
0.005395 
0.005457 
0.005519 
0.005581 
0.005643 
0.005709 
0.005774 
0.005842 
0.00591 
0.005978 
0.006047 
0.006115 
0.006183 
2.711492 
2.694576 
2.67766 
2.660745 
2.643829 
2.626913 
2.609997 
2.593082 
2.576166 
2.55925 
2.542335 
2.525419 
2.508503 
2.491587 
2.474672 
2.457756 
2.44084 
2.423924 
2.407009 
2.390093 
2.373177 
2.356261 
2.339346 
2.32243 
2.305514 
2.288598 
2.271683 
2.254767 
2.237851 
2.220935 
2.209274 
2.201263 
2.193252 
2.185242 
2.177231 
2.16922 
2.16121 
2.153199 
2.145188 
2.137178 
2.129167 
2.121156 
2.113146 
2.105135 
2.097124 
2.089113 
2.081103 
2.073092 
2.065081 
2.057071 
570 
 
733 
734 
735 
736 
737 
738 
739 
740 
741 
742 
743 
744 
745 
746 
747 
748 
749 
750 
751 
752 
753 
754 
755 
756 
757 
758 
759 
760 
761 
762 
763 
764 
765 
766 
767 
768 
769 
770 
771 
772 
773 
774 
775 
776 
777 
778 
779 
780 
781 
782 
0.017088 
0.017088 
0.017085 
0.017082 
0.017072 
0.017062 
0.017181 
0.0173 
0.017655 
0.01801 
0.018365 
0.018719 
0.019174 
0.019629 
0.020149 
0.02067 
0.021229 
0.021787 
0.02264 
0.023493 
0.023698 
0.023903 
0.024048 
0.024193 
0.024193 
0.024193 
0.024101 
0.024008 
0.023697 
0.023387 
0.023008 
0.022629 
0.022249 
0.021869 
0.021487 
0.021106 
0.020722 
0.020339 
0.019956 
0.019573 
0.019189 
0.018806 
0.018423 
0.01804 
0.017662 
0.017284 
0.016979 
0.016673 
0.016368 
0.016063 
0.006251 
0.006319 
0.006406 
0.006493 
0.006598 
0.006704 
0.006809 
0.006915 
0.00702 
0.007126 
0.007231 
0.007336 
0.007448 
0.00756 
0.007678 
0.007795 
0.007913 
0.008031 
0.008149 
0.008267 
0.008385 
0.008502 
0.008608 
0.008713 
0.008806 
0.008899 
0.008992 
0.009085 
0.009178 
0.009271 
0.009364 
0.009457 
0.009557 
0.009656 
0.009761 
0.009867 
0.009972 
0.010078 
0.010183 
0.010288 
0.010394 
0.010499 
0.010592 
0.010685 
0.010766 
0.010847 
0.010927 
0.011008 
0.011088 
0.011169 
2.04906 
2.041049 
2.033261 
2.027098 
2.020936 
2.014774 
2.008611 
2.002449 
1.996287 
1.990125 
1.983962 
1.9778 
1.971638 
1.965476 
1.959313 
1.953151 
1.946989 
1.940826 
1.934664 
1.928502 
1.92234 
1.916177 
1.910015 
1.903853 
1.897691 
1.891528 
1.885366 
1.879204 
1.873041 
1.866879 
1.860717 
1.854555 
1.844935 
1.834974 
1.825013 
1.815052 
1.805091 
1.79513 
1.785169 
1.775208 
1.765247 
1.755286 
1.745325 
1.735364 
1.725403 
1.715442 
1.705481 
1.69552 
1.685559 
1.675598 
571 
 
783 
784 
785 
786 
787 
788 
789 
790 
791 
792 
793 
794 
795 
796 
797 
798 
799 
800 
801 
802 
803 
804 
805 
806 
807 
808 
809 
810 
811 
812 
813 
814 
815 
816 
817 
818 
819 
820 
821 
822 
823 
824 
825 
826 
827 
828 
829 
830 
831 
832 
0.015758 
0.015453 
0.015148 
0.014843 
0.014567 
0.014291 
0.014051 
0.013811 
0.013571 
0.01333 
0.01309 
0.01285 
0.012649 
0.012449 
0.012289 
0.01213 
0.01197 
0.01181 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.01125 
0.01133 
0.011402 
0.011473 
0.011535 
0.011597 
0.011659 
0.011721 
0.011783 
0.011845 
0.011907 
0.011969 
0.012081 
0.012192 
0.012353 
0.012515 
0.012583 
0.012651 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
1.667512 
1.659546 
1.651579 
1.643613 
1.635647 
1.627681 
1.619715 
1.611749 
1.603782 
1.595816 
1.58785 
1.579884 
1.571918 
1.563951 
1.555985 
1.548019 
1.540053 
1.532087 
1.524121 
1.516154 
1.508188 
1.500222 
1.492256 
1.48429 
1.476323 
1.468357 
1.460391 
1.452425 
1.444459 
1.436493 
1.428526 
1.42056 
1.412594 
1.404628 
1.396662 
1.388696 
1.380729 
1.372763 
1.364797 
1.356831 
1.348865 
1.340898 
1.332932 
1.324966 
1.317 
1.309034 
1.301068 
1.293101 
1.285135 
1.277169 
572 
 
833 
834 
835 
836 
837 
838 
839 
840 
841 
842 
843 
844 
845 
846 
847 
848 
849 
850 
851 
852 
853 
854 
855 
856 
857 
858 
859 
860 
861 
862 
863 
864 
865 
866 
867 
868 
869 
870 
871 
872 
873 
874 
875 
876 
877 
878 
879 
880 
881 
882 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
1.269203 
1.261237 
1.25327 
1.245304 
1.237338 
1.229372 
1.221406 
1.21344 
1.205473 
1.197507 
1.189541 
1.181575 
1.173609 
1.165642 
1.157676 
1.14971 
1.141744 
1.133778 
1.125812 
1.117845 
1.109879 
1.101913 
1.093947 
1.085981 
1.078014 
1.070048 
1.062082 
1.054116 
1.04615 
1.038184 
1.030217 
1.022251 
1.014285 
1.006319 
0.998353 
0.990387 
0.98242 
0.974454 
0.966488 
0.958522 
0.950556 
0.942589 
0.934623 
0.926657 
0.918691 
0.910725 
0.902759 
0.894792 
0.886826 
0.87886 
573 
 
883 
884 
885 
886 
887 
888 
889 
890 
891 
892 
893 
894 
895 
896 
897 
898 
899 
900 
 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
 
0.870894 
0.862928 
0.854961 
0.846995 
0.839029 
0.831063 
0.823097 
0.815131 
0.807164 
0.799198 
0.791232 
0.783266 
0.7753 
0.767333 
0.759367 
0.751401 
0.743435 
0.735469 
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